PT J
AU Nguyen, KV
   Sharlef, FS
   Chan, SSL
   Copeland, WC
   Naviaux, RK
AF Nguyen, Khue V.
   Sharlef, Farida S.
   Chan, Sherine S. L.
   Copeland, William C.
   Naviaux, Robert K.
TI Molecular diagnosis of Alpers syndrome
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Alpers-Huttenlocher syndrome; POLG; mtDNA depletion; seizures; cirrhosis
ID dna-polymerase-gamma; progressive external ophthalmoplegia; deoxyguanosine kinase gene; base excision-repair; mitochondrial-dna; polg mutations; accessory subunit; neuronal degeneration; depletion; ataxia
AB Background/Aims: Alpers syndrome is a developmental mitochondrial DNA depletion syndrome leading to fatal brain and liver disease in children and young adults. Mutations in the gene for the mitochondrial DNA polymerase (POLG) have recently been shown to cause this disorder. Methods: The POLG locus was sequenced in 15 sequential probands diagnosed with Alpers syndrome. In addition, the POLG mutations found to cause Alpers syndrome in the 20 cases published to date were analyzed. Results: POLG DNA testing accurately diagnosed 87% (13/15 = 87%: 95% confidence interval = 60-98%) of cases. Five new POLG amino acid substitutions (F749S, R852C, T914P, L966R, and L1173fsX) were found that were associated with Alpers syndrome in five unrelated kindreds, and 14 different allelic combinations of POLG mutations were found to cause Alpers syndrome in the 20 probands published to date. The most common Alpers-causing mutation was the A467T substitution, located in the linker region of the pol gamma protein, which accounted for about 40% of the alleles and was present in 65% of the patients. All patients with POLG mutations had either the A467T or the W748S substitution in the linker region. Conclusions: Screening for A467T and W748S substitutions in POLG now constitutes the most rapid and sensitive test available for confirming the clinical diagnosis of Alpers syndrome. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 Univ Calif San Diego, San Diego Sch Med, Dept Med, San Diego, CA 92103 USA.
   Univ Calif San Diego, San Diego Sch Med, Dept Pediat, San Diego, CA 92103 USA.
   Univ Calif San Diego, San Diego Sch Med, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
   NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Naviaux, RK (corresponding author), Univ Calif San Diego, San Diego Sch Med, Dept Med, Bldg CTF,Rm C-103,214 Dickinson St, San Diego, CA 92103 USA.
EM naviaux@ucsd.edu
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Copeland William C, 2003, SCIENTIFICWORLDJOURNAL, V3, P34
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Heath EM, 2001, ARCH PATHOL LAB MED, V125, P127
   Hübscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   LONGLEY MJ, 2005, GENE, V0, P0
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Pinz KG, 2006, DNA REPAIR, V5, P121, DOI 10.1016/j.dnarep.2005.08.014
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 41
TC 100
Z9 106
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD JUL 15
PY 2006
VL 45
IS 1
BP 108
EP 116
DI 10.1016/j.jhep.2005.12.026
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 060DK
UT WOS:000238782200014
PM 16545482
DA 2024-11-01
ER

PT J
AU Shutt, TE
   Gray, MW
AF Shutt, Timothy E.
   Gray, Michael W.
TI Twinkle, the mitochondrial replicative DNA helicase, is widespread in the eukaryotic radiation and may also be the mitochondrial DNA primase in most eukaryotes
SO JOURNAL OF MOLECULAR EVOLUTION
LA English
DT Article
DE twinkle; mitochondrial; helicase; primase; DNA replication; T7 phage
ID rna-polymerase; crystal-structure; escherichia-coli; linker region; gene; sequence; bacterial; transcription; organization; phylogeny
AB Recently, the human protein responsible for replicative mtDNA helicase activity was identified and designated Twinkle. Twinkle has been implicated in autosomal dominant progressive external ophthalmoplegia (adPEO), a mitochondrial disorder characterized by mtDNA deletions. The Twinkle protein appears to have evolved from an ancestor shared with the bifunctional primase-helicase found in the T-odd bacteriophages. However, the question has been raised as to whether human Twinkle possesses primase activity, due to amino acid sequence divergence and absence of a zinc-finger motif thought to play an integral role in DNA binding. To date, a primase protein participating in mtDNA replication has not been identified in any eukaryote. Here we investigate the wider phylogenetic distribution of Twinkle by surveying and analyzing data from ongoing EST and genome sequencing projects. We identify Twinkle homologues in representatives from five of six major eukaryotic assemblages ("supergroups") and present the sequence of the complete Twinkle gene from two members of Amoebozoa, a supergroup of amoeboid protists at the base of the opisthokont (fungal/metazoan) radiation. Notably, we identify conserved primase motifs including the zinc finger in all Twinkle sequences outside of Metazoa. Accordingly, we propose that Twinkle likely serves as the primase as well as the helicase for mtDNA replication in most eukaryotes whose genome encodes it, with the exception of Metazoa.
C1 Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 1X5, Canada.
   Dalhousie Univ, Canadian Inst Adv Res, Program Evolutionary Biol, Halifax, NS B3H 1X5, Canada.
C3 Dalhousie University; Dalhousie University; Canadian Institute for Advanced Research (CIFAR)
RP Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Sir Charles Tupper Med Bldg,5850 Coll St,Room 8F-, Halifax, NS B3H 1X5, Canada.
EM m.w.gray@dal.ca
CR Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972
   Biswas TK, 2002, J BIOL CHEM, V277, P45704, DOI 10.1074/jbc.M202565200
   Cavalier-Smith T, 2004, P ROY SOC B-BIOL SCI, V271, P1251, DOI 10.1098/rspb.2004.2705
   Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Clement SL, 2001, GENE, V272, P209, DOI 10.1016/S0378-1119(01)00538-8
   DESAI SD, 1989, BIOCHEM BIOPH RES CO, V160, P525, DOI 10.1016/0006-291X(89)92464-9
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6
   Fahrni JF, 2003, MOL BIOL EVOL, V20, P1881, DOI 10.1093/molbev/msg201
   Filée J, 2002, J MOL EVOL, V54, P763, DOI 10.1007/s00239-001-0078-x
   Fölsch H, 1998, EMBO J, V17, P6508, DOI 10.1093/emboj/17.22.6508
   Grams J, 2002, J BIOL CHEM, V277, P16952, DOI 10.1074/jbc.M200662200
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Hall TA, 1999, NUCL ACIDS S SERIES, V41, P95, DOI 10.14344/IOC.ML.11.1
   Harper JT, 2005, INT J SYST EVOL MICR, V55, P487, DOI 10.1099/ijs.0.63216-0
   Hedtke B, 2000, EMBO REP, V1, P435, DOI 10.1093/embo-reports/kvd086
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243
   Johnson CE, 1999, MOL BIOCHEM PARASIT, V102, P205, DOI 10.1016/S0166-6851(99)00082-1
   Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3
   Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161
   Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563
   LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x
   Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9
   Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4
   Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937
   Lee SJ, 2005, J BIOL CHEM, V280, P26984, DOI 10.1074/jbc.M504817200
   Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200
   Leipe DD, 2000, GENOME RES, V10, P5
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902
   Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4
   Nikolaev SI, 2004, P NATL ACAD SCI USA, V101, P8066, DOI 10.1073/pnas.0308602101
   Sarkar G, 1993, PCR METHODS APPL, V2, P318
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Sedman T, 2000, MOL CELL BIOL, V20, P1816, DOI 10.1128/MCB.20.5.1816-1824.2000
   Seow F, 2005, MOL BIOCHEM PARASIT, V141, P145, DOI 10.1016/j.molbiopara.2005.02.002
   Simpson AGB, 2004, CURR BIOL, V14, PR693, DOI 10.1016/j.cub.2004.08.038
   Simpson AGB, 2003, INT J SYST EVOL MICR, V53, P1759, DOI 10.1099/ijs.0.02578-0
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Soultanas P, 2005, STRUCTURE, V13, P839, DOI 10.1016/j.str.2005.04.006
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542
   Stoltzfus A, 1997, P NATL ACAD SCI USA, V94, P10739, DOI 10.1073/pnas.94.20.10739
   Sverdlov AV, 2004, GENE, V338, P85, DOI 10.1016/j.gene.2004.05.027
   Thirlway J, 2004, NUCLEIC ACIDS RES, V32, P2977, DOI 10.1093/nar/gkh628
   Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8
   TOUGU K, 1994, J BIOL CHEM, V269, P4675
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   VERSALOVIC J, 1993, GENE, V136, P281, DOI 10.1016/0378-1119(93)90480-Q
   VISHWANATHA JK, 1986, NUCLEIC ACIDS RES, V14, P8467, DOI 10.1093/nar/14.21.8467
   Weber KL, 1998, BIOTECHNIQUES, V25, P415, DOI 10.2144/98253st02
   WONG TW, 1985, J BIOL CHEM, V260, P1530
   Zettler LAA, 2001, J EUKARYOT MICROBIOL, V48, P293, DOI 10.1111/j.1550-7408.2001.tb00317.x
NR 61
TC 79
Z9 100
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0022-2844
EI 1432-1432
J9 J MOL EVOL
JI J. Mol. Evol.
PD MAY 15
PY 2006
VL 62
IS 5
BP 588
EP 599
DI 10.1007/s00239-005-0162-8
PG 12
WC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Evolutionary Biology; Genetics & Heredity
GA 041WO
UT WOS:000237487400007
PM 16612544
DA 2024-11-01
ER

PT J
AU Yang, FY
AF Yang Fuyu
TI Keshan disease and mitochondrial cardiomyopathy
SO SCIENCE IN CHINA SERIES C-LIFE SCIENCES
LA English
DT Review
DE mitochondrial disease; Keshan disease; mitochondrial cardlomyopathy
ID mutation; dna; se
AB Keshan disease (KD) is a potentially fatal form of cardiornyopathy (disease of the heart muscle) endemic in certain areas of China. From 1984 to 1986, a national comprehensive scientific investigation on KD in Chuxiong region of Yunnan Province in the southwest China was conducted. The investigation team was composed of epidemiologists, clinic doctors, pathologists, biochemists, biophysicists and specialists in ecological environment. Results of pathological, biochemical and biophysical as well as clinical studies showed: an obvious increase of enlarged and swollen mitochondria with distended crista membranes in myocardium from patients with KD; significant reductions in the activity of oxidative phosphorylation (succinate dehydrogenase, cytochrome oxidase, succinate oxidase, H+-ATPase) of affected mitochondria; decrease in CoQ, cardiolipin, Se and GSHPx activity, while obvious increase in the Ca2+ content. So, it was suggested that mitochondria are the predominant target of the pathogenic factors of KD. Before Chuxiong KD survey only a few cases of mitochondrial cardiornyopathy were studied. During the multidisciplinary scientific investigation on KD in Chuxiong a large amount of samples from KD cases and the positive controls were examined. On the basis of the results obtained it was suggested that KD might be classified as a "Mitochondrial Cardiomyopathy" endemic in China. This is one of the achievements in the three years' survey in Chuxiong and is valuable not only to the deeper understanding of pathogenic mechanism of KD but also to the study of mitochondrial cardiomyopathy in general. Keshan disease is not a genetic disease, but is closely related to the malnutrition (especially microelement Se deficiency). KD occurs along a low Se belt, and Se supplementation has been effective in prevention of such disease. The incidence of KD has sharply decreased along with the steady raise of living standard and realization of preventive measures. At present, patients of KD are very sparse. In recent years the research on the non-KD mitochondrial cardiomyopathy has progressed rapidly. Given the advances in this aspect a minireview is written to evaluate the classification of KD as a kind of mitochondrial cardiomyopathy.
C1 Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Biophysics, CAS
RP Yang, FY (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
EM Yangfy@sun5.ibp.ac.cn
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   [Anonymous], 1979, CHINESE MED J-PEKING, V92, P471
   Bindoff L, 2003, EUR HEART J, V24, P221, DOI 10.1016/S0195-668X(02)00694-2
   BOGOUSSLAVSKY J, 1982, J NEUROL SCI, V55, P351, DOI 10.1016/0022-510X(82)90132-0
   CHEN X, 1981, SELENIUM BIOL MED, V0, P171
   CHINNERY PF, 2003, MITOCHONDRIAL DISORD, V0, P0
   *CHUX KESH DIS PAT, 1988, P COMPR SCI INV KD C, V0, P138
   DAI GH, 1988, P COMPR SCI INV KD C, V0, P193
   DENG XQ, 1988, P COMPR SCI INV KD C, V0, P130
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737
   GRANTZOW R, 1982, MONATSSCHR KINDERH, V130, P909
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Lane N, 2006, NATURE, V440, P600, DOI 10.1038/440600a
   LI FS, 1988, P COMPR SCI INV KD C, V0, P178
   LI XZ, 1974, SCI SINICA, V0, P415
   Li Y, 2000, HEART, V83, P696, DOI 10.1136/heart.83.6.696
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   MARINGARCIA J, 1994, CARDIOVASC RES, V28, P456, DOI 10.1093/cvr/28.4.456
   MarinGarcia J, 1997, PEDIATR CARDIOL, V18, P251, DOI 10.1007/s002469900169
   NIU CL, 1988, P COMPR SCI INV KD C, V0, P16
   Ren LQ, 2004, WORLD J GASTROENTERO, V10, P3299, DOI 10.3748/wjg.v10.i22.3299
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   TAN JA, 1988, P COMPR SCI INV KD C, V0, P48
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   *XIAN MED COLL LAB, 1979, NATL MED J CHINA, V59, P457
   YAGN FY, 1987, BIOCH INT, V15, P475
   YANG DS, 1982, ENDEMIC DIS COMM, V3, P1
   YANG FY, 1994, J CLIN BIOCHEM NUTR, V16, P101
   YANG FY, 1988, J TRACE ELEM ELECT H, V2, P157
   YANG FY, 1989, BIOCHEM INT, V18, P1085
   YANG FY, 1988, P COMPR SCI INV KD C, V0, P184
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 34
TC 24
Z9 27
U1 0
U2 11
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9305
EI 
J9 SCI CHINA SER C
JI Sci. China Ser. C-Life Sci.
PD DEC 15
PY 2006
VL 49
IS 6
BP 513
EP 518
DI 10.1007/s11427-006-2041-y
PG 6
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 112SA
UT WOS:000242546100001
PM 17312989
DA 2024-11-01
ER

PT J
AU Park, SY
   Lee, S
   Park, KS
   Lee, HK
   Lee, W
AF Park, SY
   Lee, S
   Park, KS
   Lee, HK
   Lee, W
TI Proteomic analysis of cellular change involved in mitochondria-to-nucleus communication in L6 GLUT4myc myocytes
SO PROTEOMICS
LA English
DT Article
DE insulin resistance; mitochondria; mitochondrial DNA; myocyte; proteome
ID skeletal-muscle; insulin-resistance; 3t3-l1 adipocytes; polyacrylamide-gels; glucose-transport; cortical actin; protein; cells; translocation; activation
AB Genetic or biochemical abnormalities in mitochondria are closely associated with apoptosis, aging, cancer, and other chronic degenerative diseases. Mitochondrial dysfunction resulting from mitochondrial DNA (mtDNA) depletion dispatches retrograde signals to the nucleus to compensate by altering the expression of various genes. In this study, a proteomic approach was used to gain insight into the nuclear gene targets of mitochondrial stress signaling and the pathophysiological mechanisms associated with mitochondrial dysfunction. We have used 2-DE to characterize the nuclear gene responses resulting from mtDNA depletion in L6 GLUT4myc myocytes. Our results showed that 77 polypeptides were differentially expressed in mtDNA-depleted cells; 3 3 polypeptides were down-regulated and 44 polypeptides were up-regulated. Of these differentially expressed polypeptides, 40 were identified as 36 different proteins by MALDI-TOF MS. These proteins are related to various cellular responses, such as apoptosis, cellular metabolism, signaling and cytoskeleton functions. It is suggested that the insulin resistance developed in mtDNA-depleted myocytes may be associated with disorganization of cytoskeleton assembly, and that cellular mtDNA depletion might promote the ability to evade apoptosis or other death effectors.
C1 Dongguk Univ, Coll Med, Dept Biochem, Kyungju 780714, Kyungpook, South Korea.
   Seoul Natl Univ, Sch Med, Dept Internal Med, Seoul 151, South Korea.
C3 Dongguk University; Seoul National University (SNU)
RP Dongguk Univ, Coll Med, Dept Biochem, Kyungju 780714, Kyungpook, South Korea.
EM wanlee@mail.dongguk.ac.kr
CR Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910
   Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512
   ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790
   Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983
   Begum N, 1998, METABOLISM, V47, P54, DOI 10.1016/S0026-0495(98)90193-7
   Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104
   Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200
   CHEN LB, 1989, METHOD CELL BIOL, V29, P103
   Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223
   Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102
   Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73
   de Hostos EL, 1999, TRENDS CELL BIOL, V9, P345, DOI 10.1016/S0962-8924(99)01620-7
   DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x
   DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163
   Duchen Michael R, 2004, MOLECULAR ASPECTS OF MEDICINE, V25, P365, DOI 10.1016/j.mam.2004.03.001
   Duchen MR, 2004, DIABETES, V53, PS96, DOI 10.2337/diabetes.53.2007.S96
   Enns GM, 2003, MOL GENET METAB, V80, P11, DOI 10.1016/j.ymgme.2003.08.009
   Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779
   GANOTE C, 1993, CARDIOVASC RES, V27, P1387, DOI 10.1093/cvr/27.8.1387
   Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113
   Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437
   Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200
   Hacker U, 1997, J CELL SCI, V110, P105
   Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300
   Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5
   Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671
   Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633
   Kabakov Alexander E, 1994, TRENDS IN CELL BIOLOGY, V4, P193, DOI 10.1016/0962-8924(94)90135-X
   KANAI F, 1993, J BIOL CHEM, V268, P14523
   Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KOBRYN CE, 1994, AM J PHYSIOL-CELL PH, V267, PC1073, DOI 10.1152/ajpcell.1994.267.4.C1073
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee CH, 1998, J IND ENG CHEM, V4, P161
   Lee MS, 2004, ANN NY ACAD SCI, V1011, P146, DOI 10.1196/annals.1293.015
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4
   Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529
   OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4
   Olson AL, 2003, ENDOCRINOLOGY, V144, P5030, DOI 10.1210/en.2003-0609
   Park SY, 2005, J BIOL CHEM, V280, P9855, DOI 10.1074/jbc.M409399200
   Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Piro Lawrence D, 2004, ONCOLOGY (WILLISTON PARK), V18, P5
   Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023
   Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296
   Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x
   Sechi AS, 1997, J CELL BIOL, V137, P155, DOI 10.1083/jcb.137.1.155
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930
   Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166
   Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6
   SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514
   Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074
   Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071
   Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054
   Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI200112348
   Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7
   Tsuda M, 2004, J BIOL CHEM, V279, P46843, DOI 10.1074/jbc.M401476200
   Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, PE572, DOI 10.1152/ajpendo.1999.277.3.E572
   VanDemark AP, 2005, MOL CELL, V17, P474, DOI 10.1016/j.molcel.2005.02.004
   Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2
   Wang QH, 1999, MOL CELL BIOL, V19, P4008
   Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wei MC, 2000, GENE DEV, V14, P2060
   Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113
   YOUNG CL, 1994, J BIOL CHEM, V269, P13997
NR 73
TC 10
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD FEB 15
PY 2006
VL 6
IS 4
BP 1210
EP 1222
DI 10.1002/pmic.200500284
PG 13
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 018HZ
UT WOS:000235756400015
PM 16402357
DA 2024-11-01
ER

PT J
AU Brantová, O
   Tesarová, M
   Hansiková, H
   Elleder, M
   Zeman, J
   Sládková, J
AF Brantova, Olga
   Tesarova, Marketa
   Hansikova, Hana
   Elleder, Milan
   Zeman, Jiri
   Sladkova, Jana
TI Ultrastructural changes of mitochondria in the cultivated skin fibroblasts of patients with point mutations in mitochondrial DNA
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE cristae; human skin fibroblasts; mitochondria; mitochondrial disease; mtDNA mutation; ultrastructure
ID blue-native-electrophoresis; oxidative-phosphorylation; electron-microscopy; lactic-acidosis; cells; membrane; dynamics; permanganate; dysfunction; morphology
AB Mitochondrial disorders represent a heterogeneous group of multisystem diseases with extreme variability in clinical phenotype. The diagnosis of mitochondrial disorders relies heavily on extensive biochemical and molecular analyses combined with morphological studies including electron microscopy. Although muscle is the tissue of choice for electron microscopic studies, the authors investigated cultivated human skin fibroblasts (HSF) harboring 3 different pathologic mtDNA mutations: 3243A > G, 8344A > G, 8993T > G. They addressed to the possibility of whether mtDNA mutations influence mitochondrial morphology in HSF and if ultrastructural changes of mitochondria may be used for differential diagnostics of mitochondrial disorders caused by mtDNA mutations. Ultrastructural analysis of patients' HSF revealed a heterogeneous mixture of mainly abnormal, partially swelling mitochondria with unusual and sparse cristae. The most characteristic cristal abnormalities were heterogeneity in size and shapes or their absence. Typical filamentous and branched mitochondria with numerous cristae as appeared in control HSF were almost not observed. In all lines of cultured HSF with various mtDNA mutations, similar ultrastructural abnormalities and severely changed mitochondrial interior were found, although no alterations in function and amount of OXPHOS were detected by routinely used biochemical methods in two lines of cultured HSF. This highlights the importance of morphological analysis, even in cultured fibroblasts, in diagnostics of mitochondrial disorders.
C1 Charles Univ, Dept Paediat, Fac Med, Prague 12808 2, Czech Republic.
C3 Charles University Prague
RP Sládková, J (corresponding author), Charles Univ, Dept Paediat, Fac Med, Ke Karlovu 2, Prague 12808 2, Czech Republic.
EM jsladkova@centrum.cz
CR Bakker A, 2000, PEDIATR RES, V48, P143, DOI 10.1203/00006450-200008000-00005
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1
   Handran SD, 1997, NEUROBIOL DIS, V3, P287, DOI 10.1006/nbdi.1996.0125
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1994, J BIOL CHEM, V269, P19060
   KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523
   LEA PJ, 1994, MICROSC RES TECHNIQ, V27, P269, DOI 10.1002/jemt.1070270402
   LUFT JH, 1956, J BIOPHYS BIOCHEM CY, V2, P799, DOI 10.1083/jcb.2.6.799
   Mannella CA, 2001, IUBMB LIFE, V52, P93, DOI 10.1080/15216540152845885
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221
   Procaccio V, 1999, J CLIN INVEST, V104, P83, DOI 10.1172/JCI6184
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   SONG JD, 1991, J STRUCT BIOL, V107, P106, DOI 10.1016/1047-8477(91)90014-N
NR 21
TC 19
Z9 19
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD JUL-AUG 15
PY 2006
VL 30
IS 4
BP 239
EP 245
DI 10.1080/01913120600820112
PG 7
WC Microscopy; Pathology
SC Microscopy; Pathology
GA 083XD
UT WOS:000240490600001
PM 16971348
DA 2024-11-01
ER

PT J
AU Calvo, S
   Jain, M
   Xie, XH
   Sheth, SA
   Chang, B
   Goldberger, OA
   Spinazzola, A
   Zeviani, M
   Carr, SA
   Mootha, VK
AF Calvo, S
   Jain, M
   Xie, XH
   Sheth, SA
   Chang, B
   Goldberger, OA
   Spinazzola, A
   Zeviani, M
   Carr, SA
   Mootha, VK
TI Systematic identification of human mitochondrial disease genes through integrative genomics
SO NATURE GENETICS
LA English
DT Article
ID respiratory-chain disorders; heterogeneity; proteins; sequence; locus; proteome; database; muscle; mouse
AB The majority of inherited mitochondrial disorders are due to mutations not in the mitochondrial genome ( mtDNA) but rather in the nuclear genes encoding proteins targeted to this organelle. Elucidation of the molecular basis for these disorders is limited because only half(1,2) of the estimated 1,500 mitochondrial proteins(3) have been identified. To systematically expand this catalog, we experimentally and computationally generated eight genome-scale data sets, each designed to provide clues as to mitochondrial localization: targeting sequence prediction, protein domain enrichment, presence of cis-regulatory motifs, yeast homology, ancestry, tandem-mass spectrometry, coexpression and transcriptional induction during mitochondrial biogenesis. Through an integrated analysis we expand the collection to 1,080 genes, which includes 368 novel predictions with a 10% estimated false prediction rate. By combining this expanded inventory with genetic intervals linked to disease, we have identified candidate genes for eight mitochondrial disorders, leading to the discovery of mutations in MPV17 that result in hepatic mtDNA depletion syndrome(4). The integrative approach promises to better define the role of mitochondria in both rare and common human diseases.
C1 MIT, Broad Inst, Cambridge, MA 02142 USA.
   Harvard Univ, Cambridge, MA 02142 USA.
   Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02446 USA.
   Natl Neurol Inst C Besta, Unite Mol Neurogenet, I-20126 Milan, Italy.
C3 Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP MIT, Broad Inst, 77 Massachusetts Ave, Cambridge, MA 02142 USA.
EM vamsi@hms.harvard.edu
CR Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094
   Andreoli C, 2004, NUCLEIC ACIDS RES, V32, PD459, DOI 10.1093/nar/gkh137
   Basel-Vanagaite L, 2004, NEUROLOGY, V62, P87, DOI 10.1212/01.WNL.0000101680.49036.69
   Christodoulou K, 2001, NEUROGENETICS, V3, P127, DOI 10.1007/s100480100112
   Cotter D, 2004, NUCLEIC ACIDS RES, V32, PD463, DOI 10.1093/nar/gkh048
   El-Shanti H, 2000, AM J HUM GENET, V66, P1229, DOI 10.1086/302858
   Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171
   Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361
   Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805
   Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L
   MARIMAN ECM, 1995, HUM GENET, V95, P56, DOI 10.1007/BF00225075
   Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Prokisch H, 2004, PLOS BIOL, V2, P795, DOI 10.1371/journal.pbio.0020160
   Rötig A, 2003, J AM SOC NEPHROL, V14, P2995, DOI 10.1097/01.ASN.0000095481.24091.C9
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Seyda A, 2001, AM J HUM GENET, V68, P386, DOI 10.1086/318196
   Shoubridge EA, 2001, SEMIN NEUROL, V21, P261, DOI 10.1055/s-2001-17943
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Steinmüller R, 1998, EUR J HUM GENET, V6, P201, DOI 10.1038/sj.ejhg.5200180
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Zeviani Massimo, 2004, SUPPL CLIN NEUROPHYSIOL, V57, P304
   ZWACKA RM, 1994, EMBO J, V13, P5129, DOI 10.1002/j.1460-2075.1994.tb06842.x
NR 30
TC 268
Z9 307
U1 0
U2 26
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD MAY 15
PY 2006
VL 38
IS 5
BP 576
EP 582
DI 10.1038/ng1776
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 037LE
UT WOS:000237147500021
PM 16582907
DA 2024-11-01
ER

PT J
AU Kirino, Y
   Yasukawa, T
   Marjavaara, SK
   Jacobs, HT
   Holt, IJ
   Watanabe, K
   Suzuki, T
AF Kirino, Y
   Yasukawa, T
   Marjavaara, SK
   Jacobs, HT
   Holt, IJ
   Watanabe, K
   Suzuki, T
TI Acquisition of the wobble modification in mitochondrial tRNA<SUP>Leu(CUN)</SUP> bearing the G12300A mutation suppresses the MELAS molecular defect
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID transfer rnaleu(uur) gene; transfer-rna; lactic-acidosis; modification deficiency; escherichia-coli; encephalopathy; myopathy; mutants; codon; biosynthesis
AB The A3243G mutation in the mitochondrial gene for human mitochondrial (mt) tRNA(Leu(UUR)), responsible for decoding of UUR codons, is associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). We previously demonstrated that this mutation causes defects in 5-taurinomethyluridine (tau m(5)U) modification at the anticodon first (wobble) position of the mutant mt tRNA(Leu(UUR)), leading to a UUG decoding deficiency and entraining severe respiratory defects. In addition, we previously identified a heteroplasmic mutation, G12300A, in the other mt leucine tRNA gene, mt tRNA(Leu(CUN)), which functions as a suppressor of the A3243G respiratory defect in cybrid cells containing A3243G mutant mtDNA. Although the G12300A mutation converts the anticodon sequence of mt tRNA(Leu(CUN)) from UAG to UAA, this tRNA carrying an unmodified wobble uridine still cannot decode the UUG codon. Mass spectrometric analysis of the suppressor mt tRNA(Leu(CUN)) carrying the G12300A mutation from the phenotypically revertant cells revealed that the wobble uridine acquires de novo tau m(5)U modification. In vitro translation confirmed the functionality of the suppressor tRNA for decoding UUG codons. These results demonstrate that the acquisition of the wobble modification in another isoacceptor tRNA is critical for suppressing the MELAS mutation, and they highlight the primary role of the UUG decoding deficiency in the molecular pathogenesis of MELAS syndrome.
C1 Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.
   Univ Tokyo, Grad Sch Engn, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1138656, Japan.
   MRC, Dunnn Human Nutr Unit, Cambridge CB2 2XY, England.
   Univ Tampere, Tampere Univ Hosp, FI-33014 Tampere, Finland.
   Univ Tampere, Inst Med Technol, FI-33014 Tampere, Finland.
   Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
C3 University of Tokyo; University of Tokyo; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Tampere University; Tampere University Hospital; Tampere University; University of Glasgow
RP Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
EM ts@chembio.t.u-tokyo.ac.jp
FU Medical Research Council [MC_U105663140] Funding Source: Medline; MRC [MC_U105663140] Funding Source: UKRI
CR Bjork GR, 1995, TRNA, V0, P165
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Brégeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701
   Colby G, 1998, J BIOL CHEM, V273, P27945, DOI 10.1074/jbc.273.43.27945
   DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133
   El Meziane A, 1998, NAT GENET, V18, P350
   ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hanada T, 2001, GENES CELLS, V6, P1019, DOI 10.1046/j.1365-2443.2001.00491.x
   Jacobs HT, 2003, HUM MOL GENET, V12, PR293, DOI 10.1093/hmg/ddg285
   Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066
   KING MP, 1993, J BIOL CHEM, V268, P10228
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   KIRINO Y, 2004, RNA BIOL, V1, P145
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379
   Lehtinen SK, 2000, GENETICS, V154, P363
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Li RH, 2003, BBA-GENE STRUCT EXPR, V1629, P53, DOI 10.1016/S0167-4781(03)00160-X
   Nakayashiki T, 1998, J BACTERIOL, V180, P2931, DOI 10.1128/JB.180.11.2931-2935.1998
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Suzuki T, 2005, TOP CURR GENET, V12, P23, DOI 10.1007/b106361
   Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200
   Watanabe Kimitsuna, 1995, P225, V0, P0
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Yasukawa T, 2002, MITOCHONDRION, V2, P129, DOI 10.1016/S1567-7249(02)00033-8
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
   Yokoyama Shigeyuki, 1995, P207, V0, P0
NR 33
TC 32
Z9 38
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 15
PY 2006
VL 15
IS 6
BP 897
EP 904
DI 10.1093/hmg/ddl007
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 018NS
UT WOS:000235771800008
PM 16446307
DA 2024-11-01
ER

PT J
AU Cortopassi, G
   Danielson, S
   Alemi, M
   Zhan, SS
   Tong, W
   Carelli, V
   Martinuzzi, A
   Marzuki, S
   Majamaa, K
   Wong, A
AF Cortopassi, Gino
   Danielson, Steven
   Alemi, Mansour
   Zhan, Shan Shan
   Tong, Warren
   Carelli, Valerio
   Martinuzzi, Andrea
   Marzuki, Sangot
   Majamaa, Kari
   Wong, Alice
TI Mitochondrial disease activates transcripts of the unfolded protein response and cell cycle and inhibits vesicular secretion and oligodendrocyte-specific transcripts
SO MITOCHONDRION
LA English
DT Article
DE mitochondrial genetic disease; microarray; unfolded protein response
ID hereditary optic neuropathy; endoplasmic-reticulum stress; orphan nuclear receptor; peripheral neuropathy; cerebral-ischemia; gene-expression; coup-tfii; dna; mutation; dysfunction
AB Mutations in gene products expressed in the mitochondrion cause a nuclear transcriptional response that leads to neurological disease. To examine the extent to which the transcriptional profile was shared among 5 mitochondrial diseases (LHON, FRDA, MELAS, KSS, and NARP), we microarrayed mutant and control groups in N-tera2, SH-SY5Y, lymphoblasts, fibroblasts, myoblasts, muscle, and osteosarcoma cybrids. Many more transcripts were observed to be significantly altered and shared among these 5 mitochondrial diseases and cell types than expected on the basis of random chance, and these genes are significantly clustered with respect to biochemical pathways. Mitochondrial disease activated multiple transcripts of the unfolded protein response (UPR), and of the cell cycle pathway, and low doses of the mitochondrial inhibitor rotenone induced UPR transcripts in the absence of cell death. By contrast, functional clusters inhibited by mitochondrial disease included: vesicular secretion, protein synthesis, and oligodendrogenesis. As it is known that UPR activation specifically inhibits vesicular secretion and protein synthesis, these data support the view that mitochondrial disease and dysfunction triggers the UPR, which in turn causes secretory defects which inhibit cellular migratory, synaptic, and oligodendrocytic functions, providing a testable hypothesis for how mitochondrial dysfunction causes disease. Since ischemic hypoxia, chemical hypoxia, and mitochondrial genetic disease (which could be considered 'genetic hypoxia') produce an overlapping induction of UPR and cell cycle genes which appears to have negative consequences, the modulation of these responses might be of benefit to patients with mitochondrial disease. (c) 2006 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.
   Univ Bologna, Dept Neurol Sci, Bologna, Italy.
   Conegliano Res Ctr, Sci Inst Eugenio Medea, Conegliano, Italy.
   Eijkman Inst Mol Biol, Jakarta 10430, Indonesia.
   Univ Oulu, Dept Neurol, Oulu, Finland.
C3 University of California System; University of California Davis; University of Bologna; IRCCS Eugenio Medea; Eijkman Institute; University of Oulu
RP Cortopassi, G (corresponding author), Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.
EM gacortopassi@ucdavis.edu
FU NEI NIH HHS [EY12245] Funding Source: Medline; NIA NIH HHS [AG16719, AG11967, AG23311] Funding Source: Medline; Telethon [GGP02323] Funding Source: Medline
CR Alfonso J, 2004, EUR J NEUROSCI, V19, P659, DOI 10.1111/j.1460-9568.2004.03178.x
   Bardoux P, 2005, DIABETES, V54, P1357, DOI 10.2337/diabetes.54.5.1357
   Bedlack RS, 2004, MUSCLE NERVE, V29, P364, DOI 10.1002/mus.10546
   Behan A, 2005, MITOCHONDRION, V5, P173, DOI 10.1016/j.mito.2005.03.002
   BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686
   Bossenmeyer-Pourié C, 2002, NEUROSCIENCE, V114, P869, DOI 10.1016/S0306-4522(02)00324-X
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Chalmers RM, 1996, BRAIN, V119, P1481, DOI 10.1093/brain/119.5.1481
   Chou WY, 1999, ALCOHOL CLIN EXP RES, V23, P963, DOI 10.1111/j.1530-0277.1999.tb04213.x
   Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200
   DANIELSON SR, 2005, BRAIN, V0, P0
   DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x
   Delsite Robert, 2002, MOL CANCER, V1, P6, DOI 10.1186/1476-4598-1-6
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221
   Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223
   Jordan EM, 2003, BIOCHEMISTRY-US, V42, P2656, DOI 10.1021/bi0268347
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kuruvilla S, 2003, TOXICOL SCI, V73, P348, DOI 10.1093/toxsci/kfg084
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Maehara K, 2003, J MOL ENDOCRINOL, V31, P47, DOI 10.1677/jme.0.0310047
   Miceli MV, 2005, EXP CELL RES, V302, P270, DOI 10.1016/j.yexcr.2004.09.006
   MIZUSAWA H, 1991, REV NEUROL, V147, P501
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Park Joo-In, 2003, KEIO JOURNAL OF MEDICINE, V52, P174
   Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x
   Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037
   Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9
   Ricard D, 2000, MOL CELL NEUROSCI, V16, P324, DOI 10.1006/mcne.2000.0888
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   Rodriguez-Gabin AG, 2001, J NEUROSCI RES, V66, P1149, DOI 10.1002/jnr.1253.abs
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Ryu EJ, 2002, J NEUROSCI, V22, P10690
   SANCHO S, 1992, SOMAT CELL MOLEC GEN, V18, P431, DOI 10.1007/BF01233083
   Schröder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056
   Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5
   Stewart MJ, 1998, BBA-GENE STRUCT EXPR, V1399, P181, DOI 10.1016/S0167-4781(98)00115-8
   Sudoyo H, 2002, J HUM GENET, V47, P594, DOI 10.1007/s100380200091
   Tan G, 2001, HUM MOL GENET, V10, P2099, DOI 10.1093/hmg/10.19.2099
   Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187
   Tiwari-Woodruff SK, 2004, J NEUROSCI RES, V77, P166, DOI 10.1002/jnr.20141
   Tripodi M, 2004, DEVELOPMENT, V131, P6119, DOI 10.1242/dev.01530
   Uusimaa J, 2003, PEDIATRICS, V111, P0, DOI 10.1542/peds.111.3.e262
   Vanopdenbosch L, 2000, J NEUROL, V247, P535, DOI 10.1007/s004150070153
   VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740
   Watson LM, 2003, J BIOL CHEM, V278, P17438, DOI 10.1074/jbc.M301006200
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   Werner H, 2001, MOL CELL NEUROSCI, V18, P593, DOI 10.1006/mcne.2001.1044
   Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896-6273(93)90147-J
   You LR, 2005, NATURE, V435, P98, DOI 10.1038/nature03511
   Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445
   ZHOU C, 2000, BIOCHIM BIOPHYS ACTA, V1470, P63
NR 63
TC 43
Z9 48
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD AUG 15
PY 2006
VL 6
IS 4
BP 161
EP 175
DI 10.1016/j.mito.2006.05.002
PG 15
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 095VM
UT WOS:000241336400001
PM 16815102
DA 2024-11-01
ER

PT J
AU Çanakçi, CF
   Tatar, A
   Çanakçi, V
   Cicek, Y
   Oztas, S
   Orbak, R
AF Canakci, Cenk Fatih
   Tatar, Abdulgani
   Canakci, Varol
   Cicek, Yasin
   Oztas, Sitki
   Orbak, Recep
TI New evidence of premature oxidative DNA damage:: Mitochondrial DNA deletion in gingival tissue of patients with periodontitis
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE chronic periodontitis; gingiva; mitochondrial DNA; oxidative stress; reactive oxygen species
ID disease; cells; stress; antioxidants; mutations; muscle
AB Background: Overproduction of reactive oxygen species (ROS) causes increased oxidative stress in gingival tissue. It has been generally accepted that increased oxidative stress might contribute to additional damage of lipids, proteins, and DNA molecules. The mitochondrial DNA (mtDNA) mutation is a superb biomarker of oxidative damage. The aim of the present study was to investigate the mtDNA deletions in the gingival tissue of patients with periodontitis and to explain the correlations between mtDNA deletion in gingival tissue and clinical parameters of periodontitis and age. Methods: Gingival tissue and blood samples were collected from 30 patients with chronic periodontitis (CP group) and 30 healthy control subjects (H group). To determine the clinical condition of each subject, the plaque index, gingival index, clinical attachment level, and probing depth were measured. Using the polymerase chain reaction (PCR) method, we examined the 7.4- and 5-kbp mtDNA deletions in tissue and blood samples. Three different pairs of PCR primers were used in this study. Results: In this study, we did not detect any deletions in blood DNA samples in either the CP or H group. Also, the 7.4-kbp mtDNA deletion was not detected in gingival tissues of subjects. However, the 5-kbp mtDNA deletion was detected in 24 of the 30 subjects (80%) in the CP group and was not detected in the H group (0%). Significant correlations were found between the occurrence of the 5-kbp mtDNA deletion and all clinical parameters (P < 0.01). A similar correlation was found between the occurrence of the 5-kbp mtDNA deletion and age (P < 0.05). Conclusions: The overproduction of ROS by activated polymorphonuclear leukocytes in chronic inflammation may lead to premature oxidative damage of the mtDNA. In this study, the occurrence of the 5-kbp mtDNA deletion in 24 periodontitis subjects may be evidence of premature oxidative DNA damage.
C1 Ataturk Univ, Fac Dent, Dept Periodont, TR-25240 Erzurum, Turkey.
C3 Ataturk University
RP Çanakçi, CF (corresponding author), Ataturk Univ, Fac Dent, Dept Periodont, TR-25240 Erzurum, Turkey.
EM cfcanakci@yahoo.com
CR Armitage G C, 1999, ANN PERIODONTOL, V4, P1, DOI 10.1902/annals.1999.4.1.1
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Çanakçi CF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P619, DOI 10.1007/s10541-005-0161-9
   Chapple ILC, 1997, J CLIN PERIODONTOL, V24, P287, DOI 10.1111/j.1600-051X.1997.tb00760.x
   Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X
   KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899
   LAMSTER IB, 1992, CRIT REV ORAL BIOL M, V3, P31, DOI 10.1177/10454411920030010501
   Lee HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P309, DOI 10.1006/abbi.1998.1036
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   Liu TY, 1996, MUTAT RES-GENET TOX, V367, P25, DOI 10.1016/S0165-1218(96)90018-X
   Loe H, 1963, ACTA ODONTOL SCAND, V21, P531
   MILLER DR, 1984, J CLIN PERIODONTOL, V11, P1, DOI 10.1111/j.1600-051X.1984.tb01303.x
   Moseley R, 1997, BBA-MOL BASIS DIS, V1362, P221, DOI 10.1016/S0925-4439(97)00083-5
   Ozmeric N, 2004, CLIN CHIM ACTA, V343, P1, DOI 10.1016/j.cccn.2004.01.022
   Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427
   RIMOIN DL, 2002, MITOCHONDIRAL GENES, V1, P299
   SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0
   Sculley DV, 2002, P NUTR SOC, V61, P137, DOI 10.1079/PNS2001141
   Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0
   SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297
   SILNESS J, 1964, ACTA ODONTOL SCAND, V22, P121, DOI 10.3109/00016356408993968
   Sugano N, 2000, J ORAL SCI, V42, P221
   Takane M, 2002, J PERIODONTOL, V73, P551, DOI 10.1902/jop.2002.73.5.551
   Tamori A, 2004, J GASTROENTEROL, V39, P1063, DOI 10.1007/s00535-004-1445-3
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
NR 29
TC 39
Z9 44
U1 0
U2 19
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA
SN 0022-3492
EI 
J9 J PERIODONTOL
JI J. Periodont.
PD NOV 15
PY 2006
VL 77
IS 11
BP 1894
EP 1900
DI 10.1902/jop.2006.060108
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 130LM
UT WOS:000243801100014
PM 17076616
DA 2024-11-01
ER

PT J
AU Ramelli, GP
   Gallati, S
   Weis, J
   Krähenbühl, S
   Burgunder, JM
AF Ramelli, GP
   Gallati, S
   Weis, J
   Krähenbühl, S
   Burgunder, JM
TI Point mutation tRNA<i><SUP>Ser(UCN)</SUP></i> in a child with hearing loss and myoclonus epilepsy
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID mitochondrial; disease; gene; melas; chain; merrf
AB We report on a family with a 12-year-old boy who suffered from a maternally inherited syndrome characterized by a combination of sensorineural hearing loss, myoclonus epilepsy, ataxia, severe psychomotor retardation, short stature, and diabetes mellitus. First, he showed a muscular hypotonia with hearing loss; later, he developed a myoclonus epilepsy, growth failure, and severe psychomotor retardation. At the age of 10 years, he developed diabetes mellitus. After initiation of combined ubiquinone and vitamin C treatment, we observed a progression in psychomotor development. Lactate and pyruvate levels in blood and cerebrospinal fluid were normal. No ragged red fibers or ultrastructural abnormalities were seen in a skeletal muscle biopsy. Biochemical assays of respiratory chain complex activities revealed decreased activity of complexes I and IV. By sequence analysis of mitochondrial DNA encoding transfer ribonucleic acids (RNAs), a homoplasmic T to C substitution at nucleotide position 7512 was found affecting a highly conserved base pair in the tRNA(ser(UCN)) acceptor stem. Asymptomatic family members of the maternal line were heteroplasmic for the mutation in blood samples. Analysis of mitochondrial DNA in patients with hearing loss and myoclonus epilepsy is recommended, even in the absence of laboratory findings. Therapeutically, ubiquinone and antioxidants can be beneficial.
C1 Osped San Giovanni Bellinzona, Dept Pediat, CH-6500 Bellinzona, Switzerland.
   Univ Bern, Dept Pediat, Div Human Genet, Bern, Switzerland.
   Univ Bern, Inst Pathol, Bern, Switzerland.
   Univ Basel Hosp, Div Clin Pharmacol & Toxicol, Basel, Switzerland.
   Univ Bern, Inselspital, Dept Neurol, Bern, Switzerland.
C3 Regional Hospital of Bellinzona & Valleys, San Giovanni; University of Bern; University of Bern; University of Basel; University of Bern; University Hospital of Bern
RP Ramelli, GP (corresponding author), Osped San Giovanni Bellinzona, Dept Pediat, CH-6500 Bellinzona, Switzerland.
EM gianpaolo.ramelli@eoc.ch
CR BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Ikejiri Y, 1996, NEUROLOGY, V47, P583, DOI 10.1212/WNL.47.2.583
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Krahenbuhl S, 1996, CLIN CHIM ACTA, V253, P79, DOI 10.1016/0009-8981(96)06338-3
   Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338
   MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884
   Munnich A, 1996, EUR J PEDIATR, V155, P262
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   SARVIDEI S, 1996, NEUROMUSCULAR DISORD, V6, P11
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Wallace DC, 1995, HUMAN GENE MAPPING 1, V0, P910
NR 14
TC 4
Z9 4
U1 0
U2 1
PU B C DECKER INC
PI HAMILTON
PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA
SN 0883-0738
EI 
J9 J CHILD NEUROL
JI J. Child Neurol.
PD MAR 15
PY 2006
VL 21
IS 3
BP 253
EP 255
DI 10.2310/7010.2006.00047
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 049FX
UT WOS:000238002500016
PM 16901431
DA 2024-11-01
ER

PT J
AU D'Angelo, MG
   Bresolin, N
AF D'Angelo, Maria Grazia
   Bresolin, Nereo
TI Cognitive impairment in neuromuscular disorders
SO MUSCLE & NERVE
LA English
DT Review
DE adult polyglucosan body disease; amyotrophic lateral sclerosis; Becker muscular dystrophy; cognitive impairment; congenital muscular dystrophy; Duchenne muscular dystrophy; facioscapulohumeral dystrophy; limb-girdle muscular dystrophy; mitochondrial encephalomyopathy; myotonic dystrophy; neuromuscular disorders; spinal muscular atrophy
ID duchenne muscular-dystrophy; amyotrophic-lateral-sclerosis; polyglucosan body disease; positron-emission-tomography; cerebral-blood-flow; hereditary optic neuropathy; mitochondrial-dna mutation; central-nervous-system; motor-neuron disease; magnetic-resonance spectroscopy
AB Several studies have suggested the presence of central nervous system involvement manifesting as cognitive impairment in diseases traditionally confined to the peripheral nervous system. The aim of this review is to highlight the character of clinical, genetic, neurofunctional, cognitive, and psychiatric deficits in neuromuscular disorders. A high correlation between cognitive features and cerebral protein expression or function is evident in Duchenne muscular dystrophy, myotonic dystrophy (Steinert disease), and mitochondrial encephalomyopathies; direct correlation between tissue-specific protein expression and cognitive deficits is still elusive in certain neuromuscular disorders presenting with or without a cerebral abnormality, such as congenital muscular dystrophies, congenital myopathies, amyotrophic lateral sclerosis, adult polyglucosan body disease, and limb-girdle muscular dystrophies. No clear cognitive deficits have been found in spinal muscular atrophy and facioscapulohumeral dystrophy.
C1 Ist Ric & Cura Carattere Sci E Medea, I-23842 Bosisio Parini, Italy.
   Univ Milan, Dipartimento Sci Neurol, Osped Maggiore Policlin Mangiagalli & Regina Elen, Ctr Dino Ferrari,Fdn Ist Ric & Cura Carettere Sci, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan
RP D'Angelo, MG (corresponding author), Ist Ric & Cura Carattere Sci E Medea, La Nostra Famiglia,Via Luigi Monza 20, I-23842 Bosisio Parini, Italy.
EM grazia.dangelo@bp.lnf.it
CR Abe K, 1997, J NEUROL SCI, V148, P95, DOI 10.1016/S0022-510X(96)05338-5
   Abrahams S, 1997, J NEUROL NEUROSUR PS, V62, P464, DOI 10.1136/jnnp.62.5.464
   Abrahams S, 2005, J NEUROL, V252, P321, DOI 10.1007/s00415-005-0646-x
   Abrahams S, 2004, BRAIN, V127, P1507, DOI 10.1093/brain/awh170
   ABRAHAMS S, 1995, J NEUROL SCI, V129, P54, DOI 10.1016/0022-510X(95)00063-8
   Abrahams S, 1996, BRAIN, V119, P2105, DOI 10.1093/brain/119.6.2105
   ALQUDAH AA, 1990, PEDIATR NEUROL, V6, P57, DOI 10.1016/0887-8994(90)90081-B
   ANDERSON SW, 1988, DEV MED CHILD NEUROL, V30, P328
   ANDERSON VER, 1995, J NEUROL SCI, V129, P75, DOI 10.1016/0022-510X(95)00069-E
   Annane D, 1998, NEUROMUSCULAR DISORD, V8, P39, DOI 10.1016/S0960-8966(97)00144-2
   AUSTIN RC, 1995, HUM MOL GENET, V4, P1475
   Austin RC, 2000, NEUROMUSCULAR DISORD, V10, P187, DOI 10.1016/S0960-8966(99)00105-4
   Balasubramanyam A, 1998, J COMP NEUROL, V394, P309, DOI 10.1002/(SICI)1096-9861(19980511)394:3<309::AID-CNE3>3.0.CO;2-5
   Bardoni A, 1999, LANCET, V353, P897, DOI 10.1016/S0140-6736(98)05801-2
   Beltran-Valero de Bernabé D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Berul CI, 1999, J CLIN INVEST, V103, PR1, DOI 10.1172/JCI5346
   Billard C, 1998, DEV MED CHILD NEUROL, V40, P12, DOI 10.1111/j.1469-8749.1998.tb15351.x
   BILLARD C, 1992, NEUROMUSCULAR DISORD, V2, P371, DOI 10.1016/S0960-8966(06)80008-8
   BIRD TD, 1983, J NEUROL NEUROSUR PS, V46, P971, DOI 10.1136/jnnp.46.11.971
   BLACK FW, 1973, J PSYCHOL, V84, P333, DOI 10.1080/00223980.1973.9923848
   Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241
   BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   BRADLEY WG, 1978, MUSCLE NERVE, V1, P111, DOI 10.1002/mus.880010204
   BRESOLIN N, 1994, NEUROMUSCULAR DISORD, V4, P359, DOI 10.1016/0960-8966(94)90072-8
   Brockington M, 2001, AM J HUM GENET, V69, P1198, DOI 10.1086/324412
   BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5
   BRUMBACK RA, 1987, PSYCHOL REP, V60, P783, DOI 10.2466/pr0.1987.60.3.783
   BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189
   Bungener C, 1998, J NEUROL NEUROSUR PS, V65, P353, DOI 10.1136/jnnp.65.3.353
   BUSHBY KMD, 1993, J NEUROL, V240, P105, DOI 10.1007/BF00858726
   BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77
   Cagliani R, 2001, NEUROMUSCULAR DISORD, V11, P389, DOI 10.1016/S0960-8966(00)00207-8
   Carelli V, 2002, BBA-MOL BASIS DIS, V1588, P7, DOI 10.1016/S0925-4439(02)00097-2
   CARTER CT, 1995, AM J PHYS MED REHAB, V74, PS150, DOI 10.1097/00002060-199509001-00009
   CENSORI B, 1994, ACTA NEUROL SCAND, V90, P211
   CHANG L, 1993, ARCH NEUROL-CHICAGO, V50, P917, DOI 10.1001/archneur.1993.00540090024006
   CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0
   Chiyonobu T, 2005, NEUROMUSCULAR DISORD, V15, P416, DOI 10.1016/j.nmd.2005.03.009
   CHUDLEY AE, 1985, AM J MED GENET, V20, P145, DOI 10.1002/ajmg.1320200118
   Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.3.CO;2-K
   Cotton S, 2001, DEV MED CHILD NEUROL, V43, P497, DOI 10.1017/S0012162201000913
   Culligan K, 2001, BMC CELL BIOL, V2, P0, DOI 10.1186/1471-2121-2-2
   Culligan KG, 1998, INT J MOL MED, V2, P639
   CUTHILL J, 1988, CAN J PSYCHIAT, V33, P203, DOI 10.1177/070674378803300308
   Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388
   DEBOULOGNE GBA, 1973, NEUROLOGICAL CLASSIC, V0, P50
   Delaporte C, 1998, ARCH NEUROL-CHICAGO, V55, P635, DOI 10.1001/archneur.55.5.635
   Desmond JE, 1997, J NEUROSCI, V17, P9675
   Di Constanzo A, 2001, EUR NEUROL, V46, P131, DOI 10.1159/000050786
   Di Costanzo A, 2002, NEUROMUSCULAR DISORD, V12, P476, DOI 10.1016/S0960-8966(01)00324-8
   DOBYNS WB, 1989, AM J MED GENET, V32, P195, DOI 10.1002/ajmg.1320320213
   DORMAN C, 1988, DEV MED CHILD NEUROL, V30, P316, DOI 10.1111/j.1469-8749.1988.tb14556.x
   DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805
   Dubowitz Victor, 2002, NEUROMUSCUL DISORD, V12, P421, DOI 10.1016/S0960-8966(02)00006-8
   DUNCAN DB, 1995, ANN NEUROL, V37, P351, DOI 10.1002/ana.410370311
   DYKEN PR, 1973, NEUROLOGY, V23, P465, DOI 10.1212/WNL.23.5.465
   Ebralidze A, 2004, SCIENCE, V303, P383, DOI 10.1126/science.1088679
   Emery A E, 1989, PROG CLIN BIOL RES, V306, P15
   Endo A, 2000, ACTA NEUROPATHOL, V100, P513, DOI 10.1007/s004010000216
   Eslinger PJ, 2002, CORTEX, V38, P273, DOI 10.1016/S0010-9452(08)70658-0
   Felisari G, 2000, NEUROLOGY, V55, P559, DOI 10.1212/WNL.55.4.559
   FIORELLI M, 1991, NEURORADIOLOGY, V33, P258, DOI 10.1007/BF00588231
   FIORELLI M, 1992, NEUROLOGY, V42, P91, DOI 10.1212/WNL.42.1.91
   FLOREK M, 1977, EUR J PEDIATR, V126, P275, DOI 10.1007/BF00477054
   Frank B, 1997, CLIN NEUROL NEUROSUR, V99, P79, DOI 10.1016/S0303-8467(96)00598-7
   FUJII T, 1995, BRAIN DEV-JPN, V17, P89, DOI 10.1016/0387-7604(94)00115-E
   FUKUYAMA Y, 1981, BRAIN DEV-JPN, V3, P1
   Funakoshi M, 1998, NEUROLOGY, V50, P1791, DOI 10.1212/WNL.50.6.1791
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   González E, 2000, FEBS LETT, V482, P209, DOI 10.1016/S0014-5793(00)02044-5
   Goossens E, 2000, GENET COUNSEL, V11, P317
   Gorecki DC, 1997, EUR J NEUROSCI, V9, P965, DOI 10.1111/j.1460-9568.1997.tb01447.x
   Guglieri M, 2005, CLIN CHIM ACTA, V361, P54, DOI 10.1016/j.cccn.2005.05.020
   Haenggi T, 2004, NEUROSCIENCE, V129, P403, DOI 10.1016/j.neuroscience.2004.06.079
   Hamblet NS, 1997, MUTAT RES-FUND MOL M, V379, P253, DOI 10.1016/S0027-5107(97)00158-9
   HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M
   HARPER PS, 1989, MYOTONIC DYSTROPY, V0, P0
   HAUSMANOI, 1968, J NEUROL SCI, V6, P269, DOI 10.1016/0022-510X(68)90096-8
   HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216
   Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1
   Hinton VJ, 2000, NEUROLOGY, V54, P2127, DOI 10.1212/WNL.54.11.2127
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUBER SJ, 1989, ARCH NEUROL-CHICAGO, V46, P536, DOI 10.1001/archneur.1989.00520410070026
   HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217
   Inagaki T, 1997, BIOL PSYCHIAT, V42, P1067, DOI 10.1016/S0006-3223(97)00351-X
   ISHITSU T, 1987, NEUROLOGY, V37, P1867, DOI 10.1212/WNL.37.12.1867
   JAGADHA V, 1988, PEDIATR NEUROL, V4, P87, DOI 10.1016/0887-8994(88)90047-1
   Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316
   Jiang H, 2004, HUM MOL GENET, V13, P3079, DOI 10.1093/hmg/ddh327
   Jones KJ, 2001, J MED GENET, V38, P649, DOI 10.1136/jmg.38.10.649
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583
   KARAGAN NJ, 1980, J NERV MENT DIS, V168, P419, DOI 10.1097/00005053-198007000-00005
   KARPATI G, 1991, REV NEUROL, V147, P455
   KARTSOUNIS LD, 1992, ARCH NEUROL-CHICAGO, V49, P158, DOI 10.1001/archneur.1992.00530260058020
   KATO S, 1993, J NEUROL SCI, V116, P52, DOI 10.1016/0022-510X(93)90089-H
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   KEW JJM, 1993, BRAIN, V116, P655, DOI 10.1093/brain/116.3.655
   KEW JJM, 1993, BRAIN, V116, P1399, DOI 10.1093/brain/116.6.1399
   KIERNAN JA, 1994, BRAIN, V117, P747, DOI 10.1093/brain/117.4.747
   KIM JJ, 1994, J CHILD NEUROL, V9, P275, DOI 10.1177/088307389400900309
   Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490
   Knuesel I, 1999, EUR J NEUROSCI, V11, P4457, DOI 10.1046/j.1460-9568.1999.00887.x
   KOENIG M, 1989, AM J HUM GENET, V45, P498
   Kornblum C, 2004, J NEUROL, V251, P710, DOI 10.1007/s00415-004-0408-1
   Kotchoubey B, 2003, EUR J NEUROL, V10, P551, DOI 10.1046/j.1468-1331.2003.00647.x
   KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870
   Kuo HC, 2005, BRAIN DEV-JPN, V27, P291, DOI 10.1016/j.braindev.2004.09.002
   Lancel M, 1999, SLEEP, V22, P33, DOI 10.1093/sleep/22.1.33
   LEDERFEIN D, 1993, HUM MOL GENET, V2, P1883, DOI 10.1093/hmg/2.11.1883
   Lee JS, 2002, MUSCLE NERVE, V26, P506, DOI 10.1002/mus.10238
   LEIBOWITZ D, 1981, DEV MED CHILD NEUROL, V23, P577
   LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329
   Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125
   Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307
   Lossos A, 1998, ANN NEUROL, V44, P867, DOI 10.1002/ana.410440604
   LOSSOS A, 1991, ANN NEUROL, V30, P655, DOI 10.1002/ana.410300505
   LUDOLPH AC, 1992, ACTA NEUROL SCAND, V85, P81, DOI 10.1111/j.1600-0404.1992.tb04003.x
   LYLE R, 1995, GENOMICS, V28, P389, DOI 10.1006/geno.1995.1166
   Magarinos AM, 1997, P NATL ACAD SCI USA, V94, P14002, DOI 10.1073/pnas.94.25.14002
   Marín O, 2003, DEVELOPMENT, V130, P1889, DOI 10.1242/dev.00417
   Marquez FG, 2003, NEUROSCIENCE, V118, P957, DOI 10.1016/S0306-4522(03)00063-0
   Massman PJ, 1996, J NEUROL NEUROSUR PS, V61, P450, DOI 10.1136/jnnp.61.5.450
   MCDONALD TD, 1993, NEUROLOGY, V43, P785, DOI 10.1212/WNL.43.4.785
   Mehler MF, 2000, BRAIN RES REV, V32, P277, DOI 10.1016/S0165-0173(99)00090-9
   MEHLER MF, 1992, P NATL ACAD SCI USA, V89, P2461, DOI 10.1073/pnas.89.6.2461
   Meola G, 1999, NEUROLOGY, V53, P1042, DOI 10.1212/WNL.53.5.1042
   Meola G, 2003, NEUROMUSCULAR DISORD, V13, P813, DOI 10.1016/S0960-8966(03)00137-8
   Mercuri E, 2003, ANN NEUROL, V53, P537, DOI 10.1002/ana.10559
   Mercuri E, 2002, NEUROLOGY, V58, P1354, DOI 10.1212/WNL.58.9.1354
   Mercuri Eugenio, 2002, SEMIN PEDIATR NEUROL, V9, P120, DOI 10.1053/spen.2002.33802
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Miladi N, 1999, NEUROMUSCULAR DISORD, V9, P352, DOI 10.1016/S0960-8966(99)00006-1
   Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439
   Misuri G, 2000, CHEST, V117, P447, DOI 10.1378/chest.117.2.447
   Miura K, 1998, NEUROPEDIATRICS, V29, P239, DOI 10.1055/s-2007-973568
   Modoni A, 2004, ARCH NEUROL-CHICAGO, V61, P1943, DOI 10.1001/archneur.61.12.1943
   Moghadaszadeh B, 1998, AM J HUM GENET, V62, P1439, DOI 10.1086/301882
   Moizard MP, 1998, AM J MED GENET, V80, P32, DOI 10.1002/(SICI)1096-8628(19981102)80:1<32::AID-AJMG6>3.0.CO;2-Y
   Moizard MP, 2000, EUR J HUM GENET, V8, P552, DOI 10.1038/sj.ejhg.5200488
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838
   MORGANHUGHES JA, 1982, BRAIN, V105, P553, DOI 10.1093/brain/105.3.553
   Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4
   Nakano I, 1996, ACTA NEUROPATHOL, V91, P313, DOI 10.1007/s004010050431
   NEARY D, 1990, J NEUROL NEUROSUR PS, V53, P23, DOI 10.1136/jnnp.53.1.23
   Neary D, 1995, ANN NY ACAD SCI, V769, P15, DOI 10.1111/j.1749-6632.1995.tb38128.x
   North KN, 1996, NEUROLOGY, V46, P461, DOI 10.1212/WNL.46.2.461
   Odawara M, 1998, HUM GENET, V102, P708, DOI 10.1007/s004390050768
   OGASAWARA A, 1989, AM J MENT RETARD, V93, P544
   ORTIZ RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1525, DOI 10.1001/archopht.1993.01090110091031
   OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465
   PALMER BW, 1994, J CLIN EXP NEUROPSYC, V16, P784, DOI 10.1080/01688639408402692
   Pan TC, 2003, AM J HUM GENET, V73, P355, DOI 10.1086/377107
   PEAVY GM, 1992, NEUROLOGY, V42, P1004, DOI 10.1212/WNL.42.5.1004
   Pegoraro E, 1998, NEUROLOGY, V51, P101, DOI 10.1212/WNL.51.1.101
   Perini GI, 1999, BIOL PSYCHIAT, V46, P425, DOI 10.1016/S0006-3223(99)00016-5
   Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737
   PHILPOT J, 1995, NEUROMUSCULAR DISORD, V5, P301, DOI 10.1016/0960-8966(94)00069-L
   PORTWOOD MM, 1986, ARCH PHYS MED REHAB, V67, P299
   Rae C, 1998, J NEUROL SCI, V160, P148, DOI 10.1016/S0022-510X(98)00190-7
   RAPAPORT D, 1992, J BIOL CHEM, V267, P21289
   REDDING GJ, 1985, ARCH PHYS MED REHAB, V66, P818
   Roberts RG, 2001, GENOME BIOL, V2, P0
   Robertson NP, 1998, J NEUROL NEUROSUR PS, V65, P788, DOI 10.1136/jnnp.65.5.788
   ROBITAILLE Y, 1980, BRAIN, V103, P315, DOI 10.1093/brain/103.2.315
   ROSMAN NP, 1966, BRAIN, V89, P769, DOI 10.1093/brain/89.4.769
   ROSMAN NP, 1970, NEUROLOGY, V20, P329, DOI 10.1212/WNL.20.4.329
   Ryan MM, 2001, ANN NEUROL, V50, P312, DOI 10.1002/ana.1080
   SANTAVUORI P, 1989, BRAIN DEV-JPN, V11, P147, DOI 10.1016/S0387-7604(89)80088-9
   Santhosh J, 2004, COGNITIVE BRAIN RES, V22, P59, DOI 10.1016/j.cogbrainres.2004.07.009
   Sarkar PS, 2000, NAT GENET, V25, P110, DOI 10.1038/75500
   Sartor H, 2002, ACTA NEUROL SCAND, V106, P309, DOI 10.1034/j.1600-0404.2002.01089.x
   Schreiber H, 2005, J NEUROL, V252, P772, DOI 10.1007/s00415-005-0739-6
   SEPTIEN L, 1991, PEDIATRIE, V46, P817
   Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143
   Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717
   Sharma S, 2004, NEUROL INDIA, V52, P104
   Shishido F, 1996, NEURORADIOLOGY, V38, P102
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168
   SOLLEE ND, 1985, J CLIN EXP NEUROPSYC, V7, P486, DOI 10.1080/01688638508401280
   Spranger M, 1997, ARCH NEUROL-CHICAGO, V54, P251, DOI 10.1001/archneur.1997.00550150017009
   STEINERT H, 1909, DEUTSCHE Z NERVENH, V0, P37
   Steyaert J, 1997, CLIN GENET, V52, P135
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUZUKI T, 1990, NEURORADIOLOGY, V32, P74, DOI 10.1007/BF00593949
   SUZUKI T, 1989, J NEUROL NEUROSUR PS, V52, P920, DOI 10.1136/jnnp.52.7.920-a
   SUZUKI Y, 1995, DIABETES RES CLIN PR, V29, P137, DOI 10.1016/0168-8227(95)01113-7
   Takahashi S, 1998, J NEUROL SCI, V158, P58, DOI 10.1016/S0022-510X(98)00105-1
   Takeda S, 2003, HUM MOL GENET, V12, P1449, DOI 10.1093/hmg/ddg153
   TANABE Y, 1992, ACTA PAEDIATR, V81, P613, DOI 10.1111/j.1651-2227.1992.tb12312.x
   TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407
   Tokarz SA, 1998, MOL GENET METAB, V65, P272, DOI 10.1006/mgme.1998.2763
   TONIN P, 1992, NEUROMUSCULAR DISORD, V2, P419, DOI 10.1016/S0960-8966(06)80014-3
   TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269
   TRACEY I, 1995, LANCET, V345, P1260, DOI 10.1016/S0140-6736(95)90923-0
   TUIKKA RA, 1993, EUR NEUROL, V33, P436, DOI 10.1159/000116989
   Turconi AC, 1999, J NEUROL SCI, V170, P57, DOI 10.1016/S0022-510X(99)00199-9
   TURPENNY P, 1994, J MED GENET, V31, P300
   Ubogu EE, 2005, MUSCLE NERVE, V32, P675, DOI 10.1002/mus.20384
   Ueda H, 2000, HISTOL HISTOPATHOL, V15, P753, DOI 10.14670/HH-15.753
   Vaillend C, 2002, HIPPOCAMPUS, V12, P713, DOI 10.1002/hipo.10068
   Vaillend C, 2004, NEUROBIOL DIS, V17, P10, DOI 10.1016/j.nbd.2004.05.004
   Vaillend C, 1999, SYNAPSE, V33, P59, DOI 10.1002/(SICI)1098-2396(199907)33:1<59::AID-SYN6>3.0.CO;2-K
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   VANSPAENDONCK KPM, 1995, ACTA NEUROL SCAND, V91, P456
   Vercelletto M, 1999, EUR J NEUROL, V6, P295, DOI 10.1046/j.1468-1331.1999.630295.x
   Vermersch P, 1996, NEUROLOGY, V47, P711, DOI 10.1212/WNL.47.3.711
   von Gontard A, 2002, NEUROMUSCULAR DISORD, V12, P130, DOI 10.1016/S0960-8966(01)00274-7
   Watanabe Y, 1998, J NUCL MED, V39, P961
   Westerlaken JHAM, 2003, BRAIN RES, V971, P116, DOI 10.1016/S0006-8993(03)02430-2
   WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063
   Wicksell RK, 2004, DEV MED CHILD NEUROL, V46, P154, DOI 10.1017/S0012162204000283
   WIGHTMAN G, 1992, NEUROSCI LETT, V139, P269, DOI 10.1016/0304-3940(92)90569-S
   Wijmenga C, 1990, LANCET, V336, P651, DOI 10.1016/0140-6736(90)92148-B
   WIKSTROM J, 1982, ARCH NEUROL-CHICAGO, V39, P681, DOI 10.1001/archneur.1982.00510230007002
   Winblad S, 2005, NEUROMUSCULAR DISORD, V15, P287, DOI 10.1016/j.nmd.2004.12.003
   Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3
   YOSHIMURA N, 1990, CLIN NEUROPATHOL, V9, P234
   YOSHIOKA M, 1980, ARCH DIS CHILD, V55, P589, DOI 10.1136/adc.55.8.589
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1992, BRAIN PATHOL, V2, P121, DOI 10.1111/j.1750-3639.1992.tb00680.x
   Ziemssen F, 2000, ANN NEUROL, V47, P536, DOI 10.1002/1531-8249(200004)47:4<536::AID-ANA22>3.3.CO;2-B
NR 231
TC 63
Z9 72
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUL 15
PY 2006
VL 34
IS 1
BP 16
EP 33
DI 10.1002/mus.20535
PG 18
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 058TR
UT WOS:000238688000002
PM 16544320
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Schwartz, M
   Frederiksen, AL
   Wibrand, F
   Olsen, DB
   Vissing, J
AF Jeppesen, Tina D.
   Schwartz, Marianne
   Frederiksen, Anja L.
   Wibrand, Flemming
   Olsen, David B.
   Vissing, John
TI Muscle phenotype and mutation load in 51 persons with the 3243A&gt;G mitochondrial DNA mutation
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID hereditary optic neuropathy; kearns-sayre syndrome; mtdna mutation; a3243g mutation; clinical-features; skeletal-muscle; t8993g mutation; melas mutation; spectrum; encephalomyopathy
AB Background: Mitochondrial disorders are generally not associated with a clear phenotype-genotype relationship, which complicates the understanding of the disease and genetic counseling. Objective: To investigate the relationship between the muscle and blood mitochondrial DNA mutation load and phenotype. Design: Survey. Setting: The Neuromuscular Research Unit, Rigshospitalet, Copenhagen, Denmark. Participants: Fifty-one persons with the 3243A > G point mutation of mitochondrial DNA, and 20 healthy control subjects. Methods: We recorded the maximal oxygen uptake (VO2 max), maximal workload, resting and peak-exercise plasma lactate levels, muscle and blood mutation load, muscle morphology, and presence of diabetes mellitus and hearing impairment in all subjects. Results: Muscle mutation load (mean +/- SE, 50% +/- 5%; range, 2%-95%) correlated with VO2 max and resting plasma lactate level (P < .001; R >= 0.64). All persons except 5 with a muscle mutation load above 50% had abnormal VO2 max and morphology on muscle biopsy findings. Persons with hearing impairment and diabetes mellitus had a muscle mutation load above 65%. The mutation load in blood (mean +/- SE, 18% +/- 3%; range, 0%-61%) did not correlate with VO2 max, resting plasma lactate levels, or presence of hearing impairment or diabetes mellitus. Conclusions: This study demonstrates a close relationship between the muscle mutation load and phenotype in persons carrying the 3243A > G mutation. The lack of correlation between the mutation load in blood and symptoms from other tissues emphasizes the importance of assessing phenotype-genotype correlations in the same tissue in mitochondrial disease. The results indicate that the threshold of muscle mutation load at which oxidative impairment occurs can be as low as 50%, which is as much as 40% lower than that suggested by in vitro studies.
C1 Univ Copenhagen, Natl Hosp, Rigshosp, Copenhagen Muscle Res Ctr, Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Dept Neurol, Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Neuromuscular Res Unit, Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Dept Clin Genet, Copenhagen, Denmark.
   Ribe Cty Hosp, Dept Endocrinol, DK-6700 Esbjerg, Denmark.
   John F Kennedy Inst, DK-2600 Glostrup, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet
RP Jeppesen, TD (corresponding author), Rigshosp, Neuromuscular Res Unit, Sect 7611,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM dysgaard@rh.dk
CR CAMPOS Y, 1995, ACTA NEUROL SCAND, V91, P62
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HART LT, 1996, HUM MUTAT, V7, P193
   HOLT IJ, 1988, LANCET, V1, P1462
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   Jacobi FK, 2001, INVEST OPHTH VIS SCI, V42, P1208
   Jeppesen TD, 2003, J NEUROL, V250, P293, DOI 10.1007/s00415-003-0993-4
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Kaplanová V, 2004, J NEUROL SCI, V223, P149, DOI 10.1016/j.jns.2004.05.001
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kiyomoto BH, 1997, J NEUROL SCI, V152, P160, DOI 10.1016/S0022-510X(97)00158-5
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   LIOU CW, 1994, ACTA NEUROL SCAND, V90, P354
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   MARTINUZZI A, 1992, J NEUROL SCI, V113, P222, DOI 10.1016/0022-510X(92)90250-O
   MORAES CT, 1989, BIOCHEM BIOPH RES CO, V160, P765, DOI 10.1016/0006-291X(89)92499-6
   OZAWA M, 1995, NEUROMUSCULAR DISORD, V5, P483, DOI 10.1016/0960-8966(95)00009-C
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SHIRAIWA N, 1993, J NEUROL SCI, V120, P174, DOI 10.1016/0022-510X(93)90270-9
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Van Hall G, 2000, ACTA PHYSIOL SCAND, V168, P643, DOI 10.1046/j.1365-201x.2000.00716.x
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Weber K, 1997, AM J HUM GENET, V60, P373
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
NR 42
TC 61
Z9 71
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD DEC 15
PY 2006
VL 63
IS 12
BP 1701
EP 1706
DI 10.1001/archneur.63.12.1701
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 115KK
UT WOS:000242733000005
PM 17172609
DA 2024-11-01
ER

PT J
AU Morava, E
   Rodenburg, RJ
   Hol, F
   de Vries, M
   Janssen, A
   van den Heuvel, L
   Nijtmans, L
   Smeitink, J
AF Morava, E
   Rodenburg, RJ
   Hol, F
   de Vries, M
   Janssen, A
   van den Heuvel, L
   Nijtmans, L
   Smeitink, J
TI Clinical and biochemical characteristics in patients with a high mutant load of the mitochondrial T8993G/C mutations
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE T8993C/G; mitochondrial mutation; Leigh syndrome; complex V; assembly defect
ID atp-synthase; leigh-syndrome; oxidative-phosphorylation; electron-microscopy; narp syndrome; dna mutation; mtdna; gene; deficiency; subunit-6
AB We retrospectively analyzed the clinical, histological, and biochemical data of 11 children, five of which carried the maternally-inherited mitochondrial T8993C and six carrying the T8993G point mutations in the ATP synthase 6 gene. The percentage of heteroplasmy was 95% or higher in muscle and in blood. All patients had an early clinical presentation with muscle hypotonia, severe extrapyramidal dysfunction and Leigh disease demonstrated by the cranial MRI. A slower clinical progression and more frequent sensory-neuronal involvement were noted in the patients carrying the T8993C mutation in a high Mutation load in muscle and blood. No histological abnormality was found, In 9 out of 11 patients a decreased ATP production was detected, and complex V activity was deficient in all children. The activities of the respiratory enzyme complexes II and IV were normal, whereas an associated combined complex I and III deficiency were present in two patients. No obvious difference was found between the biochemical parameters of the two patient groups harboring different mutations in the same gene. No correlation was found between the degree of complex V enzyme deficiency and the severity of the phenotype. We confirmed an impaired assembly/stability of complex V in our patients. This is the first report of decreased activity and impaired assembly/stability of complex V in patients with T8993C mutations measured in muscle tissue. (c) 2006 Wiley-Liss, Inc.
C1 Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Morava, E (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM E.Morava@cukz.umcn.nl
CR Baracca A, 2000, J BIOL CHEM, V275, P4177, DOI 10.1074/jbc.275.6.4177
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200
   Coskun U, 2004, J BIOL CHEM, V279, P38644, DOI 10.1074/jbc.M406196200
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Fujii T, 1998, PEDIATR NEUROL, V18, P275, DOI 10.1016/S0887-8994(97)00187-2
   García JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Majander A, 1997, FEBS LETT, V412, P351, DOI 10.1016/S0014-5793(97)00757-6
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Parfait B, 1999, EUR J PEDIATR, V158, P55, DOI 10.1007/s004310051009
   PASTORES GM, 1994, AM J MED GENET, V50, P265, DOI 10.1002/ajmg.1320500310
   ROBINSON BH, 1994, J BIOENERG BIOMEMBR, V26, P311, DOI 10.1007/BF00763102
   Ronaghi M, 2001, GENOME RES, V11, P3, DOI 10.1101/gr.11.1.3
   Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608
   Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281
   SGARBI G, 2006, BIOCH J, V0, P0
   Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800
   TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390
   TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
NR 27
TC 62
Z9 64
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4825
EI 
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD APR 15
PY 2006
VL 140A
IS 8
BP 863
EP 868
DI 10.1002/ajmg.a.31194
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 029OC
UT WOS:000236571700008
PM 16532470
DA 2024-11-01
ER

PT J
AU Kasahara, T
   Kubota, M
   Miyauchi, T
   Noda, Y
   Mouri, A
   Nabeshima, T
   Kato, T
AF Kasahara, T.
   Kubota, M.
   Miyauchi, T.
   Noda, Y.
   Mouri, A.
   Nabeshima, T.
   Kato, T.
TI Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes
SO MOLECULAR PSYCHIATRY
LA English
DT Article
DE bipolar disorder; chronic progressive external ophthalmoplegia; mitochondria; POLG; lithium; wheel-running activity; circadian rhythm
ID progressive external ophthalmoplegia; magnetic-resonance-spectroscopy; bipolar affective-disorder; brain energy-metabolism; prepulse inhibition; polg mutations; invivo p-31; ant1 gene; dysfunction; polymerase
AB There is no established genetic model of bipolar disorder or major depression, which hampers research of these mood disorders. Although mood disorders are multifactorial diseases, they are sometimes manifested by one of pleiotropic effects of a single major gene defect. We focused on chronic progressive external ophthalmoplegia (CPEO), patients with which sometimes have comorbid mood disorders. Chronic progressive external ophthalmoplegia is a mitochondrial disease, which is accompanied by accumulation of mitochondrial DNA (mtDNA) deletions caused by mutations in nuclear-encoded genes such as POLG (mtDNA polymerase). We generated transgenic mice, in which mutant POLG was expressed in a neuron-specific manner. The mice showed forebrain-specific defects of mtDNA and had altered monoaminergic functions in the brain. The mutant mice exhibited characteristic behavioral phenotypes, a distorted day-night rhythm and a robust periodic activity pattern associated with estrous cycle. These abnormal behaviors resembling mood disorder were worsened by tricyclic antidepressant treatment and improved by lithium, a mood stabilizer. We also observed antidepressant-induced mania-like behavior and long-lasting irregularity of activity in some mutant animals. Our data suggest that accumulation of mtDNA defects in brain caused mood disorder-like mental symptoms with similar treatment responses to bipolar disorder. These findings are compatible with mitochondrial dysfunction hypothesis of bipolar disorder.
C1 RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama 3510198, Japan.
   Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol, Nagoya, Aichi, Japan.
   Nagoya Univ, Grad Sch Med, Hosp Pharm, Nagoya, Aichi, Japan.
C3 RIKEN; Nagoya University; Nagoya University
RP Kato, T (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.jp
CR [Anonymous], 2000, DIAGN STAT MAN MENT, V0, P0
   BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61
   Barrett SL, 2005, PSYCHOL MED, V35, P1737, DOI 10.1017/S0033291705005702
   Belke TW, 1997, J EXP ANAL BEHAV, V67, P337, DOI 10.1901/jeab.1997.67-337
   Blehar MC, 1998, PSYCHOPHARMACOL BULL, V34, P239
   Bschor T, 2003, PHARMACOPSYCHIATRY, V36, P0
   Carney SM, 2005, ACTA PSYCHIAT SCAND, V111, P7, DOI 10.1111/j.1600-0447.2005.00521.x
   Charney DS, 1998, J CLIN PSYCHIAT, V59, P11
   Dager SR, 2004, ARCH GEN PSYCHIAT, V61, P450, DOI 10.1001/archpsyc.61.5.450
   DAIMON K, 1992, J AFFECT DISORDERS, V26, P191, DOI 10.1016/0165-0327(92)90015-X
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Einat Haim, 2003, PSYCHOPHARMACOL BULL, V37, P47
   Goldberg JF, 2003, BIPOLAR DISORD, V5, P407, DOI 10.1046/j.1399-5618.2003.00067.x
   Goodwin FK, 2007, MANIC DEPRESSIVE ILL, V0, P0
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hahn CG, 2005, AM J PSYCHIAT, V162, P616, DOI 10.1176/appi.ajp.162.3.616
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hirschfeld RMA, 2000, J CLIN PSYCHIAT, V61, P4
   Iwamoto K, 2005, HUM MOL GENET, V14, P241, DOI 10.1093/hmg/ddi022
   Karadag F, 2004, BIPOLAR DISORD, V6, P253, DOI 10.1111/j.1399-5618.2004.00112.x
   KASAMATSU H, 1971, P NATL ACAD SCI USA, V68, P2252, DOI 10.1073/pnas.68.9.2252
   Kato T, 1997, BIOL PSYCHIAT, V42, P871, DOI 10.1016/S0006-3223(97)00012-7
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3
   KATO T, 1993, J AFFECT DISORDERS, V27, P53, DOI 10.1016/0165-0327(93)90097-4
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Krishnan KRR, 2005, PSYCHOSOM MED, V67, P1, DOI 10.1097/01.psy.0000151489.36347.18
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Ludewig S, 2005, J PSYCHIATR NEUROSCI, V30, P37
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Machado-Vieira R, 2004, PROG NEURO-PSYCHOPH, V28, P209, DOI 10.1016/j.pnpbp.2003.10.015
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250
   Merikangas Kathleen Ries, 2004, CURR PSYCHIATRY REP, V6, P411, DOI 10.1007/s11920-004-0004-1
   Miyamoto Y, 2002, J NEUROSCI, V22, P2335, DOI 10.1523/JNEUROSCI.22-06-02335.2002
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015
   Murashita J, 2000, PSYCHOL MED, V30, P107, DOI 10.1017/S0033291799001439
   NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327
   Perry W, 2001, BIOL PSYCHIAT, V50, P418, DOI 10.1016/S0006-3223(01)01184-2
   Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166
   Rango M, 2001, J CEREBR BLOOD F MET, V21, P85, DOI 10.1097/00004647-200101000-00011
   Rasgon N, 2005, J PSYCHIAT RES, V39, P77, DOI 10.1016/j.jpsychires.2004.05.006
   Rich BA, 2005, BIPOLAR DISORD, V7, P198, DOI 10.1111/j.1399-5618.2005.00183.x
   Ruf T, 1999, BIOL RHYTHM RES, V30, P178, DOI 10.1076/brhm.30.2.178.1422
   Sherwin CM, 1998, ANIM BEHAV, V56, P11, DOI 10.1006/anbe.1998.0836
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Simon NM, 2004, AM J PSYCHIAT, V161, P2222, DOI 10.1176/appi.ajp.161.12.2222
   Soares JC, 1997, PSYCHOPHARMACOL BULL, V33, P685
   Sobczak S, 2002, BIPOLAR DISORD, V4, P347, DOI 10.1034/j.1399-5618.2002.01217.x
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   STEINER M, 1980, ACTA PSYCHIAT SCAND, V61, P96, DOI 10.1111/j.1600-0447.1980.tb00569.x
   Stork C, 2005, MOL PSYCHIATR, V10, P900, DOI 10.1038/sj.mp.4001711
   STORLIEN LH, 1985, PHARMACOL BIOCHEM BE, V22, P119, DOI 10.1016/0091-3057(85)90494-0
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Washizuka S, 2004, BIOL PSYCHIAT, V56, P483, DOI 10.1016/j.biopsych.2004.07.004
   World Health Organization, 1992, ICD 10 INT STAT CLAS, V0, P0
   Yamawaki S, 1996, J PSYCHIATR NEUROSCI, V21, P321
   YOUNG LT, 1994, BIOL PSYCHIAT, V35, P121, DOI 10.1016/0006-3223(94)91201-7
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 67
TC 127
Z9 148
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD JUN 15
PY 2006
VL 11
IS 6
BP 577
EP 593
DI 10.1038/sj.mp.4001824
PG 17
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 047RB
UT WOS:000237895300008
PM 16619054
DA 2024-11-01
ER

PT J
AU Ortube, MC
   Bhola, R
   Demer, JL
AF Ortube, Maria Carolina
   Bhola, Rahul
   Demer, Joseph L.
TI Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: Specific diagnostic findings
SO JOURNAL OF AAPOS
LA English
DT Article; Proceedings Paper
ID mitochondrial-dna; strabismus; neuroophthalmology; deletions; features; diseases; pulleys; humans
AB INTRODUCTION Chronic progressive external ophthalmoplegia (CPEO) is characterized by slowly progressive bilateral oplithalmoplegia and blepharoptosis. Molecular diagnosis is problematic because sporadic mitochondrial DNA deletions can be causative. We sought findings using magnetic resonance imaging (MRI) that might support the diagnosis of CPEO. METHODS Two men (ages 31 and 47 years) and 3 women (ages 40-49 years) with CPEO and symptom durations of 8 months to 28 years underwent high-resolution (2-mm slice thickness, 312 micron pixels), surface coil, T1-weighted orbital MRI in coronal planes. Images were analyzed quantitatively to determine extraocular muscle (EOM) sizes and were compared with 10 age- and gender-matched normal volunteers, one subject with myasthenia gravis, and with 30 subjects having EOM paralysis caused by oculomotor, trochlear,0 and abducens neuropathies. RESULTS EOM function was clinically diminished in CPEO, most markedly for the superior rectus (SR) and levator muscles. All EOMs in CPEO exhibited unusual qualitative T1 MRI signal abnormalities. Unlike the profound EOM atrophy typical of neurogenic paralysis, anterior volumes of medial rectus, lateral rectus, and inferior rectus muscles in CPEO were not smaller than normal (p > 0.003). Anterior volumes of the SR muscle-levator complex and superior oblique were significantly reduced (p < 0.003). Denervated EOMs exhibited statistically significant volume reduction when compared with normal and CPEO groups. Volume of the SR muscle-levator complex was the same in subjects with CPEO and oculomotor palsies. CONCLUSIONS CPEO is associated with minimal EOM volume reduction despite clinically severe weakness. This combination of findings may be specific for CPEO and could resolve the diagnostic dilemma in difficult cases.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA.
   Univ Calif Los Angeles, Bioengn Interdept Programs, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles
RP Demer, JL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, 100 Stein Pl, Los Angeles, CA 90095 USA.
EM jld@ucla.edu
FU NEI NIH HHS [R01 EY008313, EY 08313] Funding Source: Medline; NIDCD NIH HHS [P50 DC005224] Funding Source: Medline
CR Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   Biousse V, 2001, SEMIN NEUROL, V21, P275, DOI 10.1055/s-2001-17945
   BRODSKY MC, 1996, PEDIAT NEUROOPHTHALM, V0, P390
   Carta A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1441
   Clark RA, 1999, J AAPOS, V3, P18, DOI 10.1016/S1091-8531(99)70090-X
   DEMER JL, 1995, INVEST OPHTH VIS SCI, V36, P1125
   DEMER JL, 1994, J PEDIAT OPHTH STRAB, V31, P177
   Demer JL, 2000, INVEST OPHTH VIS SCI, V41, P1280
   Demer JL, 1997, INVEST OPHTH VIS SCI, V38, P1774
   Demer JL, 2005, INVEST OPHTH VIS SCI, V46, P530, DOI 10.1167/iovs.04-1125
   Demer JL, 2002, J AAPOS, V6, P337, DOI 10.1067/mpa.2002.129040
   Demer JL, 2002, ANN NY ACAD SCI, V956, P17, DOI 10.1111/j.1749-6632.2002.tb02805.x
   Demer JL, 2001, AM J OPHTHALMOL, V132, P757, DOI 10.1016/S0002-9394(01)01099-6
   Demer JL, 1999, CLIN STRABISMUS MANA, V0, P84
   DURSTON JHJ, 1974, BRIT J OPHTHALMOL, V58, P193, DOI 10.1136/bjo.58.3.193
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   KAISSAR G, 1991, RADIOLOGY, V179, P541, DOI 10.1148/radiology.179.2.2014307
   KOORNNEEF L, 1977, ACTA MORPHOL NEER SC, V15, P35
   MILLER NR, 1985, WALSH HOYTS CLIN NEU, V2, P811
   Oh SY, 2001, INVEST OPHTH VIS SCI, V42, P17
   Oh SY, 2001, INVEST OPHTH VIS SCI, V42, P10
   Okamoto K, 1996, J NEURO-OPHTHALMOL, V16, P286
   PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4
   Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30
   RINGEL SP, 1979, ANN NEUROL, V6, P326, DOI 10.1002/ana.410060406
   ROWLAND LP, 1992, HDB CLIN NEUROLOGY, V18, P287
   Shin GS, 1996, J PEDIATR OPHTHALMOL, V33, P282
   Spencer R F, 1988, REV OCULOMOT RES, V2, P33
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Thacker NM, 2005, J AAPOS, V9, P174, DOI 10.1016/j.jaapos.2004.12.005
   Vilarinho L, 1998, EUR NEUROL, V39, P148, DOI 10.1159/000007925
   VONGRAEFE A, 1868, GESSELSCHAFTEN BERLI, V5, P125
NR 32
TC 22
Z9 24
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
EI 1528-3933
J9 J AAPOS
JI J. AAPOS
PD OCT 15
PY 2006
VL 10
IS 5
BP 414
EP 418
DI 10.1016/j.jaapos.2006.04.012
PG 5
WC Ophthalmology; Pediatrics
SC Ophthalmology; Pediatrics
GA 104ZG
UT WOS:000241998500010
PM 17070475
DA 2024-11-01
ER

PT J
AU Galbiati, S
   Bordoni, A
   Papadimitriou, D
   Toscano, A
   Rodolico, C
   Katsarou, E
   Sciacco, M
   Garufi, A
   Prelle, A
   Aquennouz, M
   Bonsignore, M
   Crimi, M
   Martinuzzi, A
   Bresolin, N
   Papadimitriou, A
   Comi, GP
AF Galbiati, S
   Bordoni, A
   Papadimitriou, D
   Toscano, A
   Rodolico, C
   Katsarou, E
   Sciacco, M
   Garufi, A
   Prelle, A
   Aquennouz, M
   Bonsignore, M
   Crimi, M
   Martinuzzi, A
   Bresolin, N
   Papadimitriou, A
   Comi, GP
TI New mutations in <i>TK2</i> gene associated with mitochondrial DNA depletion
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID deoxyguanosine kinase gene; thymidine kinase; mtdna depletion; myopathy; localization; deficiency; childhood; deletions; infant
AB Mitochondrial deoxyribonucleic acid depletion syndromes are autosomal recessive disorders characterized by a reduction of the amount of mitochondrial deoxyribonucleic acid, which impairs the synthesis of respiratory chain complexes. Mutations in the deoxyguanosine kinase and polymerase gamma genes have been identified in hepatocerebral forms, whereas thymidine kinase 2 gene mutations have been found in patients with isolated myopathy, encephalomyopathy, or spinal muscular atrophy. Mutations in the gene encoding the P subunit of the adenosine diphosphate-forming succinyl-coenzyme A synthetase have also been reported in a family. In this report, the clinical, molecular, morphologic, and biochemical features of five children from two independent families with an infantile encephalomyopathy are characterized. The affected children manifested muscle mitochondrial deoxyribonucleic acid depletion and three novel thymidine kinase 2 gene mutations. They consist of a homozygous substitution resulting in Ala to Val change at the highly conserved position 181 of thymidine kinase in the first family, and two heterozygous substitutions in the second family: a Cys to Trp change at residue 108 and a Len to Pro change at residue 257 of the enzyme. Common clinical features associated with these TK2 mutations are a normal early developmental phase followed by psychomotor regression, encephalopathy often with epileptic seizures, and myopathy with features of a progressive dystrophic process. (c) 2006 by Elsevier Inc. All rights reserved.
C1 Univ Milan, Dept Neurol Sci, Ctr Dino Ferrari, IRCCS,Osped Maggiore Policlin, Milan, Italy.
   Univ Larissa, Larisa, Greece.
   Red Cross Hosp, Athens, Greece.
   Univ Athens, Dept Pediat 1, Athens, Greece.
   Univ Messina Policlin, Dept Neurosci Psychiat & Anaesthesiol, Neurol Clin 2, Messina, Italy.
   IRCCS Eugenio Medea, Veneto, Italy.
   IRCCS Eugenio Medea, Parini, Italy.
   Univ Messina Policlin, Dept Pediat & Pediat Surg Sci, Messina, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; National & Kapodistrian University of Athens; AOU Policlinico Gaetano Martino; University of Messina; IRCCS Eugenio Medea; IRCCS Eugenio Medea; AOU Policlinico Gaetano Martino
RP Univ Milan, Dept Neurol Sci, Ctr Dino Ferrari, IRCCS,Fdn Osped Maggiore Policlin, Milan, Italy.
EM neurogene@policlinico.mi.it
FU Telethon [GTF02008] Funding Source: Medline
CR ANDREETTA F, 1991, J NEUROL SCI, V105, P88, DOI 10.1016/0022-510X(91)90123-O
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   BONILLA E, 1975, J ULTRA MOL STRUCT R, V51, P404, DOI 10.1016/S0022-5320(75)80103-1
   Bradshaw PC, 2005, AM J PHYSIOL-CELL PH, V288, PC989, DOI 10.1152/ajpcell.00530.2004
   BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1445, DOI 10.1001/archneur.60.10.1445
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   PRELLE A, 1994, ACTA NEUROPATHOL, V87, P371
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
NR 38
TC 53
Z9 56
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD MAR 15
PY 2006
VL 34
IS 3
BP 177
EP 185
DI 10.1016/j.pediatrneurol.2005.07.013
PG 9
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 022EO
UT WOS:000236037800002
PM 16504786
DA 2024-11-01
ER

PT J
AU Schoffer, K
   Grant, I
AF Schoffer, K
   Grant, I
TI Multiple lipomas, alcoholism, and neuropathy: Madelung's disease or MERRF?
SO MUSCLE & NERVE
LA English
DT Article
DE Madelung's disease; MERRF; mitochondrial myopathy; multiple symmetrical lipomatosis; neuropathy
ID symmetric lipomatosis; mitochondrial dysfunction; mutation; manifestation; epilepsy; dna
AB We report a 51-year-old alcoholic man with a 10-year history of cervical lipomas and progressive symmetrical sensory neuropathy, initially diagnosed with Madelung's disease, an idiopathic syndrome often attributed to chronic alcoholism. The eventual development of proximal weakness led to pathological and genetic testing which identified a A8344G mutation in the mitochondrial tRNA lysine gene, associated with MERRF (myoclonic epilepsy with ragged-red fibers). This case demonstrates how the varied terminology for this syndrome has resulted in a lack of consistent recognition and assessment for mitochondrial cytopathy.
C1 Dalhousie Univ, Div Neurol, Halifax, NS, Canada.
C3 Dalhousie University
RP Royal Brisbane & Womens Hosp, Dept Neurol, Herston Rd, Herston, Qld 4029, Australia.
EM schoffer@bigpond.net.au
CR Abenavoli FM, 2002, BRIT J PLAST SURG, V55, P536, DOI 10.1054/bjps.2002.3911
   Becker-Wegerich P, 1998, ARCH DERMATOL RES, V290, P652, DOI 10.1007/s004030050368
   BERKOVIC SF, 1991, ANN NEUROL, V29, P566, DOI 10.1002/ana.410290519
   BRODIE BC, 1846, PATHOLOGY SURG, V0, P275
   Busetto L, 2003, INT J OBESITY, V27, P1419, DOI 10.1038/sj.ijo.0802427
   CALABRESI PA, 1994, MUSCLE NERVE, V17, P943, DOI 10.1002/mus.880170815
   ENZI G, 1984, MEDICINE, V63, P56, DOI 10.1097/00005792-198401000-00004
   ENZI G, 1985, MEDICINE, V64, P388, DOI 10.1097/00005792-198511000-00003
   Feliciani C, 1999, NEW ENGL J MED, V340, P1481, DOI 10.1056/NEJM199905133401906
   Guastella C, 2002, OTOLARYNG HEAD NECK, V126, P191, DOI 10.1067/mhn.2002.122004
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hervás ES, 2000, BRIT J DERMATOL, V143, P684
   Klopstock T, 1997, MOL CELL BIOCHEM, V174, P271, DOI 10.1023/A:1006877012241
   Kratz C, 2000, EUR J PAEDIATR NEUROL, V4, P63, DOI 10.1053/ejpn.2000.0264
   LANOIS PE, 1898, B MEM SOC MED HOP P, V1, P298
   Lee HW, 2003, DERMATOL SURG, V29, P235, DOI 10.1046/j.1524-4725.2003.29056.x
   Madelung OW, 1888, ARCH KLIN CHIR, V37, P106
   Martínez-Escribano JA, 1999, INT J DERMATOL, V38, P551, DOI 10.1046/j.1365-4362.1999.00743.x
   Muñoz-Málaga A, 2000, MUSCLE NERVE, V23, P538, DOI 10.1002/(SICI)1097-4598(200004)23:4<538::AID-MUS12>3.3.CO;2-K
   NAUMANN M, 1995, MUSCLE NERVE, V18, P693, DOI 10.1002/mus.880180704
   Naumann M, 1997, MUSCLE NERVE, V20, P833, DOI 10.1002/(SICI)1097-4598(199707)20:7<833::AID-MUS7>3.0.CO;2-8
   Nisoli E, 2002, J PATHOL, V198, P378, DOI 10.1002/path.1212
   POLLOCK M, 1988, BRAIN, V111, P1157, DOI 10.1093/brain/111.5.1157
   RUZICKA T, 1987, J AM ACAD DERMATOL, V17, P663, DOI 10.1016/S0190-9622(87)70253-9
   Stavropoulos PG, 1997, DERMATOLOGY, V194, P26, DOI 10.1159/000246052
   Stoll C, 1996, ANN GENET-PARIS, V39, P193
   Vargas-Díez E, 2000, J AM ACAD DERMATOL, V42, P511, DOI 10.1016/S0190-9622(00)90230-5
   Wilson D, 1994, W V MED J, V90, P145
NR 28
TC 15
Z9 17
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JAN 15
PY 2006
VL 33
IS 1
BP 142
EP 146
DI 10.1002/mus.20406
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 000JC
UT WOS:000234456500017
PM 16007676
DA 2024-11-01
ER

PT J
AU Morava, E
   van den Heuvel, L
   Hol, F
   de Vries, MC
   Hogeveen, M
   Rodenburg, RJ
   Smeitink, JAM
AF Morava, E.
   van den Heuvel, L.
   Hol, F.
   de Vries, M. C.
   Hogeveen, M.
   Rodenburg, R. J.
   Smeitink, J. A. M.
TI Mitochondrial disease criteria - Diagnostic applications in children
SO NEUROLOGY
LA English
DT Article
ID disorders
AB Background: Based on a previous prospective clinical and biochemical study, a consensus mitochondrial disease scoring system was established to facilitate the diagnosis in patients with a suspected mitochondrial disorder. Objective: To evaluate the specificity of the diagnostic system, we applied the mitochondrial disease score in 61 children with a multisystem disease and a suspected oxidative phosphorylation disorder who underwent a muscle biopsy and were consecutively diagnosed with a genetic mutation. Methods: We evaluated data of 44 children diagnosed with a disorder in oxidative phosphorylation, carrying a mutation in the mitochondrial or nuclear DNA. We compared them with 17 children who, based on the clinical and metabolic features, also had a muscle biopsy but were finally diagnosed with a nonmitochondrial multisystem disorder by further genetic analysis. Results: All children with a genetically established diagnosis of a primary oxidative phosphorylation disorder had a mitochondrial disease score above 6 (probable mitochondrial disorder), and 73% of the children had a score above 8 (definite mitochondrial disorder) at evaluation of the muscle biopsy. In the nonmitochondrial multisystem disorder group, the score was significantly lower, and no patients reached a score comparable with a definite respiratory chain disorder. Conclusions: The mitochondrial disease criteria system has a high specificity to distinguish between mitochondrial and other multisystem disorders. The method could also be applied in children with a suspected mitochondrial disorder, prior to performing a muscle biopsy.
C1 Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Human Genet, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Morava, E (corresponding author), Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
EM E.Morava@cukz.umcn.nl
CR BILLARD C, 1989, NEUROPEDIATRICS, V20, P12, DOI 10.1055/s-2008-1071258
   HOWSE DCN, 1979, CAN J PHYSIOL PHARM, V57, P205, DOI 10.1139/y79-030
   Hui J, 2006, DEV MED CHILD NEUROL, V48, P132, DOI 10.1017/S0012162206000284
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   LOWRY RB, 1982, AM J MED GENET, V13, P209, DOI 10.1002/ajmg.1320130211
   Noguera A, 2004, PEDIATRICS, V114, PE598, DOI 10.1542/peds.2004-0955
   Rubio-Gozalbo ME, 2000, NEUROPEDIATRICS, V31, P114, DOI 10.1055/s-2000-7491
   Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001
   Smeitink JAM, 2003, J INHERIT METAB DIS, V26, P199, DOI 10.1023/A:1024489218004
   Straussberg R, 2002, NEUROLOGY, V59, P983, DOI 10.1212/WNL.59.7.983
   Thabet H, 2000, AM J EMERG MED, V18, P508, DOI 10.1053/ajem.2000.3981
   Thauvin-Robinet C, 2004, J INHERIT METAB DIS, V27, P700, DOI 10.1023/B:BOLI.0000043017.90837.93
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Yager JY, 2002, DEV NEUROSCI-BASEL, V24, P367, DOI 10.1159/000069049
NR 15
TC 203
Z9 222
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD NOV 28
PY 2006
VL 67
IS 10
BP 1823
EP 1826
DI 10.1212/01.wnl.0000244435.27645.54
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 109WI
UT WOS:000242339900018
PM 17130416
DA 2024-11-01
ER

PT J
AU Wong, LJC
   Yim, D
   Bai, RK
   Kwon, H
   Vacek, MM
   Zane, J
   Hoppel, CL
   Kerr, DS
AF Wong, L-J C.
   Yim, D.
   Bai, R-K
   Kwon, H.
   Vacek, M. M.
   Zane, J.
   Hoppel, C. L.
   Kerr, D. S.
TI A novel mutation in the mitochondrial tRNA <SUP>Ser(AGY)</SUP> gene associated with mitochondrial myopathy, encephalopathy, and complex I deficiency
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID gradient gel-electrophoresis; quantitative pcr analysis; lactic-acidosis; oxidative-phosphorylation; diagnostic-criteria; dna mutations; disease; disorders; encephalomyopathy; quantification
AB Purpose: To identify molecular defects in a girl with clinical features of MELAS (mitochondrial encephalomyopathy and lactic acidosis) and MERRF (ragged-red fibres) syndromes. Methods: The enzyme complex activities of the mitochondrial respiratory chain were assayed. Temporal temperature gradient gel electrophoresis was used to scan the entire mitochondrial genome for unknown mitochondrial DNA (mtDNA) alterations, which were then identified by direct DNA sequencing. Results: A novel heteroplasmic mtDNA mutation, G12207A, in the tRNA(Ser(AGY)) gene was identified in the patient who had a history of developmental delay, feeding difficulty, lesions within her basal ganglia, cerebral atrophy, proximal muscle weakness, increased blood lactate, liver dysfunction, and fatty infiltration of her muscle. Muscle biopsy revealed ragged red fibres and pleomorphic mitochondria. Study of skeletal muscle mitochondria revealed complex I deficiency associated with mitochondrial proliferation. Real time quantitative PCR analysis showed elevated mtDNA content, 2.5 times higher than normal. The tRNASer(AGY) mutation was found in heteroplasmic state (92%) in the patient's skeletal muscle. It was not present in her unaffected mother's blood or in 200 healthy controls. This mutation occurs at the first nucleotide of the 59 end of tRNA, which is involved in the formation of the stem region of the amino acid acceptor arm. Mutation at this position may affect processing of the precursor RNA, the stability and amino acid charging efficiency of the tRNA, and overall efficiency of protein translation. Conclusion: This case underscores the importance of comprehensive mutational analysis of the entire mitochondrial genome when a mtDNA defect is strongly suggested.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Kaiser Permanente Med Grp, Honolulu, HI USA.
   NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA.
   Case Western Reserve Univ, Sch Med, Ctr Inherited Disorders Energy Metab, Cleveland, OH 44106 USA.
C3 Baylor College of Medicine; Georgetown University; Kaiser Permanente; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University System of Ohio; Case Western Reserve University
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bertrand E, 1996, FOLIA NEUROPATHOL, V34, P193
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Liang HM, 1998, CLIN CHEM, V44, P1578
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   MITA S, 1995, MUSCLE NERVE, V0, PS113
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OLDFORS A, 1995, ACTA NEUROPATHOL, V90, P328
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Puchowicz MA, 2004, MITOCHONDRION, V4, P377, DOI 10.1016/j.mito.2004.07.004
   ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885
   SERVIDEI S, 2003, NEUROMUSCULAR DISORD, V13, P685
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 2005, MITOMAP HUMAN MITOCH, V0, P0
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2004, ELECTROPHORESIS, V25, P2602, DOI 10.1002/elps.200406016
   Wong LJC, 2003, J MED GENET, V40, P0
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
NR 35
TC 23
Z9 25
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP 15
PY 2006
VL 43
IS 9
BP 
EP 
DI 10.1136/jmg.2005.040626
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 080HV
UT WOS:000240239400011
PM 16950817
DA 2024-11-01
ER

PT J
AU Stuart, GR
   Santos, JH
   Strand, MK
   Van Houten, B
   Copeland, WC
AF Stuart, GR
   Santos, JH
   Strand, MK
   Van Houten, B
   Copeland, WC
TI Mitochondrial and nuclear DNA defects in <i>Saccharomyces cerevisiae</i> with mutations in DNA polymerase γ associated with progressive external ophthalmoplegia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID accessory subunit; multiple deletions; yeast mitochondria; catalytic subunit; genome stability; damage; repair; mtdna; polg; gene
AB A number of nuclear mutations have been identified in a variety of mitochondrial diseases including progressive external ophthalmoplegia (PEO), Alpers syndrome and other neuromuscular and oxidative phosphorylation defects. More than 50 mutations have been identified in POLG, which encodes the human mitochondrial DNA (mtDNA) polymerase gamma, PEO and Alpers patients. To rapidly characterize the effects of these mutations, we have developed a versatile system that enables the consequences of homologous mutations, introduced in situ into the yeast mtDNA polymerase gene MIP1, to be evaluated in vivo in haploid and diploid cells. Overall, distinct phenotypes for expression of each of the mip1-PEO mutations were observed, including respiration-defective cells with decreased viability, dominant-negative mutant polymerases, elevated levels of mitochondrial and nuclear DNA damage and chromosomal mutations. Mutations in the polymerase domain caused the most severe phenotype accompanied by loss of mtDNA and cell viability, whereas the mutation in the exonuclease domain showed mild dominance with loss of mtDNA. Interestingly, the linker region mutation caused elevated mitochondrial and nuclear DNA damage. The cellular processes contributing to these observations in the mutant yeast cells are potentially relevant to understanding the pathologies observed in human mitochondrial disease patients.
C1 NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
   Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University
RP NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU Intramural NIH HHS Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   [Anonymous], 1991, METHODS ENZYMOL, V194, P1
   Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054
   Barrientos A, 2003, IUBMB LIFE, V55, P83, DOI 10.1080/1521654031000098122
   Bendich AJ, 1996, J MOL BIOL, V255, P564, DOI 10.1006/jmbi.1996.0048
   Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003
   BYRNE E, 1991, REV NEUROL, V147, P532
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001
   Chen XJ, 1999, MOL GEN GENET, V262, P898, DOI 10.1007/s004380051156
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FLURY F, 1976, GENETICS, V83, P645
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Foury F, 2002, CURR OPIN CHEM BIOL, V6, P106, DOI 10.1016/S1367-5931(01)00276-9
   FOURY F, 1989, J BIOL CHEM, V264, P20552
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Karthikeyan G, 2005, DNA REPAIR, V4, P141, DOI 10.1016/j.dnarep.2004.07.004
   Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349
   Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351
   Kaukonen JA, 1996, AM J HUM GENET, V58, P763
   LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080
   Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Lucas P, 2004, MITOCHONDRION, V4, P13, DOI 10.1016/j.mito.2004.04.001
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   MALESZKA R, 1991, EMBO J, V10, P3923, DOI 10.1002/j.1460-2075.1991.tb04962.x
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rasmussen AK, 2003, NUCLEIC ACIDS RES, V31, P3909, DOI 10.1093/nar/gkg446
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Santos Janine H, 2002, METHODS MOL BIOL, V197, P159, DOI 10.1385/1-59259-284-8:159
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630
   Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X
   SHERMAN F, 1991, METHOD ENZYMOL, V194, P21
   Sherman F, 1986, METHODS YEAST GENETI, V0, P0
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837
   Strand MK, 2003, EUKARYOT CELL, V2, P809, DOI 10.1128/EC.2.4.809-820.2003
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859
   Trancíková A, 2004, FEMS YEAST RES, V5, P149, DOI 10.1016/j.femsyr.2004.06.014
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VANHOUTEN B, 2006, IN PRESS DNA REPAIR, V0, P0
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   WHELAN WL, 1979, GENETICS, V91, P35
   Williamson D, 2002, NAT REV GENET, V3, P475, DOI 10.1038/nrg814
   Williamson D H, 1979, METHODS ENZYMOL, V56, P728
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
NR 62
TC 58
Z9 64
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 15
PY 2006
VL 15
IS 2
BP 363
EP 374
DI 10.1093/hmg/ddi454
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 002RZ
UT WOS:000234630400018
PM 16368709
DA 2024-11-01
ER

PT J
AU Saxena, R
   de Bakker, PIW
   Singer, K
   Mootha, V
   Burtt, N
   Hirschhorn, JN
   Gaudet, D
   Isomaa, B
   Daly, MJ
   Groop, L
   Ardlie, KG
   Altshuler, D
AF Saxena, Richa
   de Bakker, Paul I. W.
   Singer, Karyn
   Mootha, Vamsi
   Burtt, Noel
   Hirschhorn, Joel N.
   Gaudet, Daniel
   Isomaa, Bo
   Daly, Mark J.
   Groop, Leif
   Ardlie, Kristin G.
   Altshuler, David
TI Comprehensive association testing of common mitochondrial DNA variation in metabolic disease
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID insulin-resistance; parkinsons-disease; friedreichs-ataxia; skeletal-muscle; polymorphisms; longevity; population; variant; humans; risk
AB Many lines of evidence implicate mitochondria in phenotypic variation: ( a) rare mutations in mitochondrial proteins cause metabolic, neurological, and muscular disorders; ( b) alterations in oxidative phosphorylation are characteristic of type 2 diabetes, Parkinson disease, Huntington disease, and other diseases; and ( c) common missense variants in the mitochondrial genome ( mtDNA) have been implicated as having been subject to natural selection for adaptation to cold climates and contributing to "energy deficiency" diseases today. To test the hypothesis that common mtDNA variation influences human physiology and disease, we identified all 144 variants with frequency > 1% in Europeans from > 900 publicly available European mtDNA sequences and selected 64 tagging single-nucleotide polymorphisms that efficiently capture all common variation ( except the hypervariable D-loop). Next, we evaluated the complete set of common mtDNA variants for association with type 2 diabetes in a sample of 3,304 diabetics and 3,304 matched nondiabetic individuals. Association of mtDNA variants with other metabolic traits ( body mass index, measures of insulin secretion and action, blood pressure, and cholesterol) was also tested in subsets of this sample. We did not find a significant association of common mtDNA variants with these metabolic phenotypes. Moreover, we failed to identify any physiological effect of alleles that were previously proposed to have been adaptive for energy metabolism in human evolution. More generally, this comprehensive association-testing framework can readily be applied to other diseases for which mitochondrial dysfunction has been implicated.
C1 Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA.
   Childrens Hosp, Div Genet, Boston, MA 02115 USA.
   Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
   Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   MIT, Cambridge, MA USA.
   Univ Montreal, Chicoutimi Hosp, Community Genom Ctr, Montreal, PQ, Canada.
   Folkhalsan Res Ctr, Folkhalsan Genet Inst, Helsinki, Finland.
   Malmska Municipal Hlth Ctr & Hosp, Pietarsaari, Finland.
   Lund Univ, Malmo Univ Hosp, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden.
C3 Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Universite de Montreal; Folkhalsan Research Center; Lund University; Skane University Hospital
RP Altshuler, D (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Sinches Res Bldg,175 Cambridge St,CPZN-6818, Boston, MA 02114 USA.
EM altshuler@molbio.mgh.harvard.edu
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Barrett TG, 2001, BEST PRACT RES CL EN, V15, P325, DOI 10.1053/beem.2001.0149
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Chinnery PF, 2005, LANCET, V366, P1650, DOI 10.1016/S0140-6736(05)67492-2
   Dato S, 2004, EUR J HUM GENET, V12, P1080, DOI 10.1038/sj.ejhg.5201278
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   De Benedictis G, 2000, ANN NY ACAD SCI, V908, P208
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Florez JC, 2004, DIABETES, V53, P3313, DOI 10.2337/diabetes.53.12.3313
   Giacchetti M, 2004, J MED GENET, V41, P293, DOI 10.1136/jmg.2003.015289
   Herrnstadt C, 2004, MITOCHONDRION, V4, P791, DOI 10.1016/j.mito.2004.07.041
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Jazin EE, 1996, P NATL ACAD SCI USA, V93, P12382, DOI 10.1073/pnas.93.22.12382
   Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944
   Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776
   Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Mohlke KL, 2005, HUM GENET, V118, P245, DOI 10.1007/s00439-005-0046-4
   Momiyama Y, 2003, BIOCHEM BIOPH RES CO, V312, P858, DOI 10.1016/j.bbrc.2003.10.195
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7
   Niemi AK, 2005, EUR J HUM GENET, V13, P166, DOI 10.1038/sj.ejhg.5201308
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Petersen KF, 2005, PLOS MED, V2, P879, DOI 10.1371/journal.pmed.0020233
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Poulton J, 2002, DIABETIC MED, V19, P969, DOI 10.1046/j.0742-3071.2002.00836.x
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133
   Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8
   Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Savage DB, 2005, HYPERTENSION, V45, P828, DOI 10.1161/01.HYP.0000163475.04421.e4
   Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9
   Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166
   Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001
   Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8
   Tanaka Masashi, 2002, JOURNAL OF NEUROLOGY, V249, P11
   Tang K, 2004, J PROTEOME RES, V3, P218, DOI 10.1021/pr034080s
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Torroni A, 1996, GENETICS, V144, P1835
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Winckler W, 2005, DIABETES, V54, P886, DOI 10.2337/diabetes.54.3.886
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 59
TC 153
Z9 166
U1 0
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
EI 
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUL 15
PY 2006
VL 79
IS 1
BP 54
EP 61
DI 10.1086/504926
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 053YD
UT WOS:000238341200006
PM 16773565
DA 2024-11-01
ER

PT J
AU Cassandrini, D
   Savasta, S
   Bozzola, M
   Tessa, A
   Pedemonte, M
   Assereto, S
   Stringara, S
   Minetti, C
   Santorelli, FM
   Bruno, C
AF Cassandrini, Denise
   Savasta, Salvatore
   Bozzola, Mauro
   Tessa, Alessandra
   Pedemonte, Marina
   Assereto, Stefania
   Stringara, Silvia
   Minetti, Carlo
   Santorelli, Filippo M.
   Bruno, Claudio
TI Mitochondrial DNA deletion in a child with mitochondrial encephalomyopathy, growth hormone deficiency, and hypoparathyroidism
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID kearns-sayre syndrome; c-oxidase deficiency; pearson-syndrome; endocrinopathy
AB We report an 11-year-old boy with short stature, bilateral ptosis, sensorineural hearing loss, muscle weakness, and endocrine abnormalities. Brain magnetic resonance imaging (MRI) showed a bilateral abnormal signal in the globus pallidus and in the midbrain tegment. Muscle biopsy specimens showed ragged red and cytochrome c oxidase negative fibers, and biochemical analysis of muscle homogenate showed a partial defect of complex I and IV activities of the respiratory chain enzymes. Analysis of mitochondrial DNA by a polymerase chain reaction screening procedure and Southern blot revealed a novel heteroplasmic single mitochondrial DNA deletion of 7.8 kb in different tissues. This deletion was absent in the blood DNA of his mother and brother. This case further expands and confirms the wide clinical spectrum of mitochondrial disorders associated with single large-scale mitochondrial DNA deletions.
C1 Univ Genoa, Ist Giannina Gaslini, Dept Pediat, Neuromuscular Dis Unit, I-16147 Genoa, Italy.
   Univ Pavia, Policlin San Matteo, Dept Pediat Sci, I-27100 Pavia, Italy.
   Bambino Gesu Pediat Hosp, Mol Med Unit, Rome, Italy.
C3 University of Genoa; IRCCS Istituto Giannina Gaslini; University of Pavia; IRCCS Fondazione San Matteo; IRCCS Bambino Gesu
RP Bruno, C (corresponding author), Univ Genoa, Ist Giannina Gaslini, Dept Pediat, Neuromuscular Dis Unit, Largo G Gaslini 5, I-16147 Genoa, Italy.
EM claudiobruno@ospedale-gaslini.ge.it
CR Bruno C, 2002, CLIN GENET, V61, P465, DOI 10.1034/j.1399-0004.2002.610612.x
   Bruno C, 2002, J CHILD NEUROL, V17, P233, DOI 10.1177/088307380201700318
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   DiMauro S, 2002, J CHILD NEUROL, V17, P0
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Gücüyener K, 1998, J INHERIT METAB DIS, V21, P173, DOI 10.1023/A:1005304015278
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   Matsuzaki M, 2002, NEUROPEDIATRICS, V33, P271, DOI 10.1055/s-2002-36742
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NIAUDET P, 1994, PEDIATR NEPHROL, V8, P164, DOI 10.1007/BF00865468
   Nicolino M, 1997, J CLIN ENDOCR METAB, V82, P3063, DOI 10.1210/jc.82.9.3063
   Santorelli FM, 1996, NEUROLOGY, V47, P1320, DOI 10.1212/WNL.47.5.1320
NR 13
TC 13
Z9 13
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD NOV 15
PY 2006
VL 21
IS 11
BP 983
EP 985
DI 10.1177/08830738060210111001
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 121GY
UT WOS:000243147300015
PM 17092469
DA 2024-11-01
ER

PT J
AU Feigenbaum, A
   Bai, RK
   Doherty, ES
   Kwon, H
   Tan, D
   Sloane, A
   Cutz, E
   Robinson, BH
   Wong, LJC
AF Feigenbaum, Annette
   Bai, Ren-Kui
   Doherty, Emily S.
   Kwon, Haeyoung
   Tan, Duanjun
   Sloane, Avril
   Cutz, Ernest
   Robinson, Brian H.
   Wong, Lee-Jun C.
TI Novel mitochondrial DNA mutations associated with myopathy, cardiomyopathy, renal failure, and deafness
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE mtDNA mutation; mitochondrial myopathy; cardiomyopathy; 5783G > A; 15458T > C; 15519T > C
ID quantification; amplification; sequence
AB Patients with mitochondrial disease usually manifest multisystemic dysfunction with a broad clinical spectrum. When the tests for common mitochondrial DNA (mtDNA) point mutations are negative and the mtDNA defects are still hypothesized, it is necessary to screen the entire mitochondrial genome for unknown mutations in order to confirm the diagnosis. We report an 8-year-old girl who had a long history of ragged-red fiber myopathy, short statute, and deafness, who ultimately developed renal failure and fatal cardiac dysfunction. Respiratory chain enzyme analysis on muscle biopsy revealed deficiency in complexes I, II/III, and IV. Whole mitochondrial genome sequencing analysis was performed. Three novel changes: homoplasmic 15458T > C and 15519T > C in cytochrome b, and a near homoplasmic 5783G > A in tRNA(cys), were found in the proband in various tissues. Her mother and asymptomatic sibling also carry the two homoplasmic mutations and the heteroplasmic 5783G > A mutation in blood, hair follicles, and buccal cells, at lower percentage. The 5783G > A mutation occurs at the T arm of tRNA(cys), resulting in the disruption of the stem structure, which may reduce the stability of the tRNA. 15458T > C changes an amino acid serine to proline at a conserved alpha-helix, which may force the helix to bend. These two mutations may have pathogenic significance. This case emphasizes the importance of pursuing more extensive mutational analysis of mtDNA in the absence of common mtDNA point mutations or large deletions, when there is a high suspicion of a mitochondrial disorder. (c) 2006 Wiley-Liss, Inc.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada.
   NHGRI, NIH, Bethesda, MD 20892 USA.
   Dongduk Womens Univ, Dept Appl Chem, Seoul, South Korea.
   Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Hosp Sick Children, Div Pathol, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada.
C3 Baylor College of Medicine; University of Toronto; Hospital for Sick Children (SickKids); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Dongduk Women's University; Georgetown University; University of Toronto; Hospital for Sick Children (SickKids)
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.tmc.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   Kramer KA, 2005, CLIN CHEM, V51, P2110, DOI 10.1373/clinchem.2005.050146
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MERANTE F, 1995, AM J HUM GENET S, V57, P0
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2003, J MED GENET, V40, P0
NR 24
TC 20
Z9 22
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD OCT 15
PY 2006
VL 140A
IS 20
BP 2216
EP 2222
DI 10.1002/ajmg.a.31436
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 091TJ
UT WOS:000241050900009
PM 16955414
DA 2024-11-01
ER

PT J
AU Kin, T
   Sugie, K
   Hirano, M
   Goto, Y
   Nishino, I
   Ueno, S
AF Kin, Tesseki
   Sugie, Kazuma
   Hirano, Makito
   Goto, Yu-ichi
   Nishino, Ichizo
   Ueno, Satoshi
TI Humanin expression in skeletal muscles of patients with chronic progressive external ophthalmoplegia
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE humanin; chronic progressive external ophthalmoplegia; mitochondrial disease; ragged-red fiber; Leigh syndrome
ID mitochondrial; mutations; melas
AB We showed that humanin (HN), an endogenous peptide against Alzheimer disease-related insults, was expressed in muscles of patients with chronic progressive external ophthalmoplegia (CPEO), a major mitochondrial disease. Because HN was recently found to block proapoptotic Bax function and exert its versatile cytoprotective effects in association with an increase in ATP levels, HN expression may thus reflect a physiological response against degenerative changes in the muscles of patients with CPEO. We found HN expression in all four patients examined, each of whom had different mitochondrial DNA mutations including two different single DNA deletions, multiple deletions, and no major mutations detected. We also found that HN expression was not linked to focal cytochrome c deficiency, strongly associated with the subtype of CPEO with single deletions. These results suggest that HN expression is more closely related to degenerative changes in all types of CPEO. Notably, HN was also expressed in non-degenerative muscle fibers of patients with CPEO or Leigh syndrome, who had the 8993T > G mutation in the mitochondrial ATPase 6 gene known to be associated with impaired ATP synthesis. Collectively, our findings suggest that HN may be specifically expressed in response to defects in energy production in muscles with mitochondrial abnormalities.
C1 Nara Med Univ, Sch Med, Dept Neurol, Kashihara, Nara 6348522, Japan.
   Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
   Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan.
C3 Nara Medical University; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan
RP Hirano, M (corresponding author), Nara Med Univ, Sch Med, Dept Neurol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.
EM hirano_makito@yahoo.co.jp
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1995, MUSCLE NERVE S, V3, P107
   Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Kariya S, 2005, ACTA NEUROPATHOL, V109, P367, DOI 10.1007/s00401-004-0965-5
   Kariya S, 2005, NEUROPEPTIDES, V39, P97, DOI 10.1016/j.npep.2004.11.004
   Kariya S, 2003, MOL CELL BIOCHEM, V254, P83, DOI 10.1023/A:1027372519726
   Lee Andrew G, 2002, CURR NEUROL NEUROSCI REP, V2, P413, DOI 10.1007/s11910-002-0067-5
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORGANHUGHES JA, 1994, MYOLOGY BASIC CLIN, V2, P1610
   Sgarbi G, 2006, BIOCHEM J, V395, P493, DOI 10.1042/BJ20051748
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   Wallace DC, 2000, AM HEART J, V139, PS70, DOI 10.1067/mhj.2000.103934
NR 17
TC 32
Z9 33
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD JUN 15
PY 2006
VL 51
IS 6
BP 555
EP 558
DI 10.1007/s10038-006-0397-2
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 056NX
UT WOS:000238532300008
PM 16639504
DA 2024-11-01
ER

PT J
AU Hinttala, R
   Smeets, R
   Moilanen, JS
   Ugalde, C
   Uusimaa, J
   Smeitink, JAM
   Majamaa, K
AF Hinttala, R.
   Smeets, R.
   Moilanen, J. S.
   Ugalde, C.
   Uusimaa, J.
   Smeitink, J. A. M.
   Majamaa, K.
TI Analysis of mitochondrial DNA sequences in patients with isolated or combined oxidative phosphorylation system deficiency
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID phylogenetic network; genome variation; selection; mutation; disease; errors
AB Background: Enzyme deficiencies of the oxidative phosphorylation ( OXPHOS) system may be caused by mutations in the mitochondrial DNA ( mtDNA) or in the nuclear DNA. Objective: To analyse the sequences of the mtDNA coding region in 25 patients with OXPHOS system deficiency to identify the underlying genetic defect. Results: Three novel non-synonymous substitutions in protein-coding genes, 4681T -> C in MT-ND2, 9891T -> C in MT-CO3 and 14122A -> G in MT-ND5, and one novel substitution in the 12S rRNA gene, 686A -> G, were found. The definitely pathogenic mutation 3460G -> A was identified in an 18-year-old woman who had severe isolated complex I deficiency and progressive myopathy. Conclusions: Bioinformatic analyses suggest a pathogenic role for the novel 4681T -> C substitution found in a boy with Leigh's disease. These results show that the clinical phenotype caused by the primary Leber's hereditary optic neuropathy mutation 3460G -> A is more variable than has been thought. In the remaining 23 patients, the role of mtDNA mutations as a cause of the OXPHOS system deficiency could be excluded. The deficiency in these children probably originates from mutations in the nuclear genes coding for respiratory enzyme subunits or assembly factors.
C1 Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
   Univ Oulu, Dept Neurol, Oulu, Finland.
   Univ Oulu, Dept Pediat, Oulu, Finland.
   Univ Nijmegen, Med Ctr, Dept Pediat, Ctr Mitochondrial Disorders, Nijmegen, Netherlands.
   Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland.
C3 University of Turku; University of Oulu; University of Oulu; Radboud University Nijmegen; Tampere University
RP Majamaa, K (corresponding author), Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
EM kari.majamaa@utu.fi
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bandelt HJ, 2005, BIOCHEM BIOPH RES CO, V333, P122, DOI 10.1016/j.bbrc.2005.04.055
   Bandelt HJ, 2001, INT J LEGAL MED, V115, P64, DOI 10.1007/s004140100228
   Coble MD, 2004, INT J LEGAL MED, V118, P137, DOI 10.1007/s00414-004-0427-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Finnilä S, 2000, AM J HUM GENET, V66, P1017, DOI 10.1086/302802
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Herrnstadt C, 2003, AM J HUM GENET, V72, P1585, DOI 10.1086/375406
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Howell N, 2003, AM J HUM GENET, V72, P1460, DOI 10.1086/375537
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   JOHNS DR, 1992, ARCH OPHTHALMOL-CHIC, V110, P1577, DOI 10.1001/archopht.1992.01080230077025
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Meulemans A, 2004, EUR J PAEDIATR NEURO, V8, P299, DOI 10.1016/j.ejpn.2004.07.006
   Moilanen JS, 2003, MOL BIOL EVOL, V20, P1195, DOI 10.1093/molbev/msg121
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   UGALDE C, 2006, IN PRESS MOL GENET M, V0, P0
   VAN SENUS AHC, 1963, DOC OPHTHALMOL, V17, P1
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 27
TC 20
Z9 22
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD NOV 15
PY 2006
VL 43
IS 11
BP 881
EP 886
DI 10.1136/jmg.2006.042168
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 101YW
UT WOS:000241778500008
PM 16738010
DA 2024-11-01
ER

PT J
AU Emma, F
   Pizzini, C
   Tessa, A
   Di Giandomenico, S
   Onetti-Muda, A
   Santorelli, FM
   Bertini, E
   Rizzoni, G
AF Emma, F
   Pizzini, C
   Tessa, A
   Di Giandomenico, S
   Onetti-Muda, A
   Santorelli, FM
   Bertini, E
   Rizzoni, G
TI "Bartter-like" phenotype in Kearns-Sayre syndrome
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE mitochondrial DNA; Kearns-Sayre syndrome; Bartter syndrome; heteroplasmy
ID mitochondrial-dna deletion; deficient muscle-fibers; involvement; patient; dysfunction; disorders; acidosis; disease
AB Kearns-Sayre syndrome (KSS) is a mitochondrial disease caused by large deletions in mitochondrial DNA (mtDNA). In most patients the disease is characterized by mtDNA heteroplasmy, where a mixture of wild-type and mutated mtDNA co-exist within cells in variable proportion, modulating the severity of the phenotype in different tissues. We report on the case of a 14-year-old child with classical symptoms of KSS and a renal phenotype characterized by hypokalaemic alkalosis, hypomagnesaemia, hyperreninaemia, hyperaldosteronism and nephrocalcinosis, resembling Bartter syndrome. Analysis of mtDNA demonstrated an 8,661 bp deletion involving eight mitochondrial genes. Uneven degrees of mtDNA heteroplasmy were demonstrated in several tissues, ranging from 24% to 60% of deleted/total mtDNA. Variable degrees of expression of mitochondrial enzymes were also found in biopsy specimens of renal and skeletal muscle by histocytochemistry. In particular, preserved cytochrome c oxidase was observed in tubular structures within medullary rays. It is proposed that a "Bartter-like" phenotype can arise in some patients with KSS as a result of heteroplasmy. In these cases aldosterone-responsive tubular structures have been spared during renal embryogenesis, allowing for the development of hypokalaemic alkalosis in response to salt and water losses from the more damaged tubular segments.
C1 Bambino Gesu Childrens Hosp & Res Inst, Div Nephrol, Dept Nephrol & Urol, I-00165 Rome, Italy.
   Bambino Gesu Childrens Hosp & Res Inst, Mol Med Lab, Dept Lab Med, Rome, Italy.
   Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy.
C3 IRCCS Bambino Gesu; IRCCS Bambino Gesu; Sapienza University Rome
RP Emma, F (corresponding author), Bambino Gesu Childrens Hosp & Res Inst, Div Nephrol, Dept Nephrol & Urol, Piazza S Onofrio 4, I-00165 Rome, Italy.
EM emma@opbg.net
CR DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761
   GARG LC, 1981, AM J PHYSIOL, V240, PF536, DOI 10.1152/ajprenal.1981.240.6.F536
   GOTO Y, 1990, J PEDIATR-US, V116, P904, DOI 10.1016/S0022-3476(05)80648-1
   Guéry B, 2003, J AM SOC NEPHROL, V14, P2099, DOI 10.1097/01.ASN.0000080180.51098.02
   Gullans SR, 1996, METABOLIC BASES ION, V0, P211
   HANSEN GP, 1980, KIDNEY INT, V17, P326, DOI 10.1038/ki.1980.38
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   Katsanos KH, 2001, AM J NEPHROL, V21, P150, DOI 10.1159/000046239
   MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007
   Menegon LF, 2004, RENAL FAILURE, V26, P195, DOI 10.1081/JDI-120038522
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MOE OW, 1991, AM J PHYSIOL, V260, PF130, DOI 10.1152/ajprenal.1991.260.1.F130
   MORI K, 1991, AM J MED GENET, V38, P583, DOI 10.1002/ajmg.1320380417
   Neiberger RE, 2002, AM J KIDNEY DIS, V39, P12, DOI 10.1053/ajkd.2002.29872
   Niaudet P, 1997, KIDNEY INT, V51, P1000, DOI 10.1038/ki.1997.140
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Rose BD, 1994, CLIN PHYSL ACID BASE, V4th, P0
   Rötig A, 2003, J NEPHROL, V16, P286
   Rötig A, 2003, J AM SOC NEPHROL, V14, P2995, DOI 10.1097/01.ASN.0000095481.24091.C9
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SIMOPOULOS AP, 1971, J PEDIATR-US, V79, P633, DOI 10.1016/S0022-3476(71)80312-8
   SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181
NR 25
TC 36
Z9 37
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0931-041X
EI 
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD MAR 15
PY 2006
VL 21
IS 3
BP 355
EP 360
DI 10.1007/s00467-005-2092-5
PG 6
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 013ZN
UT WOS:000235448600010
PM 16382326
DA 2024-11-01
ER

PT J
AU Matthes, T
   Rustin, P
   Trachsel, H
   Darbellay, R
   Costaridou, S
   Xaidara, A
   Rideau, A
   Beris, P
AF Matthes, Thomas
   Rustin, Pierre
   Trachsel, Hedwige
   Darbellay, Regis
   Costaridou, S.
   Xaidara, A.
   Rideau, Alexandra
   Beris, Photis
TI Different pathophysiological mechanisms of intramitochondrial iron accumulation in acquired and congenital sideroblastic anemia caused by mitochondrial DNA deletion
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE sideroblastic anemia; mitochondrial DNA; respiratory chain function; Pearson's disease; iron metabolism
ID kearns-sayre syndrome; cytochrome-c-oxidase; energy-dependent accumulation; myelodysplastic syndrm; pearson-syndrome; gene-mutations; mtdna; ferrochelatase; deficiency; disorder
AB Sideroblastic anemias (SA) are characterized by iron accumulation in the mitochondria of erythroblasts. Although we have evidence of mitochondrial gene alterations in sporadic congenital cases, the origin of acquired forms [refractory anemia with ring sideroblasts (RARS)], is still largely unknown. Here, we report the analysis of respiratory chain function in a patient with a large mitochondrial deletion and in patients with RARS. A young boy with SA showed symptoms typical of a mitochondrial disease with metabolic acidosis, muscle weakness and cerebral involvement. His bone marrow DNA was analyzed for the presence of mitochondrial deletions. We found a new mitochondrial (mt)DNA deletion spanning 3614 bp and including all the mt genes encoding complex IV, plus ATPase 6 and 8, and several transfer (t)RNAs. All tissues analyzed (liver, skeletal muscle, brain, pancreas) showed a heteroplasmic distribution of this mutant DNA. Bone marrow homogenates were obtained from five patients with RARS and from three patients with normal bone marrow and respiratory chain function assayed by spectrophotometric analysis. Cytochrome c oxidase (CCO) activity was greatly reduced in the patient's bone marrow. In contrast, CCO activity and global respiratory chain function were conserved in patients with RARS. We conclude that deficient CCO activity secondary to mtDNA deletions is related to intramitochondrial iron accumulation, as in our patient or in those with Pearson's syndrome, whereas other mechanisms, e.g. nuclear DNA mutations, have to be proposed to be involved in the acquired forms of SA.
C1 Univ Hosp Geneva, Dept Internal Med, Unit Clin Hematol, Geneva, Switzerland.
   Hop Necker Enfants Malad, Paris, France.
   Aghia Sophia Childrens Hosp, Athens, Greece.
C3 University of Geneva; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; The Aghia Sophia Children's Hospital
RP Matthes, T (corresponding author), Hop Cantonal Univ Geneva, Serv Hematol, CH-1211 Geneva 14, Switzerland.
EM thomas.matthes@hcuge.ch
CR Bröker S, 1998, EUR J BIOCHEM, V258, P132, DOI 10.1046/j.1432-1327.1998.2580132.x
   CASADEMONT J, 1994, HUM MOL GENET, V3, P1945, DOI 10.1093/hmg/3.11.1945
   Chretien D, 1998, BIOCHEM J, V329, P249, DOI 10.1042/bj3290249
   FISCHELGHODSIAN N, 1992, PEDIATR RES, V31, P557, DOI 10.1203/00006450-199206000-00004
   FLATMARK T, 1975, J BIOL CHEM, V250, P6433
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   Jacobs LJAM, 2004, J INHERIT METAB DIS, V27, P47, DOI 10.1023/B:BOLI.0000016601.49372.18
   Matthes TW, 2000, BRIT J HAEMATOL, V111, P843, DOI 10.1046/j.1365-2141.2000.02425.x
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NORBY S, 1994, J MED GENET, V31, P45, DOI 10.1136/jmg.31.1.45
   Parfait B, 1997, HUM GENET, V101, P247, DOI 10.1007/s004390050625
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   PORRA RJ, 1963, BIOCHEM J, V87, P186, DOI 10.1042/bj0870186
   PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181
   Reddy PL, 2002, BRIT J HAEMATOL, V116, P564, DOI 10.1046/j.0007-1048.2001.03323.x
   ROMSLO I, 1974, BIOCHIM BIOPHYS ACTA, V357, P34, DOI 10.1016/0005-2728(74)90109-1
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Shin MG, 2003, BLOOD, V101, P3118, DOI 10.1182/blood-2002-06-1825
   TANG HY, 1993, EUR J IMMUNOL, V23, P899, DOI 10.1002/eji.1830230420
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 23
TC 6
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD AUG 15
PY 2006
VL 77
IS 2
BP 169
EP 174
DI 10.1111/j.1600-0609.2006.00674.x
PG 6
WC Hematology
SC Hematology
GA 059QO
UT WOS:000238747500012
PM 16856911
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Cerase, A
   Sicurelli, F
   Malandrini, A
   De Stefano, N
   Stromillo, ML
   Battisti, C
   Dotti, MT
   Federico, A
AF Cardaioli, E
   Da Pozzo, P
   Cerase, A
   Sicurelli, F
   Malandrini, A
   De Stefano, N
   Stromillo, ML
   Battisti, C
   Dotti, MT
   Federico, A
TI Rapidly progressive neurodegeneration in a case with the 7472insC mutation and the A7472C polymorphism in the mtDNA tRNA<SUP>ser(UCN)</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA; tRNASer(UCN); heteroplasmy
ID creutzfeldt-jakob-disease; hearing-loss; mitochondrial mutation; herpes-encephalitis; cerebrospinal-fluid; mr; myopathy; brain; tau
AB The authors report the clinical, neuroimaging, muscle biopsy and mtDNA findings in a patient affected by bilateral hearing loss and mental retardation since infancy, presenting at age 31 years with a rapid deterioration of mental status and ataxia leading to vegetative condition and death at the age of 32 years. Clinical and genetic studies have been also performed in the mother, affected by neurosensorial hearing loss. Muscle biopsy showed severe mitochondrial alterations in the propositus and evidence of mitochondrial alterations in his mother. Direct mtDNA sequencing in all family members revealed the known 7472insC mutation and the recently described A7472C sequence variation in the tRNA(Ser(UCN)) gene. RFLP-PCR confirmed the heteroplasmic nature of the two mutations and failed to find the second transversion in 200 controls. The percentage of mutant genomes harbouring 7472insC ranged from 3 to 7% in asymptomatic family members to 70% in the proband and his mother, whereas the percentage of A7472C mutant genomes was about 90% in all maternal relatives except the proband (56%) and his sister (5%). In conclusion, this is the first report of a rapidly progressive encephalopathy in association with the 7472insC mutation in mtDNA, combined with an A > C variation at the same nucleotide with a possible suppression effect on the pathogenic mutation. (C) 2005 Elsevier B.V. All rights reserved.
C1 Univ Siena, Sch Med, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
   Azienda Osped Univ Senese, Interdept Ctr Nucl Magnet Resonance, Dept Neurosci, Siena, Italy.
   Azienda Osped Univ Senese, Unit Diagnost & Therapeut Neuroradiol, Siena, Italy.
C3 University of Siena; University of Siena; University Hospital of Siena; University of Siena; University Hospital of Siena
RP Univ Siena, Sch Med, Dept Neurol & Behav Sci, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
CR Bahn MM, 1999, ARCH NEUROL-CHICAGO, V56, P577, DOI 10.1001/archneur.56.5.577
   Burkhard PR, 2001, NEUROLOGY, V56, P1528, DOI 10.1212/WNL.56.11.1528
   Chinnery PF, 1999, J MED GENET, V36, P505, DOI 10.1136/jmg.36.7.505
   Collie DA, 2003, AM J NEURORADIOL, V24, P1560
   de Toledo M, 2001, REV NEUROLOGIA, V33, P148, DOI 10.33588/rn.3302.2001016
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617
   Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, V2nd, P0
   ELVERLAND HH, 1991, AM J OTOL, V12, P459
   Ensink RJH, 1998, ARCH OTOLARYNGOL, V124, P886, DOI 10.1001/archotol.124.8.886
   Fetoni V, 2004, NEUROMUSCULAR DISORD, V14, P723, DOI 10.1016/j.nmd.2004.07.002
   Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007
   Fujioka M, 1997, STROKE, V28, P584, DOI 10.1161/01.STR.28.3.584
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   JOHNS DR, 1993, NEUROLOGY, V43, P2471, DOI 10.1212/WNL.43.12.2471
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021
   Marchington DR, 1996, HUM MOL GENET, V5, P473, DOI 10.1093/hmg/5.4.473
   Murata T, 2002, AM J NEURORADIOL, V23, P1164
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Schwaninger M, 1997, J NEUROL NEUROSUR PS, V63, P408, DOI 10.1136/jnnp.63.3.408
   Sharfstein SR, 1999, ARCH NEUROL-CHICAGO, V56, P241, DOI 10.1001/archneur.56.2.241
   TAKAHASHI S, 1993, RADIOLOGY, V189, P449, DOI 10.1148/radiology.189.2.8210374
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Urbach H, 1998, NEURORADIOLOGY, V40, P65, DOI 10.1007/s002340050542
   Van Everbroeck B, 2002, J NEUROL NEUROSUR PS, V73, P79, DOI 10.1136/jnnp.73.1.79
   VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 32
TC 15
Z9 16
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN 15
PY 2006
VL 16
IS 1
BP 26
EP 31
DI 10.1016/j.nmd.2005.11.001
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 009ZG
UT WOS:000235151700005
PM 16368237
DA 2024-11-01
ER

PT J
AU Davidzon, G
   Greene, P
   Mancuso, M
   Klos, KJ
   Ahlskog, JE
   Hirano, M
   DiMauro, S
AF Davidzon, G
   Greene, P
   Mancuso, M
   Klos, KJ
   Ahlskog, JE
   Hirano, M
   DiMauro, S
TI Early-onset familial Parkinsonism due to <i>POLG</i> mutations
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID mitochondrial-dna polymerase; disease; gamma; ophthalmoplegia; neuropathy; disorders; gene
AB Objective: To define the Molecular etiology of early-onset parkinsonism and peripheral neuropathy. Methods: Two sisters had early-onset parkinsonism (dystonic toe curling, action tremor, masked face, bradykinesia, stooped posture, and rigidity), together with clinical and electrophysiological signs of sensorimotor axonal peripheral neuropathy. Results: No mutations were found in the genes for Parkin or PINK1. Muscle biopsies showed ragged-red and cytochrome c oxidase-negative Fibers, and biochemistry showed decreased activities of respiratory chain complexes containing mitochondrial DNA-encoded subunits. Multiple mitochondrial DNA deletions were seen by long polymerase chain reaction, and sequencing of the POLG gene showed that the patients were compound heterozygous for two patogenic mutations. Interpretation: POLG mutations can cause early-onset parkinsonism in the absence of progressive external ophthalmoplegia.
C1 Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
   Univ Pisa, Dept Neurol, Inst Neurol, Pisa, Italy.
   Mayo Clin, Dept Neurol, Rochester, MN USA.
C3 Columbia University; University of Pisa; Mayo Clinic
RP 4-420 Coll Phys & Surg,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DIMAURO S, 1993, NEUROLOGY, V43, P2170, DOI 10.1212/WNL.43.11.2170
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mizuno Y, 1998, ANN NEUROL, V44, PS99, DOI 10.1002/ana.410440715
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Sambrook J, 2001, MOL CLONING LAB MANU, V0, P69
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shiba M, 2000, MOVEMENT DISORD, V15, P669, DOI 10.1002/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Tay SKH, 2004, NEUROMUSCULAR DISORD, V14, P253, DOI 10.1016/j.nmd.2003.12.006
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x
NR 20
TC 188
Z9 201
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD MAY 15
PY 2006
VL 59
IS 5
BP 859
EP 862
DI 10.1002/ana.20831
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 037RM
UT WOS:000237164600020
PM 16634032
DA 2024-11-01
ER

PT J
AU Oskoui, M
   Davidzon, G
   Pascual, J
   Erazo, R
   Gurgel-Giannetti, J
   Krishna, S
   Bonilla, E
   De Vivo, DC
   Shanske, S
   DiMauro, S
AF Oskoui, Maryam
   Davidzon, Guido
   Pascual, Juan
   Erazo, Ricardo
   Gurgel-Giannetti, Juliana
   Krishna, Sindu
   Bonilla, Eduardo
   De Vivo, Darryl C.
   Shanske, Sara
   DiMauro, Salvatore
TI Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID deoxyguanosine kinase; mtdna depletion; polg mutations; myopathy; deficiency
AB Background: Mitochondrial DNA depletion syndrome is an autosomal recessive disorder characterized by decreased mitochondrial DNA copy numbers in affected tissues. It has been linked to 4 genes involved in deoxyribonucleotide triphosphate metabolism: thymidine kinase 2 (TK2), deoxyguanosine kinase (DGUOK), polymerase gamma (POLG), and SUCLA2, the gene encoding the beta-subunit of the adenosine diphosphate-forming succinyl coenzyme A synthetase ligase. Objective: To highlight the variability in the clinical spectrum of TK2-related mitochondrial DNA depletion syndrome. Design: Review of patients and the literature. Setting: Tertiary care university. Patients: Four patients with mitochondrial DNA depletion syndrome and mutations in the TK2 gene. Main Outcome Measures: Definition of clinical variability. Results: Patient 1 had evidence of lower motoneuron disease and was initially diagnosed as having spinal muscular atrophy type 3. Patient 2, who is alive and ambulatory at age 9 years, presented at age 2 years with a slowly progressive mitochondrial myopathy. Patient 3 had a more severe myopathy, with onset in infancy and death at age 6 years of respiratory failure. Patient 4 had a rapidly progressive congenital myopathy with rigid spine syndrome and he died at age 19 months. Conclusion: The clinical spectrum of TK2 mutations is not limited to severe infantile myopathy with motor regression and early death but includes spinal muscular atrophy type 3-like presentation, rigid spine syndrome, and subacute myopathy without motor regression and with longer survival.
C1 Columbia Univ, Coll Phys & Surg 4420, Dept Neurol, Med Ctr, New York, NY 10032 USA.
   Hosp Ninos Luis Calvo Mackenna, Div Pediat Neurol, Santiago, Chile.
   Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
C3 Columbia University; Universidad de Chile; Universidade Federal de Minas Gerais
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg 4420, Dept Neurol, Med Ctr, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
CR Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 19
TC 93
Z9 106
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD AUG 15
PY 2006
VL 63
IS 8
BP 1122
EP 1126
DI 10.1001/archneur.63.8.1122
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 072ER
UT WOS:000239656400011
PM 16908738
DA 2024-11-01
ER

PT J
AU Forli, F
   Mancuso, M
   Santoro, A
   Dotti, MT
   Siciliano, G
   Berrettini, S
AF Forli, F.
   Mancuso, M.
   Santoro, A.
   Dotti, M. T.
   Siciliano, G.
   Berrettini, S.
TI Auditory neuropathy in a patient with mitochondrial myopathy and multiple mtDNA deletions
SO JOURNAL OF LARYNGOLOGY AND OTOLOGY
LA English
DT Article
DE auditory; neuropathy; cochlear nerve; sensorineural deafness; mitochondrial myopathy; mtDNA deletions
ID hearing-loss; otoacoustic emissions; audiological findings; mutations; dna; deafness; otof; gene
AB Auditory neuropathy (AN) is a hearing disorder characterized by the absence or severe distortion of the auditory brainstem responses, in the presence of preserved otoacoustic emissions. This peculiar combination suggests the presence of a defect impinging upon the functional complex formed by inner hair cells, the primary afferents (spiral ganglion neurones) and the first order synapses between hair cells and the cochlear nerve. Typically, AN patients show a severe speech perception impairment, which appears reduced out of proportion to pure tone threshold, but the clinical presentation of AN is quite complex. Hearing loss is a common symptom associated with mitochondrial diseases; however, AN has only rarely been reported in these disorders. Here we report a rare association, the first case observed in Italy, in a patient with autosomal recessive mitochondrial myopathy and mitochondrial DNA multiple deletions, and a hearing deficit with the audiological and electrophysiological features of AN.
C1 Univ Pisa, Dept Neurosci, ENT Div, I-56126 Pisa, Italy.
   Univ Pisa, Dept Neurosci, Neurol Clin, I-56126 Pisa, Italy.
   Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
C3 University of Pisa; University of Pisa; University of Siena
RP Berrettini, S (corresponding author), Univ Pisa, Dept Neurosci, ENT Div, Via Savi N 10, I-56126 Pisa, Italy.
EM s.berrettini@med.unipi.it
CR Berlin CI, 1998, EAR HEARING, V19, P37, DOI 10.1097/00003446-199802000-00002
   Brown DK, 2001, J OTOLARYNGOL, V30, P46
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Corley V M, 1999, J AM ACAD AUDIOL, V10, P484
   DAVIS H, 1979, AUDIOLOGY, V18, P445
   Deltenre E, 1999, AUDIOLOGY, V38, P187
   Deltenre P, 1997, EVOKED POTENTIAL, V104, P17, DOI 10.1016/S0168-5597(96)96635-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   ELVERLAND HH, 1991, AM J OTOL, V12, P459
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fischel-Ghodsian N, 2003, EAR HEARING, V24, P303, DOI 10.1097/01.AUD.0000079802.82344.B5
   Harrison RV, 1998, EAR HEARING, V19, P355, DOI 10.1097/00003446-199810000-00002
   Korres S, 2002, ORL-J OTO-RHIN-LARYN, V64, P315, DOI 10.1159/000066078
   Madden C, 2002, ARCH OTOLARYNGOL, V128, P1026, DOI 10.1001/archotol.128.9.1026
   Mancuso M, 2004, ACTA NEUROL SCAND, V110, P72, DOI 10.1111/j.1600-0404.2004.00254.x
   Marco J, 2000, ACTA OTO-LARYNGOL, V120, P201
   Park MS, 1998, ACTA OTO-LARYNGOL, V118, P496, DOI 10.1080/00016489850154612
   Rance G, 1999, EAR HEARING, V20, P238, DOI 10.1097/00003446-199906000-00006
   Rapin I, 2003, INT J PEDIATR OTORHI, V67, P707, DOI 10.1016/S0165-5876(03)00103-4
   Rodríguez-Ballesteros M, 2003, HUM MUTAT, V22, P451, DOI 10.1002/humu.10274
   Salvi RJ, 1999, SCAND AUDIOL, V28, P1
   Santarelli R, 2002, HEARING RES, V170, P32, DOI 10.1016/S0378-5955(02)00450-1
   Sawada S, 1997, AM J OTOL, V18, P332
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Seidman MD, 1996, LARYNGOSCOPE, V106, P777, DOI 10.1097/00005537-199606000-00021
   Starr A, 2000, JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY, V11, P215
   Starr A, 2001, EAR HEARING, V22, P91, DOI 10.1097/00003446-200104000-00002
   Starr A, 1996, BRAIN, V119, P741, DOI 10.1093/brain/119.3.741
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Varga R, 2003, J MED GENET, V40, P45, DOI 10.1136/jmg.40.1.45
NR 31
TC 10
Z9 10
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022-2151
EI 1748-5460
J9 J LARYNGOL OTOL
JI J. Laryngol. Otol.
PD OCT 15
PY 2006
VL 120
IS 10
BP 888
EP 891
DI 10.1017/S0022215106001472
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 103VA
UT WOS:000241913700023
PM 16719954
DA 2024-11-01
ER

PT J
AU Taivassalo, T
   Gardner, JL
   Taylor, RW
   Schaefer, AM
   Newman, J
   Barron, MJ
   Haller, RG
   Turnbull, DM
AF Taivassalo, Tanja
   Gardner, Julie L.
   Taylor, Robert W.
   Schaefer, Andrew M.
   Newman, Jane
   Barron, Martin J.
   Haller, Ronald G.
   Turnbull, Douglass M.
TI Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions
SO BRAIN
LA English
DT Article
DE mitochondrial myopathy; deletions; exercise training
ID dna deletions; exercise; disease; capacity; lactate
AB At present there are limited therapeutic interventions for patients with mitochondrial myopathies. Exercise training has been suggested as an approach to improve physical capacity and quality of life but it is uncertain whether it offers a safe and effective treatment for patients with heteroplasmic mitochondrial DNA (mtDNA) mutations. The objectives of this study were to assess the effects of exercise training and detraining in eight patients with single, large-scale mtDNA deletions to determine: (i) the efficacy and safety of endurance training (14 weeks) in this patient population; (ii) to determine the effect of more prolonged (total of 28 weeks) exercise training upon muscle and cardiovascular function and (iii) to evaluate the effect of discontinued training (14 weeks) upon muscle and cardiovascular function. Our results show that: (i) 14 weeks of exercise training significantly improved tolerance of submaximal exercise and peak capacity for work, oxygen utilization and skeletal muscle oxygen extraction with no change in the level of deleted mtDNA; (ii) continued training for an additional 14 weeks maintained these beneficial adaptations; (iii) the cessation of training (detraining) resulted in loss of physiological adaptation to baseline capacity with no overall change in mutation load. Patients' self assessment of quality of life as measured by the SF-36 questionnaire improved with training and declined with detraining. Whilst our findings of beneficial effects of training on physiological outcome and quality of life without increases in the percentage of deleted mtDNA are encouraging, we did not observe changes in mtDNA copy number. Therefore there remains a need for longer term studies to confirm that endurance exercise is a safe and effective treatment for patients with mitochondrial myopathies. The effects of detraining clearly implicate physical inactivity as an important mechanism in reducing exercise capacity and quality of life in patients with mitochondrial myopathy.
C1 McGill Univ, Dept Kinesiol, Montreal, PQ, Canada.
   Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Presbyterian Med Ctr, Neuromuscular Ctr, Inst Exercise & Environm Med, Dallas, TX USA.
   Univ Texas, SW Med Ctr, Dallas, TX 75230 USA.
   VA Med Ctr, Dallas, TX USA.
C3 McGill University; Newcastle University - UK; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas Dallas
RP Turnbull, DM (corresponding author), Univ Newcastle, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   BORG G, 1985, EUR J APPL PHYSIOL, V54, P343, DOI 10.1007/BF02337176
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Chinnery P F, 2003, NEUROMUSCUL DISORD, V13, P757, DOI 10.1016/S0960-8966(03)00097-X
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Saltin B, 1983, SKELETAL MUSCLE ADAP, V0, P555
   Sciacco M, 1996, METHODS ENZYMOL, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Taivassalo Tanja, 1997, NEUROLOGY, V48, P0
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Wang H, 1999, EUR J APPL PHYSIOL O, V80, P22, DOI 10.1007/s004210050553
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 23
TC 145
Z9 153
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD DEC 15
PY 2006
VL 129
IS 
BP 3391
EP 3401
DI 10.1093/brain/awl282
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 111RE
UT WOS:000242471100030
PM 17085458
DA 2024-11-01
ER

PT J
AU Desler, C
   Munch-Petersen, B
   Rasmussen, LJ
AF Desler, C.
   Munch-Petersen, B.
   Rasmussen, L. J.
TI The role of mitochondrial dNTP levels in cells with reduced TK2 activity
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
DE thymidine kinase 2; mitochondrial dNTP imbalance; dNTP transport
ID depletion myopathy; kinase; dna; triphosphate
AB Both the nuclear and mitochondrial DNA (mtDNA) depend on separate balanced pools of dNTPs for correct function of DNA replication and repair of DNA damage. Import of dNTPs from the cytosolic compartment to the mitochondria has been suggested to have the potential of rectifying a mitochondrial dNTP imbalance. Reduced TK2 activity has been demonstrated to result in mitochondrial dNTP imbalance and consequently mutations of mtDNA in non-dividing cells. In this study, the consequences of a reduced thymidine kinase 2 (TK2) activity were measured in proliferating HeLa cells, on both whole-cell as well as mitochondrial dNTP levels. With the exception of increased mitochondrial dCTP level no significant difference was found in cells with reduced TK2 activity. Our results suggest that import of cytosolic dNTPs in mitochondria of proliferating cells can compensate a TK2 induced imbalance of the mitochondrial dNTP pool.
C1 Roskilde Univ Ctr, Dept Chem & Life Sci, Roskilde, Denmark.
C3 Roskilde University
RP Munch-Petersen, B (corresponding author), Roskilde Univ Ctr, Dept Life Sci, DK-4000 Roskilde, Denmark.
EM bmp@virgil.ruc.dk
CR ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946
   GAO WY, 1994, J BIOL CHEM, V269, P12633
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WICKREMASINGHE RG, 1980, J CLIN INVEST, V65, P26, DOI 10.1172/JCI109656
NR 11
TC 8
Z9 10
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PD JUN 15
PY 2006
VL 25
IS 9-11
BP 1171
EP 1175
DI 10.1080/15257770600894501
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 105GS
UT WOS:000242019000037
PM 17065084
DA 2024-11-01
ER

PT J
AU De Vriese, AS
   Van Coster, R
   Smet, J
   Seneca, S
   Lovering, A
   Van Haute, LL
   Vanopdenbosch, LJ
   Martin, JJ
   Ceuterick-de Groote, C
   Vandecasteele, S
   Boelaert, JR
AF De Vriese, AS
   Van Coster, R
   Smet, J
   Seneca, S
   Lovering, A
   Van Haute, LL
   Vanopdenbosch, LJ
   Martin, JJ
   Ceuterick-de Groote, C
   Vandecasteele, S
   Boelaert, JR
TI Linezolid-induced inhibition of mitochondrial protein synthesis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID oxidative-phosphorylation; peripheral neuropathy; lactic-acidosis; level
AB Background Linezolid is an oxazolidinone antibiotic that is increasingly used to treat drug-resistant, gram-positive pathogens. The mechanism of action is inhibition of bacterial protein synthesis. Optic and/or peripheral neuropathy and lactic acidosis are reported side effects, but the underlying pathophysiological mechanism has not been unravelled. Methods. We studied mitochondrial ultrastructure, mitochondrial respiratory chain enzyme activity, and mitochondrial DNA ( mtDNA) in muscle, liver, and kidney samples obtained from a patient who developed optic neuropathy, encephalopathy, skeletal myopathy, lactic acidosis, and renal failure after prolonged use of linezolid. In addition, we evaluated mtDNA, respiratory chain enzyme activity, and protein amount in muscle and liver samples obtained from experimental animals that received linezolid or placebo. Results. In the patient, mitochondrial respiratory chain enzyme activity was decreased in affected tissues, without ultrastructural mitochondrial abnormalities and without mutations or depletion of mtDNA. In the experimental animals, linezolid induced a dose-and time-dependent decrease of the activity of respiratory chain complexes containing mtDNA-encoded subunits and a decreased amount of protein of these complexes, whereas the amount of mtDNA was normal. Conclusion. These results provide direct evidence that linezolid inhibits mitochondrial protein synthesis with potentially severe clinical consequences. Prolonged courses of linezolid should be avoided if alternative treatment options are available.
C1 AZ St Jan Brugge, Dept Internal Med, B-8000 Brugge, Belgium.
   AZ St Jan Brugge, Dept Neurol, B-8000 Brugge, Belgium.
   State Univ Ghent Hosp, Dept Pediat, Div Pediat Neurol & Metab, B-9000 Ghent, Belgium.
   Dutch Speaking Free Univ Brussels, Ctr Med Genet, Univ Hosp, Brussels, Belgium.
   Univ Antwerp, Lab Neuropathol & Electron Microscopy, Born Bunge Inst, B-2020 Antwerp, Belgium.
   Southmead Gen Hosp, Antimicrobial Reference Lab, Dept Med Microbiol, Bristol, Avon, England.
C3 Ghent University; Ghent University Hospital; Vrije Universiteit Brussel; University of Antwerp; Southmead Hospital
RP De Vriese, AS (corresponding author), AZ St Jan Brugge, Dept Internal Med, Ruddershove 10, B-8000 Brugge, Belgium.
EM an.devriese@azbrugge.be
CR Apodaca AA, 2003, NEW ENGL J MED, V348, P86, DOI 10.1056/NEJM200301023480123
   Birmingham MC, 2003, CLIN INFECT DIS, V36, P159, DOI 10.1086/345744
   Bressler AM, 2004, LANCET INFECT DIS, V4, P528, DOI 10.1016/S1473-3099(04)01109-0
   DENSLOW ND, 1978, EUR J BIOCHEM, V91, P441, DOI 10.1111/j.1432-1033.1978.tb12696.x
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Ferry T, 2005, INFECTION, V33, P151, DOI 10.1007/s15010-005-4057-9
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Frippiat F, 2004, J ANTIMICROB CHEMOTH, V53, P1114, DOI 10.1093/jac/dkh199
   Hancock MR, 2002, ANN CLIN BIOCHEM, V39, P456, DOI 10.1258/000456302320314467
   Kuter DJ, 2001, PHARMACOTHERAPY, V21, P1010, DOI 10.1592/phco.21.11.1010.34517
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   Meka VG, 2004, CLIN INFECT DIS, V39, P1010, DOI 10.1086/423841
   Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9
   Palenzuela L, 2005, CLIN INFECT DIS, V40, PE113, DOI 10.1086/430441
   Rho JP, 2004, MAYO CLIN PROC, V79, P927, DOI 10.4065/79.7.927
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1
   Slatter JG, 2002, XENOBIOTICA, V32, P907, DOI 10.1080/00498250210158249
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Tobin CM, 2001, J ANTIMICROB CHEMOTH, V48, P605, DOI 10.1093/jac/48.5.605
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Zivkovic SA, 2005, NEUROLOGY, V64, P926, DOI 10.1212/01.WNL.0000152883.53691.5B
NR 24
TC 200
Z9 205
U1 0
U2 13
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
EI 
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 15
PY 2006
VL 42
IS 8
BP 1111
EP 1117
DI 10.1086/501356
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 023CC
UT WOS:000236101800008
PM 16575728
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Schwartz, M
   Olsen, DB
   Wibrand, F
   Krag, T
   Duno, M
   Hauerslev, S
   Vissing, J
AF Jeppesen, Tina D.
   Schwartz, Marianne
   Olsen, David B.
   Wibrand, Flemming
   Krag, Thomas
   Duno, Morten
   Hauerslev, Simon
   Vissing, John
TI Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy
SO BRAIN
LA English
DT Article
DE mitochondrial myopathy; training; mtDNA; mutation load
ID skeletal-muscle; oxidative capacity; mutation; mtdna; expression; apoptosis; index; fibers
AB Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO2max (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO2max and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO2max and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO2max and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.
C1 Natl Univ Hosp, Neoromuscular Res Unit, Sect 7611, Rigshosp,Dept Neurol,Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
   Natl Univ Hosp, Dept Clin Genet, Rigshosp, DK-2100 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen
RP Jeppesen, TD (corresponding author), Natl Univ Hosp, Neoromuscular Res Unit, Sect 7611, Rigshosp,Dept Neurol,Copenhagen Muscle Res Ctr, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM dysgaard@rh.dk
CR Ansved T, 2001, ACTA PHYSIOL SCAND, V171, P359, DOI 10.1046/j.1365-201x.2001.00839.x
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Di Mauro S, 2004, MYOLOGY PHILADELPHIA, V0, P1623
   Fischer CP, 2004, AM J PHYSIOL-ENDOC M, V287, PE1189, DOI 10.1152/ajpendo.00206.2004
   Frederiksen AL, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.039339
   GOLLNICK PD, 1982, CLIN PHYSIOL, V2, P1, DOI 10.1111/j.1475-097X.1982.tb00001.x
   HOPPELER H, 1973, PFLUG ARCH EUR J PHY, V344, P217, DOI 10.1007/BF00588462
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   JONES DA, 1986, J PHYSIOL-LONDON, V375, P435, DOI 10.1113/jphysiol.1986.sp016126
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Marcuello A, 2005, J APPL PHYSIOL, V99, P1372, DOI 10.1152/japplphysiol.00289.2005
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Olsen DB, 2005, NEUROLOGY, V64, P1064, DOI 10.1212/01.WNL.0000150584.45055.27
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Orngreen MC, 2005, ANN NEUROL, V57, P754, DOI 10.1002/ana.20460
   Rodríguez LP, 2002, AM J PHYS MED REHAB, V81, P651, DOI 10.1097/00002060-200209000-00004
   ROWELL LB, 1986, AM J PHYSIOL, V251, P1038
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Suomalainen A, 1998, METH MOL B, V86, P121
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1999, MUSCLE NERVE, V22, P1239, DOI 10.1002/(SICI)1097-4598(199909)22:9<1239::AID-MUS11>3.0.CO;2-W
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Turner DL, 1997, ACTA PHYSIOL SCAND, V161, P459, DOI 10.1046/j.1365-201X.1997.00246.x
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
NR 33
TC 145
Z9 152
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD DEC 15
PY 2006
VL 129
IS 
BP 3402
EP 3412
DI 10.1093/brain/awl149
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 111RE
UT WOS:000242471100031
PM 16815877
DA 2024-11-01
ER

PT J
AU Baruffini, E
   Lodi, T
   Dallabona, C
   Puglisi, A
   Zeviani, M
   Ferrero, I
AF Baruffini, Enrico
   Lodi, Tiziana
   Dallabona, Cristina
   Puglisi, Andrea
   Zeviani, Massimo
   Ferrero, Iliana
TI Genetic and chemical rescue of the <i>Saccharomyces cerevisiae</i> phenotype induced by mitochondrial DNA polymerase mutations associated with progressive external ophthalmoplegia in humans
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID adenine-nucleotide translocator; ribonucleotide reductase; small-subunit; catalytic subunit; gamma; mtdna; yeast; deletions; protein; damage
AB The human POLG gene encodes the catalytic subunit of mitochondrial DNA polymerase gamma (pol gamma). Mutations in pol gamma are associated with a spectrum of disease phenotypes including autosomal dominant and recessive forms of progressive external ophthalmoplegia, spino-cerebellar ataxia and epilepsy, and Alpers-Huttenlocher hepatocerebral poliodystrophy. Multiple deletions, or depletion of mtDNA in affected tissues, are the molecular hallmarks of pol gamma mutations. To shed light on the pathogenic mechanisms leading to these phenotypes, we have introduced in MIP1, the yeast homologue of POLG, two mutations equivalent to the human Y955C and G268A mutations, which are associated with dominant and recessive PEO, respectively. Both mutations induced the generation of petite colonies, carrying either rearranged (rho(-)) or no (rho(0)) mtDNA. Mutations in genes that control the mitochondrial supply of deoxynucleotides (dNTP) affect the mtDNA integrity in both humans and yeast. To test whether the manipulation of the dNTP pool can modify the effects of pol gamma mutations in yeast, we have overexpressed a dNTP checkpoint enzyme, ribonucleotide reductase, RNR1, or deleted its inhibitor, SML1. In both mutant strains, the petite mutability was dramatically reduced. The same result was obtained by exposing the mutant strains to dihydrolipoic acid, an anti-oxidant agent. Therefore, an increase of the mitochondrial dNTP pool and/or a decrease of reactive oxygen species can prevent the mtDNA damage induced by pol gamma mutations in yeast and, possibly, in humans.
C1 Natl Neurol Inst C Besta, Div Mol Neurogenet, Pierfranco & Luisa Mariana Ctr Mitochondrial Dis, I-20126 Milan, Italy.
   Univ Parma, Dept Genet, I-43100 Parma, Italy.
   Univ Catholique Louvain, Fac Ingn Biol, Inst Sci Vie, B-1348 Louvain, Belgium.
   Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland.
   Univ Geneva, NCCR Program Frontiers Genet, CH-1211 Geneva 4, Switzerland.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Parma; Universite Catholique Louvain; University of Geneva; University of Geneva
RP Zeviani, M (corresponding author), Natl Neurol Inst C Besta, Div Mol Neurogenet, Pierfranco & Luisa Mariana Ctr Mitochondrial Dis, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
FU Telethon [GGP030039] Funding Source: Medline
CR [Anonymous], 1983, COLD SPRING HARBOR L, V0, P0
   BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026
   Boiteux S, 2004, DNA REPAIR, V3, P1, DOI 10.1016/j.dnarep.2003.10.002
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8
   CHI NW, 1994, J BIOL CHEM, V269, P29984
   DEFONTAINE A, 1991, NUCLEIC ACIDS RES, V19, P185, DOI 10.1093/nar/19.1.185
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Doudican NA, 2005, MOL CELL BIOL, V25, P5196, DOI 10.1128/MCB.25.12.5196-5204.2005
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740
   ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Foury F, 2004, CELL MOL LIFE SCI, V61, P2799, DOI 10.1007/s00018-004-4220-y
   FOURY F, 1989, J BIOL CHEM, V264, P20552
   Fukuhara H, 1977, MITOCHONDRIA, V0, P123
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   LAWSON JE, 1988, J BIOL CHEM, V263, P14812
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   MATHE G, 1977, CANCER IMMUNOL IMMUN, V2, P139
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   ORourke TW, 2005, GENE, V354, P86, DOI 10.1016/j.gene.2005.03.031
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NEUROL CLIN, V7, P123, DOI 10.1016/S0733-8619(18)30832-6
   Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544
   Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4
   Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299
NR 48
TC 73
Z9 81
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 1
PY 2006
VL 15
IS 19
BP 2846
EP 2855
DI 10.1093/hmg/ddl219
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 086TO
UT WOS:000240696100002
PM 16940310
DA 2024-11-01
ER

PT J
AU Houshmand, M
   Panahi, MSS
   Hosseini, BN
   Dorraj, G
   Tabassi, AR
AF Houshmand, M.
   Panahi, M. Shafa Shariat
   Hosseini, B. N.
   Dorraj, Gh.
   Tabassi, A. R.
TI Investigation on mtDNA deletions and twinkle gene mutation (G1423C) in Iranian patients with chronic progressive external opthalmoplagia
SO NEUROLOGY INDIA
LA English
DT Article
DE CPEO; mitochondria; mtDNA deletion; twinkle gene
ID mitochondrial-dna deletions; multiple deletions; ophthalmoplegia; genome; kinase; polg; ant1
AB Background: Chronic progressive external ophthalmoplagia (CPEO) is a phenotypic mitochondrial disorder that affects external ocular and skeletal muscles and is associated with a single or multiple mitochondrial DNA (mtDNA) deletions and also nuclear gene mutations. There are also some reports about the relationship between CPEO and the nuclear Twinkle gene which encodes a kind of mitochondrial protein called Twinkle. Aims: To study the mtDNA deletions and Twinkle gene G1423C point mutation in Iranian patients with CPEO. Materials and Methods: We collected 23 muscle samples from patients with CPEO, 9 women (mean age 34.3 years) and 14 men (36.7 years). Multiplex polymerase chain reaction (PCR) method was used to find the presence of single or multiple deletions in mtDNA. Single stranded conformational polymorphism (SSCP) and restriction fragment length polymorphism (PCR-RFLP) methods were carried out to investigate point mutation (G1423C) in the Twinkle gene in all DNA samples. Results: Different sizes of mtDNA deletions were detected in 16 patients (69.6%). Each of the 5.5, 7, 7.5 and 9 kb deletions existed only in 1 patient. Common deletion (4977bp) and 8 kb deletion were detected in 5 and 3 patients respectively. Multiple deletions were also present in 4 patients. Out of 23 patients included in our study, two cases (8.7%) had Twinkle gene mutation (G1423C) and 5 patients (21.7%) did not show any deletions in mtDNA or the Twinkle gene mutation. Conclusion: Our study provides evidence that the investigation of mtDNA and Twinkle gene mutations in CPEO may help with early diagnosis and prevention of the disease. Patients who did not show deletions in the mtDNA or G1423C mutation in the Twinkle gene may have other mtDNA, Twinkle or nuclear gene mutations.
C1 Farabi Eyes Hosp, NIGEB, Dept Med Genet, Tehran, Iran.
C3 Tehran University of Medical Sciences
RP Houshmand, M (corresponding author), Farabi Eyes Hosp, NIGEB, Dept Med Genet, 17th Km Tehran Karaj Highway,Pajoohesh Blvd,POB 1, Tehran, Iran.
EM massoudh@nrcgeb.ac.ir
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430
   Chaturvedi S, 2005, MED SCI MONITOR, V11, P0
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Grossman LI, 1996, BIOESSAYS, V18, P983, DOI 10.1002/bies.950181208
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   Quigley A, 2001, J CLIN NEUROMUSCUL DIS, V3, P77, DOI 10.1097/00131402-200112000-00006
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Shimko JW, 2005, AMERICAN ORTHOPTIC JOURNAL, V55, P13, DOI 10.3368/aoj.55.1.13
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 25
TC 11
Z9 14
U1 0
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0028-3886
EI 1998-4022
J9 NEUROL INDIA
JI Neurol. India
PD JUN 15
PY 2006
VL 54
IS 2
BP 182
EP 185
DI 
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 066EG
UT WOS:000239211900015
PM 16804265
DA 2024-11-01
ER

PT J
AU Valentino, ML
   Barboni, P
   Rengo, C
   Achilli, A
   Torroni, A
   Lodi, R
   Tonon, C
   Barbiroli, B
   Fortuna, F
   Montagna, P
   Baruzzi, A
   Carelli, V
AF Valentino, M. L.
   Barboni, P.
   Rengo, C.
   Achilli, A.
   Torroni, A.
   Lodi, R.
   Tonon, C.
   Barbiroli, B.
   Fortuna, F.
   Montagna, P.
   Baruzzi, A.
   Carelli, V.
TI The 13042G→A/ND5 mutation in mtDNA is pathogenic and can be associated also with a prevalent ocular phenotype
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID hereditary optic neuropathy; lhon/melas overlap syndrome; mitochondrial-dna mutation; melas-syndrome; complex-i; clinical-features; g13513a mutation; frequent cause; nd5 mutation; hot-spot
AB Background: Overlapping phenotypes including LHON, MELAS, and Leigh syndrome have recently been associated with numerous mtDNA point mutations in the ND5 gene of complex I, now considered a mutational hot spot. Objective: To identify the mtDNA defect in a family with a prevalent ocular phenotype, including LHON-like optic neuropathy, retinopathy, and cataract, but characterised also by strokes, early deaths, and miscarriages on the maternal line. Results: Sequencing of the entire mitochondrial genome from the proband's muscle DNA identified the heteroplasmic 13042G -> A transition, which was previously described only once in a patient with a different mitochondrial disease. This mutation fulfils the major pathogenic criteria, inducing an amino acid change (A236T) at an invariant position in a highly conserved domain of the ND5 gene. Phosphorus magnetic resonance spectroscopy in the proband disclosed an in vivo brain and skeletal muscle energy metabolism deficit. Conclusions: These findings conclusively establish the pathogenic role of the 13042G -> A mutation and underscore its variable clinical expression.
C1 Univ Bologna, Dipartimento Sci Neurol, I-40123 Bologna, Italy.
   Ctr Oftalmol Salus, Bologna, Italy.
   Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy.
   Univ Bologna, Dipartimento Med Clin & Biotecnol Applicata D Cam, Bologna, Italy.
C3 University of Bologna; University of Pavia; University of Bologna
RP Carelli, V (corresponding author), Univ Bologna, Dipartimento Sci Neurol, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
EM carelli@neuro.unibo.it
FU Telethon [GGP02323] Funding Source: Medline
CR Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   BOTTOMLY PA, 1989, CLIN CHEM, V59, P392
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   *EEC CONC RES PROJ, 1995, MAGN RESON IMAGING, V13, P115
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Lodi R, 2000, BRAIN, V123, P1896, DOI 10.1093/brain/123.9.1896
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   Petruzzella V, 2003, NEUROLOGY, V61, P1017, DOI 10.1212/01.WNL.0000080363.10902.E9
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   RUMMELT V, 1993, OPHTHALMOLOGY, V100, P1757
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
   Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
NR 26
TC 23
Z9 24
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD JUL 15
PY 2006
VL 43
IS 7
BP 
EP 
DI 10.1136/jmg.2005.037507
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 059DP
UT WOS:000238713800020
PM 16816025
DA 2024-11-01
ER

PT J
AU Kumleh, HH
   Riazi, GH
   Houshmand, M
   Sanati, MH
   Gharagozli, K
   Shafa, M
AF Kumleh, HH
   Riazi, GH
   Houshmand, M
   Sanati, MH
   Gharagozli, K
   Shafa, M
TI Complex I deficiency in Persian multiple sclerosis patients
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE multiple sclerosis; mitochondrial complex I; encephalomyopathy; mitochondrial DNA; spectrophotometry
ID hereditary optic neuropathy; mitochondrial-dna mutation; disease; association
AB Multiple sclerosis (MS) is a demyelinating disease of the central nervous system characterized by the morphological hallmarks of inflammation, demyelination and axonal loss. Until now, little attention has been paid to the contribution of mitochondrial respiratory chain enzyme activities to MS. In this study, kinetic analysis of mitochondrial respiratory chain complex I enzyme (measured as NADH-ferricyanide reductase) was performed oil intact mitochondria isolated from fresh skeletal Muscle ill MS patients (n = 10) and control subjects (n = 11). Mitochondrial DNA common deletion and deletions were also tested in MS patients. Our findings showed that complex I activities were significantly reduced (P = 0.007) in patients compared with control. However, We could not find deletion in mtDNA of patients with MS. The presupposition of relationship between MS and mitochondrial disorders is due to predominant maternal transmission of MS in affected parent-child pairs, pathoaetiological role of respiratory chain dysfunction in multisystem disorders and important role of it in neurodegenerative disorders, a number of patients Such as LHON or other mtDNA abnormality with developed neurological symptoms indistinguishable From MS and similarity of clinical symptoms ill mitochondrial disorders to those of MS. This Study Suggested that a biochemical defect in complex I activity may be involved in pathogenesis of MS. (c) 2005 Elsevier B.V. All rights reserved.
C1 NIGEB, Dept Med Genet, Tehran, Iran.
   Univ Tehran, Inst Biochem & Biophys, Tehran, Iran.
   Loghman Hosp, Dept Neurol, Tehran, Iran.
C3 University of Tehran
RP NIGEB, Dept Med Genet, POB 14155-6343, Tehran, Iran.
EM massoudh@nregeb.ac.ir
CR BOOKELMAN H, 1978, BIOCHEM MED METAB B, V19, P366, DOI 10.1016/0006-2944(78)90037-6
   Böttcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200
   CARRARA F, 1995, AM J HUM GENET, V57, P1949
   COMPSTON DAS, 1995, ACTA NEUROL SCAND, V91, P43, DOI 10.1111/j.1600-0404.1995.tb05855.x
   COOPER JM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P198, DOI 10.1016/S0005-2728(05)80019-2
   DeVries DD, 1996, AM J HUM GENET, V58, P703
   DOOIJEWAARD G, 1976, BIOCHIM BIOPHYS ACTA, V440, P1, DOI 10.1016/0005-2728(76)90109-2
   FLANIGAN KM, 1993, NEUROLOGY, V43, P2720, DOI 10.1212/WNL.43.12.2720
   Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6
   Houshmand M, 2004, EUR NEUROL, V51, P68, DOI 10.1159/000075518
   Kalman B, 1998, ACTA NEUROL SCAND, V98, P232, DOI 10.1111/j.1600-0404.1998.tb07301.x
   KELLARWOOD H, 1994, ANN NEUROL, V36, P109, DOI 10.1002/ana.410360121
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   LEES F, 1964, J NEUROL NEUROSUR PS, V27, P415, DOI 10.1136/jnnp.27.5.415
   LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F
   Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9
   MARKWELL MAK, 1981, METHOD ENZYMOL, V72, P290
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   OLSEN NK, 1995, ACTA NEUROL SCAND, V91, P326, DOI 10.1111/j.1600-0404.1995.tb07016.x
   POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302
   Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426
   RIORDANEVA P, 1995, BRAIN, V118, P319, DOI 10.1093/brain/118.2.319
   SADOVNICK AD, 1991, ANN NEUROL, V29, P252, DOI 10.1002/ana.410290304
   SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   von Kleist-Retzow JC, 2003, EXP PHYSIOL, V88, P155, DOI 10.1113/eph8802509
   Vyshkina T, 2005, J NEUROL SCI, V228, P55, DOI 10.1016/j.jns.2004.09.027
   Williamson D, 1985, PARKS, V10, P5
NR 29
TC 37
Z9 38
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2006
VL 243
IS 1-2
BP 65
EP 69
DI 10.1016/j.jns.2005.11.030
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 032AU
UT WOS:000236747100013
PM 16413582
DA 2024-11-01
ER

PT J
AU Meulemans, A
   Seneca, S
   Lagae, L
   Lissens, W
   De Paepe, B
   Smet, J
   Van Coster, R
   De Meirleir, L
AF Meulemans, Ann
   Seneca, Sara
   Lagae, Lieven
   Lissens, Willy
   De Paepe, Boel
   Smet, Joel
   Van Coster, Rudy
   De Meirleir, Linda
TI A novel mitochondrial transfer RNA<SUP>Asn</SUP> mutation causing multiorgan failure
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID respiratory-chain; molecular investigations; trna(asn) gene; transfer-rnas; dna; diagnosis; disease; disorders; defect; mtdna
AB Background: Mitochondrial cytopathies are a heterog eneous group of disorders with a broad spectrum of clim cal symptoms. Objective: To characterize a novel mutation in the transfer RNA(Asn) (m.5728A > G) identified in a 13-year-old boy with multiorgan failure. Design: Biochemical and immunocytochemical studies were performed in combination with transmitochondrial cybrid analysis. Setting: A university hospital. Molecular and biochemical analyses were performed in collaboration between 2 other university hospitals. Patient: Thirteen-year-old boy with multiorgan failure. Results: In the patient's muscle tissue and cultured skin fibroblasts, a combined deficiency of complexes I and IV was found using spectrophotometric analysis and activity staining in the gel following blue native polyacrylamide gel electrophoresis. An identical biochemical profile was seen in transmitochondrial cybrids carrying more than 55% mutant mitochondrial DNA. Conclusion: These data suggest that the m.5728A > G transition is a pathogenic mutation and is the cause of the respiratory chain dysfunction in the propositus.
C1 Vrije Univ Brussels, AZ, Ctr Genet Med, B-1090 Brussels, Belgium.
   Vrije Univ Brussels, AZ, Dept Pediat Neurol, B-1090 Brussels, Belgium.
   Catholic Univ Louvain, Dept Pediat Neurol, B-3000 Louvain, Belgium.
   Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
   Univ Ghent, Dept Pediat Neurol & Metab, B-9000 Ghent, Belgium.
C3 Vrije Universiteit Brussel; Vrije Universiteit Brussel; Universite Catholique Louvain; KU Leuven; University Hospital Leuven; Ghent University
RP Meulemans, A (corresponding author), Vrije Univ Brussels, AZ, Ctr Genet Med, Laarbeeklaan 101, B-1090 Brussels, Belgium.
EM ann.meulemans@vub.ac.be
CR BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025
   De Paepe B, 2006, PEDIATR RES, V59, P2, DOI 10.1203/01.pdr.0000191294.34122.ab
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165
   Gellerich FN, 2004, MITOCHONDRION, V4, P427, DOI 10.1016/j.mito.2004.07.007
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Seneca S, 1998, J MED GENET, V35, P963, DOI 10.1136/jmg.35.11.963
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere PA, 1969, METHODS IN ENZYMOLOGY, V13, P3
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
NR 18
TC 27
Z9 28
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9942
EI 
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD AUG 15
PY 2006
VL 63
IS 8
BP 1194
EP 1198
DI 10.1001/archneur.63.8.1194
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 072ER
UT WOS:000239656400025
PM 16908752
DA 2024-11-01
ER

PT J
AU Chan, DC
AF Chan, David C.
TI Mitochondria: Dynamic organelles in disease, aging, and development
SO CELL
LA English
DT Review
ID dominant optic atrophy; respiratory-chain function; substantia-nigra neurons; human skeletal-muscle; cytochrome-c release; axonal-transport; dna mutations; human-cells; degenerative diseases; missense mutation
AB Mitochondria are the primary energy-generating system in most eukaryotic cells. Additionally, they participate in intermediary metabolism, calcium signaling, and apoptosis. Given these well-established functions, it might be expected that mitochondrial dysfunction would give rise to a simple and predictable set of defects in all tissues. However, mitochondrial dysfunction has pleiotropic effects in multicellular organisms. Clearly, much about the basic biology of mitochondria remains to be understood. Here we discuss recent work that suggests that the dynamics (fusion and fission) of these organelles is important in development and disease.
C1 CALTECH, Div Biol, Pasadena, CA 91125 USA.
C3 California Institute of Technology
RP Chan, DC (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.
EM dchan@caltech.edu
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014
   BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059
   Brierley EJ, 1997, MOL CELL BIOCHEM, V174, P325, DOI 10.1023/A:1006847319162
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   COOPER JM, 1992, J NEUROL SCI, V113, P91, DOI 10.1016/0022-510X(92)90270-U
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7
   Fransson Å, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200
   Frederick RL, 2004, J CELL BIOL, V167, P87, DOI 10.1083/jcb.200405100
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148
   Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200
   Guo XF, 2005, NEURON, V47, P379, DOI 10.1016/j.neuron.2005.06.027
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316
   Kamei S, 2005, INVEST OPHTH VIS SCI, V46, P4288, DOI 10.1167/iovs.03-1407
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3
   Larsen NB, 2005, MITOCHONDRION, V5, P89, DOI 10.1016/j.mito.2005.02.002
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.e02-06-0330
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Mattenberger Y, 2003, FEBS LETT, V538, P53, DOI 10.1016/S0014-5793(03)00124-8
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315
   Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087
   Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699
   Shoubridge E A, 2000, HUM REPROD, V15 Suppl 2, P229
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2
   Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200
   Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
   Züchner S, 2005, J MOL MED-JMM, V83, P935, DOI 10.1007/s00109-005-0694-9
NR 89
TC 1599
Z9 1851
U1 9
U2 414
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA
SN 0092-8674
EI 
J9 CELL
JI Cell
PD JUN 30
PY 2006
VL 125
IS 7
BP 1241
EP 1252
DI 10.1016/j.cell.2006.06.010
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 064QP
UT WOS:000239104500009
PM 16814712
DA 2024-11-01
ER

PT J
AU Heidenreich, JO
   Klopstock, T
   Schirmer, T
   Saemann, P
   Mueller-Felber, W
   Auer, DP
AF Heidenreich, Jens O.
   Klopstock, Thomas
   Schirmer, Timo
   Saemann, Philipp
   Mueller-Felber, Wolfgang
   Auer, Dorothee P.
TI Chronic progressive external ophthalmoplegia: MR spectroscopy and MR diffusion studies in the brain
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE brain; CNS; diffusion-weighted MRI; MRI; ophthalmoplegia
ID kearns-sayre syndrome; magnetic-resonance-spectroscopy; mitochondrial encephalomyopathy; photic-stimulation; melas; metabolism; myopathy; encephalopathy; disorders; diseases
AB OBJECTIVE. The purpose of our study was to show how, despite pathognomonic signs of cerebral involvement in chronic progressive external ophthalmoplegia (CPEO), mitochondrial respiratory chain insufficiency is associated with increased lactate and reduced N-acetylaspartate. CPEO and mitochondrial myopathy are caused by mitochondrial DNA mutations leading to impaired oxidative phosphorylation. Cortical and subcortical metabolites, cerebral diffusivity, and structural MRI were assessed to characterize possible subclinical cerebral pathology in CPEO. SUBJECTS AND METHODS. Ten patients with CPEO (n = 8), mitochondrial myopathy (n = 1), and Kearns-Sayre syndrome (n = 1) and 13 control group volunteers were studied by MRI, both long TE (144) proton MR spectroscopic imaging (H-1 MRSI), and diffusion-weighted imaging. Relative concentrations of N-acetylaspartate, choline, creatine, and lactate were estimated by Linear Combination of Model Spectra (LCModel) in healthy-appearing white matter, gray matter, and white matter hyperintensities. RESULTS. Of five patients with cortical atrophy, it was moderate in three and severe in two. One patient had severe and four had moderate cerebellar atrophy. Six of 10 patients showed unspecific white matter lesions, whereas the remainder had hyperintensities in the pyramidal tract (n = 2) and middle cerebellar peduncle (n = 1) despite clinical signs. No basal ganglia lesions were found. Physiologic metabolite ratios were normal and lactate was absent in supratentorial healthy-appearing cortex and subcortical white matter. Global diffusion histogram metrics revealed no abnormalities. CONCLUSION. Normal spectroscopic imaging in radiologic unaffected brain and healthy global brain parenchymal diffusion findings do not support the hypothesis of a generalized cerebral energy loss in CPEO. Bilateral structural alteration of central motor pathways in two patients without clinical pyramidal signs may, however, reflect subclinical axonal injury in predilection sites in some patients.
C1 Dept Radiol & Nucl Med, D-12200 Berlin, Germany.
   AG NMR, Max Planck Inst Psychiat, Dept Radiol, Munich, Germany.
   Univ Munich, Klinikum Grosshadern, Dept Neurol, Munich, Germany.
   Friedrich Baur Inst, Munich, Germany.
C3 Max Planck Society; University of Munich; University of Munich
RP Heidenreich, JO (corresponding author), Dept Radiol & Nucl Med, Charite Campus Benjamin Franklin,Hindenburgdamm 3, D-12200 Berlin, Germany.
CR Auer DP, 2001, NEUROLOGY, V56, P635, DOI 10.1212/WNL.56.5.635
   BARKOVICH AJ, 1993, AM J NEURORADIOL, V14, P1119
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Carlow TJ, 1998, AM J NEURORADIOL, V19, P95
   CASTILLO M, 1995, AM J NEURORADIOL, V16, P233
   Clark JM, 1996, NEUROLOGY, V46, P223, DOI 10.1212/WNL.46.1.223
   Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319
   DAROFF RB, 1966, NEUROLOGY, V16, P161, DOI 10.1212/WNL.16.2_Part_1.161
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   Dichgans M, 2003, AM J NEURORADIOL, V24, P1083
   Engelbrecht V, 2002, RADIOLOGY, V222, P410, DOI 10.1148/radiol.2222010492
   Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kapeller P, 1996, J NEUROL SCI, V135, P126, DOI 10.1016/0022-510X(95)00290-I
   Kato T, 1998, J NEUROL SCI, V155, P182, DOI 10.1016/S0022-510X(97)00308-0
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   KUWABARA T, 1994, NEUROLOGY, V44, P557, DOI 10.1212/WNL.44.3_Part_1.557
   LEUTNER C, 1994, AM J NEURORADIOL, V15, P681
   MATTHEWS PM, 1991, ANN NEUROL, V29, P435, DOI 10.1002/ana.410290416
   OLDORFS A, 1990, ACTA NEUROPATHOL BER, V80, P541
   Pavlakis SG, 1998, ARCH NEUROL-CHICAGO, V55, P849, DOI 10.1001/archneur.55.6.849
   PELLOCK JM, 1978, ANN NEUROL, V3, P455, DOI 10.1002/ana.410030519
   PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604
   Provenzale JM, 1996, NEUROLOGY, V46, P826, DOI 10.1212/WNL.46.3.826
   Purucker M, 1996, J EPILEPSY, V9, P79, DOI 10.1016/0896-6974(95)00072-0
   Salvan AM, 1998, EUR NEUROL, V40, P46, DOI 10.1159/000007955
   WRAY SH, 1995, AM J NEURORADIOL, V16, P1167
NR 27
TC 16
Z9 16
U1 0
U2 4
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD SEP 15
PY 2006
VL 187
IS 3
BP 820
EP 824
DI 10.2214/AJR.05.0180
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 080PF
UT WOS:000240259300038
PM 16928952
DA 2024-11-01
ER

PT J
AU Grazina, M
   Pratas, J
   Silva, F
   Oliveira, S
   Santana, I
   Oliveira, C
AF Grazina, M
   Pratas, J
   Silva, F
   Oliveira, S
   Santana, I
   Oliveira, C
TI Genetic basis of Alzheimer's dementia: role of mtDNA mutations
SO GENES BRAIN AND BEHAVIOR
LA English
DT Review
DE 16S rRNA; age of onset; Alzheimer's disease; amyloid; gene; mitochondria; mtDNA; ND1; oxidative stress; point mutation
ID amyloid-beta-peptide; cytochrome-c-oxidase; mitochondrial-dna mutations; point mutations; precursor protein; oxidative damage; a-beta; parkinsons-disease; nadh dehydrogenase; apolipoprotein-e
AB Alzheimer's disease (AD) is the most common neurodegenerative disorder associated to dementia in late adulthood. Amyloid precursor protein, presenilin 1 and presenilin 2 genes have been identified as causative genes for familial AD, whereas apolipoprotein E epsilon 4 allele has been associated to the risk for late onset AD. However, mutations on these genes do not explain the majority of cases. Mitochondrial respiratory chain (MRC) impairment has been detected in brain, muscle, fibroblasts and platelets of Alzheimer's patients, indicating a possible involvement of mitochondrial DNA (mtDNA) in the aetiology of the disease. Several reports have identified mtDNA mutations in Alzheimer's patients, suggesting the existence of related causal factors probably of mtDNA origin, thus pointing to the involvement of mtDNA in the risk contributing to dementia, but there is no consensual opinion in finding the cause for impairment. However, mtDNA mutations might modify age of onset, contributing to the neurodegenerative process, probably due to an impairment of MRC and/or translation mechanisms.
C1 Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal.
   Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal.
   Univ Hosp Coimbra, Neurol Unit, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC)
RP Univ Coimbra, Fac Med, Inst Biochem, Rua Larga, P-3004504 Coimbra, Portugal.
EM catarina@cnc.cj.uc.pt
CR Abe T, 2002, J NEUROSCI RES, V70, P447, DOI 10.1002/jnr.10349
   Aksenov MY, 1999, NEUROCHEM RES, V24, P767, DOI 10.1023/A:1020783614031
   Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977
   Aliyev A, 2005, J NEUROL SCI, V229, P285, DOI 10.1016/j.jns.2004.11.040
   Alzheimer A, 1907, ALLGEMEINE ZEITSCHRIFT FUR PSYCHIATRIE UND PSYCHISCH-GERICHTLICHE MEDIZIN, V0, P146
   Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Apelt J, 2004, INT J DEV NEUROSCI, V22, P475, DOI 10.1016/j.ijdevneu.2004.07.006
   Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0
   Arias C, 2002, EXP NEUROL, V176, P163, DOI 10.1006/exnr.2002.7912
   Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92
   BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B
   BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4
   Behl C, 2005, SUB CELL BIOCHEM, V38, P65
   BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7
   BLANCHARD BJ, 1993, NEUROREPORT, V4, P799, DOI 10.1097/00001756-199306000-00051
   BLASS JP, 1991, REV NEUROL, V147, P513
   Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087
   Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0
   BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099
   Burns MP, 2003, MOL BRAIN RES, V110, P119, DOI 10.1016/S0169-328X(02)00647-2
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6
   Byrne E, 2002, J CLIN NEUROSCI, V9, P497, DOI 10.1054/jocn.2001.0991
   CANDY JM, 1983, J NEUROL SCI, V59, P277, DOI 10.1016/0022-510X(83)90045-X
   Canevari L, 2004, NEUROCHEM RES, V29, P637, DOI 10.1023/B:NERE.0000014834.06405.af
   Cardoso SM, 2005, BRAIN RES, V1050, P1, DOI 10.1016/j.brainres.2005.04.078
   Cardoso SM, 2004, J NEUROCHEM, V89, P1417, DOI 10.1111/j.1471-4159.2004.02438.x
   Cardoso SM, 2004, NEUROBIOL AGING, V25, P105, DOI 10.1016/S0197-4580(03)00033-2
   Cardoso SM, 2001, FASEB J, V15, P1439, DOI 10.1096/fj.00-0561fje
   Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Casadesus G, 2005, CELL MOL LIFE SCI, V62, P293, DOI 10.1007/s00018-004-4384-0
   Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x
   Castellani R, 2002, J NEUROSCI RES, V70, P357, DOI 10.1002/jnr.10389
   Castellani RJ, 2004, AGEING RES REV, V3, P319, DOI 10.1016/j.arr.2004.01.002
   CHALMERS RM, 1995, J NEUROL, V242, P332, DOI 10.1007/BF00878877
   Chang SW, 2000, BIOCHEM BIOPH RES CO, V273, P203, DOI 10.1006/bbrc.2000.2885
   Chong ZZ, 2005, BRAIN RES REV, V49, P1, DOI 10.1016/j.brainresrev.2004.11.005
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Cortopassi GA, 1994, AMERICAN JOURNAL OF HUMAN GENETICS, V55, P0
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   DAVIS JN, 1995, MOL MED TODAY, V1, P240, DOI 10.1016/S1357-4310(95)91532-X
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   de la Monte SM, 2000, LAB INVEST, V80, P1323, DOI 10.1038/labinvest.3780140
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   Dickson DW, 2004, J CLIN INVEST, V114, P23, DOI 10.1172/JC1200422317
   Dong HH, 2004, J NEUROSCI, V24, P8950, DOI 10.1523/JNEUROSCI.2106-04.2004
   DUARA R, 1993, NEUROLOGY, V43, P1377, DOI 10.1212/WNL.43.7.1377
   Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3
   Edland SD, 2002, ALZ DIS ASSOC DIS, V16, P1, DOI 10.1097/00002093-200201000-00001
   Edland SD, 1996, NEUROLOGY, V47, P254, DOI 10.1212/WNL.47.1.254
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004
   Fodero LR, 2004, J NEUROCHEM, V88, P1186, DOI 10.1046/j.1471-4159.2003.02296.x
   Franciosi S, 2005, J NEUROIMMUNOL, V159, P66, DOI 10.1016/j.jneuroim.2004.10.006
   German DC, 2004, REV NEUROSCIENCE, V15, P353, DOI 10.1515/REVNEURO.2004.15.5.353
   Ghosh SS, 1999, ANN NY ACAD SCI, V893, P176, DOI 10.1111/j.1749-6632.1999.tb07825.x
   Gibson GE, 2002, FRONT BIOSCI, V7, PD1007, DOI 10.2741/gibson
   Gibson GE, 1998, AGE, V21, P7, DOI 10.1007/s11357-998-0002-z
   Gleason CE, 2005, CELL MOL LIFE SCI, V62, P299, DOI 10.1007/s00018-004-4385-z
   Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527
   Graeber MB, 1998, J NEUROSCI RES, V52, P1
   Grazina M, 2005, EUR NEUROL, V53, P121, DOI 10.1159/000085555
   Grazina M, 2004, NEUROBIOL DIS, V15, P306, DOI 10.1016/j.nbd.2003.11.004
   Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205
   Hamblet NS, 1997, MUTAT RES-FUND MOL M, V379, P253, DOI 10.1016/S0027-5107(97)00158-9
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   HARRIS ME, 1995, NEUROREPORT, V6, P1875, DOI 10.1097/00001756-199510020-00013
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HESS J, 1995, LANCET, V346, P189, DOI 10.1016/S0140-6736(95)91251-7
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532
   Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576
   Hoyer A, 2005, J NEURAL TRANSM, V112, P239, DOI 10.1007/s00702-004-0176-1
   HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892
   Hutchin TP, 1997, BIOCHEM BIOPH RES CO, V241, P221, DOI 10.1006/bbrc.1997.7793
   Inestrosa NC, 2005, SUB CELL BIOCHEM, V38, P299
   Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008
   Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099
   Janetzky B, 1996, EUR NEUROL, V36, P149, DOI 10.1159/000117233
   Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004
   Kawahara M, 2004, CURR ALZHEIMER RES, V1, P87, DOI 10.2174/1567205043332234
   Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Klemm T, 2001, EXP CLIN ENDOCR DIAB, V109, P283, DOI 10.1055/s-2001-16348
   Kok CC, 2000, NEUROMUSCULAR DISORD, V10, P604, DOI 10.1016/S0960-8966(00)00144-9
   Kontush A, 2004, ANN NY ACAD SCI, V1031, P249, DOI 10.1196/annals.1331.025
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   KOSEL S, 1994, BIOCHEM BIOPH RES CO, V203, P745, DOI 10.1006/bbrc.1994.2245
   KUMAR U, 1994, LIFE SCI, V54, P1855, DOI 10.1016/0024-3205(94)90142-2
   Kuo YM, 1996, J BIOL CHEM, V271, P4077
   LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960
   Lee HC, 1997, J BIOMED SCI, V4, P319, DOI 10.1007/BF02258357
   Lee HG, 2004, J ALZHEIMERS DIS, V6, P137
   Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825
   LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622
   Li R, 2004, J NEUROSCI, V24, P1760, DOI 10.1523/JNEUROSCI.4580-03.2004
   LIN FH, 1992, BIOCHEM BIOPH RES CO, V182, P238, DOI 10.1016/S0006-291X(05)80136-6
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230
   Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204
   Maillet M, 2004, CURR ALZHEIMER RES, V1, P79, DOI 10.2174/1567205043332252
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   Mark RJ, 1996, MOL NEUROBIOL, V12, P211, DOI 10.1007/BF02755589
   Mark RJ, 1997, J NEUROCHEM, V68, P255
   Mattson MP, 2004, ANN NY ACAD SCI, V1012, P37, DOI 10.1196/annals.1306.004
   Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3
   Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081
   Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621
   MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510
   Meltzer CC, 1998, NEUROPSYCHOPHARMACOL, V18, P407
   Mighore L, 2005, NEUROBIOL AGING, V26, P567, DOI 10.1016/j.neurobiolaging.2004.07.016
   Moreira P, 2000, ANTIOXID REDOX SIGN, V2, P317, DOI 10.1089/ars.2000.2.2-317
   Moreira PI, 2001, BIOSCIENCE REP, V21, P789, DOI 10.1023/A:1015536808304
   Mori T, 2001, J NEUROPATH EXP NEUR, V60, P778, DOI 10.1093/jnen/60.8.778
   NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.bi.60.070191.001203
   ODay DH, 2004, BIOCHEM BIOPH RES CO, V320, P1051, DOI 10.1016/j.bbrc.2004.06.070
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015
   Pereira C, 2005, CNS NEUROL DISORD-DR, V4, P383, DOI 10.2174/1568007054546117
   Pereira C, 2004, J MOL NEUROSCI, V23, P97, DOI 10.1385/JMN:23:1-2:097
   PEREIRA C, 2001, MITOCHONDRIAL UBIQUI, V0, P283
   PETRUZZELLA V, 1992, BIOCHEM BIOPH RES CO, V186, P491, DOI 10.1016/S0006-291X(05)80834-4
   Praticò D, 2005, NEUROBIOL AGING, V26, P581, DOI 10.1016/j.neurobiolaging.2004.09.020
   Praticò D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972
   Praticò D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9
   Qiu XZ, 2001, BRAIN RES, V893, P261, DOI 10.1016/S0006-8993(00)03190-5
   Rademakers Rosa, 2003, SCIENTIFICWORLDJOURNAL, V3, P497
   Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140
   Rogers JT, 2004, CURR DRUG TARGETS, V5, P535, DOI 10.2174/1389450043345272
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Ruppert V, 2004, BIOCHEM BIOPH RES CO, V318, P535, DOI 10.1016/j.bbrc.2004.04.061
   Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704
   SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467
   SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047
   Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Simpkins JW, 2005, CELL MOL LIFE SCI, V62, P271, DOI 10.1007/s00018-004-4382-2
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626
   STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330
   STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399
   Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007
   Sung S, 2004, FASEB J, V18, P0, DOI 10.1096/fj.03-0961fje
   Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045
   Swerdlow RH, 2002, INT REV NEUROBIOL, V53, P341
   Takuma K, 2005, J PHARMACOL SCI, V97, P312, DOI 10.1254/jphs.CPJ04006X
   Tannenberg RK, 2004, CURR ALZHEIMER RES, V1, P11, DOI 10.2174/1567205043480591
   Tanno Y, 1998, NEUROBIOL AGING, V19, PS47, DOI 10.1016/S0197-4580(98)00028-1
   TERRY RD, 1983, ANN NEUROL, V14, P497, DOI 10.1002/ana.410140502
   TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   Tuppo EE, 2005, INT J BIOCHEM CELL B, V37, P289, DOI 10.1016/j.biocel.2004.07.009
   Tysoe C, 1996, J MED GENET, V33, P1002, DOI 10.1136/jmg.33.12.1002
   VAN BROECKHOVEN C, 1992, NAT GENET, V2, P335, DOI 10.1038/ng1292-335
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005
   Verkhratsky A, 2003, J CELL MOL MED, V7, P351, DOI 10.1111/j.1582-4934.2003.tb00238.x
   Vina Jose, 2004, MOLECULAR ASPECTS OF MEDICINE, V25, P117, DOI 10.1016/j.mam.2004.02.013
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Walker ES, 2005, J NEUROCHEM, V92, P294, DOI 10.1111/j.1471-4159.2004.02858.x
   Wallace DC, 1992, AMERICAN JOURNAL OF HUMAN GENETICS, V51, P0
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010
   Walsh DM, 2004, PROTEIN PEPTIDE LETT, V11, P213, DOI 10.2174/0929866043407174
   Webber KM, 2005, ANN NY ACAD SCI, V1052, P201, DOI 10.1196/annals.1347.020
   Webber KM, 2004, ACTA NEUROBIOL EXP, V64, P113, DOI 10.55782/ane-2004-1497
   White JA, 2005, NEUROBIOL DIS, V18, P459, DOI 10.1016/j.nbd.2004.12.013
   Wirths O, 2004, J NEUROCHEM, V91, P513, DOI 10.1111/j.1471-4159.2004.02737.x
   Wragg MA, 1995, NEUROSCI LETT, V201, P107, DOI 10.1016/0304-3940(95)12146-3
   Yan SD, 2005, INT J EXP PATHOL, V86, P161, DOI 10.1111/j.0959-9673.2005.00427.x
   Zhu Xiongwei, 2004, AM J ALZHEIMERS DIS OTHER DEMEN, V19, P345, DOI 10.1177/153331750401900611
NR 183
TC 39
Z9 51
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD JUN 15
PY 2006
VL 5
IS 
BP 92
EP 107
DI 10.1111/j.1601-183X.2006.00225.x
PG 16
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 036TO
UT WOS:000237098600009
PM 16681804
DA 2024-11-01
ER

PT J
AU Zoccolella, S
   Torraco, A
   Amati, A
   Lamberti, P
   Serlenga, L
   Papa, S
   Petruzzella, V
AF Zoccolella, Stefano
   Torraco, Alessandra
   Amati, Angela
   Lamberti, Paolo
   Serlenga, Luigi
   Papa, Sergio
   Petruzzella, Vittoria
TI Unusual clinical presentation of a patient carrying a novel single 1.8 kb deletion of mitochondrial DNA
SO FUNCTIONAL NEUROLOGY
LA English
DT Article
DE cerebellar ataxia; Kearns-Sayre syndrome; mitochondrial DNA deletion
ID kearns-sayre-syndrome; mutation
AB Kearns-Sayre syndrome (KSS) is a mitochondrial encephalomyopathy characterized by progressive external ophthalmoplegia (PEO), pigmentary retinopathy and onset before the age of 20 years. Cerebellar ataxia, as well as short stature and increased protein content in the cerebrospinal fluid, are frequent additional symptoms. A single large mitochondrial (mt) DNA deletion of 4,977 bp is the most common molecular defect in KSS. Recently, different mutations have also been associated with incomplete, KSS-like phenotypes. We describe the unusual clinical presentation of a patient carrying a novel 1,814-bp deletion of mtDNA. In contrast with typical KSS, the clinical picture of this patient did not include either palpebral ptosis or IPEO and was dominated by an ataxic syndrome.
C1 Univ Bari, Dept Med Biochem Med Biol & Med Phys, I-70124 Bari, Italy.
   Univ Bari, Dept Neurol Sci, I-70124 Bari, Italy.
   L Bonomo Hosp, Dept Neurol, Bari, Italy.
   Italian Res Council, Inst Biomembranes & Bioenerget, Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro
RP Petruzzella, V (corresponding author), Univ Bari, Dept Med Biochem Med Biol & Med Phys, Piazza Giulio Cesare 11, I-70124 Bari, Italy.
EM v.petruzzella@biochem.uniba.it
CR Becher MW, 1999, HUM PATHOL, V30, P577, DOI 10.1016/S0046-8177(99)90204-6
   *EM U CTR MOL MED, 2002, MIT HUM MIT GEN DAT, V0, P0
   Marin-Garcia J, 2000, J CHILD NEUROL, V15, P555, DOI 10.1177/088307380001500812
   Petruzzella V, 2004, CLIN GENET, V65, P64, DOI 10.1111/j..2004.00185.x
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   SCIACCO M, 1994, HUM MOL GENET, V3, P687
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Tanji K, 1999, ANN NEUROL, V45, P377, DOI 10.1002/1531-8249(199903)45:3<377::AID-ANA14>3.0.CO;2-M
   Vázquez-Acevedo M, 2002, NEUROL SCI, V23, P247, DOI 10.1007/s100720200050
NR 10
TC 5
Z9 6
U1 0
U2 5
PU C I C-EDIZIONI INTERNAZIONALI SRL
PI ROME
PA CORSO TRIESTE, 42, 00198 ROME, ITALY
SN 0393-5264
EI 
J9 FUNCT NEUROL
JI Funct. Neurol.
PD JAN-MAR 15
PY 2006
VL 21
IS 1
BP 39
EP 41
DI 
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 062AG
UT WOS:000238916000005
PM 16735000
DA 2024-11-01
ER

PT J
AU Kanaumi, T
   Hirose, S
   Goto, Y
   Naitou, E
   Mitsudome, A
AF Kanaumi, T
   Hirose, S
   Goto, Y
   Naitou, E
   Mitsudome, A
TI An infant with a mitochondrial A3243G mutation demonstrating the MELAS phenotype
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID lateralized epileptiform discharges; evolution
AB Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a syndrome associated with mitochondrial DNA mutations such as A3243G, the most common mutation. Ragged-red fibers and strongly succinate dehydrogenase-reactive blood vessels in the muscle are diagnostic pathologic features of MELAS. In general, the first typical attack of MELAS occurs in children at school age; it is rare for stroke-like episodes to occur in early infancy. This report describes a 4-month-old male harboring A3243G, whose phenotype at onset was consistent with that of MELAS in infancy. The patient was admitted because of disturbances of consciousness and ventilatory insufficiency. Remarkable lactic acidosis was observed. MRI revealed several bilateral lesions. Periodic lateralized epileptic discharges on the EEG suggested regional lesions. Biopsied muscle displayed scattered ragged-red fibers and succinate dehydrogenase-reactive blood vessels; over 90% of muscle mitochondrial DNA had A3243G. This case suggests that MELAS can develop in early infancy with its typical clinical presentation. The high percentage of A3243G may contribute to the early onset of the MELAS phenotype in this patient. (c) 2006 by Elsevier Inc. All rights reserved.
C1 Fukuoka Univ, Sch Med, Dept Pediat, Jonan Ku, Fukuoka 8140180, Japan.
   Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Natl Ctr Neurol & Psychiat, Tokyo, Japan.
   Univ Tokushima, Sch Med, Fac Pediat, Tokushima 770, Japan.
C3 Fukuoka University; National Center for Neurology & Psychiatry - Japan; Tokushima University
RP Fukuoka Univ, Sch Med, Dept Pediat, Jonan Ku, 45-1,7 Chome, Fukuoka 8140180, Japan.
EM hirose@fukuoka-u.ac.jp
CR Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   Chabolla DR, 1996, ELECTROEN CLIN NEURO, V98, P5, DOI 10.1016/0013-4694(95)00211-1
   de Lonlay-Debeney P, 2000, J PEDIATR-US, V136, P209, DOI 10.1016/S0022-3476(00)70103-X
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Funakawa I, 1997, ELECTROEN CLIN NEURO, V103, P370, DOI 10.1016/S0013-4694(97)00020-9
   García-Morales I, 2002, J CLIN NEUROPHYSIOL, V19, P172, DOI 10.1097/00004691-200203000-00009
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   SCHWARTZ MS, 1973, BRAIN, V96, P613, DOI 10.1093/brain/96.3.613
   SHOTTNER JM, 1995, METABOLIC MOL BASIS, V0, P1535
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   WESTMORELAND BF, 1986, ARCH NEUROL-CHICAGO, V43, P494, DOI 10.1001/archneur.1986.00520050066024
NR 13
TC 13
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD MAR 15
PY 2006
VL 34
IS 3
BP 235
EP 238
DI 10.1016/j.pediatrneurol.2005.08.024
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 022EO
UT WOS:000236037800012
PM 16504796
DA 2024-11-01
ER

PT J
AU Yang, YL
   Sun, F
   Zhang, Y
   Qian, N
   Yuan, Y
   Wang, ZX
   Qi, Y
   Xiao, JX
   Wang, XY
   Qi, ZY
   Zhang, YH
   Jiang, YW
   Bao, XH
   Qin, J
   Wu, XR
AF Yang, YL
   Sun, F
   Zhang, Y
   Qian, N
   Yuan, Y
   Wang, ZX
   Qi, Y
   Xiao, JX
   Wang, XY
   Qi, ZY
   Zhang, YH
   Jiang, YW
   Bao, XH
   Qin, J
   Wu, XR
TI Clinical and laboratory survey of 65 Chinese patients with Leigh syndrome
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Leigh syndrome; mitochondrial genes; cytochrome c oxidase deficiency; SURF1 gene
ID cytochrome-c-oxidase; surf1 gene-mutations; mitochondrial-dna; deficiency; children; disease; gc/ms
AB Background Leigh syndrome is an inherited neurodegenerative disease that emerges in infancy and childhood and presents with a clinically heterogeneous variety of neuromuscular and non-neuromuscular disorders. It can result from the inheritance of mutations in either nuclear or mitochondrial DNA. In the current study, we performed a retrospective study in 65 patients in order to investigate the clinical and genetic characteristics of Leigh syndrome in Chinese patients. Methods Sixty-five unrelated cases (35 men and 30 women) who were hospitalized in the past 12 years were reviewed. Diagnosis was based on both the clinical presentation and the characteristic neuropathologic findings of bilateral symmetric necrotizing lesions in the basal ganglia and brain stem as detected using cranial computed tomography (CT) scan or magnetic resonance imaging (MRI). The differential diagnosis of organic acidurias and fatty acid beta-oxidation defects were performed. Specific point mutations and deletions in mitochondrial DNA (T8993G; T8993C, T9176C, A8344G, A3243G) were screened by PCR-restriction analysis and Southern blot. The SURF1 gene was sequenced. Skeletal muscle biopsies were performed in 17 (26.2%) of the patients. The diagnosis was confirmed by autopsy in 6 (9.2%) patients. Results The patients had various forms of metabolic encephalomyopathy. Fifty-nine (90.8%) of the patients had the typical neuroradiological features of Leigh syndrome, including symmetrical necrotizing lesions scattered within the basal ganglia, thalamus and brain stem. Twenty (30.8%) patients were confirmed by genetic, biochemical analysis and autopsy. Specific point mutations in mitochondrial DNA were found in 5 cases (7.7%). Of these, the A8344G mutation was detected in 2 patients. The T8993G, T8993C, and A3243G point mutations were identified in 3 other patients, respectively. SURF1 mutations associated with cytochrome c oxidase deficiency were identified in 8 (12.3%) families by DNA sequencing. A G604C mutation was identified in 6 (9.2%) patients. The genotypes of 52 patients remained unknown. Conclusions Leigh syndrome presents as a diverse array of clinical features and can result from specific mutations in nuclear or mitochondrial DNA. In this study, SURF1 mutations associated with cytochrome c oxidase deficiency were identified in 8 (12.3%) out of 65 patients with Leigh syndrome. It indicates that SURF1 mutations might be a common cause of Leigh syndrome in China. The etiology of Leigh syndrome in Chinese patients represents a persistent challenge to clinicians.
C1 Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China.
   Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
   Peking Univ, Hosp 1, Cent Lab, Beijing 100034, Peoples R China.
   Peking Univ, Hosp 1, Dept Med Radiol, Beijing 100034, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking University
RP Peking Univ, Hosp 1, Dept Pediat, Beijing 100034, Peoples R China.
EM organic.acid@126.com
CR Akagi M, 2002, NEUROMUSCULAR DISORD, V12, P53, DOI 10.1016/S0960-8966(01)00242-5
   Darin N, 2003, NEUROPEDIATRICS, V34, P311
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Fu XW, 2000, EARLY HUM DEV, V58, P41, DOI 10.1016/S0378-3782(00)00053-0
   Fujii T, 1998, PEDIATR NEUROL, V18, P275, DOI 10.1016/S0887-8994(97)00187-2
   Head RA, 2004, J INHERIT METAB DIS, V27, P57, DOI 10.1023/B:BOLI.0000016622.05609.b8
   Hori D, 2005, BRAIN DEV-JPN, V27, P39, DOI 10.1016/j.braindev.2004.04.004
   Jiang YW, 2002, J CHILD NEUROL, V17, P450, DOI 10.1177/088307380201700611
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Moroni I, 2002, NEUROPEDIATRICS, V33, P79, DOI 10.1055/s-2002-32372
   Moslemi AR, 2003, NEUROLOGY, V61, P991, DOI 10.1212/01.WNL.0000082391.98672.0A
   Munnich A, 2001, METABOLIC MOL BASES, V0, P2261
   Ogawa Y, 2002, PEDIATR NEUROL, V26, P196, DOI 10.1016/S0887-8994(01)00382-4
   Poyau A, 1999, FEBS LETT, V462, P416, DOI 10.1016/S0014-5793(99)01571-9
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Shigematsu Y, 2002, J CHROMATOGR B, V776, P39, DOI 10.1016/S1570-0232(02)00077-6
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   [王朝霞 Wang Zhaoxia], 2003, 中华神经科杂志 CHINESE JOURNAL OF NEUROLOGY, V36, P28
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 24
TC 32
Z9 43
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAR 5
PY 2006
VL 119
IS 5
BP 373
EP 377
DI 10.1097/00029330-200603010-00004
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021NT
UT WOS:000235990600004
PM 16542579
DA 2024-11-01
ER

PT J
AU Spikings, EC
   Alderson, J
   St John, JC
AF Spikings, E. C.
   Alderson, J.
   St John, J. C.
TI Transmission of mitochondrial DNA following assisted reproduction and nuclear transfer
SO HUMAN REPRODUCTION UPDATE
LA English
DT Review
DE assisted reproduction technology; mitochondrial DNA; nuclear transfer
ID embryonic stem-cells; kearns-sayre-syndrome; in-vitro fertilization; progressive external ophthalmoplegia; intracytoplasmic sperm injection; hereditary optic neuropathy; germinal vesicle transfer; transcription factor-a; rabbit cloned embryos; human oocytes
AB Mitochondria are the organelles responsible for producing the majority of a cell's ATP and also play an essential role in gamete maturation and embryo development. ATP production within the mitochondria is dependent on proteins encoded by both the nuclear and the mitochondrial genomes, therefore co-ordination between the two genomes is vital for cell survival. To assist with this co-ordination, cells normally contain only one type of mitochondrial DNA (mtDNA) termed homoplasmy. Occasionally, however, two or more types of mtDNA are present termed heteroplasmy. This can result from a combination of mutant and wild-type mtDNA molecules or from a combination of wild-type mtDNA variants. As heteroplasmy can result in mitochondrial disease, various mechanisms exist in the natural fertilization process to ensure the maternal-only transmission of mtDNA and the maintenance of homoplasmy in future generations. However, there is now an increasing use of invasive oocyte reconstruction protocols, which tend to bypass mechanisms for the maintenance of homoplasmy, potentially resulting in the transmission of either form of mtDNA heteroplasmy. Indeed, heteroplasmy caused by combinations of wild-type variants has been reported following cytoplasmic transfer (CT) in the human and following nuclear transfer (NT) in various animal species. Other techniques, such as germinal vesicle transfer and pronuclei transfer, have been proposed as methods of preventing transmission of mitochondrial diseases to future generations. However, resulting embryos and offspring may contain mtDNA heteroplasmy, which itself could result in mitochondrial disease. It is therefore essential that uniparental transmission of mtDNA is ensured before these techniques are used therapeutically.
C1 Univ Birmingham, Sch Med, Mitochondrial & Reprod Genet Grp, Birmingham B15 2TT, W Midlands, England.
C3 University of Birmingham
RP St John, JC (corresponding author), Univ Birmingham, Sch Med, Mitochondrial & Reprod Genet Grp, Birmingham B15 2TT, W Midlands, England.
EM j.stjohn.1@bham.ac.uk
CR Alam TI, 2003, NUCLEIC ACIDS RES, V31, P1640, DOI 10.1093/nar/gkg251
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   AnkelSimons F, 1996, P NATL ACAD SCI USA, V93, P13859, DOI 10.1073/pnas.93.24.13859
   BARRITT JA, 2001, REPROD BIOMED ONLINE, V3, P47
   Bavister B D, 2000, HUM REPROD, V15 Suppl 2, P189
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Brenner CA, 2000, FERTIL STERIL, V74, P573, DOI 10.1016/S0015-0282(00)00681-6
   BRISON DR, 1991, J REPROD FERTIL, V93, P245, DOI 10.1530/jrf.0.0930245
   BROWN DR, 1989, J ANIM SCI, V67, P1926
   BROWN MD, 1992, GENETICS, V130, P163
   Campbell KHS, 2005, REPROD DOMEST ANIM, V40, P256, DOI 10.1111/j.1439-0531.2005.00591.x
   Chang KH, 2003, FERTIL STERIL, V80, P1380, DOI 10.1016/j.fertnstert.2003.07.006
   Chen DY, 2002, BIOL REPROD, V67, P637, DOI 10.1095/biolreprod67.2.637
   Chen Y, 2003, CELL RES, V13, P251, DOI 10.1038/sj.cr.7290170
   Chinnery PF, 2001, AM J MED GENET, V98, P235, DOI 10.1002/1096-8628(20010122)98:3<235::AID-AJMG1086>3.0.CO;2-O
   Chung YG, 2002, BIOL REPROD, V66, P1178, DOI 10.1095/biolreprod66.4.1178
   Cibelli JB, 2002, NAT BIOTECHNOL, V20, P13, DOI 10.1038/nbt0102-13
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cortesini R, 2005, TRANSPL IMMUNOL, V15, P81, DOI 10.1016/j.trim.2005.09.013
   Cui LB, 2005, HUM REPROD, V20, P1624, DOI 10.1093/humrep/deh826
   Cummins J, 1998, REV REPROD, V3, P172, DOI 10.1530/revreprod/3.3.172
   Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Dailey T, 1996, AM J HUM GENET, V59, P176
   Danan C, 1999, AM J HUM GENET, V65, P463, DOI 10.1086/302484
   Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883
   De Block CEM, 2004, EXP CLIN ENDOCR DIAB, V112, P80, DOI 10.1055/s-2004-815754
   Dean NL, 2003, MOL HUM REPROD, V9, P631, DOI 10.1093/molehr/gag077
   Dumollard R, 2003, DEVELOPMENT, V130, P683, DOI 10.1242/dev.00296
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Eichenlaub-Ritter U, 2004, REPROD BIOMED ONLINE, V8, P45, DOI 10.1016/S1472-6483(10)60497-X
   EISEN A, 1985, J CELL BIOL, V100, P1522, DOI 10.1083/jcb.100.5.1522
   El Shourbagy SH, 2006, REPRODUCTION, V131, P233, DOI 10.1530/rep.1.00551
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   FISHER RP, 1985, J BIOL CHEM, V260, P1330
   FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496
   Fulka H, 2004, REPRODUCTION, V127, P195, DOI 10.1530/rep.1.00093
   Gahan ME, 2001, J CLIN VIROL, V22, P241, DOI 10.1016/S1386-6532(01)00195-0
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0
   Hammer CJ, 2001, THERIOGENOLOGY, V55, P1447, DOI 10.1016/S0093-691X(01)00493-9
   Han ZM, 2004, MOL REPROD DEV, V67, P207, DOI 10.1002/mrd.10398
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686
   He ZY, 2003, FERTIL STERIL, V79, P347, DOI 10.1016/S0015-0282(02)04674-5
   HECHT NB, 1984, EXP CELL RES, V154, P293, DOI 10.1016/0014-4827(84)90688-8
   Hiendleder S, 1999, MOL REPROD DEV, V54, P24, DOI 10.1002/(SICI)1098-2795(199909)54:1<24::AID-MRD4>3.0.CO;2-S
   Hiendleder S, 2004, CLONING STEM CELLS, V6, P150, DOI 10.1089/1536230041372391
   Hiendleder S, 2003, BIOL REPROD, V68, P159, DOI 10.1095/biolreprod.102.008201
   Holden C, 2005, SCIENCE, V310, P1402, DOI 10.1126/science.310.5753.1402
   Houghton FD, 1996, MOL REPROD DEV, V44, P476, DOI 10.1002/(SICI)1098-2795(199608)44:4<476::AID-MRD7>3.0.CO;2-I
   Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399
   Inoue K, 2004, GENESIS, V39, P79, DOI 10.1002/gene.20029
   Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758
   Jansen RPS, 1998, MOL CELL ENDOCRINOL, V145, P81, DOI 10.1016/S0303-7207(98)00173-7
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   KEEFE DL, 1995, FERTIL STERIL, V64, P577, DOI 10.1016/S0015-0282(16)57796-6
   Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirches E, 2001, J MED GENET, V38, P312, DOI 10.1136/jmg.38.5.312
   KLOPSTOCK T, 1995, ACTA NEUROPATHOL, V90, P126
   KOEHLER CM, 1991, GENETICS, V129, P247
   KONDO R, 1992, GENET RES, V59, P81, DOI 10.1017/S0016672300030287
   KONDO R, 1990, GENETICS, V126, P657
   Kong Ling-hong, 2003, DI YI JUN YI DA XUE XUE BAO, V23, P747
   Kong Ling-hong, 2004, ZHONGHUA FU CHAN KE ZA ZHI, V39, P105
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Laflamme MA, 2005, AM J PATHOL, V167, P663, DOI 10.1016/S0002-9440(10)62041-X
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   Larsson NG, 1997, HUM MOL GENET, V6, P185, DOI 10.1093/hmg/6.2.185
   LEESE HJ, 1993, BIOESSAYS, V15, P259, DOI 10.1002/bies.950150406
   Lertrit P, 1999, HUM GENET, V105, P127, DOI 10.1007/s004390051074
   Lestienne P, 1997, MOL HUM REPROD, V3, P811, DOI 10.1093/molehr/3.9.811
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   Lin DPC, 2004, FERTIL STERIL, V81, P73, DOI 10.1016/j.fertnstert.2003.05.005
   Liu H, 1999, HUM REPROD, V14, P2357, DOI 10.1093/humrep/14.9.2357
   Liu L, 2001, CELL CALCIUM, V30, P423, DOI 10.1054/ceca.2001.0251
   Liu SZ, 2004, MOL REPROD DEV, V69, P296, DOI 10.1002/mrd.20091
   LLOYD RE, 2006, GENETICS, V0, P0
   Ludwig Michael, 2001, REPROD BIOMED ONLINE, V3, P230
   Luetjens CM, 1999, LANCET, V353, P1240, DOI 10.1016/S0140-6736(99)80059-2
   Macháty Z, 2001, MOL REPROD DEV, V58, P39, DOI 10.1002/1098-2795(200101)58:1<39::AID-MRD6>3.0.CO;2-B
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Marchington DR, 2002, MOL HUM REPROD, V8, P1046, DOI 10.1093/molehr/8.11.1046
   Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5
   May-Panloup P, 2005, HUM REPROD, V20, P593, DOI 10.1093/humrep/deh667
   McConnell JML, 2004, REPROD BIOMED ONLINE, V9, P418, DOI 10.1016/S1472-6483(10)61277-1
   McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604
   McKenzie M, 2000, J BIOL CHEM, V275, P31514, DOI 10.1074/jbc.M004070200
   McKenzie M, 2004, P NATL ACAD SCI USA, V101, P1685, DOI 10.1073/pnas.0303184101
   McKenzie M, 2003, MOL BIOL EVOL, V20, P1117, DOI 10.1093/molbev/msg132
   Meirelles FV, 1998, GENETICS, V148, P877
   Meirelles FV, 1997, GENETICS, V145, P445
   Meirelles FV, 2001, GENETICS, V158, P351
   MEUSEL MS, 1993, CURR GENET, V24, P539, DOI 10.1007/BF00351719
   MICHAELS GS, 1982, DEV BIOL, V94, P246, DOI 10.1016/0012-1606(82)90088-4
   MONNAT RJ, 1985, CANCER RES, V45, P1809
   Moyes CD, 1998, J EXP BIOL, V201, P299
   MUNNE S, 1995, FERTIL STERIL, V64, P382, DOI 10.1016/S0015-0282(16)57739-5
   Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5
   Nagao Y, 1998, GENES GENET SYST, V73, P21, DOI 10.1266/ggs.73.21
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nishi Yayoi, 2003, JOURNAL OF NIPPON MEDICAL SCHOOL, V70, P408, DOI 10.1272/jnms.70.408
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Nishimura Y, 2006, P NATL ACAD SCI USA, V103, P1382, DOI 10.1073/pnas.0506911103
   Normile D, 2005, SCIENCE, V307, P664, DOI 10.1126/science.307.5710.664
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Palermo GD, 2002, HUM REPROD, V17, P2165, DOI 10.1093/humrep/17.8.2165
   Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079
   PIKO L, 1976, DEV BIOL, V49, P1, DOI 10.1016/0012-1606(76)90253-0
   PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2
   PONZETTO C, 1990, J NEUROL SCI, V96, P207, DOI 10.1016/0022-510X(90)90133-8
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   Reynier P, 2001, MOL HUM REPROD, V7, P425, DOI 10.1093/molehr/7.5.425
   Reynier P, 1997, CR ACAD SCI III-VIE, V320, P629, DOI 10.1016/S0764-4469(97)85696-X
   Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5
   Rubart M, 2006, HANDB EXP PHARM, V174, P73
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Santos TA, 2006, FERTIL STERIL, V85, P584, DOI 10.1016/j.fertnstert.2005.09.017
   Sathananthan A H, 2000, HUM REPROD, V15 Suppl 2, P148
   Sathananthan Henry, 2002, REPROD BIOMED ONLINE, V4, P56
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   SAZER S, 1990, J CELL SCI, V97, P509
   Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3
   Schon E A, 2000, HUM REPROD, V15 Suppl 2, P160
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Seifer DB, 2002, FERTIL STERIL, V78, P1046, DOI 10.1016/S0015-0282(02)04214-0
   SHERRATT HSA, 1991, REV NEUROL, V147, P417
   Shitara H, 2000, GENETICS, V156, P1277
   Shoubridge E A, 2000, HUM REPROD, V15 Suppl 2, P229
   Siciliano G, 2000, NEUROL SCI, V21, PS985, DOI 10.1007/s100720070017
   SMITH LC, 1993, J REPROD FERTIL, V0, P31
   Sokolova VA, 2004, MOL REPROD DEV, V68, P299, DOI 10.1002/mrd.20075
   Spelbrink JN, 1998, HUM GENET, V102, P327, DOI 10.1007/s004390050700
   Spiropoulos J, 2002, MOL HUM REPROD, V8, P719, DOI 10.1093/molehr/8.8.719
   St John J, 2000, LANCET, V355, P200, DOI 10.1016/S0140-6736(99)03842-8
   St John JC, 2005, MOL REPROD DEV, V72, P450, DOI 10.1002/mrd.20370
   St John JC, 2005, CLONING STEM CELLS, V7, P141, DOI 10.1089/clo.2005.7.141
   St John JC, 2004, REPRODUCTION, V127, P631, DOI 10.1530/rep.1.00138
   St John JC, 2004, REPROD BIOMED ONLINE, V8, P34, DOI 10.1016/S1472-6483(10)60496-8
   St John JC, 2004, GENETICS, V167, P897, DOI 10.1534/genetics.103.025049
   St John JC, 2002, HUM REPROD, V17, P1954, DOI 10.1093/humrep/17.8.1954
   St John JC, 2001, MOL HUM REPROD, V7, P103, DOI 10.1093/molehr/7.1.103
   Steinborn R, 1998, FEBS LETT, V426, P352, DOI 10.1016/S0014-5793(98)00350-0
   Steinborn R, 2002, GENETICS, V162, P823
   Steuerwald N, 2000, ZYGOTE, V8, P209, DOI 10.1017/S0967199400001003
   Stojanovski D, 2003, EXP PHYSIOL, V88, P57, DOI 10.1113/eph8802501
   Stojkovic M, 2001, BIOL REPROD, V64, P904, DOI 10.1095/biolreprod64.3.904
   Sturmey RG, 2003, REPRODUCTION, V126, P197, DOI 10.1530/rep.0.1260197
   Sun QY, 2001, REPRODUCTION, V122, P155, DOI 10.1530/rep.0.1220155
   Sun YH, 2005, BIOL REPROD, V72, P510, DOI 10.1095/biolreprod.104.031302
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Sutarno, 2002, THERIOGENOLOGY, V57, P1603, DOI 10.1016/S0093-691X(02)00664-7
   Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P88, DOI 10.1002/jemt.10319
   Sutovsky P, 1999, NATURE, V402, P371, DOI 10.1038/46466
   Takeda K, 2006, MOL REPROD DEV, V73, P306, DOI 10.1002/mrd.20403
   Takeda K, 2005, BIOL REPROD, V72, P1397, DOI 10.1095/biolreprod.104.036129
   Takeda K, 2003, MOL REPROD DEV, V64, P429, DOI 10.1002/mrd.10279
   Takeuchi T, 2005, BIOL REPROD, V72, P584, DOI 10.1095/biolreprod.104.032391
   Takeuchi T, 2001, HUM REPROD, V16, P730, DOI 10.1093/humrep/16.4.730
   Taylor H, 2005, CURR OPIN BIOTECH, V16, P487, DOI 10.1016/j.copbio.2005.08.005
   Tessa A, 2000, FUNCT NEUROL, V15, P211
   Thompson JG, 1996, J REPROD FERTIL, V106, P299, DOI 10.1530/jrf.0.1060299
   Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615
   Trounce IA, 2004, J BIOENERG BIOMEMBR, V36, P421, DOI 10.1023/B:JOBB.0000041778.84464.16
   Trounson A, 2001, REPROD FERT DEVELOP, V13, P31, DOI 10.1071/RD01007
   Tsaousis AD, 2005, MOL BIOL EVOL, V22, P925, DOI 10.1093/molbev/msi084
   Vajta G, 2001, CLONING, V3, P89, DOI 10.1089/15204550152475590
   Van Blerkom J, 2000, HUM REPROD, V15, P2621, DOI 10.1093/humrep/15.12.2621
   Van Blerkom J, 2002, HUM REPROD, V17, P393, DOI 10.1093/humrep/17.2.393
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VANBLERKOM J, 1995, HUM REPROD, V10, P415, DOI 10.1093/oxfordjournals.humrep.a135954
   Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399
   WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200
   White DJ, 2001, AIDS, V15, P1061, DOI 10.1097/00002030-200105250-00017
   White K L, 1999, CLONING, V1, P47, DOI 10.1089/15204559950020085
   WIESNER RJ, 1992, BIOCHEM BIOPH RES CO, V183, P553, DOI 10.1016/0006-291X(92)90517-O
   Wilding M, 2001, HUM REPROD, V16, P909, DOI 10.1093/humrep/16.5.909
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
   XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yang CX, 2003, MOL REPROD DEV, V65, P396, DOI 10.1002/mrd.10320
   Yang L, 2005, MOL REPROD DEV, V71, P431, DOI 10.1002/mrd.20311
   Zhang J, 1999, FERTIL STERIL, V71, P726, DOI 10.1016/S0015-0282(98)00549-4
   Zhao X, 2004, HEREDITY, V93, P399, DOI 10.1038/sj.hdy.6800516
   ZOUROS E, 1992, NATURE, V359, P412, DOI 10.1038/359412a0
NR 198
TC 60
Z9 76
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1355-4786
EI 1460-2369
J9 HUM REPROD UPDATE
JI Hum. Reprod. Update
PD JUL-AUG 15
PY 2006
VL 12
IS 4
BP 401
EP 415
DI 10.1093/humupd/dml011
PG 15
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 056PO
UT WOS:000238537800007
PM 16581809
DA 2024-11-01
ER

PT J
AU Chance, B
   Im, J
   Nioka, S
   Kushmerick, M
AF Chance, Britton
   Im, Joohee
   Nioka, Shoko
   Kushmerick, Martin
TI Skeletal muscle energetics with PNMR: personal views and historic perspectives
SO NMR IN BIOMEDICINE
LA English
DT Review
DE phosphorylcreatine; ATP; oxidative phosphorylation; glycolysis; human muscle; muscle disorders
ID magnetic-resonance-spectroscopy; compartmentalized energy-transfer; noninvasive tissue oximetry; mitochondrial-dna mutations; p-31 nmr-spectroscopy; human calf muscle; coupling in-vivo; oxidative-phosphorylation; creatine-kinase; adenosine-triphosphate
AB This article reviews historical and current NMR approaches to describing in vivo bioenergetics of skeletal muscles in normal and diseased populations. It draws upon the first author's more than 70 years of personal experience in enzyme kinetics and the last author's physiological approaches. The development of in vivo PNMR jointly with researchers around the world is described. It is explained how non-invasive PNMR has advanced human exercise biochemistry, physiology and pathology. Further, after a brief explanation of bioenergetics with PNMR on creatine kinase, anerobic glycolysis and mitochondrial oxidative phosphorylation, some basic and controversial subjects are focused upon, and the authors' view of the subjects are offered, with questions and answers. Some of the research has been introduced in exercise physiology. Future directions of NMR on bioenergetics, as a part of system biological approaches, are indicated. Copyright (C) 2006 John Wiley & Sons, Ltd.
C1 Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.
   Temple Univ, Dept Kinesiol, Philadelphia, PA 19140 USA.
   Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
   Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   Univ Washington, Dept Physiol, Seattle, WA 98195 USA.
   Univ Washington, Dept Biophys, Seattle, WA 98195 USA.
C3 University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle
RP Chance, B (corresponding author), Univ Penn, Dept Biochem & Biophys, 250 Anat Chem Bldg, Philadelphia, PA 19104 USA.
EM chance@mail.med.upenn.edu
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   ADAMS GR, 1990, J APPL PHYSIOL, V69, P968, DOI 10.1152/jappl.1990.69.3.968
   Aliev MK, 1997, BIOPHYS J, V73, P428, DOI 10.1016/S0006-3495(97)78082-2
   Aliev MK, 1998, MOL CELL BIOCHEM, V184, P209, DOI 10.1023/A:1006871903596
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Arnett DC, 1999, J PHYS CHEM B, V103, P2014, DOI 10.1021/jp984464j
   Asperio RM, 2001, RADIOLOGY, V220, P413, DOI 10.1148/radiology.220.2.r01au03413
   BANK W, 1994, ANN NEUROL, V36, P830, DOI 10.1002/ana.410360606
   Barbiroli B, 1999, BIOFACTORS, V9, P253, DOI 10.1002/biof.5520090221
   Beard DA, 2005, PLOS COMPUT BIOL, V1, P252, DOI 10.1371/journal.pcbi.0010036
   BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446
   BINZONI T, 1992, J APPL PHYSIOL, V73, P1644, DOI 10.1152/jappl.1992.73.4.1644
   BITTL JA, 1985, J BIOL CHEM, V260, P3512
   BLEI ML, 1993, J PHYSIOL-LONDON, V465, P203, DOI 10.1113/jphysiol.1993.sp019673
   BOTTOMLEY PA, 1985, SCIENCE, V229, P769, DOI 10.1126/science.4023711
   Bottomley PA, 2001, RADIOLOGY, V219, P411, DOI 10.1148/radiology.219.2.r01ma39411
   Bourdel-Marchasson I, 2001, AM J CLIN NUTR, V73, P832
   Brooks G, 2004, EXERCISE PHYSL HUMAN, V4th, P0
   BURT CT, 1982, BIOCHIM BIOPHYS ACTA, V721, P492, DOI 10.1016/0167-4889(82)90107-0
   BUSBY SJW, 1978, BIOCHEM J, V170, P103, DOI 10.1042/bj1700103
   CAIN DF, 1963, BIOCHIM BIOPHYS ACTA, V74, P735, DOI 10.1016/0006-3002(63)91425-2
   CAIN DF, 1962, NATURE, V196, P214, DOI 10.1038/196214a0
   CAIN DF, 1962, BIOCHEM BIOPH RES CO, V8, P361, DOI 10.1016/0006-291X(62)90008-6
   Cea G, 2002, BRAIN, V125, P1635, DOI 10.1093/brain/awf163
   Chan A, 1998, J NEUROL, V245, P681, DOI 10.1007/s004150050267
   CHANCE B, 1970, P NATL ACAD SCI USA, V66, P1175, DOI 10.1073/pnas.66.4.1175
   CHANCE B, 1951, REV SCI INSTRUM, V22, P634, DOI 10.1063/1.1746021
   CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925
   CHANCE B, 1955, J BIOL CHEM, V217, P429
   CHANCE B, 1957, NATURE, V179, P1235, DOI 10.1038/1791235a0
   CHANCE B, 1982, P NATL ACAD SCI-BIOL, V79, P7714, DOI 10.1073/pnas.79.24.7714
   Chance B, 1983, ACTA RADIOL SUPPL, V365, P73
   CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458
   CHANCE B, 1981, P NATL ACAD SCI-BIOL, V78, P6714, DOI 10.1073/pnas.78.11.6714
   CHANCE B, 1975, ANAL BIOCHEM, V67, P552, DOI 10.1016/0003-2697(75)90331-0
   Chance B, 1962, MUSCLE AS A TISSUE, V0, P128
   Chaussain M, 1992, EUR J MED, V1, P457
   Chung YR, 1998, AM J PHYSIOL-CELL PH, V274, PC846, DOI 10.1152/ajpcell.1998.274.3.C846
   Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404
   Conley KE, 1997, AM J PHYSIOL-CELL PH, V273, PC306, DOI 10.1152/ajpcell.1997.273.1.C306
   Conley KE, 1998, J PHYSIOL-LONDON, V511, P935, DOI 10.1111/j.1469-7793.1998.935bg.x
   Conley KE, 2000, J PHYSIOL-LONDON, V526, P211, DOI 10.1111/j.1469-7793.2000.00211.x
   CONLEY KE, 1994, ADV VET SCI COMP MED, V38, P1
   Conley KE, 2001, J EXP BIOL, V204, P3189
   COOPER C, 1955, BIOCHIM BIOPHYS ACTA, V18, P159, DOI 10.1016/0006-3002(55)90034-2
   Crowther GJ, 2002, AM J PHYSIOL-ENDOC M, V282, PE67, DOI 10.1152/ajpendo.2002.282.1.E67
   Crowther GJ, 2002, AM J PHYSIOL-ENDOC M, V282, PE74, DOI 10.1152/ajpendo.2002.282.1.E74
   Damon BM, 2003, MAGNET RESON MED, V49, P233, DOI 10.1002/mrm.10384
   DAVIES R E, 1952, BIOCHEM J, V50, P0
   DAVIES RE, 1951, BIOCHEM J, V50, P119, DOI 10.1042/bj0500119
   DAVIES RE, 1963, NATURE, V199, P1068, DOI 10.1038/1991068a0
   de Haan JH, 2003, MAGNET RESON MED, V50, P1302, DOI 10.1002/mrm.10630
   Dengler R, 1996, MUSCLE NERVE, V19, P456, DOI 10.1002/(SICI)1097-4598(199604)19:4<456::AID-MUS5>3.0.CO;2-B
   DESMEDT JE, 1977, J PHYSIOL-LONDON, V264, P673, DOI 10.1113/jphysiol.1977.sp011689
   DUBOC D, 1987, NEUROLOGY, V37, P663, DOI 10.1212/WNL.37.4.663
   Duteil S, 2004, AM J PHYSIOL-REG I, V287, PR1441, DOI 10.1152/ajpregu.00242.2004
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   ELEFF S, 1980, FED PROC, V39, P6
   ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584
   FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311
   FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147
   Fitts R H, 1996, EXERC SPORT SCI REV, V24, P427
   Gabr RE, 2006, J MAGN RESON, V179, P152, DOI 10.1016/j.jmr.2005.11.004
   GADIAN DG, 1976, P NATL ACAD SCI USA, V73, P4446, DOI 10.1073/pnas.73.12.4446
   Grassi B, 1998, J APPL PHYSIOL, V85, P1404, DOI 10.1152/jappl.1998.85.4.1404
   Greenman RL, 2005, LANCET, V366, P1711, DOI 10.1016/S0140-6736(05)67696-9
   Grehl T, 1998, NEUROMUSCULAR DISORD, V8, P480, DOI 10.1016/S0960-8966(98)00066-2
   GYULAI L, 1985, J BIOL CHEM, V260, P3947
   Han YS, 2003, J APPL PHYSIOL, V94, P2188, DOI 10.1152/japplphysiol.00618.2002
   Harkema SJ, 1997, AM J PHYSIOL-CELL PH, V272, PC491, DOI 10.1152/ajpcell.1997.272.2.C491
   HEERSCHAP A, 1993, MUSCLE NERVE, V16, P367, DOI 10.1002/mus.880160405
   Hill AV, 1920, J PHYSIOL-LONDON, V54, P84
   HILL AV, 1949, J PHYSL, V109, P8
   HOCHACHKA PW, 1985, J EXP BIOL, V115, P149
   HOGAN MC, 1992, J APPL PHYSIOL, V73, P1662, DOI 10.1152/jappl.1992.73.4.1662
   Horská A, 2000, AM J PHYSIOL-ENDOC M, V279, PE333, DOI 10.1152/ajpendo.2000.279.2.E333
   HOULT DI, 1974, NATURE, V252, P285, DOI 10.1038/252285a0
   Hsu AC, 2003, MAGNET RESON MED, V49, P626, DOI 10.1002/mrm.10412
   Hug F, 2005, MED SCI SPORT EXER, V37, P846, DOI 10.1249/01.MSS.0000162616.20085.B4
   JENESON JAL, 1992, AM J PHYSIOL, V263, PC357, DOI 10.1152/ajpcell.1992.263.2.C357
   Jeneson JAL, 2000, AM J PHYSIOL-CELL PH, V279, PC813, DOI 10.1152/ajpcell.2000.279.3.C813
   Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995
   Johansen KL, 2001, INT J ARTIF ORGANS, V24, P183, DOI 10.1177/039139880102400402
   JONG YSA, 1983, ARCH BIOCHEM BIOPHYS, V222, P179, DOI 10.1016/0003-9861(83)90515-5
   Jubrias SA, 2003, J PHYSIOL-LONDON, V553, P589, DOI 10.1113/jphysiol.2003.045872
   Keilin D, 1929, P R SOC LOND B-CONTA, V104, P206, DOI 10.1098/rspb.1929.0009
   Keilin D, 1938, NATURE, V141, P870, DOI 10.1038/141870a0
   KEMP GJ, 1994, MAGNET RESON MED, V31, P103, DOI 10.1002/mrm.1910310203
   Kemp GJ, 2001, J VASC SURG, V34, P1103, DOI 10.1067/mva.2001.117152
   Kemper WF, 2001, P NATL ACAD SCI USA, V98, P723, DOI 10.1073/pnas.011387598
   Kent-Braun JA, 2000, J APPL PHYSIOL, V89, P1072, DOI 10.1152/jappl.2000.89.3.1072
   KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367
   KEYNES RD, 1964, NATURE, V203, P261, DOI 10.1038/203261a0
   Korzeniewski B, 2001, BIOPHYS CHEM, V92, P17, DOI 10.1016/S0301-4622(01)00184-3
   KORZENIEWSKI B, 1992, BIOCHIM BIOPHYS ACTA, V1102, P67, DOI 10.1016/0167-4838(92)90500-D
   Korzeniewski B, 2000, BIOPHYS CHEM, V83, P19, DOI 10.1016/S0301-4622(99)00120-9
   KREBS MA, 1937, ENZYMOLOGIA, V4, P149
   KUHL CK, 1994, RADIOLOGY, V192, P223, DOI 10.1148/radiology.192.1.8208943
   KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096
   Kutsuzawa T, 2001, MED SCI SPORT EXER, V33, P901, DOI 10.1097/00005768-200106000-00008
   Lanza IR, 2004, J APPL PHYSIOL, V97, P967, DOI 10.1152/japplphysiol.01351.2003
   LARDY HA, 1969, ANNU REV BIOCHEM, V38, P991, DOI 10.1146/annurev.bi.38.070169.005015
   LEIGH JS, 1981, FED PROC, V40, P586
   Linnane AW, 2002, ANN NY ACAD SCI, V959, P396, DOI 10.1111/j.1749-6632.2002.tb02110.x
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Malucelli Emil, 2005, DYN MED, V4, P7, DOI 10.1186/1476-5918-4-7
   Mancini L, 2005, MAGN RESON MED, V54, P1065, DOI 10.1002/mrm.20659
   Marcinek DJ, 2005, J PHYSIOL-LONDON, V569, P467, DOI 10.1113/jphysiol.2005.097782
   Marcinek DJ, 2004, AM J PHYSIOL-CELL PH, V286, PC457, DOI 10.1152/ajpcell.00237.2003
   Marcinek DJ, 2003, AM J PHYSIOL-HEART C, V285, PH1900, DOI 10.1152/ajpheart.00192.2003
   Mattei JP, 2002, BBA-BIOENERGETICS, V1554, P129, DOI 10.1016/S0005-2728(02)00226-8
   MATTHEWS PM, 1982, BIOCHIM BIOPHYS ACTA, V721, P312, DOI 10.1016/0167-4889(82)90084-2
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   MCCULLY KK, 1989, J APPL PHYSIOL, V67, P926, DOI 10.1152/jappl.1989.67.3.926
   MCCULLY KK, 1993, J APPL PHYSIOL, V75, P813, DOI 10.1152/jappl.1993.75.2.813
   MCFARLAND EW, 1994, BIOPHYS J, V67, P1912, DOI 10.1016/S0006-3495(94)80674-5
   MEYER RA, 1984, AM J PHYSIOL, V246, PC365, DOI 10.1152/ajpcell.1984.246.5.C365
   MEYER RA, 1988, AM J PHYSIOL, V254, PC548, DOI 10.1152/ajpcell.1988.254.4.C548
   MEYER RA, 1996, HDB PHYSL, V0, P0
   MEYERHOFF O, 1949, S RESP ENZYM, V0, P3
   MINOTTI JR, 1990, J APPL PHYSIOL, V68, P289, DOI 10.1152/jappl.1990.68.1.289
   OGAWA S, 1982, BIOCHEMISTRY-US, V21, P4467, DOI 10.1021/bi00261a042
   OZAWA T, 1995, BIOCHEM BIOPH RES CO, V213, P432, DOI 10.1006/bbrc.1995.2150
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Pette D, 1990, REV PHYSIOL BIOCHEM PHARMACOL, V116, P1
   PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x
   QUISTORFF B, 1993, BIOCHEM J, V291, P681, DOI 10.1042/bj2910681
   Richardson RS, 2002, BIOCHEM SOC T, V30, P232, DOI 10.1042/BST0300232
   Richardson RS, 2001, J APPL PHYSIOL, V91, P1845, DOI 10.1152/jappl.2001.91.4.1845
   Robergs RA, 2004, AM J PHYSIOL-REG I, V287, PR502, DOI 10.1152/ajpregu.00114.2004
   Rossiter HB, 2002, J APPL PHYSIOL, V93, P2059, DOI 10.1152/japplphysiol.00446.2002
   SAHLIN K, 1988, ACTA PHYSIOL SCAND, V134, P175, DOI 10.1111/j.1748-1716.1988.tb08477.x
   Sako T, 2001, J APPL PHYSIOL, V90, P338, DOI 10.1152/jappl.2001.90.1.338
   SAKS VA, 1977, BIOCHIM BIOPHYS ACTA, V465, P550, DOI 10.1016/0005-2736(77)90272-3
   SATRUSTEGUI J, 1988, MECH AGEING DEV, V42, P105, DOI 10.1016/0047-6374(88)90066-8
   Saupe KW, 1998, CIRC RES, V82, P898
   SCHAEFER S, 1988, J AM COLL CARDIOL, V12, P1449, DOI 10.1016/S0735-1097(88)80008-1
   Scheuermann-Freestone M, 2003, CIRCULATION, V107, P3040, DOI 10.1161/01.CIR.0000072789.89096.10
   Schneider-Gold C, 2004, MUSCLE NERVE, V30, P636, DOI 10.1002/mus.20156
   Schunk K, 1998, INVEST RADIOL, V33, P329, DOI 10.1097/00004424-199806000-00003
   Short KR, 2005, J APPL PHYSIOL, V99, P95, DOI 10.1152/japplphysiol.00129.2005
   Smith NP, 2005, PROG BIOPHYS MOL BIO, V88, P1, DOI 10.1016/j.pbiomolbio.2003.11.014
   Smith SA, 2004, J APPL PHYSIOL, V96, P2288, DOI 10.1152/japplphysiol.01021.2003
   SOBOLL S, 1978, EUR J BIOCHEM, V87, P377, DOI 10.1111/j.1432-1033.1978.tb12387.x
   t Zandt HJAI, 1999, NMR BIOMED, V12, P327, DOI 10.1002/(SICI)1099-1492(199910)12:6<327::AID-NBM570>3.0.CO;2-9
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   TWIEG DB, 1989, MAGN RESON MED, V12, P291, DOI 10.1002/mrm.1910120302
   Van Dorsten FA, 1998, AM J PHYSIOL-HEART C, V275, PH1191, DOI 10.1152/ajpheart.1998.275.4.H1191
   VANDENBORNE K, 1995, AM J PHYSIOL-CELL PH, V268, PC869, DOI 10.1152/ajpcell.1995.268.4.C869
   VANDENBORNE K, 1993, AM J PHYSIOL, V265, PC1332, DOI 10.1152/ajpcell.1993.265.5.C1332
   VANDENBORNE K, 1991, P NATL ACAD SCI USA, V88, P5714, DOI 10.1073/pnas.88.13.5714
   Vendelin M, 2000, AM J PHYSIOL-CELL PH, V278, PC747, DOI 10.1152/ajpcell.2000.278.4.C747
   Vicini P, 2000, AM J PHYSIOL-CELL PH, V279, PC213, DOI 10.1152/ajpcell.2000.279.1.C213
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7
   WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021
   WALLIMANN T, 1984, J BIOL CHEM, V259, P5238
   Warburg O, 1929, BIOCHEM Z, V214, P64
   Wasserman K, 1986, ADV CARDIOL, V35, P1
   Wegener G, 2002, BIOCHEM SOC T, V30, P264, DOI 10.1042/bst0300264
   Whipp BJ, 2002, BIOCHEM SOC T, V30, P237, DOI 10.1042/BST0300237
   WILLIAMS RJP, 1976, TRENDS BIOCHEM SCI, V1, PN222, DOI 10.1016/0968-0004(76)90158-4
   WOLEDGE RC, 1986, ENERGETIC ASPECTS MU, V0, P0
   YOSHIZAKI K, 1982, BIOPHYS J, V38, P209, DOI 10.1016/S0006-3495(82)84549-9
   Yu X, 1995, BIOPHYS J, V69, P2090, DOI 10.1016/S0006-3495(95)80080-9
   Zange J, 2003, MUSCLE NERVE, V27, P728, DOI 10.1002/mus.10377
   ZATINA MA, 1986, J VASC SURG, V3, P411
NR 168
TC 80
Z9 84
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3480
EI 1099-1492
J9 NMR BIOMED
JI NMR Biomed.
PD NOV 15
PY 2006
VL 19
IS 7
BP 904
EP 926
DI 10.1002/nbm.1109
PG 23
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 114DK
UT WOS:000242646700010
PM 17075955
DA 2024-11-01
ER

PT J
AU Minczuk, M
   Papworth, MA
   Kolasinska, P
   Murphy, MP
   Klug, A
AF Minczuk, Michal
   Papworth, Monika A.
   Kolasinska, Paulina
   Murphy, Michael P.
   Klug, Aaron
TI Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
LA English
DT Article
DE gene therapy; mitochondria; mitochondrial diseases; synthetic zinc finger peptides; nuclear export signal
ID transcription factors; gene-regulation; drug discovery; proteins; methyltransferases; binding; mouse; inhibition; therapy; disease
AB We used engineered zinc finger pepticles (ZFPs) to bind selectively to predetermined sequences in human mtDNA. Surprisingly, we found that engineered ZFPs cannot be reliably routed to mitochondria by using only conventional mitochondrial targeting sequences. We here show that addition of a nuclear export signal allows zinc finger chimeric enzymes to be imported into human mitochondria. The selective binding of mitochondria-specific ZFPs to mtDNA was exemplified by targeting the T8993G mutation, which causes two mitochondrial diseases, neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) and also maternally inherited Leigh's syndrome. To develop a system that allows the monitoring of site-specific alteration of mtDNA we combined a UP with the easily assayed DNA-modifying activity of hDNMT3a methylase. Expression of the mutation-specific chimeric methylase resulted in the selective methylation of cytosines adjacent to the mutation site. This is a proof of principle that it is possible to target and alter mtDNA in a sequence-specific manner by using zinc finger technology.
C1 MRC, Mol Biol Lab, Cambridge CB2 2QH, England.
   MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England.
C3 MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research
RP Minczuk, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.
EM mminczuk@mrc-lmb.cam.ac.uk; akl@mrc-lmb.cam.ac.uk
FU Medical Research Council [MC_U105184324, MC_U105663142] Funding Source: Medline; MRC [MC_U105184324, MC_U105663142] Funding Source: UKRI
CR Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758
   Carvin CD, 2003, NUCLEIC ACIDS RES, V31, P6493, DOI 10.1093/nar/gkg853
   CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   Eichwald V, 2002, J VIROL, V76, P10307, DOI 10.1128/JVI.76.20.10307-10319.2002
   Falke D, 2003, CURR OPIN MOL THER, V5, P161
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710
   Handa V, 2005, J MOL BIOL, V348, P1103, DOI 10.1016/j.jmb.2005.02.044
   HARTMANN CM, 1993, EUR J BIOCHEM, V218, P905, DOI 10.1111/j.1432-1033.1993.tb18446.x
   Isalan M, 1998, BIOCHEMISTRY-US, V37, P12026, DOI 10.1021/bi981358z
   Izquierdo JM, 2000, BIOCHEM J, V346, P849, DOI 10.1042/0264-6021:3460849
   Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087
   Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010
   Klug A, 2005, P JPN ACAD B-PHYS, V81, P87, DOI 10.2183/pjab.81.87
   Maekawa M, 2004, CLIN CHEM, V50, P1480, DOI 10.1373/clinchem.2004.035139
   Margeot A, 2005, GENE, V354, P64, DOI 10.1016/j.gene.2005.04.022
   McNamara AR, 2002, NUCLEIC ACIDS RES, V30, P3818, DOI 10.1093/nar/gkf501
   Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647
   Moore M, 2001, P NATL ACAD SCI USA, V98, P1437, DOI 10.1073/pnas.98.4.1437
   Mund C, 2004, BIOCHEM J, V378, P763, DOI 10.1042/BJ20031567
   Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1
   Papworth M, 2006, GENE, V366, P27, DOI 10.1016/j.gene.2005.09.011
   Papworth M, 2003, P NATL ACAD SCI USA, V100, P1621, DOI 10.1073/pnas.252773399
   Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006
   Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237
   Schon EA, 2000, TRENDS BIOCHEM SCI, V25, P555, DOI 10.1016/S0968-0004(00)01688-1
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793
   Urnov FD, 2005, NATURE, V435, P646, DOI 10.1038/nature03556
   Xu GL, 1997, NAT GENET, V17, P376, DOI 10.1038/ng1297-376
NR 33
TC 126
Z9 154
U1 1
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 26
PY 2006
VL 103
IS 52
BP 19689
EP 19694
DI 10.1073/pnas.0609502103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 123GX
UT WOS:000243285500017
PM 17170133
DA 2024-11-01
ER

PT J
AU Naïmi, M
   Bannwarth, S
   Procaccio, V
   Pouget, J
   Desnuelle, C
   Pellissier, JF
   Rötig, A
   Munnich, A
   Calvas, P
   Richelme, C
   Jonveaux, P
   Castelnovo, G
   Simon, M
   Clanet, M
   Wallace, D
   Paquis-Flucklinger, V
AF Naimi, Mourad
   Bannwarth, Sylvie
   Procaccio, Vincent
   Pouget, Jean
   Desnuelle, Claude
   Pellissier, Jean-Francois
   Rotig, Agnes
   Munnich, Arnold
   Calvas, Patrick
   Richelme, Christian
   Jonveaux, Philippe
   Castelnovo, Giovanni
   Simon, Melvin
   Clanet, Michel
   Wallace, Douglas
   Paquis-Flucklinger, Veronique
TI Molecular analysis of <i>ANT1</i>, <i>TWINKLE</i> and <i>POLG</i> in patients with multiple deletions or depletion of mitochondrial DNA by a dHPLC-based assay
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mtDNA multiple deletions; mtDNA depletion; dHPLC; ANT1; TWINKLE; POLG
ID progressive external ophthalmoplegia; polymerase-gamma mutations; ataxic neuropathy; alpers-syndrome; spacer-region
AB ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), spino-cerebellar ataxia and epilepsy (SCAE) or Alpers syndrome. In this study, we report on the mutational analysis of ANT1, TWINKLE and POLG genes in 15 unrelated patients, using a dHPLC-based protocol. This series of patients illustrates the large array of clinical presentations associated with mtDNA stability defects, ranging from isolated benign PEO to fatal Alpers syndrome. A total of seven different mutations were identified in six of 15 patients (40%). Six different recessive mutations were found in POLG, one in TWINKLE while no mutation was identified in ANT1. Among the POLG mutations, three are novel and include two missense and one frameshift changes. Seventeen neutral changes and polymorphisms were also identified, including four novel neutral polymorphisms. Overall, this study illustrates the variability of phenotypes associated with mtDNA stability defects, increases the mutational spectrum of POLG variants and provides an efficient and reliable detection protocol for ANT1, TWINKLE and POLG mutational screening.
C1 CHU Nice, Dept Med Genet, Archet Hosp 2, F-06202 Nice 3, France.
   INSERM, U145, Sch Med, Nice, France.
   Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA USA.
   CHU Marseille, Timone Hosp, Dept Neurol, Marseille, France.
   Archet Hosp 2, Dept Reeducat, Nice, France.
   CHU Marseille, Timone Hosp, Dept Neuropathol, Marseille, France.
   Hop Necker Enfants Malad, INSERM, U393, Paris, France.
   CHU Toulouse, Purpan Hosp, Dept Genet, Toulouse, France.
   CHU Nice, Dept Pediat, Archet Hosp 2, Nice, France.
   CHU Nancy, Brabois Hosp, Dept Genet, Nancy, France.
   CHU Nimes, Caremeau Hosp, Dept Neurol, Nimes, France.
   CHU Toulouse, Purpan Hosp, Dept Neurol, Toulouse, France.
   CNRS, UMR 6543, Sch Med, F-06034 Nice, France.
C3 CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Cote d'Azur; University of California System; University of California Irvine; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Nice; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU Nice; CHU de Nancy; Universite de Montpellier; CHU de Nimes; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)
RP Paquis-Flucklinger, V (corresponding author), CHU Nice, Dept Med Genet, Archet Hosp 2, 151,Route St Antoine Ginestiere,BP 3079, F-06202 Nice 3, France.
EM paquis@hermes.unice.fr
CR Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 15
TC 41
Z9 43
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD AUG 15
PY 2006
VL 14
IS 8
BP 917
EP 922
DI 10.1038/sj.ejhg.5201627
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 067TU
UT WOS:000239326300009
PM 16639411
DA 2024-11-01
ER

PT J
AU Longley, MJ
   Clark, S
   Man, CYW
   Hudson, G
   Durham, SE
   Taylor, RW
   Nightingale, S
   Turnbull, DM
   Copeland, WC
   Chinnery, PF
AF Longley, Matthew J.
   Clark, Susanna
   Man, Cynthia Yu Wai
   Hudson, Gavin
   Durham, Steve E.
   Taylor, Robert W.
   Nightingale, Simon
   Turnbull, Douglass M.
   Copeland, William C.
   Chinnery, Patrick F.
TI Mutant <i>POLG2</i> disrupts DNA polymerase γ subunits and causes progressive external ophthalmoplegia
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID accessory subunit; alpers-syndrome; autosomal-dominant; mutations; binding; identification; depletion; deletions; muscle
AB DNA polymerase gamma (pol gamma) is required to maintain the genetic integrity of the 16,569-bp human mitochondrial genome (mtDNA). Mutation of the nuclear gene for the catalytic subunit of pol gamma (POLG) has been linked to a wide range of mitochondrial diseases involving mutation, deletion, and depletion of mtDNA. We describe a heterozygous dominant mutation (c.1352G -> A/p.G451E) in POLG2, the gene encoding the p55 accessory subunit of pol gamma, that causes progressive external ophthalmoplegia with multiple mtDNA deletions and cytochrome c oxidase (COX)-deficient muscle fibers. Biochemical characterization of purified, recombinant G451E-substituted p55 protein in vitro revealed incomplete stimulation of the catalytic subunit due to compromised subunit interaction. Although G451E p55 retains a wild-type ability to bind DNA, it fails to enhance the DNA-binding strength of the p140-p55 complex. In vivo, the disease most likely arises through haplotype insufficiency or heterodimerization of the mutated and wild-type proteins, which promote mtDNA deletions by stalling the DNA replication fork. The progressive accumulation of mtDNA deletions causes COX deficiency in muscle fibers and results in the clinical phenotype.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Natl Inst Environm Hlth Sci, Mol Genet Lab, NIH, Res Triangle Pk, NC USA.
   Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Royal Shrewsbury Hosp, Shrewsbury, Salop, England.
C3 Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Newcastle University - UK
RP Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
FU Intramural NIH HHS Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline
CR Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley Matthew J, 2002, METHODS MOL BIOL, V197, P245, DOI 10.1385/1-59259-284-8:245
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 26
TC 181
Z9 200
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
EI 
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN 15
PY 2006
VL 78
IS 6
BP 1026
EP 1034
DI 10.1086/504303
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 042TZ
UT WOS:000237553800011
PM 16685652
DA 2024-11-01
ER

PT J
AU Scaglia, F
   Northrop, JL
AF Scaglia, Fernando
   Northrop, Jennifer L.
TI The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome - A review of treatment options
SO CNS DRUGS
LA English
DT Review
ID magnetic-resonance-spectroscopy; wobble modification deficiency; c-oxidase deficiency; point mutation; cytochrome-c; l-arginine; trna(leu(uur)) gene; nitric-oxide; lipid-peroxidation; clinical-features
AB Mitochondrial encephalomyopathies are a multisystemic group of disorders that are characterised by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Among this group of disorders, the mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome is one of the most frequently occurring, maternally inherited mitochondrial disorders. As the name implies, stroke-like episodes are the defining feature of the MELAS syndrome, often occurring before the age of 15 years. The clinical course of this disorder is highly variable, ranging from asymptomatic, with normal early development, to progressive muscle weakness, lactic acidosis, cognitive dysfunction, seizures, stroke-like episodes, encephalopathy and premature death. This syndrome is associated with a number of point mutations in the mitochondrial DNA, with over 80% of the mutations occurring in the dihydrouridine loop of the mitochondrial transfer RNALeu(UUR) [tRNALeu(UUR)] gene. The pathophysiology of the disease is not completely understood; however, several different mechanisms are proposed to contribute to this disease. These include decreased aminoacylation of mitochondrial tRNA, resulting in decreased mitochondrial protein synthesis; changes in calcium homeostasis; and alterations in nitric oxide metabolism. Currently, no consensus criteria exist for treating the MELAS syndrome or mitochondrial dysfunction in other diseases. Many of the therapeutic strategies used have been adopted as the result of isolated case reports or limited clinical studies that have included a heterogeneous population of patients with the MELAS syndrome, other defects in oxidative phosphorylation or lactic acidosis due to disorders of pyruvate metabolism. Current approaches to the treatment of the MELAS syndrome are based on the use of antioxidants, respiratory chain substrates and cofactors in the form of vitamins, however, no consistent benefits have been observed with these treatments.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Texas Childrens Hosp, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine
RP Scaglia, F (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Suite 1560,6621 Fannin,Mail Code CC1560, Houston, TX 77030 USA.
EM fscaglia@bcm.tmc.edu
CR ABE K, 1991, ACTA NEUROL SCAND, V83, P356, DOI 10.1111/j.1600-0404.1991.tb03962.x
   ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Bank William, 1998, BIOFACTORS, V7, P243
   BARAK Y, 1995, ISRAEL J MED SCI, V31, P224
   BARBIROLI B, 1995, J NEUROL, V242, P472, DOI 10.1007/BF00873552
   Barisic N, 2002, NEUROPEDIATRICS, V33, P157, DOI 10.1055/s-2002-33679
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   CHABROL B, 1994, EUR J PEDIATR, V153, P133, DOI 10.1007/BF01959226
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   CLARK AS, 1987, J CLIN INVEST, V79, P588, DOI 10.1172/JCI112851
   COOPER JM, 1992, BRAIN, V115, P991
   COTARIU D, 1988, CLIN CHEM, V34, P890
   Craigen WJ, 1996, PEDIATR NEUROL, V14, P69, DOI 10.1016/0887-8994(96)00005-7
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   De Vivo D, 1990, INT PEDIATR, V5, P134
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DOUGHERTY FE, 1994, J PEDIATR-US, V125, P758, DOI 10.1016/S0022-3476(94)70073-7
   ENNS GM, 2000, J PEDIATR, V136, P147
   Fabrizi GM, 1996, J NEUROL NEUROSUR PS, V61, P47, DOI 10.1136/jnnp.61.1.47
   FRACKOWIAK RSJ, 1988, BRAIN, V111, P1009, DOI 10.1093/brain/111.5.1009
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GUBBAY SS, 1989, MED J AUSTRALIA, V151, P100, DOI 10.5694/j.1326-5377.1989.tb101170.x
   Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411
   HAGENFELDT L, 1994, MUSCLE NERVE, V17, P1236
   HARRIS RC, 1992, CLIN SCI, V83, P367, DOI 10.1042/cs0830367
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   HeimanPatterson TD, 1997, MUSCLE NERVE, V20, P1219, DOI 10.1002/(SICI)1097-4598(199710)20:10<1219::AID-MUS2>3.0.CO;2-F
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   HSU CC, 1995, ACTA NEUROL SCAND, V92, P252
   ICHIKI T, 1988, ANN NEUROL, V23, P287, DOI 10.1002/ana.410230312
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Ikejiri Y, 1996, NEUROLOGY, V47, P583, DOI 10.1212/WNL.47.2.583
   IMADA I, 1989, ARCH GERONTOL GERIAT, V8, P323, DOI 10.1016/0167-4943(89)90014-9
   Jacob S, 1996, EXP CLIN ENDOCR DIAB, V104, P284, DOI 10.1055/s-0029-1211455
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kariya S, 2005, NEUROPEPTIDES, V39, P97, DOI 10.1016/j.npep.2004.11.004
   Kariya S, 2003, MOL CELL BIOCHEM, V254, P83, DOI 10.1023/A:1027372519726
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Koge Y, 1998, ANN NEUROL, V43, P835, DOI 10.1002/ana.410430620
   Kubota M, 2004, BRAIN DEV-JPN, V26, P481, DOI 10.1016/j.braindev.2004.01.006
   Kuroda Y, 1997, J PEDIATR-US, V131, P450, DOI 10.1016/S0022-3476(97)80075-3
   Kurogouchi F, 1998, AM J NEPHROL, V18, P551, DOI 10.1159/000013406
   Lam CW, 1997, EUR J PEDIATR, V156, P562, DOI 10.1007/s004310050663
   LANDI L, 1984, BIOCHEM J, V222, P463, DOI 10.1042/bj2220463
   Lenaz G, 2004, BBA-BIOENERGETICS, V1658, P89, DOI 10.1016/j.bbabio.2004.03.013
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa K, 1997, MOL CELL BIOCHEM, V174, P291, DOI 10.1023/A:1006833200371
   Majamaa K, 1996, LIFE SCI, V58, P691, DOI 10.1016/0024-3205(95)02338-0
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   MASTAGLIA FL, 1980, AUST NZ J MED, V10, P660, DOI 10.1111/j.1445-5994.1980.tb04250.x
   MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368
   MATTHEWS PM, 1993, NEUROLOGY, V43, P884, DOI 10.1212/WNL.43.5.884
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   Mori M, 2004, BRAIN DEV-JPN, V26, P453, DOI 10.1016/j.braindev.2003.12.009
   Morovvati S, 2002, ACTA NEUROL SCAND, V106, P104, DOI 10.1034/j.1600-0404.2002.01172.x
   MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   NAKAKI T, 1990, LANCET, V336, P696, DOI 10.1016/0140-6736(90)92196-O
   Napolitano A, 2000, NEUROL SCI, V21, PS981, DOI 10.1007/s100720070015
   Oguro H, 2004, INTERNAL MED, V43, P427, DOI 10.2169/internalmedicine.43.427
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohkoshi N, 1998, J MED, V29, P13
   Pavlakis SG, 1998, ARCH NEUROL-CHICAGO, V55, P849, DOI 10.1001/archneur.55.6.849
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Pisano P, 1996, EUR J CLIN PHARMACOL, V51, P167, DOI 10.1007/s002280050179
   PONCHAUT S, 1992, BIOCHEM PHARMACOL, V43, P644, DOI 10.1016/0006-2952(92)90590-F
   RADDA GK, 1995, BBA-MOL BASIS DIS, V1271, P15, DOI 10.1016/0925-4439(95)00004-N
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   RATNIKOVA L A, 1978, BIOKHIMIYA, V43, P1989
   Remes AM, 2002, NEUROLOGY, V59, P1275, DOI 10.1212/WNL.59.8.1275
   Rossi FH, 2002, NEUROLOGIST, V8, P313, DOI 10.1097/00127893-200209000-00004
   RUMBACH L, 1986, MOL PHARMACOL, V30, P270
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Sampson V, 2001, EUR J BIOCHEM, V268, P6534, DOI 10.1046/j.0014-2956.2001.02608.x
   SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x
   SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   SHIMOMURA T, 1994, LANCET, V344, P625, DOI 10.1016/S0140-6736(94)92015-X
   Shoffner JM, 2001, METABOLIC MOL BASES, V0, P2367
   SHOFFNER JM, 1997, CURRENT THERAPY NEUR, V0, P332
   SKOGLUND RR, 1979, NEUROLOGY, V29, P717, DOI 10.1212/WNL.29.5.717
   Spruijt L, 2001, MUSCLE NERVE, V24, P916, DOI 10.1002/mus.1089.abs
   STACPOOLE PW, 1990, FUND APPL TOXICOL, V14, P327, DOI 10.1016/0272-0590(90)90212-3
   Stacpoole PW, 1998, ENVIRON HEALTH PERSP, V106, P989, DOI 10.1289/ehp.98106s4989
   STANSBIE D, 1976, CLIN SCI MOL MED, V51, P445, DOI 10.1042/cs0510445
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Takanashi J, 1997, J NEUROL SCI, V145, P83, DOI 10.1016/S0022-510X(96)00248-1
   TAMOPOLSKY MA, 2001, ANN NEUROL, V49, P561
   Tanaka J, 1997, BRAIN DEV-JPN, V19, P262, DOI 10.1016/S0387-7604(97)00573-1
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor D E, 1996, NEW HORIZ, V4, P420
   Thambisetty M, 2002, NEUROLOGIST, V8, P302, DOI 10.1097/00127893-200209000-00003
   Toda N, 2003, PHARMACOL REV, V55, P271, DOI 10.1124/pr.55.2.3
   TORII H, 1985, J PHARMACOBIO-DYNAM, V8, P457
   TRITSCHLER HJ, 1993, NEUROLOGY, V43, P280, DOI 10.1212/WNL.43.2.280
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   VOROBJEV IA, 1983, FEBS LETT, V163, P311, DOI 10.1016/0014-5793(83)80842-4
   Vos MH, 2001, BIOCHEMISTRY-US, V40, P7806, DOI 10.1021/bi010060x
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310
   Wilichowski E, 1999, NEUROPEDIATRICS, V30, P256, DOI 10.1055/s-2007-973500
   WILLMORE LJ, 1984, J NEUROSURG, V60, P467, DOI 10.3171/jns.1984.60.3.0467
   Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
   Zeviani Massimo, 1993, EUROPEAN JOURNAL OF HUMAN GENETICS, V1, P80
NR 132
TC 69
Z9 84
U1 0
U2 12
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1172-7047
EI 1179-1934
J9 CNS DRUGS
JI CNS Drugs
PD JUN 15
PY 2006
VL 20
IS 6
BP 443
EP 464
DI 10.2165/00023210-200620060-00002
PG 22
WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 063WP
UT WOS:000239050900002
PM 16734497
DA 2024-11-01
ER

PT J
AU Yamasoba, T
   Goto, YI
   Komaki, H
   Mimaki, M
   Sudo, A
   Suzuki, M
AF Yamasoba, T
   Goto, YI
   Komaki, H
   Mimaki, M
   Sudo, A
   Suzuki, M
TI Cochlear damage due to germanium-induced mitochondrial dysfunction in guinea pigs
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE hearing loss; mitochondrial myopathy; mitochondrial DNA; cochlea; muscle; kidney
ID hearing-loss; myopathy; deafness; dna; mutation; dioxide; disease; melas; model; gene
AB This investigation addressed the effect of germanium dioxide (GeO2)-induced mitochondrial dysfunction on hearing acuity. Guinea pigs were fed chow that contained 0%, 0.15%, or 0.5% GeO2. The animals that were fed 0.5% GeO2 for 2 months developed hearing impairment chiefly due to degeneration of stria vascularis and cochlear supporting cells, which exhibited electron-dense mitochondrial inclusions. Cytochrome c oxidase activity was decreased in the skeletal muscles and kidney, which also exhibited electron-dense mitochondrial inclusions. No apparent pathological changes were observed in the utricle, semicircular canal, or among the vestibular nerve fibers, or in the liver or heart The untreated animals and those treated with 0.15% GeO2 did not exhibit hearing impairment or pathological changes in any organs. These findings suggest that administration of 0.5% GeO2 induces mitochondrial dysfunction in the stria vascularis and supporting cells in the cochlea, as in the skeletal muscles and kidney, thereby causing hearing impairment in the guinea pigs. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Tokyo, Dept Otolaryngol Head & Neck Surg, Bunkyo Ku, Tokyo 1138655, Japan.
   Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
C3 University of Tokyo; National Center for Neurology & Psychiatry - Japan
RP Yamasoba, T (corresponding author), Univ Tokyo, Dept Otolaryngol Head & Neck Surg, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.
EM tyamasoba-tky@umin.ac.jp
CR Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Fischel-Ghodsian N, 2003, EAR HEARING, V24, P303, DOI 10.1097/01.AUD.0000079802.82344.B5
   HIGUCHI I, 1989, ACTA NEUROPATHOL, V79, P300, DOI 10.1007/BF00294665
   HIGUCHI I, 1991, ACTA NEUROPATHOL, V82, P55, DOI 10.1007/BF00310923
   Hoya N, 2004, NEUROREPORT, V15, P1597, DOI 10.1097/01.wnr.0000133226.94662.80
   Li Xiaodong, 2001, CHINESE MEDICAL SCIENCES JOURNAL, V16, P157
   LINDSAY JR, 1976, ARCH OTOLARYNGOL, V102, P747
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   SANAI T, 1990, TOXICOL APPL PHARM, V103, P345, DOI 10.1016/0041-008X(90)90234-L
   SANAI T, 1990, NEPHRON, V54, P53, DOI 10.1159/000185810
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Sugawara M, 2005, JARO-J ASSOC RES OTO, V6, P136, DOI 10.1007/s10162-004-5050-1
   Takahashi K, 2003, LARYNGOSCOPE, V113, P1362, DOI 10.1097/00005537-200308000-00018
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   WU CM, 1992, MUSCLE NERVE, V15, P1258, DOI 10.1002/mus.880151107
   Yamasoba T, 1996, LARYNGOSCOPE, V106, P49, DOI 10.1097/00005537-199601000-00010
   Yamasoba T, 1999, BRAIN RES, V815, P317, DOI 10.1016/S0006-8993(98)01100-7
   Yamasoba T, 1999, NEUROLOGY, V52, P1705, DOI 10.1212/WNL.52.8.1705
   Yamasoba T, 1996, HEARING RES, V102, P116, DOI 10.1016/S0378-5955(96)00159-1
NR 20
TC 18
Z9 19
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0304-3940
EI 
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD FEB 27
PY 2006
VL 395
IS 1
BP 18
EP 22
DI 10.1016/j.neulet.2005.10.045
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 013KK
UT WOS:000235408000004
PM 16289317
DA 2024-11-01
ER

PT J
AU Procaccio, V
   Neckelmann, N
   Paquis-Flucklinger, V
   Bannwarth, S
   Jimenez, R
   Davila, A
   Poole, JC
   Wallace, DC
AF Procaccio, Vincent
   Neckelmann, Nicolas
   Paquis-Flucklinger, Veronique
   Bannwarth, Sylvic
   Jimenez, Richard
   Davila, Antonio
   Poole, Jason C.
   Wallace, Douglas C.
TI Detection of low levels of the mitochondrial tRNA<SUP>Leu</SUP>(UUR) 3243A&gt;G mutation in blood derived from patients with diabetes
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Article
ID stroke-like episodes; lactic-acidosis; dna mutations; point mutation; deafness; a3243g; melas; gene; encephalomyopathy; electrophoresis
AB Background: Mutations in the human mitochondrial genome have been suspected to play a significant role in the etiological development of mitochondrial diabetes. Detection of the 3243A>G mutation in the mitochondrial transfer RNA(Leu)(UUR) gene (MTTL1), especially at low heteroplasmy levels, is highly desirable since it facilitates the diagnosis and subsequent management of the disease. The proportions of mutant mitochondrial DNA (mtDNA) can vary between tissues and are usually significantly higher in muscle than in blood, but muscle biopsies from patients with diabetes are rarely available. Methods: Here, we describe a technique that can not only determine the presence of MTTL1 3243A>G. but can also estimate the percentage of mutant DNA. The technique is based on the use of the WAVE(R) system for the high-performance liquid chromatography (HPLC)-mediated analysis of mutation-specific restriction fragments derived from mutant PCR amplicons. PCR amplicon restriction fragment analysis by HPLC (PARFAH) can also be used for the detection of other mutations. Results: This PARFAH analytical approach led to the discovery of the 3243A>G mutation in blood samples from a series of patients who had initially been reported to lack the mutation, even though matrilineal relatives had been shown to harbor the mutation associated with maternally inherited diabetes and deafness (MIDD) or mitochondrial myopathy encephalopathy lactic acidosis stroke-like episodes (MELAS) phenotypes. We have established that the PARFAH method can reliably detect as little as 1% mutant DNA in a sample, which would normally be missed by commonly used gel electrophoresis or sequencing methods. Conclusions: The PARFAH method not only provides a sensitive, high-throughput. and cost-effective strategy for the detection of low levels of mtDNA mutations in peripheral tissues, but also facilitates the estimation of the percentage of mutant DNA in the sample. The fact that samples can be readily obtained from peripheral tissues in many cases will avoid the need for invasive muscle biopsies. Our ability to detect low levels of mtDNA mutations in blood samples of carriers will allow us to reassess the prevalence of the MTTL1 3243A>G mutation in patients with diabetes.
C1 Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
   Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA.
   Transgenomic Inc, Omaha, NE USA.
   Archet 2 Hosp, Dept Med Genet, Nice, France.
   Univ Nice, Sch Med, FRE CNRS UNSA 2720, Nice, France.
   Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92717 USA.
C3 University of California System; University of California Irvine; University of California System; University of California Irvine; CHU Nice; Universite Cote d'Azur; University of California System; University of California Irvine
RP Procaccio, V (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
EM vproca@uci.edu
FU NHLBI NIH HHS [HL64017] Funding Source: Medline; NIA NIH HHS [AG13154, AG24373] Funding Source: Medline; NIDDK NIH HHS [DK73691] Funding Source: Medline; NINDS NIH HHS [NS41850, NS21328] Funding Source: Medline
CR BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Gebhart SSP, 1996, METABOLISM, V45, P526, DOI 10.1016/S0026-0495(96)90231-0
   Girald-Rosa W, 2005, CLIN CHEM, V51, P305, DOI 10.1373/clinchem.2004.040311
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guigas B, 2004, BIOCHEM J, V382, P877, DOI 10.1042/BJ20040885
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   King M P, 1996, METHODS ENZYMOL, V264, P339, DOI 10.1016/S0076-6879(96)64032-4
   Lamson Davis W, 2002, ALTERN MED REV, V7, P94
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Olsson C, 2001, EUR J HUM GENET, V9, P917, DOI 10.1038/sj.ejhg.5200742
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   THART LM, 1994, DIABETOLOGIA, V37, P1169
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334
   Trounce I A, 1996, METHODS ENZYMOL, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, P0, DOI 10.1093/nar/28.20.e89
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VIALETTES B, 1995, DIABETES CARE, V18, P1023, DOI 10.2337/diacare.18.7.1023
   Wallace DC, 2002, EMERY AND RIMOINS PRINCIPLES AND PRACTICE OF MEDICAL GENETICS, V0, P299
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
NR 31
TC 8
Z9 11
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PD JUN 15
PY 2006
VL 10
IS 6
BP 381
EP 389
DI 10.1007/BF03256215
PG 9
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 127EF
UT WOS:000243567400006
PM 17154655
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, Salvatore
TI Mitochondrial myopathies
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE Alpers syndrome; coenzyme Q10 deficiency; mitochondrial DNA; mitochondrial DNA depletion; multiple mitochondrial DNA deletions; nuclear DNA
ID polg mutations; dna; deficiency; cardiolipin; gene; disease; encephalomyopathy; diagnosis; subunits; spectrum
AB Purpose of review Our understanding of mitochondrial diseases (defined restrictively as defects of the mitochondrial respiratory chain) is expanding rapidly. In this review, I will give the latest information on disorders affecting predominantly or exclusively skeletal muscle. Recent findings The most recently described mitochondrial myopathies are due to defects in nuclear DNA, including coenzyme Q10 deficiency and mutations in genes controlling mitochondrial DNA abundance and structure, such as POLG, TK2, and MPV17. Barth syndrome, an X-linked recessive mitochondrial myopathy/cardiopathy, is associated with decreased amount and altered structure of cardiolipin, the main phospholipid of the inner mitochondrial membrane, but a secondary impairment of respiratory chain function is plausible. The role of mutations in protein-coding genes of mitochondrial DNA in causing isolated myopathies has been confirmed. Mutations in tRNA genes of mitochondrial DNA can also cause predominantly myopathic syndromes and - contrary to conventional wisdom - these mutations can be homoplasmic. Summary Defects in the mitochondrial respiratory chain impair energy production and almost invariably involve skeletal muscle, causing exercise intolerance, cramps, recurrent myoglobinuria, or fixed weakness, which often affects extraocular muscles and results in droopy eyelids (ptosis) and progressive external ophthalmoplegia.
C1 Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
C3 Columbia University
RP DiMauro, S (corresponding author), 4 420 Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline
CR Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Crimi M, 2005, IUBMB LIFE, V57, P811, DOI 10.1080/15216540500460269
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Curbo S, 2006, GENOMICS, V87, P410, DOI 10.1016/j.ygeno.2005.09.017
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   DIMAURO S, 2006, MITOCHONDRIAL MED, V0, P0
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Goios A, 2005, J INHERIT METAB DIS, V28, P769, DOI 10.1007/s10545-005-0023-z
   Hays AP, 2006, MITOCHONDRIAL MEDICINE, V0, P45
   Hirano M, 2006, MITOCHONDRIAL MEDICINE, V0, P27
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamperti C, 2005, ARCH NEUROL-CHICAGO, V62, P1709, DOI 10.1001/archneur.62.11.1709
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   McPherson E, 2006, AM J MED GENET A, V140A, P184, DOI 10.1002/ajmg.a.31041
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Owczarek J, 2005, PHARMACOL REP, V57, P23
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Pulkes T, 2005, NEUROLOGY, V64, P1091, DOI 10.1212/01.WNL.0000154471.33156.55
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Sedlák E, 2006, BIOCHEMISTRY-US, V45, P746, DOI 10.1021/bi050870z
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200
NR 51
TC 79
Z9 94
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8711
EI 1531-6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD NOV 15
PY 2006
VL 18
IS 6
BP 636
EP 641
DI 10.1097/01.bor.0000245729.17759.f2
PG 6
WC Rheumatology
SC Rheumatology
GA 108VF
UT WOS:000242266600012
PM 17053512
DA 2024-11-01
ER

PT J
AU Durham, SE
   Samuels, DC
   Chinnery, PF
AF Durham, S. E.
   Samuels, D. C.
   Chinnery, P. F.
TI Is selection required for the accumulation of somatic mitochondrial DNA mutations in post-mitotic cells?
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA; ageing; mutation
ID mtdna point mutations; control region; human tissue; muscle; replication; age; transcription; polymerase; frequency; sequence
AB Mitochondrial DNA (mtDNA) mutations accumulate in the skeletal muscle of patients with mtDNA disease, and also as part of healthy ageing. Simulations of human muscle fibres suggest that, over many decades, the continuous destruction and copying of mtDNA (relaxed replication) can lead to dramatic changes in the percentage level of mutant mtDNA in non-dividing cells through random genetic drift. This process should apply to both pathogenic and neutral mutations. To test this hypothesis we sequenced the entire mitochondrial genome for 20 muscle fibres from a healthy elderly 85-year-old individual, chosen because of the low frequency of cytochrome c oxidase negative fibres. Phenotypically neutral single base substitutions were detected in 15% of the healthy fibres, supporting the hypothesis that positive selection is not essential for the clonal expansion of mtDNA point mutations during human life. Treatments that enhance mtDNA replication, such as vigorous excercise, could amplify this process, with potentially detrimental long-term consequences. (C) 2006 Elsevier B.V. All fights reserved.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
   Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Virginia Polytechnic Institute & State University; Newcastle University - UK
RP Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, M4014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Calloway CD, 2000, AM J HUM GENET, V66, P1384, DOI 10.1086/302844
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014
   CORTOPASSI G, 1990, NUCLEIC ACIDS RES, V275, P169
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   DELBO R, 2003, NEUROLOGY, V0, P0
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   KUNKEL TA, 1986, J BIOL CHEM, V261, P3581
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Michikawa Y, 1999, SOMAT CELL MOL GENET, V25, P333, DOI 10.1023/A:1019972500785
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Samuels DC, 2003, NUCLEIC ACIDS RES, V31, P6043, DOI 10.1093/nar/gkg784
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 27
TC 17
Z9 18
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN 15
PY 2006
VL 16
IS 6
BP 381
EP 386
DI 10.1016/j.nmd.2006.03.012
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 064ZT
UT WOS:000239129900005
PM 16684599
DA 2024-11-01
ER

PT J
AU Engel, WK
   Askanas, V
AF Engel, WK
   Askanas, V
TI Inclusion-body myositis - Clinical, diagnostic, and pathologic aspects
SO NEUROLOGY
LA English
DT Article
ID amyloid precursor protein; mitochondrial-dna deletions; paired-helical filaments; alzheimers-disease; muscle-fibers; transthyretin val122ile; cardiac amyloidosis; tau epitopes; a-beta; ubiquitin
AB The diagnostic aspects of sporadic inclusion-body myositis (s-IBM), and a few comments on our own approach to its treatment, are presented to foster the goals of this symposium, which was organized to provoke new ideas concerning the cause and treatment of this currently unsolvable disease. s-IBM is the most common, progressive, debilitating muscle disease beginning in persons over age 50 years, and it is more common in men. Diagnostic parameters reviewed are clinical, muscle-biopsy histochemistry, electrophysiologic and CSF evaluations. Overall, the degenerative phenomena in s-IBM muscle fibers seem to be the major cause of the progressive, unstoppable weakness, rather than the lymphocytic inflammation. Available treatments are of only slight, temporary benefit for only some s-IBM patients, indicating a desperate need for definitive therapies.
C1 USC, Good Samaritan Hosp, Neuromuscular Ctr,Keck Sch Med, Dept Neurol, Los Angeles, CA 90017 USA.
C3 University of Southern California; University of Southern California Keck Hospital
RP USC, Good Samaritan Hosp, Neuromuscular Ctr,Keck Sch Med, Dept Neurol, 637 S Lucas Ave, Los Angeles, CA 90017 USA.
EM askanas@hsc.usc.edu
FU NIA NIH HHS [AG16768] Funding Source: Medline; NINDS NIH HHS [NS31836, NS34103] Funding Source: Medline
CR ALROY J, 2004, MYOLOGY BASIC CLIN, V0, P565
   Alvarez RB, 2000, NEUROLOGY, V54, P0
   Alvarez RB, 1998, NEUROLOGY, V50, P0
   Argov Z, 1998, INCLUSION BODY MYOSI, V0, P200
   Askanas V, 2000, ANN NEUROL, V48, P439
   ASKANAS V, 1992, ACTA NEUROPATHOL, V84, P335
   Askanas V, 2006, NEUROLOGY, V66, PS39, DOI 10.1212/01.wnl.0000192128.13875.1e
   Askanas V, 2005, MICROSC RES TECHNIQ, V67, P114, DOI 10.1002/jemt.20186
   ASKANAS V, 1993, NEUROLOGY, V43, P1265, DOI 10.1212/WNL.43.6.1265-a
   Askanas V, 2000, ANN NEUROL, V47, P544, DOI 10.1002/1531-8249(200004)47:4<544::AID-ANA24>3.0.CO;2-D
   Askanas V, 2003, CURR OPIN RHEUMATOL, V15, P737, DOI 10.1097/00002281-200311000-00009
   Askanas V, 2003, NEUROLOGY, V61, P257, DOI 10.1212/01.WNL.0000071219.85847.4E
   Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002
   Askanas V, 1996, ANN NEUROL, V39, P389, DOI 10.1002/ana.410390318
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   ASKANAS V, 1992, NEUROSCI LETT, V143, P96, DOI 10.1016/0304-3940(92)90241-X
   ASKANAS V, 1992, NEUROLOGY, V42, P460, DOI 10.1212/WNL.42.2.460
   Askanas V, 2001, J NEUROPATH EXP NEUR, V60, P1
   ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408
   ASKANAS V, 1994, AM J PATHOL, V144, P177
   Askanas V, 1998, ANN NY ACAD SCI, V841, P28, DOI 10.1111/j.1749-6632.1998.tb10908.x
   Askanas V, 1997, NEUROLOGY, V48, P41002
   ASKANAS V, 2003, MOL GENETIC BASIS NE, V0, P501
   ASKANAS V, 1977, PATHOGENESIS HUMAN M, V0, P856
   ASKANAS V, 1998, INCLUSION BODY MYOSI, V0, P3
   Askanas Valerie, 1993, CURRENT OPINION IN RHEUMATOLOGY, V5, P732
   Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164
   Cupler EJ, 1996, BRAIN, V119, P1887, DOI 10.1093/brain/119.6.1887
   Dalakas Marinos C, 2001, CURRENT OPINION IN PHARMACOLOGY, V1, P300, DOI 10.1016/S1471-4892(01)00053-4
   Dalakas MC, 2006, NEUROLOGY, V66, PS33, DOI 10.1212/01.wnl.0000192129.65677.87
   Dalakas MC, 1997, NEUROLOGY, V48, P712, DOI 10.1212/WNL.48.3.712
   de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001
   Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718
   Engel W K, 2003, ACTA MYOL, V22, P97
   Engel WK, 1998, INCLUSION BODY MYOSI, V0, P351
   ENGEL WK, 1962, NEUROLOGY, V12, P778, DOI 10.1212/WNL.12.11.778
   ENGEL WK, 1979, ARCH NEUROL-CHICAGO, V36, P329, DOI 10.1001/archneur.1979.00500420039003
   ENGEL WK, 1990, NEW ENGL J MED, V323, P552
   ENGEL WK, 1977, J NEUROL, V215, P161, DOI 10.1007/BF00312474
   ENGEL WK, 1973, NEW ENGL J MED, V289, P485
   ENGEL WK, 1970, J HISTOCHEM CYTOCHEM, V18, P55, DOI 10.1177/18.1.55
   ENGEL WK, 1975, NEUROLOGY, V25, P173, DOI 10.1212/WNL.25.2.173
   Engel WK, 2001, LANCET, V358, P2086, DOI 10.1016/S0140-6736(01)07123-9
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Engel WK, 1997, NEUROLOGY, V48, P2101
   ENGEL WK, 1977, SCI APPROACHES CLIN, V0, P0
   ENGEL WK, 1971, EXCERPTA MED INT C S, V237, P28
   ENGEL WK, 1965, P INT C NEUROLOGY, V2, P67
   ENGEL WK, 1979, PERONEAL ATROPHIES R, V0, P339
   Glabe CG, 2006, NEUROLOGY, V66, PS74, DOI 10.1212/01.wnl.0000192103.24796.42
   Griggs RC, 2006, NEUROLOGY, V66, PS30, DOI 10.1212/01.wnl.0000192262.29924.9e
   Hampton T, 2005, JAMA-J AM MED ASSOC, V294, P411, DOI 10.1001/jama.294.4.411
   Hashimoto M, 2003, NEUROMOL MED, V4, P21, DOI 10.1385/NMM:4:1-2:21
   Jacobson DR, 1997, NEW ENGL J MED, V336, P466, DOI 10.1056/NEJM199702133360703
   KARPATI G, 1968, NEUROLOGY, V18, P447
   KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410
   KULA RW, 1977, LANCET, V1, P92
   Mastaglia FL, 2003, MUSCLE NERVE, V27, P407, DOI 10.1002/mus.10313
   McFerrin J, 1998, NEUROREPORT, V9, P3201, DOI 10.1097/00001756-199810050-00013
   Mendell JT, 2005, CELL CYCLE, V0, P4
   Mirabella M, 1996, J NEUROPATH EXP NEUR, V55, P774, DOI 10.1097/00005072-199607000-00003
   MOKOL J, 2004, INCLUSION BODY MYOSI, V2, P1367
   MOREIRA PI, 2005, IN PRESS EXP NEUROL, V0, P0
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   NEVILLE HE, 1992, NEUROLOGY, V42, P897, DOI 10.1212/WNL.42.4.897
   Nixon RA, 2005, NEUROBIOL AGING, V26, P373, DOI 10.1016/j.neurobiolaging.2004.09.018
   Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113
   Oldfors A, 2006, NEUROLOGY, V66, PS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Ozden S, 2001, CLIN INFECT DIS, V32, P510, DOI 10.1086/318506
   Paulson H, 2006, NEUROLOGY, V66, PS114, DOI 10.1212/01.wnl.0000192310.07041.53
   Phillips BA, 2001, MUSCLE NERVE, V24, P1526, DOI 10.1002/mus.1178
   Prayson RA, 1997, HUM PATHOL, V28, P887, DOI 10.1016/S0046-8177(97)90002-2
   Rezaie P, 2005, J HISTOCHEM CYTOCHEM, V53, P929, DOI 10.1369/jhc.4A6551.2005
   RINGEL SP, 1976, J HISTOCHEM CYTOCHEM, V24, P1033, DOI 10.1177/24.9.965713
   Salama I, 2005, BIOCHEM BIOPH RES CO, V328, P221, DOI 10.1016/j.bbrc.2004.12.157
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Semino-Mora C, 1998, HUM PATHOL, V29, P1128, DOI 10.1016/S0046-8177(98)90425-7
   Stein TD, 2002, J NEUROSCI, V22, P7380
   WATTS G, 2001, NAT GENET, V36, P377
NR 79
TC 83
Z9 90
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 15
PY 2006
VL 66
IS 
BP S20
EP S29
DI 10.1212/01.wnl.0000192260.33106.bb
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 005RX
UT WOS:000234842600004
PM 16432141
DA 2024-11-01
ER

PT J
AU Liu, CS
   Cheng, WL
   Lee, CF
   Ma, YS
   Lin, CY
   Huang, CC
   Wei, YH
AF Liu, CS
   Cheng, WL
   Lee, CF
   Ma, YS
   Lin, CY
   Huang, CC
   Wei, YH
TI Alteration in the copy number of mitochondrial DNA in leukocytes of patients with mitochondrial encephalomyopathies
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
DE MERRF; MELAS; copy number; mitochondrial DNA; heteroplasmy; age
ID red fibers merrf; oxidative stress; myoclonic epilepsy; quantitative pcr; human-cells; mutation; depletion; mtdna; phenotype; melas
AB Objectives - We investigated whether mutation of mitochondrial DNA (mtDNA) affects the copy number of the mitochondrial genome in patients with mitochondrial myopathy encephalopathy with lactic acidosis and stroke-like episodes (MELAS) and those with myoclonic epilepsy with ragged-red fiber (MERRF) syndromes. Materials and methods - Forty-eight Taiwanese patients with MELAS syndrome and 20 patients with MERRF syndrome were recruited in this study. Results - In relation to controls, the copy numbers of mtDNA in leukocytes of patients with MELAS or MERRF syndrome were significantly higher at a young age but lower at an advanced age. In addition, MELAS patients harboring higher proportions of mtDNA with A3243G transition had lower mtDNA copy numbers. The MELAS or MERRF patients with multi-system disorders had lower mtDNA copy numbers in leukocytes. Furthermore, higher proportions of mtDNA with 4977 bp deletion were found in leukocytes of MERRF patients with multi-system involvement. Conclusion - In leukocytes, alteration in the copy number of mtDNA is related to the proportion of mtDNA with a point mutation or large-scale deletion, which may serve as a biomarker in the pathogenesis and disease progression of MELAS and MERRF syndromes.
C1 Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
   Changhua Christian Hosp, Vasc & Genom Res Ctr, Changhua, Taiwan.
   Chung Shan Med Univ Hosp, Taichung, Taiwan.
   Chung Shan Med Univ, Dept Neurol, Taichung, Taiwan.
   Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan.
   Chang Gung Mem Hosp, Dept Neurol, Taoyuan, Taiwan.
C3 National Yang Ming Chiao Tung University; Changhua Christian Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Changhua Christian Hospital; Chang Gung Memorial Hospital
RP Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
CR Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Chen DX, 2002, J NEUROCHEM, V81, P1273, DOI 10.1046/j.1471-4159.2002.00916.x
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CHU NS, 1994, MUSCLE NERVE, V17, P1230
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   FANG W, 1994, MUSCLE NERVE, V17, P52, DOI 10.1002/mus.880170107
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Kapsa RMI, 1998, NUCLEIC ACIDS RES, V26, P4365, DOI 10.1093/nar/26.19.4365
   Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172
   Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425
   Liu CS, 2003, FREE RADICAL RES, V37, P1307, DOI 10.1080/10715760310001621342
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mita S, 1998, MUSCLE NERVE, V21, P490, DOI 10.1002/(SICI)1097-4598(199804)21:4<490::AID-MUS7>3.0.CO;2-4
   MITA S, 1995, MUSCLE NERVE S, V3, P113
   Mohamed SA, 2004, EXP GERONTOL, V39, P181, DOI 10.1016/j.exger.2003.10.011
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Müller-Höcker J, 2002, HUM PATHOL, V33, P247, DOI 10.1053/hupa.2002.31477
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Pollack M, 2001, J GERONTOL A-BIOL, V56, PB475, DOI 10.1093/gerona/56.11.B475
   SCELSI R, 1992, PATHOL RES PRACT, V188, P607, DOI 10.1016/S0344-0338(11)80065-8
   SHONER JM, 1990, CELL, V61, P931
   Steensberg A, 2001, EUR J APPL PHYSIOL, V84, P155, DOI 10.1007/s004210000351
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   Wei YH, 2003, ADV CLIN CHEM, V37, P83, DOI 10.1016/S0065-2423(03)37007-6
   Wong Alice, 2002, METHODS MOL BIOL, V197, P129, DOI 10.1385/1-59259-284-8:129
   Yano S, 2003, J INHERIT METAB DIS, V26, P481, DOI 10.1023/A:1025125427868
NR 35
TC 55
Z9 60
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD MAY 15
PY 2006
VL 113
IS 5
BP 334
EP 341
DI 10.1111/j.1600-0404.2006.00586.x
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 028BB
UT WOS:000236459200009
PM 16629770
DA 2024-11-01
ER

PT J
AU Enns, GM
   Bai, RK
   Beck, AE
   Wong, LJ
AF Enns, Gregory M.
   Bai, Ren-Kui
   Beck, Anita E.
   Wong, Lee-Jun
TI Molecular-clinical correlations in a family with variable tissue mitochondrial DNA T8993G mutant load
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Leigh syndrome; NARP; mitochondrial DNA mutation T8993G; mitochondrial DNA segregation; prenatal diagnosis
ID heteroplasmic mtdna mutation; leigh-syndrome; nucleotide 8993; prenatal-diagnosis; rapid segregation; human oocytes; disease; patient; nt-8993
AB Unlike many pathogenic mitochondrial DNA mutations, the T8993G mutation associated with Leigh syndrome (LS) and neurogenic muscle weakness, ataxia, retinitis pigmentosa (NARP) typically shows little variation in mutant load between different tissue types. We describe the molecular and clinical findings in a family with variable disease severity and tissue T8993G mutant loads. Real-time ARMS qPCR testing showed that two brothers with features of NARP and LS had high mutant loads (> 90%) in all tissues tested, similar to previously reported cases. Their sister, who has mild speech delay but attends normal school, was found to have a relatively high mutant load (mean 93%) in tissues derived from endoderm. (buccal mucosa) and mesoderm (blood and skin fibroblasts). However, in tissue derived from ectoderm (hair bulbs), she carried a considerably lower proportion of mutant mtDNA. Because both surface ectoderm, which gives rise to outer epithelia and hair, and neuroectoderm, which gives rise to the central nervous system, are derived from ectoderm, it is tempting to speculate that the mutant load detected in the oligosymptomatic sister's hair bulbs is a reflection of the brain mutant load. We conclude that significant variation in tissue mutant load may occur in at least some individuals that harbor the T8993G mutation. This adds additional complexity to genetic counseling and prenatal diagnosis in such instances. Given the shared embryonic origin of hair bulbs and brain, we recommend performing hair bulb mtDNA analysis in asymptomatic or oligosymptomatic individuals that have high blood mutant loads in order to understand better the genotype-phenotype correlations related to the T8993G mutation. (c) 2006 Elsevier Inc. All rights reserved.
C1 Stanford Univ, Dept Pediat, Div Med Genet, Stanford, CA 94305 USA.
   Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA.
C3 Stanford University; Baylor College of Medicine
RP Enns, GM (corresponding author), Stanford Univ, Dept Pediat, Div Med Genet, 300 Pasteur Dr H-315, Stanford, CA 94305 USA.
EM greg.enns@stanford.edu
CR ASHLEY MV, 1989, NUCLEIC ACIDS RES, V17, P7325, DOI 10.1093/nar/17.18.7325
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bartley J, 1996, AMERICAN JOURNAL OF HUMAN GENETICS, V59, P0
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   Dahl H H, 2000, HUM REPROD, V15 Suppl 2, P246
   Degoul F, 1997, J INHERIT METAB DIS, V20, P49, DOI 10.1023/A:1005357506614
   Degoul F, 1995, J INHERIT METAB DIS, V18, P682, DOI 10.1007/BF02436757
   Ferlin T, 1997, J PEDIATR-US, V131, P447, DOI 10.1016/S0022-3476(97)80074-1
   FRYER A, 1994, ARCH DIS CHILD, V71, P419, DOI 10.1136/adc.71.5.419
   HANDYSIDE AH, 1984, J EXP ZOOL, V231, P429, DOI 10.1002/jez.1402310317
   HARDING AE, 1992, AM J HUM GENET, V50, P629
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   LERTRIT P, 1992, HUM GENET, V90, P251
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   Moore KL, 1982, DEV HUMAN CLIN ORIEN, V0, P0
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Poulton J, 2002, REPRODUCTION, V123, P751, DOI 10.1530/rep.0.1230751
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tsao CY, 2001, J CHILD NEUROL, V16, P533, DOI 10.1177/088307380101600716
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   White SL, 1999, PRENATAL DIAG, V19, P1165, DOI 10.1002/(SICI)1097-0223(199912)19:12<1165::AID-PD719>3.3.CO;2-4
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2002, GENET MED, V4, P78, DOI 10.1097/00125817-200203000-00005
   YOSHINAGA H, 1993, J CHILD NEUROL, V8, P129, DOI 10.1177/088307389300800204
NR 37
TC 27
Z9 28
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD AUG 15
PY 2006
VL 88
IS 4
BP 364
EP 371
DI 10.1016/j.ymgme.2006.02.001
PG 8
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine
GA 077LB
UT WOS:000240029700010
PM 16546428
DA 2024-11-01
ER

PT J
AU Mayr, JA
   Moslemi, AR
   Förster, H
   Kamper, A
   Idriceanu, C
   Muss, W
   Huemer, M
   Oldfors, A
   Sperl, W
AF Mayr, Johannes A.
   Moslemi, Ali-Reza
   Foerster, Holger
   Kamper, Adrian
   Idriceanu, Carmen
   Muss, Wolfgang
   Huemer, Michael
   Oldfors, Anders
   Sperl, Wolfgang
TI A novel sporadic mutation G14739A of the mitochondrial tRNA<SUP>Glu</SUP> in a girl with exercise intolerance
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondria; mtDNA; tRNA; mitochondrial myopathy
ID heteroplasmic mutations; dna; encephalomyopathy; deletions; mtdna
AB We describe a 7-year-old girl who presented with loss of appetite, weakness and exercise intolerance. Enzyme investigation of the respiratory chain in muscle tissue revealed a combined complex I, III and IV deficiency. A novel heteroplasmic G -> A exchange at nucleotide position 14739 was found in the MTTE gene of the tRNA glutamic acid. The mutation load in muscle was 72%, urine sediment 38%, blood 31% and fibroblasts 29% and it correlated with COX-negative fibres. Our patient presented with a predominantly myopathic phenotype. The G14739A mutation is the third reported in the mitochondrial tRNA glutamic acid gene, and it occurred in a sporadic case. (C) 2006 Elsevier B.V. All rights reserved.
C1 Paracelsus Private Med Univ, Univ Childrens Hosp, A-5020 Salzburg, Austria.
   Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Paracelsus Private Med Univ, Dept Pathol, Salzburg, Austria.
   Kardinal Schwarzenberg Hosp, Schwarzach, Austria.
C3 Paracelsus Private Medical University; Sahlgrenska University Hospital; Paracelsus Private Medical University
RP Mayr, JA (corresponding author), Paracelsus Private Med Univ, Univ Childrens Hosp, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM h.mayr@salk.at
CR DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 10
TC 11
Z9 11
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC 15
PY 2006
VL 16
IS 12
BP 874
EP 877
DI 10.1016/j.nmd.2006.08.010
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 124RT
UT WOS:000243388300011
PM 17056256
DA 2024-11-01
ER

PT J
AU Kaufmann, P
   Pascual, JM
   Anziska, Y
   Gooch, CL
   Engelstad, K
   Jhung, S
   DiMauro, S
   De Vivo, DC
AF Kaufmann, Petra
   Pascual, Juan M.
   Anziska, Yaacov
   Gooch, Clifton L.
   Engelstad, Kristin
   Jhung, Sarah
   DiMauro, Salvatore
   De Vivo, Darryl C.
TI Nerve conduction abnormalities in patients with MELAS and the A3243G mutation
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID peripheral neuropathy; mitochondrial-dna; lactic-acidosis; mtdna mutation; impairment; myopathy; disease
AB Background: Mitochondrial DNA point mutations are especially deleterious to tissues with high energy demand, including the peripheral nervous system. Neuropathy has been associated with several mitochondrial diseases, including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes). Objective: To evaluate nerve conduction in a genotypically and phenotypically homogeneous group of patients with MELAS and the A3243G mutation. Design: We studied 30 patients with MELAS and the A3243G mutation using neurophysiological techniques, medical history questionnaires, laboratory tests, and a standardized neurological examination. Results: Twenty-three subjects (77%) had abnormal nerve conduction measures. Symptoms suggestive of neuropathy were present in only half of the patients, but almost all had decreased reflexes or distal sensory findings on examination. Nerve conduction abnormalities were predominantly axonal and sensory and mainly present in the legs. Patients with nerve conduction abnormalities tended to be older and were more likely male. Conclusions: Peripheral nerve impairment is common in those with MELAS and the A3243G mutation, and may be subclinical. Male sex and older age may add to the genetic disposition to develop neuropathy.
C1 Columbia Univ, Dept Neurol, New York, NY 10032 USA.
   Columbia Univ, Dept Pediat, New York, NY 10027 USA.
C3 Columbia University; Columbia University
RP De Vivo, DC (corresponding author), Columbia Univ, Dept Neurol, 710 W 168th St, New York, NY 10032 USA.
EM dcd1@columbia.edu
FU NCRR NIH HHS [K12 RR 017648] Funding Source: Medline; NICHD NIH HHS [P01 HD 32062] Funding Source: Medline
CR Chu CC, 1997, EUR NEUROL, V37, P110, DOI 10.1159/000117420
   Colomer J, 2000, REV NEUROLOGIA, V30, P1117, DOI 10.33588/rn.3012.2000079
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   Karnofsky DA, 1949, EVALUATION CHEMOTHER, V0, P196
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   MIZUSAWA H, 1991, REV NEUROL, V147, P501
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Newman NJ, 2004, EYE, V18, P1144, DOI 10.1038/sj.eye.6701591
   PEZESHKPOUR G, 1987, J NEUROL SCI, V77, P285, DOI 10.1016/0022-510X(87)90129-8
   RUSANEN H, 1995, NEUROLOGY, V45, P1188, DOI 10.1212/WNL.45.6.1188
   Takeda K, 1989, RINSHO SHINKEIGAKU, V29, P643
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
NR 16
TC 42
Z9 47
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAY 15
PY 2006
VL 63
IS 5
BP 746
EP 748
DI 10.1001/archneur.63.5.746
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 041XQ
UT WOS:000237490600015
PM 16682545
DA 2024-11-01
ER

PT J
AU Darin, N
   Kollberg, G
   Moslemi, AR
   Tulinius, M
   Holme, E
   Gröonlund, MA
   Andersson, S
   Oldfors, A
AF Darin, N.
   Kollberg, G.
   Moslemi, A-R.
   Tulinius, M.
   Holme, E.
   Gronlund, M. Andersson
   Andersson, S.
   Oldfors, A.
TI Mitochondrial myopathy with exercise intolerance and retinal dystrophy in a sporadic patient with a G583A mutation in the mt tRNA<SUP>phe</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial; tRNA(phe); mutation; myopathy; mtDNA; retinal dystrophy
ID encephalomyopathy; childhood
AB We describe a second patient with the 583G > A mutation in the tRNA(phe) gene of mitochondrial DNA (mtDNA). This 17-year-old girl had a mitochondrial myopathy with exercise intolerance and an asymptomatic retinopathy. Muscle investigations showed occasional ragged red fibers, 30% cytochrome c oxidase (COX)-negative fibers, and reduced activities of complex I + IV in the respiratory chain. The mutation was heteroplasmic (79%) in muscle but undetectable in other tissues. Analysis of single muscle fibers revealed a significantly higher level of mutated mtDNA in COX-negative fibers. Our study indicates that the 583G > A mutation is pathogenic and expands the clinical spectrum of this mutation. (C) 2006 Elsevier B.V. All rights reserved.
C1 Sahlgrens Univ Hosp, Dept Pediat, Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Pathol, Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Pediat Ophthalmol, Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Darin, N (corresponding author), Queen Silvia Childrens Hosp, Dept Pediat, S-41685 Gothenburg, Sweden.
EM niklas.darin@vgregion.se
CR [Anonymous], 2005, MITOMAP: A HUMAN MITOCHONDRIAL GENOME DATABASE, V0, P0
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
NR 10
TC 16
Z9 19
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG 15
PY 2006
VL 16
IS 8
BP 504
EP 506
DI 10.1016/j.nmd.2006.05.010
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 101RV
UT WOS:000241759100006
PM 16806928
DA 2024-11-01
ER

PT J
AU Chan, SSL
   Longley, MJ
   Copeland, WC
AF Chan, Sherine S. L.
   Longley, Matthew J.
   Copeland, William C.
TI Modulation of the W748S mutation in DNA polymerase γ by the E1143G polymorphismin mitochondrial disorders
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID progressive external ophthalmoplegia; polg mutations; subunit; identification; deletions; toxicity; spectrum; binding; ataxia; a467t
AB DNA polymerase gamma (pol gamma) is required for replication and repair of mitochondrial DNA. Over 80 mutations in POLG, the gene encoding the catalytic subunit of pol gamma, have been linked with disease. The W748S mutation in POLG is the most common mutation in ataxia-neuropathy spectrum disorders and is generally found in cis with the common E1143G polymorphism. It has been unclear whether E1143G participates in the disease process. We investigated the biochemical consequences of pol gamma proteins containing W748S or E1143G, or both. W748S pol gamma exhibited low DNA polymerase activity, low processivity and a severe DNA-binding defect. However, interactions between the catalytic and accessory subunits were normal. Despite the benefits derived from binding with the accessory subunit, catalytic activities did not reach wild-type (WT) levels. Also, nucleotide selectivity decreased 2.1-fold compared with WT. Surprisingly, pol gamma containing only E1143G was 1.4-fold more active than WT, and this increased polymerase activity could be due to higher thermal stability for E1143G pol gamma. The E1143G substitution partially rescued the deleterious effects of the W748S mutation, as DNA binding, catalytic activity and fidelity values were intermediate for W748S-E1143G. However, W748S-E1143G had a notably lower change in enthalpy for protein folding than W748S alone. We suggest that when E1143G is in cis with other pathogenic mutations, it can modulate the effects of these mutations. For W748S-E1143G pol gamma, the benefits bestowed by E1143G include increased DNA binding and polymerase activity; however, E1143G was somewhat detrimental to protein stability.
C1 NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233,111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
CR Bienstock RJ, 2004, MITOCHONDRION, V4, P203, DOI 10.1016/j.mito.2004.05.018
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DeLano WL, 2002, THE PYMOL MOLECULAR GRAPHICS SYSTEM, V0, P0
   DeRose EF, 2004, STRUCTURE, V12, P2221, DOI 10.1016/j.str.2004.09.019
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   *GENESNPS, 2004, SNP CARD POLG, V0, P0
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Kim SJ, 2003, J BIOL CHEM, V278, P5072, DOI 10.1074/jbc.M208472200
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley Matthew J, 2002, METHODS MOL BIOL, V197, P245, DOI 10.1385/1-59259-284-8:245
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Punga AR, 2006, CLIN NEUROPHYSIOL, V117, P1434, DOI 10.1016/j.clinph.2006.03.028
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 38
TC 80
Z9 88
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2006
VL 15
IS 23
BP 3473
EP 3483
DI 10.1093/hmg/ddl424
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 108XA
UT WOS:000242271300010
PM 17088268
DA 2024-11-01
ER

PT J
AU Keränen, T
   Kuusisto, H
AF Keranen, Tapani
   Kuusisto, Hanna
TI NARP syndrome and adult-onset generalised seizures
SO EPILEPTIC DISORDERS
LA English
DT Article
DE NARP; mitochondrial disease; epilepsy; generalised; adult; retinitis pigmentosa
ID clinical presentation; retinitis-pigmentosa; dna mutation; mitochondrial; disease; mtdna; heteroplasmy; family; ataxia
AB The neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP) syndrome is a maternally inherited disorder attributable to a heteroplasmic mtDNA point mutation. Catastrophic epilepsy may accompany severe, early onset forms of NARP, but seizures seem to be rare in cases with adolescent and adult onset. We describe a patient who developed clumsiness and visual problems in her teens. She had no clinical seizures but an EEG showed generalized spike and wave discharges. At this time the patient remained without a specific diagnosis. At the age of 21, the patient developed progressive ataxia and she also experienced a tonic-clonic status epilepticus. Further examinations revealed NARP syndrome. EEG abnormalities may precede adult onset seizures in the NARP syndrome.
C1 Tampere Univ Hosp, Dept Neurol, Tampere 33251, Finland.
C3 Tampere University; Tampere University Hospital
RP Keränen, T (corresponding author), Tampere Univ Hosp, Dept Neurol, POB 2000, Tampere 33251, Finland.
EM tapani.keranen@pshp.fi
CR CIAFALONI E, 1993, J PEDIATR-US, V122, P419, DOI 10.1016/S0022-3476(05)83431-6
   Desguerre I, 2003, NEUROPEDIATRICS, V34, P265
   FRYER A, 1994, ARCH DIS CHILD, V71, P419, DOI 10.1136/adc.71.5.419
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   ORTIZ RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1525, DOI 10.1001/archopht.1993.01090110091031
   Parfait B, 1999, EUR J PEDIATR, V158, P55, DOI 10.1007/s004310051009
   PUDDU P, 1993, BRIT J OPHTHALMOL, V77, P84, DOI 10.1136/bjo.77.2.84
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tatuch Yuriy, 1994, EUROPEAN JOURNAL OF HUMAN GENETICS, V2, P35
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
NR 12
TC 9
Z9 11
U1 0
U2 0
PU JOHN LIBBEY EUROTEXT LTD
PI MONTROUGE
PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE
SN 1294-9361
EI 
J9 EPILEPTIC DISORD
JI Epileptic Disord.
PD SEP 15
PY 2006
VL 8
IS 3
BP 200
EP 203
DI 
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 098BO
UT WOS:000241495800005
PM 16987741
DA 2024-11-01
ER

PT J
AU Santoro, A
   Salvioli, S
   Raule, N
   Capri, M
   Sevini, F
   Valensin, S
   Monti, D
   Bellizzi, D
   Passarino, G
   Rose, G
   De Benedictis, G
   Franceschi, C
AF Santoro, Aurelia
   Salvioli, Stefano
   Raule, Nicola
   Capri, Miriam
   Sevini, Federica
   Valensin, Silvana
   Monti, Daniela
   Bellizzi, Dina
   Passarino, Giuseppe
   Rose, Giuseppina
   De Benedictis, Glovanna
   Franceschi, Claudio
TI Mitochondrial DNA involvement in human longevity
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
DE mitochondrial DNA; longevity; mtDNA mutation; mtDNA haplogroup; centenarian; nuclear-mitochondrial interaction; Alzheimer's disease
ID healthy old-people; human life-span; skeletal-muscle; mtdna mutations; copy number; transcription factor; parkinsons-disease; alzheimer-disease; human-evolution; phenotypic alterations
AB The main message of this review can be summarized as follows: aging and longevity, as complex traits having a significant genetic component, likely depend on a number of nuclear gene variants interacting with mtDNA variability both inherited and somatic. We reviewed the data available in the literature with particular attention to human longevity, and argued that what we hypothesize for aging and longevity could have a more general relevance and be extended to other age-related complex traits such as Alzheimer's and Parkinson's diseases. The genetics which emerges for complex traits, including aging and longevity, is thus even more complicated than previously thought, as epistatic interactions between nuclear gene polymorphisms and mtDNA variability (both somatic and inherited) as well as between mtDNA somatic mutations (tissue specific) and mtDNA inherited variants (haplogroups and sub-haplogroups) must be considered as additional players capable of explaining a part of the aging and longevity phenotype. To test this hypothesis is one of the main challenge in the genetics of aging and longevity in the next future. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Bologna, Dept Expt Pathol, Ctr Interdipartimentale L Galvani, I-40126 Bologna, Italy.
   ER Gentech Lab, I-44100 Ferrara, Italy.
   Dept Expt Pathol & Oncol, I-50134 Florence, Italy.
   Univ Calabria, Dept Cell Biol, I-87030 Arcavacata Di Rende, Italy.
   INRCA Ancona, Dept Gerontol Sci, I-60121 Ancona, Italy.
C3 University of Bologna; University of Calabria; IRCCS INRCA
RP Franceschi, C (corresponding author), Univ Bologna, Dept Expt Pathol, Ctr Interdipartimentale L Galvani, Via S Giacomo 12, I-40126 Bologna, Italy.
EM audio.franceschi@unibo.it
CR Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819
   Achilli A, 2004, AM J HUM GENET, V75, P910, DOI 10.1086/425590
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Bagnara GP, 2000, J GERONTOL A-BIOL, V55, P0
   Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Baudouin SV, 2005, LANCET, V366, P2118, DOI 10.1016/S0140-6736(05)67890-7
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Boehm M, 2005, SCIENCE, V310, P1954, DOI 10.1126/science.1115596
   Bonafé M, 2004, CELL DEATH DIFFER, V11, P962, DOI 10.1038/sj.cdd.4401415
   Bonafè M, 2002, GENE, V286, P121, DOI 10.1016/S0378-1119(01)00812-5
   Bonafè M, 1999, AM J HUM GENET, V64, P292, DOI 10.1086/302196
   Booker LM, 2006, J UROLOGY, V175, P468, DOI 10.1016/S0022-5347(05)00163-1
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Carelli V, 2002, MITOCHONDRIAL DISORD, V0, P115
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708
   Chinnery PF, 2000, NEUROLOGY, V55, P302, DOI 10.1212/WNL.55.2.302
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CLAYTON DA, 1987, PHILOS T ROY SOC B, V317, P473, DOI 10.1098/rstb.1987.0074
   Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Dato S, 2004, EUR J HUM GENET, V12, P1080, DOI 10.1038/sj.ejhg.5201278
   De Benedictis G, 1998, EUR J HUM GENET, V6, P534, DOI 10.1038/sj.ejhg.5200222
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   De Benedictis G, 2000, EXP GERONTOL, V35, P795, DOI 10.1016/S0531-5565(00)00169-8
   de Souza-Pinto NC, 2004, ONCOGENE, V23, P6559, DOI 10.1038/sj.onc.1207874
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   ELSON JL, 2006, HUM GENET, V12, P1
   Fagnoni FF, 2000, BLOOD, V95, P2860, DOI 10.1182/blood.V95.9.2860.009k35_2860_2868
   FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496
   Frahm T, 2005, MECH AGEING DEV, V126, P1192, DOI 10.1016/j.mad.2005.06.008
   Franceschi C, 2000, VACCINE, V18, P1717, DOI 10.1016/S0264-410X(99)00513-7
   Franceschi C, 2000, AGING-CLIN EXP RES, V12, P77, DOI 10.1007/BF03339894
   Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   Giacchetti M, 2004, J MED GENET, V41, P293, DOI 10.1136/jmg.2003.015289
   Gibson BW, 2005, INT J BIOCHEM CELL B, V37, P927, DOI 10.1016/j.biocel.2004.11.013
   Greco M, 2003, FASEB J, V17, P1706, DOI 10.1096/fj.02-1009fje
   Guo LJ, 2005, MITOCHONDRION, V5, P15, DOI 10.1016/j.mito.2004.09.001
   Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812
   HARRISON DE, 1975, J GERONTOL, V30, P286, DOI 10.1093/geronj/30.3.286
   Helgason A, 2005, NAT GENET, V37, P90, DOI 10.1038/ng1492
   Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012
   Imam SZ, 2006, NEUROBIOL AGING, V27, P1129, DOI 10.1016/j.neurobiolaging.2005.06.002
   Jazwinski SM, 2005, GENE, V354, P22, DOI 10.1016/j.gene.2005.03.040
   King M P, 1996, METHODS ENZYMOL, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   King M P, 1996, METHODS ENZYMOL, V264, P313, DOI 10.1016/S0076-6879(96)64030-0
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirchman PA, 1999, GENETICS, V152, P179
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Korpelainen H, 1999, HUM HERED, V49, P183, DOI 10.1159/000022871
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lezza AMS, 2001, FEBS LETT, V501, P74, DOI 10.1016/S0014-5793(01)02628-X
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Masuyama M, 2005, BBA-GEN SUBJECTS, V1723, P302, DOI 10.1016/j.bbagen.2005.03.001
   MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   Moresi R, 2005, BIOGERONTOLOGY, V6, P185, DOI 10.1007/s10522-005-7954-5
   NAGLEY P, 1970, BIOCHEM BIOPH RES CO, V39, P989, DOI 10.1016/0006-291X(70)90422-5
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Niemi AK, 2005, EUR J HUM GENET, V13, P166, DOI 10.1038/sj.ejhg.5201308
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200
   Osiewacz HD, 1999, EXP GERONTOL, V34, P901, DOI 10.1016/S0531-5565(99)00063-7
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Pesce V, 2005, J GERONTOL A-BIOL, V60, P715, DOI 10.1093/gerona/60.6.715
   Prolla TA, 2005, SCIENCE, V310, P441
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Rand DM, 2006, GENETICS, V172, P329, DOI 10.1534/genetics.105.046698
   RAND DM, 2005, SCI AGING KNOWLEDGE, V45, P0
   Reynier P, 1999, EUR J HUM GENET, V7, P404, DOI 10.1038/sj.ejhg.5200293
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Ross OA, 2001, EXP GERONTOL, V36, P1161, DOI 10.1016/S0531-5565(01)00094-8
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Salvioli S, 2001, FEBS LETT, V492, P9, DOI 10.1016/S0014-5793(01)02199-8
   Samuels DC, 2004, TRENDS GENET, V20, P226, DOI 10.1016/j.tig.2004.03.003
   SANSONI P, 1993, BLOOD, V82, P2767
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tan QH, 2001, BIOGERONTOLOGY, V2, P141, DOI 10.1023/A:1011557022985
   Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Torroni A, 1996, GENETICS, V144, P1835
   TORRONI A, 1994, J BIOENERG BIOMEMBR, V26, P261, DOI 10.1007/BF00763098
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   TORRONI A, 1994, AM J HUM GENET, V55, P760
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Turnbull DM, 1998, NAT GENET, V18, P199, DOI 10.1038/ng0398-199
   van der Walt JM, 2005, HUM GENET, V118, P115, DOI 10.1007/s00439-005-0032-x
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   van Heemst D, 2005, EXP GERONTOL, V40, P11, DOI 10.1016/j.exger.2004.10.001
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1995, AM J HUM GENET, V57, P201
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Welle S, 2003, J APPL PHYSIOL, V94, P1479, DOI 10.1152/japplphysiol.01061.2002
   Woodman R, 2005, CURR OPIN HEMATOL, V12, P123
   Yashin AI, 1999, AM J HUM GENET, V65, P1178, DOI 10.1086/302572
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 115
TC 58
Z9 66
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 1879-2650
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD SEP-OCT 15
PY 2006
VL 1757
IS 9-10
BP 1388
EP 1399
DI 10.1016/j.bbabio.2006.05.040
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 100AN
UT WOS:000241639600036
PM 16857160
DA 2024-11-01
ER

PT J
AU Haimi, M
   Elhasid, R
   Gershoni-Baruch, R
   Izraeli, S
   Randers, RJA
   Mandel, H
AF Haimi, M
   Elhasid, R
   Gershoni-Baruch, R
   Izraeli, S
   Randers, RJA
   Mandel, H
TI Myeloid dysplasia in familial 3-methylglutaconic aciduria
SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
LA English
DT Article
DE 3-methylglutaconic aciduria; myelodysplastic syndrome; acute myeloid leukemia; monosomy 7
ID mitochondrial-dna mutations; myelodysplastic syndrm; sideroblastic anemia; partial monosomy-7; pearson syndrome; gene; mechanisms; childhood; leukemia; myopathy
AB A kindred is reported with four members affected with neurodegenerative disorder and 3-methylglutaconic aciduria. Two siblings developed thrombocytopenia heralding a myelodysplastic syndrome; in one patient it evolved into acute myeloid leukemia with monosomy 7 in the marrow. The hematologic complications have hitherto not been previously reported in other cases of 3-methylglutaconic aciduria and are thus thought to represent a new disease entity. This family adds additional evidence to the genetic heterogeneity of Mendelian disorders in which the primary Mutation may have a mutator effect that could give origin to myelodysplastic syndrome and acute myeloid leukemia through acquired chromosomal changes.
C1 Technion Israel Inst Technol, Meyer Childrens Hosp, Fac Med, Rambam Med Ctr,Metab Unit, Haifa, Israel.
   Meyer Childrens Hosp, Rambam Med Ctr, Dept Pediat Hemato Oncol, Haifa, Israel.
   Technion Israel Inst Technol, Meyer Childrens Hosp, Fac Med, Rambam Med Ctr,Dept Human Genet, Haifa, Israel.
   Chaim Sheba Med Ctr, Dept Pediat Hematol, IL-52621 Tel Hashomer, Israel.
   Edmond & Lily Safra Childrens Hosp, Chaim Sheba Med Ctr, Inst Haematol, Tel Hashomer, Israel.
   Tel Aviv Med Sch, Tel Aviv, Israel.
   Univ Amsterdam, Acad Med Ctr, Dept Pediat, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands.
C3 Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; University of Amsterdam; Academic Medical Center Amsterdam
RP Technion Israel Inst Technol, Meyer Childrens Hosp, Fac Med, Rambam Med Ctr,Metab Unit, Haifa, Israel.
EM h_mandel@rainbam.health.gov.il
CR Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651
   Barth PG, 2004, AM J MED GENET A, V126A, P349, DOI 10.1002/ajmg.a.20660
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Chen WN, 2004, AM J CLIN PATHOL, V122, P588, DOI 10.1309/6UGDU03VVD0L98LO
   Crisan D, 2000, CLIN LAB MED, V20, P49
   Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013
   Gattermann N, 2000, LEUKEMIA RES, V24, P141, DOI 10.1016/S0145-2126(99)00160-5
   GIBSON KM, 1993, PEDIATR NEUROL, V9, P120, DOI 10.1016/0887-8994(93)90046-F
   GIBSON KM, 1992, J PEDIATR-US, V121, P940, DOI 10.1016/S0022-3476(05)80348-8
   Gunay-Aygun M, 2005, MOL GENET METAB, V84, P1, DOI 10.1016/j.ymgme.2004.12.003
   Hasle H, 1999, LEUKEMIA, V13, P376, DOI 10.1038/sj.leu.2401342
   Leonard C, 1997, LEUKEMIA, V11, P1478
   LICHTERKONECKI U, 1993, EUR J PEDIATR, V152, P378, DOI 10.1007/BF01956761
   Linnartz B, 2004, CANCER RES, V64, P1966, DOI 10.1158/0008-5472.CAN-03-2956
   Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466
   Ly TBN, 2003, HUM MUTAT, V21, P401, DOI 10.1002/humu.10202
   Maserati E, 2004, CANCER GENET CYTOGEN, V148, P155, DOI 10.1016/S0165-4608(03)00271-1
   Minelli A, 2001, CANCER GENET CYTOGEN, V124, P147, DOI 10.1016/S0165-4608(00)00344-7
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Reddy PL, 2002, BRIT J HAEMATOL, V116, P564, DOI 10.1046/j.0007-1048.2001.03323.x
   Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766
   Shin MG, 2003, BLOOD, V101, P3118, DOI 10.1182/blood-2002-06-1825
NR 22
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1077-4114
EI 1536-3678
J9 J PEDIAT HEMATOL ONC
JI J. Pediatr. Hematol. Oncol.
PD FEB 15
PY 2006
VL 28
IS 2
BP 69
EP 72
DI 10.1097/01.mph.0000199585.98926.55
PG 4
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 014EB
UT WOS:000235460700004
PM 16462576
DA 2024-11-01
ER

PT J
AU Gordon, N
AF Gordon, Neil
TI Alpers syndrome: progressive neuronal degeneration of children with liver disease
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Review
ID huttenlocher-syndrome; cerebral degeneration; childhood; deficiency; features; brain
AB Alpers syndrome was not clearly defined until the link between brain and liver disease was described. Alpers syndrome can now be clearly established as a disorder of oxidative metabolism related to mitochondrial dysfunction, and in most instances with an autosomal mode of inheritance. The symptoms and signs are discussed. The illness occurs in the first years of life with the sudden onset of intractable seizures associated with developmental delay, hypotonia, ataxia, cortical blindness, and hepatic failure, and death occurs within a short time. Treating the seizures with valproic acid can cause the rapid onset of liver failure and must be avoided. To establish a definite diagnosis, liver and muscle biopsies may be needed. The former shows bile duct proliferation with the evidence of cirrhosis, and the latter may support the involvement of the mitochondrial respiratory chain if there are ragged-red fibres. Genetic studies can show an association with mitochondrial DNA depletion and mutations in the polymerase gene. Cytochrome c oxidase deficiency has been demonstrated in some patients. Useful diagnostic tests include liver function tests, lactic acid levels in the blood and cerebrospinal fluid, electroencephalograms, computed tomography, and magnetic resonance imaging. The differential diagnosis will be from other forms of neuronal degeneration and disorders of mitochondrial function. There is no specific treatment, which must await further research into causes.
RP Gordon, N (corresponding author), Huntlywood,3 Styal Rd, Wilmslow SK9 4AE, Cheshire, England.
EM neil-gordon@doctors.org.uk
CR BOYD SG, 1986, NEUROPEDIATRICS, V17, P75, DOI 10.1055/s-2008-1052505
   Brett E, 1997, PEDIAT NEUROLOGY, V3, P143
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Delarue A, 2000, PEDIATR TRANSPLANT, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   Flemming K, 2002, AM J NEURORADIOL, V23, P1421
   Gauthier-Villars M, 2001, NEUROPEDIATRICS, V32, P150, DOI 10.1055/s-2001-16614
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kayihan N, 2000, PEDIATR TRANSPLANT, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Martinez-Mena JM, 1998, REV NEUROLOGIA, V26, P70, DOI 10.33588/rn.26149.981087
   MONTINE TJ, 1995, CLIN NEUROPATHOL, V14, P322
   Naudé JTW, 2004, J NEUROL NEUROSUR PS, V75, P910, DOI 10.1136/jnnp.2003.015651
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   NIKLAS D, 2005, EUR J PAEDIATR NEURO, V9, P155
   Rasmussen M, 2000, J CHILD NEUROL, V15, P473, DOI 10.1177/088307380001500709
   Schwabe MJ, 1997, PEDIATR NEUROL, V16, P337, DOI 10.1016/S0887-8994(97)00030-1
   Simonati A, 2003, ACTA NEUROPATHOL, V106, P57, DOI 10.1007/s00401-003-0698-x
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   Smith JK, 1996, CLIN IMAG, V20, P235, DOI 10.1016/0899-7071(95)00039-9
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Ulmer S, 2002, J COMPUT ASSIST TOMO, V26, P641, DOI 10.1097/00004728-200207000-00030
   UNSIMAA J, 2003, PEDIATRICS, V111, P0
   Williams A, 1998, J PAEDIATR CHILD H, V34, P395, DOI 10.1046/j.1440-1754.1998.00249.x
   Worle H, 1998, CLIN NEUROPATHOL, V17, P63
NR 25
TC 35
Z9 38
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
EI 1469-8749
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD DEC 15
PY 2006
VL 48
IS 12
BP 1001
EP 1003
DI 10.1017/S0012162206002209
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 114LS
UT WOS:000242668300015
PM 17109792
DA 2024-11-01
ER

PT J
AU Greaves, LC
   Taylor, RW
AF Greaves, Laura C.
   Taylor, Robert W.
TI Mitochondrial DNA mutations in human disease
SO IUBMB LIFE
LA English
DT Review
DE mtDNA disorders; mitochondrial genetics; neurodegenerative disease; ageing; cancer
ID mtdna mutations; transfer-rna; gene-therapy; stem-cells; disorders; segregation; polymerase; expression; haplotype; apoptosis
AB Since their first association with human disease in 1988, more than 250 pathogenic point mutations and rearrangements of the 16.6 kb mitochondrial genome (mtDNA) have been reported in a spectrum of clinical disorders which exhibit prominent muscle and central nervous system involvement. With novel mutations and disease phenotypes still being described, mtDNA disorders are recognized collectively as common, inherited genetic diseases although relatively little is still known concerning the precise pathophysiological mechanisms that lead to cell dysfunction and pathology. This review considers the basic principles of mitochondrial genetics which govern both the behaviour and investigation of pathogenic mtDNA mutations summarizing recent advances in this area, and an assessment of the ongoing debate into the role of somatic mtDNA mutations in neurodegenerative disease, ageing and cancer.
C1 Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Taylor, RW (corresponding author), Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
CR Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Borthwick Gillian M, 2006, ANN NEUROL, V59, P570, DOI 10.1002/ana.20758
   BROWN DT, 2006, IN PRESS LANCET, V0, P0
   Chinnery PF, 2005, LANCET, V366, P1650, DOI 10.1016/S0140-6736(05)67492-2
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nishimura Y, 2006, P NATL ACAD SCI USA, V103, P1382, DOI 10.1073/pnas.0506911103
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581
   Preston SL, 2003, CANCER RES, V63, P3819
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Shin MG, 2004, BLOOD, V103, P4466, DOI 10.1182/blood-2003-11-3949
   Steffann J, 2006, J MED GENET, V43, P244, DOI 10.1136/jmg.2005.032326
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, EXPERT OPIN BIOL TH, V5, P183, DOI 10.1517/14712598.5.2.183
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
NR 45
TC 35
Z9 42
U1 0
U2 39
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1521-6543
EI 
J9 IUBMB LIFE
JI IUBMB Life
PD MAR 15
PY 2006
VL 58
IS 3
BP 143
EP 151
DI 10.1080/15216540600686888
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 042SR
UT WOS:000237550300004
PM 16766381
DA 2024-11-01
ER

PT J
AU Hudson, G
   Chinnery, PF
AF Hudson, Gavin
   Chinnery, Patrick F.
TI Mitochondrial DNA polymerase-γ and human disease
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID progressive external ophthalmoplegia; polg mutations; alpers-syndrome; mtdna maintenance; male-infertility; neurogastrointestinal encephalomyopathy; transcription factor; accessory subunit; point mutations; copy number
AB The maintenance of mitochondrial DNA (mtDNA) is critically dependent upon polymerase-gamma (pol-gamma), encoded by the nuclear gene POLG. Over the last 5 years, it has become clear that mutations of POLG are a major cause of human disease. Secondary mtDNA defects characterize these disorders, with mtDNA depletion, multiple mtDNA deletions or multiple point mutations of mtDNA in clinically affected tissues. The secondary mtDNA defects cause cell and tissue-specific deficiencies of mitochondrial oxidative phosphorylation, leading to organ dysfunction and human disease. Functional genetic variants of POLG are present in up to similar to 0.5% of the general population, and pathogenic mutations have been described in most exons of the gene. Clinically, POLG mutations can present from early neonatal life to late middle age, with a spectrum of phenotypes that includes common neurological disorders such as migraine, epilepsy and Parkinsonism. Transgenic mice and biochemical studies of recombinant mutated proteins are helping to unravel mechanisms of pathogenesis, and patterns are beginning to emerge relating genotype to phenotype.
C1 Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Sch Med, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Chinnery, PF (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, M41014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
CR Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480
   BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0
   Brusco A, 2006, J ENDOCRINOL INVEST, V29, P1
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Eyer F, 2005, J CLIN PSYCHOPHARM, V25, P376, DOI 10.1097/01.jcp.0000168485.76397.5c
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   GHIVIZZANI SC, 1994, MOL CELL BIOL, V14, P7717, DOI 10.1128/MCB.14.12.7717
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   HUDSON G, 2006, IN PRESS ARCH NEUROL, V0, P0
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   KUNKEL TA, 1988, J BIOL CHEM, V263, P4450
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Lakshmipathy U, 2001, NUCLEIC ACIDS RES, V29, P668, DOI 10.1093/nar/29.3.668
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Malyarchuk BA, 2005, HUM BIOL, V77, P355, DOI 10.1353/hub.2005.0050
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Marcuello A, 2005, J APPL PHYSIOL, V99, P1372, DOI 10.1152/japplphysiol.00289.2005
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   PAGNAMENTA AT, 2006, HUM REPROD, V0, P0
   ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Taanman JW, 2005, NEUROSCI LETT, V376, P56, DOI 10.1016/j.neulet.2004.11.023
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VELTRI KL, 1990, J CELL PHYSIOL, V143, P160, DOI 10.1002/jcp.1041430122
   Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   ZEVIANI M, 1995, BBA-MOL BASIS DIS, V1271, P153, DOI 10.1016/0925-4439(95)00022-V
   ZHANG H, 1994, MOL PHARMACOL, V46, P1063
   Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998
NR 90
TC 170
Z9 194
U1 0
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2006
VL 15
IS 
BP R244
EP R252
DI 10.1093/hmg/ddl233
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 095SX
UT WOS:000241329700019
PM 16987890
DA 2024-11-01
ER

PT J
AU Laird, PW
   Mohney, BG
   Renaud, DL
AF Laird, Philip W.
   Mohney, Brian G.
   Renaud, Deborah L.
TI Bull's-eye maculopathy in an infant with Leigh disease
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID mutation
AB PURPOSE: To report a bull's-eye maculopathy-like fundus abnormality in an infant with Leigh disease. DESIGN: Observational case report. METHODS: We reviewed the medical, ophthalmic, and genetic records of an eight-month-old boy who presented with hypotonia and bilaterally decreased vision. RESULTS: The ophthalmic examination revealed poor fix, ation, marked hyperopia, attenuated retinal vessels, and bull's-eye maculopathy. A white blood cell mitochondrial DNA analysis demonstrated a T to G mutation at position 8993 in the mitochondrial ATPase 6 gene. A skeletal muscle biopsy was homoplasmic for this mutation, consistent with a severe mitochondrial disorder. CONCLUSION: Leigh disease should be included in the differential diagnosis of patients presenting with neurologic deficits and a bull's-eye maculopathy.
C1 Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   Mayo Clin, Coll Med, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Mohney, BG (corresponding author), Mayo Clin, Dept Ophthalmol, 200 1st SW, Rochester, MN 55905 USA.
EM mohney@mayo.edu
CR Hayashi N, 2000, OPHTHALMOLOGY, V107, P1397, DOI 10.1016/S0161-6420(00)00110-X
   Lamont PJ, 1998, ARCH DIS CHILD, V79, P22, DOI 10.1136/adc.79.1.22
   Yamada T, 2002, JPN J OPHTHALMOL, V46, P460, DOI 10.1016/S0021-5155(02)00499-9
NR 3
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL 15
PY 2006
VL 142
IS 1
BP 186
EP 187
DI 10.1016/j.ajo.2006.02.051
PG 2
WC Ophthalmology
SC Ophthalmology
GA 064HF
UT WOS:000239079100039
PM 16815282
DA 2024-11-01
ER

PT J
AU Sato, A
   Nakada, K
   Hayashi, JI
AF Sato, Akitsugu
   Nakada, Kazuto
   Hayashi, Jun-Ichi
TI Mitochondrial dynamics and aging: Mitochondrial interaction preventing individuals from expression of respiratory deficiency caused by mutant mtDNA
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Review
DE mitochondrial theory of aging; mitochondrial complementation; mito-mice; mtDNA recombination; gene therapy; nuclear transplantation
ID cytochrome-c-oxidase; dna recombination; functional integrity; prenatal-diagnosis; skeletal-muscle; mouse mtdna; human-heart; mutations; complementation; cells
AB In mammalian cells, there is an extensive and continuous exchange of mitochondrial DNA (mtDNA) and its products between mitochondria. This mitochondrial complementation prevents individuals from expression of respiration deficiency caused by mutant mtDNAs. Thus, the presence of mitochondrial complementation does not support the generally accepted mitochondrial theory of aging, which proposes that accumulation of somatic mutations in mtDNA is responsible for age-associated mitochondrial dysfunction. Moreover, the presence of mitochondrial complementation enables gene therapy for mitochondrial diseases using nuclear transplantation of zygotes. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Tsukuba, Grad Sch Life & Environm Sci, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Ibaraki 3058572, Japan.
   Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Tokyo 1138613, Japan.
C3 University of Tsukuba; University of Tsukuba; Tokyo Metropolitan Institute of Medical Science
RP Hayashi, JI (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Attardi G, 2002, NAT GENET, V30, P360, DOI 10.1038/ng0402-360
   Awadalla P, 1999, SCIENCE, V286, P2524, DOI 10.1126/science.286.5449.2524
   BELLIARD G, 1979, NATURE, V281, P401, DOI 10.1038/281401a0
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Dean NL, 2003, MOL HUM REPROD, V9, P631, DOI 10.1093/molehr/gag077
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   DUJON B, 1974, GENETICS, V78, P415
   Enríquez JA, 2000, J BIOL CHEM, V275, P11207, DOI 10.1074/jbc.275.15.11207
   Eyre-Walker A, 2000, PHILOS T R SOC B, V355, P1573, DOI 10.1098/rstb.2000.0718
   Eyre-Walker A, 2001, J MOL EVOL, V53, P430, DOI 10.1007/s002390010232
   Hagelberg E, 1999, P ROY SOC B-BIOL SCI, V266, P485, DOI 10.1098/rspb.1999.0663
   HARDING AE, 1992, AM J HUM GENET, V50, P629
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1994, J BIOL CHEM, V269, P6878
   HAYASHI JI, 1985, EXP CELL RES, V160, P387, DOI 10.1016/0014-4827(85)90185-5
   HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43
   HOWELL N, 1992, HUM GENET, V90, P117
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601
   Ito S, 1998, BIOCHEM BIOPH RES CO, V247, P432, DOI 10.1006/bbrc.1998.8800
   Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099
   Jendrach M, 2005, MECH AGEING DEV, V126, P813, DOI 10.1016/j.mad.2005.03.002
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   JORDE LB, 2000, SCIENCE, V288, P0
   Kajander OA, 2001, EMBO REP, V2, P1007, DOI 10.1093/embo-reports/kve233
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   Kivisild T, 2000, SCIENCE, V288, P1931a, DOI 10.1126/science.288.5473.1931a
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   KUMAR S, 2000, SCIENCE, V288, P0
   Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891
   Ladoukakis ED, 2001, MOL BIOL EVOL, V18, P1168, DOI 10.1093/oxfordjournals.molbev.a003904
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MULLERHOCKER J, 1992, MUTAT RES, V275, P115, DOI 10.1016/0921-8734(92)90016-I
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   NASS MMK, 1969, J MOL BIOL, V42, P521, DOI 10.1016/0022-2836(69)90240-X
   NASS MMK, 1970, P NATL ACAD SCI USA, V67, P1926, DOI 10.1073/pnas.67.4.1926
   Ono T, 2004, BIOCHEM BIOPH RES CO, V314, P1107, DOI 10.1016/j.bbrc.2003.12.201
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   PAABO S, 1990, J BIOL CHEM, V265, P4718
   Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1
   PARSONS TJ, 2004, SCIENCE, V288, P0
   Rokas A, 2003, TRENDS ECOL EVOL, V18, P411, DOI 10.1016/S0169-5347(03)00125-3
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Sato A, 2004, GENETICS, V167, P1855, DOI 10.1534/genetics.103.021287
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Shitara H, 2000, GENETICS, V156, P1277
   Shitara H, 1998, GENETICS, V148, P851
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SOONG NW, 1992, NAT GENET, V2, P318
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103
   Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 87
TC 37
Z9 49
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 1879-2596
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD MAY-JUN 15
PY 2006
VL 1763
IS 5-6
BP 473
EP 481
DI 10.1016/j.bbamcr.2006.03.001
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 069XB
UT WOS:000239481400009
PM 16624428
DA 2024-11-01
ER

PT J
AU Thajeb, P
   Ma, YS
   Tzen, CY
   Chuang, CK
   Wu, TY
   Chen, SC
   Wei, YH
AF Thajeb, P
   Ma, YS
   Tzen, CY
   Chuang, CK
   Wu, TY
   Chen, SC
   Wei, YH
TI Oculopharyngeal somatic myopathy in a patient with a novel large-scale 3399 bp deletion and a homoplasmic T5814C transition of the mitochondrial DNA
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Article
DE oculopharyngeal somatic myopathy; mitochondrial myopathy; large-scale deletion; mutation; polymorphism; mitochondrial DNA; tRNA(Cys)
ID melas syndrome; gene mutation; encephalopathy; sequence; a3243g; family; muscle
AB We report a 65-year-old woman with a sporadic form of progressive oculopharyngeal somatic myopathy due to a novel large-scale 3399 base pair (bp) deletion of the mitochondrial DNA (mtDNA) and co-occurrence of a homoplasmic T5814C transition. The onset of myopathy began from chronic progressive exteral ophthalmoplegia (CPEO) at age of 20 years. Bulbar weakness, neck and proximal limb paralysis, slowly progressed to eventual respiratory failure. The plasma. levels of private (1.5 mg/dL) and lactate (20.2 mg/dL) were elevated. Muscle biopsy showed decreased enzymatic activity of cytochrome c oxidase, but no ragged-red fibers. Electron microscopy showed "parking-lot" paracrystalline inclusions in the enlarged mitochondria suggestive for mitochondrial myopathy. Sequencing of the whole mitochondrial genome of the patient's muscle and leukocytes showed 3399bp deletion of the mtDNA from nucleotide position 8024 to 11,423 and a homoplasmic thymidine to cytosine transition at nucleotide position 5814 of the tRNA(Cys) gene of mtDNA (T5814C). T5814C was absent in the white blood cells of the patient's daughter and in 205 normal controls. We conclude that a large-scale deletion may coexist with T5814C transition in patients with sporadic form of mitochondrial cytopathy manifested by slowly progressive oculopharyngeal somatic myopathy. (c) 2005 Elsevier B.V. All rights reserved.
C1 Taipei Med Univ, Mackay Mem Hosp, Dept Neurol, Taipei 11499, Taiwan.
   Taipei Med Univ, Mackay Mem Hosp, Dept Med Res, Taipei 11499, Taiwan.
   Taipei Med Univ, Dept Neurol, Taipei 11499, Taiwan.
   Mackay Mem Hosp, Dept Pathol, Taipei 11499, Taiwan.
   Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
C3 Mackay Memorial Hospital; Taipei Medical University; Taipei Medical University; Mackay Memorial Hospital; Taipei Medical University; Mackay Memorial Hospital; National Yang Ming Chiao Tung University
RP Thajeb, P (corresponding author), Taipei Med Univ, Mackay Mem Hosp, Dept Neurol, POB Nei Hua 6-30, Taipei 11499, Taiwan.
EM thajebp@hotmail.com
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   DiMauro S, 1997, MOL GENETIC BASIS NE, V0, P201
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   HILTONJONES D, 2001, BRAINS DIS NERVOUS S, V0, P478
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Koga Y, 2000, ACTA NEUROPATHOL, V99, P186, DOI 10.1007/PL00007423
   Lee HC, 2001, MUTAT RES-GEN TOX EN, V493, P67, DOI 10.1016/S1383-5718(01)00160-7
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   LIOU CW, 1994, ACTA NEUROL SCAND, V90, P354
   Manfredi G, 1996, HUM MUTAT, V7, P158
   Munnich A, 2001, METABOLIC MOL BASES, V0, P2261
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Schapira AHV, 1998, ARCH NEUROL-CHICAGO, V55, P1293, DOI 10.1001/archneur.55.10.1293
   Shoffner JM, 2001, METABOLIC MOL BASES, V0, P2367
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   THAJEB P, 1997, CHIN MED J BEIJING, V110, P726
   THAJEB P, 2000, CHIN MED J TAIPEI, V63, P71
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Wallace DC, 2001, THE METABOLIC AND MOLECULAR BASIS OF INHERITED DISEASE, V0, P2425
   ZHANG Y, 2001, CHIN MED J BEIJING, V114, P129
NR 21
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0303-8467
EI 
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD JUN 15
PY 2006
VL 108
IS 4
BP 407
EP 410
DI 10.1016/j.clineuro.2005.01.004
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 043GY
UT WOS:000237589600015
PM 16644408
DA 2024-11-01
ER

PT J
AU Laloi-Michelin, M
   Virally, M
   Jardell, C
   Meas, T
   Ingster-Moati, I
   Lombès, A
   Massin, P
   Chabriat, H
   Tielmans, A
   Mikol, J
   Guillausseau, PJ
AF Laloi-Michelin, M
   Virally, M
   Jardell, C
   Meas, T
   Ingster-Moati, I
   Lombès, A
   Massin, P
   Chabriat, H
   Tielmans, A
   Mikol, J
   Guillausseau, PJ
TI Kearns Sayre syndrome:: an unusual form of mitochondrial diabetes
SO DIABETES & METABOLISM
LA English
DT Article
DE Kearns Sayre syndrome; mitochondrial DNA; mitochondrial diabetes; monogenic diabetes
ID progressive external ophthalmoplegia; dna deletions; mutation; pathology; mellitus; gene
AB Kearns Sayre syndrome (KSS) is a mitochondrial disorder characterized by the emergence before age 20 of progressive external ophthalmoplegia, pigmentary retinopathy, together with other heterogeneous clinical manifestations, including cardiac conduction defects, muscle abnormalities and endocrinopathies. KSS is associated with large heteroplasmic deletions in mitochondrial DNA. We report the case of a 43-year-old woman, with diabetes mellitus as a first manifestation at age 19. Later, she exhibited bilateral ptosis and external ophthalmoplegia with progressive worsening. DNA analysis identified a large mitochondrial DNA ((mt)DNA) deletion, which confirmed the diagnosis of KSS. By reporting this case with diabetes mellitus as first manifestation,we aim at emphasizing problems of diagnosis in these subtypes of mitochondrial diabetes.
C1 Hop Lariboisiere, Dept Internal Med Diabet & Metab Dis, AP HP, F-75010 Paris, France.
   Grp Hosp Pitie Salpetriere, INSERM, U582, F-75013 Paris, France.
   Hop Lariboisiere, Dept Biophys, F-75010 Paris, France.
   Hop Lariboisiere, Dept Ophthalmol, F-75010 Paris, France.
   Hop Lariboisiere, Dept Neurol, F-75010 Paris, France.
   Hop Lariboisiere, Dept Pathol, F-75010 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Lariboisiere-Fernand-Widal - APHP
RP Hop Lariboisiere, Dept Internal Med Diabet & Metab Dis, AP HP, 2,Rue Ambroise Pare, F-75010 Paris, France.
EM marie.laloi-michelin@lrb.ap-hop-paris.fr
CR ASHCROFT E, 1992, INSULIN MOL BIOL PAT, V0, P97
   Barragán-Campos HM, 2005, ARCH NEUROL-CHICAGO, V62, P737, DOI 10.1001/archneur.62.5.737
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Choi C, 2000, YONSEI MED J, V41, P676, DOI 10.3349/ymj.2000.41.5.676
   De Block CEM, 2004, EXP CLIN ENDOCR DIAB, V112, P80, DOI 10.1055/s-2004-815754
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   KISHIMOTO M, 1995, DIABETOLOGIA, V38, P193, DOI 10.1007/s001250050270
   Marín-García J, 2002, PEDIATR NEUROL, V27, P213, DOI 10.1016/S0887-8994(02)00426-5
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7
   POULTON J, 1995, DIABETOLOGIA, V38, P868, DOI 10.1007/s001250050366
   REICHMANN H, 1991, EUR NEUROL, V31, P108, DOI 10.1159/000116656
   ROBERTSON WC, 1979, ARCH NEUROL-CHICAGO, V36, P711, DOI 10.1001/archneur.1979.00500470081017
   Rubi-Palomares I, 2002, AN ESP PEDIATR, V56, P180
   SCHNITZLER ER, 1979, NEUROLOGY, V29, P1172, DOI 10.1212/WNL.29.8.1172
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
NR 19
TC 20
Z9 22
U1 0
U2 2
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 1262-3636
EI 1878-1780
J9 DIABETES METAB
JI Diabetes Metab.
PD APR 15
PY 2006
VL 32
IS 2
BP 182
EP 186
DI 10.1016/S1262-3636(07)70267-7
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 039OR
UT WOS:000237316600012
PM 16735969
DA 2024-11-01
ER

PT J
AU Annunen-Rasila, J
   Finnilä, S
   Mykkänen, K
   Moilanen, JS
   Veijola, J
   Pöyhönen, M
   Viitanen, M
   Kalimo, H
   Majamaa, K
AF Annunen-Rasila, Johanna
   Finnila, Saara
   Mykkanen, Kati
   Moilanen, Jukka S.
   Veijola, Johanna
   Poyhonen, Minna
   Viitanen, Matti
   Kalimo, Hannu
   Majamaa, Kari
TI Mitochondrial DNA sequence variation and mutation rate in patients with CADASIL
SO NEUROGENETICS
LA English
DT Article
DE CADASIL; mtDNA; DNA sequence analysis; genetic variation; NOTCH3
ID autosomal-dominant arteriopathy; subcortical infarcts; phylogenetic network; notch3 gene; leukoencephalopathy cadasil; skeletal-muscle; mtdna; recombination; spectrum; genome
AB Mutations in the NOTCH3 gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is clinically characterised by recurrent ischemic strokes, migraine with aura, psychiatric symptoms, cognitive decline and dementia. We have previously described a patient with CADASIL caused by a R133C mutation in the NOTCH3 gene and with a concomitant myopathy caused by a 5650G > A mutation in the MTTA gene in mitochondrial DNA (mtDNA). We assume that the co-occurrence of the two mutations is not coincidental and that mutations in the NOTCH3 gene may predispose the mtDNA to mutations. We therefore examined the nucleotide variation in the mtDNA coding region sequences in 20 CADASIL pedigrees with 77 affected patients by conformation-sensitive gel electrophoresis and sequencing. The sequence variation in mtDNA was then compared with that among 192 healthy Finns. A total of 180 mtDNA coding region sequence differences were found relative to the revised Cambridge reference sequence, including five novel synonymous substitutions, two novel nonsynonymous substitutions and one novel tRNA substitution. We found that maternal relatives in two pedigrees differed from each other in their mtDNA. Furthermore, the average number of pairwise differences in sequences from the 41 unrelated maternal lineages with CADASIL was higher than that expected among haplogroup-matched controls. The numbers of polymorphic sites and polymorphisms that were present in only one sequence were also higher among the CADASIL sequences than among the control sequences. Our results show that mtDNA sequence variation is increased within CADASIL pedigrees. These findings suggest a relationship between NOTCH3 and mtDNA.
C1 Oulu Univ, Dept Neurol, Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
   Turku Univ, Dept Med Genet, Turku, Finland.
   Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland.
   Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland.
   Univ Helsinki, Dept Med Genet, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Clin Genet, Helsinki, Finland.
   Turku Univ, Dept Geriatr Med, Turku, Finland.
   Karolinska Univ Hosp, Div Clin Geriatr, Karolinska Inst, Stockholm, Sweden.
   Univ Helsinki, Dept Pathol, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland.
   Turku Univ, Dept Pathol, Turku, Finland.
C3 University of Oulu; University of Oulu; University of Turku; University of Oulu; Tampere University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku
RP Majamaa, K (corresponding author), Turku Univ, Dept Neurol, Turku 20014, Finland.
EM Kari.Majamaa@utu.fi
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bandelt HJ, 2001, INT J LEGAL MED, V115, P64, DOI 10.1007/s004140100228
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cavelier L, 2000, HUM GENET, V107, P45, DOI 10.1007/s004390050009
   CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5
   de la Peña P, 2001, NEUROLOGY, V57, P1235, DOI 10.1212/WNL.57.7.1235
   Dichgans M, 1998, ANN NEUROL, V44, P731, DOI 10.1002/ana.410440506
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dotti MT, 2004, ARCH NEUROL-CHICAGO, V61, P942, DOI 10.1001/archneur.61.6.942
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Finnilä S, 2000, AM J HUM GENET, V66, P1017, DOI 10.1086/302802
   FU YX, 1993, GENETICS, V133, P693
   Howell N, 1996, AM J HUM GENET, V59, P501
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   HOWELL N, 1995, GENETICS, V140, P285
   Joutel A, 2004, AM J HUM GENET, V74, P338, DOI 10.1086/381506
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Lehtonen MS, 2003, HUM GENET, V113, P220, DOI 10.1007/s00439-003-0966-9
   Loogväli EL, 2004, MOL BIOL EVOL, V21, P2012, DOI 10.1093/molbev/msh209
   Malandrini A, 2002, NEUROLOGY, V59, P617, DOI 10.1212/WNL.59.4.617
   Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4
   Mazzei R, 2004, NEUROLOGY, V63, P561, DOI 10.1212/01.WNL.0000133399.37716.84
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Moilanen JS, 2003, MOL BIOL EVOL, V20, P2132, DOI 10.1093/molbev/msg230
   Moilanen JS, 2003, MOL BIOL EVOL, V20, P1195, DOI 10.1093/molbev/msg121
   Mykkänen K, 2004, EUR J HUM GENET, V12, P813, DOI 10.1038/sj.ejhg.5201221
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200
   Okeda R, 2002, STROKE, V33, P2565, DOI 10.1161/01.STR.0000032620.91848.1C
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   Rost B, 1996, METHOD ENZYMOL, V266, P525
   ROUSSET F, 1995, GENETICS, V140, P1413
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Schneider S, 2000, ARLEQUIN VER 2000 SO, V0, P0
   Schröder JM, 2005, ACTA NEUROPATHOL, V110, P587, DOI 10.1007/s00401-005-1082-9
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100
   Siguroardóttir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902
   TAJIMA F, 1983, GENETICS, V105, P437
   TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256
   Uchino M, 2002, ANN NY ACAD SCI, V977, P273, DOI 10.1111/j.1749-6632.2002.tb04826.x
   Vilmi T, 2005, J MOL EVOL, V60, P587, DOI 10.1007/s00239-003-0202-1
   WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 46
TC 15
Z9 16
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD JUL 15
PY 2006
VL 7
IS 3
BP 185
EP 194
DI 10.1007/s10048-006-0049-x
PG 10
WC Genetics & Heredity; Clinical Neurology
SC Genetics & Heredity; Neurosciences & Neurology
GA 063TQ
UT WOS:000239043000007
PM 16807713
DA 2024-11-01
ER

PT J
AU Chinnery, P
   Majamaa, K
   Turnbull, D
   Thorburn, D
AF Chinnery, P
   Majamaa, K
   Turnbull, D
   Thorburn, D
TI Treatment for mitochondrial disorders
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID kearns-sayre-syndrome; progressive external ophthalmoplegia; hereditary optic neuropathy; complex-i deficiency; magnetic-resonance spectroscopy; respiratory-chain disorders; coenzyme q(10) deficiency; c-oxidase deficiency; stroke-like episodes; dna mutations
AB Background Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. Objectives To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease. Search strategy We searched the Cochrane Neuromuscular Disease Group trials register (searched September 2003), the Cochrane Central Register of Controlled Trials, MEDLINE (January 1966 to October 3 2003), EMBASE (January 1980 to October 3 2003) and the European Neuromuscular Centre (ENMC) clinical trials register, and contacted experts in the field. Selection criteria We included randomised controlled trials (including crossover studies) and quasi-randomised trials comparing pharmacological treatments, and non-pharmacological treatments (vitamins and food supplements), and physical training in individuals with mitochondrial disorders. The primary outcome measures included an improvement in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes. Data collection and analysis Details of the number of randomised patients, treatment, study design, study category, allocation concealment and patient characteristics were extracted. Analysis was based on intention to treat data. We planned to use meta-analysis, but this did not prove necessary. Main results Six hundred and seventy-eight abstracts were reviewed, and six fulfilled the entry criteria. Two trials studied the effects of co-enzyme Q10 (ubiquinone), one reporting a subjective improvement and a significant increase in a global scale of muscle strength, but the other trial did not show any benefit. Two trials used creatine, with one reporting improved measures of muscle strength and post-exercise lactate, but the other reported no bene fit. One trial of dichloroacetate showed an improvement in secondary outcome measures of mitochondrial metabolism, and one trial using dimethylglycine showed no significant effect. Authors' conclusions There is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches.
C1 Newcastle Univ, Sch Med, Dept Neurol, Newcastle Upon Tyne NE24 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Dept Neurol, Framlington Pl, Newcastle Upon Tyne NE24 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
CR ABE K, 1991, ACTA NEUROL SCAND, V83, P356, DOI 10.1111/j.1600-0404.1991.tb03962.x
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BARBIROLI B, 1995, J NEUROL, V242, P472, DOI 10.1007/BF00873552
   Barshop BA, 2004, MOL GENET METAB, V83, P138, DOI 10.1016/j.ymgme.2004.06.009
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   BERNSEN PLJA, 1993, J NEUROL SCI, V118, P181, DOI 10.1016/0022-510X(93)90108-B
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 1998, AM J HUM GENET, V63, P1908, DOI 10.1086/302157
   Cortelli P, 1997, J NEUROL SCI, V148, P25, DOI 10.1016/S0022-510X(96)00311-5
   CURLESS RG, 1986, NEUROLOGY, V36, P872, DOI 10.1212/WNL.36.6.872
   Dahl HHM, 1998, AM J HUM GENET, V63, P1594, DOI 10.1086/302169
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DUNLOP IS, 1995, AUST NZ J OPHTHALMOL, V23, P231, DOI 10.1111/j.1442-9071.1995.tb00164.x
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   FOLKERS K, 1985, P NATL ACAD SCI USA, V82, P4513, DOI 10.1073/pnas.82.13.4513
   Gold R, 1996, EUR NEUROL, V36, P191, DOI 10.1159/000117246
   GUBBAY SS, 1989, MED J AUSTRALIA, V151, P100, DOI 10.5694/j.1326-5377.1989.tb101170.x
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HSU CC, 1995, ACTA NEUROL SCAND, V92, P252
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x
   KURLEMANN G, 1995, EUR J PEDIATR, V154, P928, DOI 10.1007/BF01957508
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Liet JM, 2003, J PEDIATR-US, V142, P62, DOI 10.1067/mpd.2003.mpd0333
   LOU HC, 1981, ARCH NEUROL-CHICAGO, V38, P469, DOI 10.1001/archneur.1981.00510070103027
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Majamaa K, 1997, MOL CELL BIOCHEM, V174, P291, DOI 10.1023/A:1006833200371
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mashima Y, 2000, J NEURO-OPHTHALMOL, V20, P166, DOI 10.1097/00041327-200020030-00006
   MASHIMA Y, 1992, LANCET, V340, P368, DOI 10.1016/0140-6736(92)91442-B
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   Mitsui T, 2002, ACTA NEUROPATHOL, V104, P260, DOI 10.1007/s00401-002-0553-5
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Mori M, 2004, BRAIN DEV-JPN, V26, P453, DOI 10.1016/j.braindev.2003.12.009
   Mowat D, 1999, J PEDIATR-US, V134, P352, DOI 10.1016/S0022-3476(99)70463-4
   MULLER W, 1990, J NEUROL SCI, V98, P442
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   NISHIKAWA Y, 1989, NEUROLOGY, V39, P399, DOI 10.1212/WNL.39.3.399
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1986, NEUROLOGY, V36, P45, DOI 10.1212/WNL.36.1.45
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Oguro H, 2004, INTERNAL MED, V43, P427, DOI 10.2169/internalmedicine.43.427
   Panetta J, 2004, J INHERIT METAB DIS, V27, P487, DOI 10.1023/B:BOLI.0000037354.66587.38
   Papadimitriou A, 1996, NEUROMUSCULAR DISORD, V6, P49, DOI 10.1016/0960-8966(95)00020-8
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Remes AM, 2002, NEUROLOGY, V59, P1275, DOI 10.1212/WNL.59.8.1275
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Tarnopolsky M, 1999, NEUROLOGY, V52, P854, DOI 10.1212/WNL.52.4.854
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor R W, 2000, HUM REPROD, V15 Suppl 2, P79
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 75
TC 116
Z9 120
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2006
VL 0
IS 1
BP 
EP 
DI 10.1002/14651858.CD004426.pub2
PG 19
WC Medicine, General & Internal
SC General & Internal Medicine
GA 007OE
UT WOS:000234978200038
DA 2024-11-01
ER

PT J
AU Durham, SE
   Brown, DT
   Turnbull, DM
   Chinnery, PF
AF Durham, Steve E.
   Brown, Denise T.
   Turnbull, Douglass M.
   Chinnery, Patrick F.
TI Progressive depletion of mtDNA in mitochondrial myopathy
SO NEUROLOGY
LA English
DT Article
ID skeletal-muscle; dna; decrease; genm; melas
AB The authors studied seven patients with mitochondrial DNA ( mtDNA) myopathy. Over time, there was a progressive depletion of mtDNA, which preferentially affected wild-type mitochondrial genomes. This suggests that loss of wild-type mtDNA is a major feature of mtDNA myopathy, and preventing wild-type mtDNA depletion has treatment implications.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.a.cuk
FU Wellcome Trust [074454] Funding Source: Medline
CR Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Horváth R, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.015024
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KAWAKAMI Y, 1994, ANN NEUROL, V35, P370, DOI 10.1002/ana.410350322
   Kovalenko SA, 1998, BIOCHEM MOL BIOL INT, V46, P1233
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Welle S, 2003, J APPL PHYSIOL, V94, P1479, DOI 10.1152/japplphysiol.01061.2002
NR 10
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD AUG 8
PY 2006
VL 67
IS 3
BP 502
EP 504
DI 10.1212/01.wnl.0000227961.55640.2f
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 071LK
UT WOS:000239603500030
PM 16894115
DA 2024-11-01
ER

PT J
AU Sparaco, M
   Feleppa, M
   Lipton, RB
   Rapoport, AM
   Bigal, ME
AF Sparaco, M
   Feleppa, M
   Lipton, RB
   Rapoport, AM
   Bigal, ME
TI Mitochondrial dysfunction and migraine: evidence and hypotheses
SO CEPHALALGIA
LA English
DT Review
DE brain oxidative metabolism; magnetic resonance spectroscopy; migraine; mitochondrial dysfunction; mutation
ID magnetic-resonance-spectroscopy; familial hemiplegic migraine; brain energy-metabolism; ragged-red fibers; transfer rnaleu(uur) gene; cytochrome-c-oxidase; lactic-acidosis; nitric-oxide; clinical-features; respiratory-chain
AB The molecular basis of migraine is still not completely understood. An impairment of mitochondrial oxidative metabolism might play a role in the pathophysiology of this disease, by influencing neuronal information processing. Biochemical assays of platelets and muscle biopsies performed in migraine sufferers have shown a decreased activity of the respiratory chain enzymes. Studies with phosphorus magnetic resonance spectroscopy (P-31-MRS) have demonstrated an impairment of the brain oxidative energy metabolism both during and between migraine attacks. However, molecular genetic studies have not detected specific mitochondrial DNA (mtDNA) mutations in patients with migraine, although other studies suggest that particular genetic markers (i.e. neutral polymorphisms or secondary mtDNA mutations) might be present in some migraine sufferers. Further studies are still needed to clarify if migraine is associated with unidentified mutations on the mtDNA or on nuclear genes that code mitochondrial proteins. In this paper, we review morphological, biochemical, imaging and genetic studies which bear on the hypothesis that migraine may be related to mitochondrial dysfunction at least in some individuals.
C1 Hosp G Rummo, Dept Neurol, Benevento, Italy.
   Hosp G Rummo, Headache Ctr, Benevento, Italy.
   Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA.
   Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
   Montefiore Headache Unit, Bronx, NY USA.
   New England Ctr Headache, Stamford, CT USA.
   Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva University; Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva University; Columbia University
RP Hosp G Rummo, Dept Neurol, Benevento, Italy.
EM marcosparaco@aliceposta.it
CR Akerman S, 2002, BRIT J PHARMACOL, V137, P62, DOI 10.1038/sj.bjp.0704842
   Almeida A, 2005, J NEUROSCI RES, V79, P166, DOI 10.1002/jnr.20281
   ANTOZZI C, 1994, NEUROLOGY, V44, P2153, DOI 10.1212/WNL.44.11.2153
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   Aurora SK, 1998, CURR OPIN NEUROL, V11, P205, DOI 10.1097/00019052-199806000-00003
   BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61
   BARBIROLI B, 1992, NEUROLOGY, V42, P1209, DOI 10.1212/WNL.42.6.1209
   BARBIROLI B, 1990, CEPHALALGIA, V10, P263, DOI 10.1046/j.1468-2982.1990.1005263.x
   Bigal Marcelo E, 2004, CURR PAIN HEADACHE REP, V8, P178, DOI 10.1007/s11916-004-0049-1
   BOLANOS JP, 1994, J NEUROCHEM, V63, P910
   BOLANOS JP, 2004, FREE RADIC BIOL MED, V21, P995
   Boles RG, 1997, LANCET, V350, P1299, DOI 10.1016/S0140-6736(05)62477-4
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Boska MD, 2002, NEUROLOGY, V58, P1227, DOI 10.1212/WNL.58.8.1227
   BRESOLIN N, 1991, J NEUROL SCI, V104, P182, DOI 10.1016/0022-510X(91)90308-T
   Buzzi MG, 2000, NEUROLOGY, V54, P1005, DOI 10.1212/WNL.54.4.1005
   Cao Y, 2002, NEUROLOGY, V59, P72, DOI 10.1212/WNL.59.1.72
   Capuano A, 2004, CLIN TER, V155, P79
   Casas F, 2000, FEBS LETT, V482, P71, DOI 10.1016/S0014-5793(00)02023-8
   Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700
   CHANCE B, 1985, CIRCULATION, V72, P103
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Christiansen I, 1999, CEPHALALGIA, V19, P660, DOI 10.1046/j.1468-2982.1999.019007660.x
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Cidad P, 2004, BIOCHEM J, V384, P629, DOI 10.1042/BJ20040886
   CORTELLI P, 1995, LANCET, V345, P1120, DOI 10.1016/S0140-6736(95)90853-6
   CURTRER FM, 2000, NEUROLOGY S2, V55, P0
   De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081
   DEVOTO M, 1986, CEPHALALGIA, V6, P101, DOI 10.1046/j.1468-2982.1986.0602101.x
   Di Gennaro G, 2000, HEADACHE, V40, P568, DOI 10.1046/j.1526-4610.2000.00088.x
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1990, NEUROL CLIN, V8, P483, DOI 10.1016/S0733-8619(18)30332-3
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Ducros A, 2001, NEW ENGL J MED, V345, P17, DOI 10.1056/NEJM200107053450103
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   ELEFF SM, 1990, ANN NEUROL, V27, P626, DOI 10.1002/ana.410270607
   Estevez M, 2004, HUM GENET, V114, P225, DOI 10.1007/s00439-003-1055-9
   Finnilä S, 2001, J MED GENET, V38, P400, DOI 10.1136/jmg.38.6.400
   FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686
   Goadsby PJ, 1997, NEUROL CLIN, V15, P27, DOI 10.1016/S0733-8619(05)70293-0
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Haan J, 1999, CEPHALALGIA, V19, P20, DOI 10.1046/j.1468-2982.1999.1901020.x
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hao HL, 1999, HUM MOL GENET, V8, P1117, DOI 10.1093/hmg/8.6.1117
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Huoponen K, 2001, NEUROGENETICS, V3, P119, DOI 10.1007/s100480100115
   Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kabbouche MA, 2003, HEADACHE, V43, P490, DOI 10.1046/j.1526-4610.2003.03095.x
   Kalfakis N, 1996, HEADACHE, V36, P320, DOI 10.1046/j.1526-4610.1996.3605320.x
   Klopstock T, 1996, NEUROLOGY, V46, P1735, DOI 10.1212/WNL.46.6.1735
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107
   LAURITZEN M, 1983, ANN NEUROL, V14, P569, DOI 10.1002/ana.410140512
   Lefai E, 1997, BBA-BIOENERGETICS, V1318, P191, DOI 10.1016/S0005-2728(96)00136-3
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   LITTLEWOOD J, 1984, J NEUROL NEUROSUR PS, V47, P338, DOI 10.1136/jnnp.47.4.338
   Lodi R, 2001, BRAIN RES BULL, V54, P437, DOI 10.1016/S0361-9230(01)00440-3
   Majamaa K, 1998, LANCET, V352, P455, DOI 10.1016/S0140-6736(05)79190-X
   Marriage B, 2003, J AM DIET ASSOC, V103, P1029, DOI 10.1016/S0002-8223(03)00476-0
   MOCHI M, 1993, CEPHALALGIA, V13, P389, DOI 10.1046/j.1468-2982.1993.1306389.x
   MONTAGNA P, 1988, HEADACHE, V28, P477, DOI 10.1111/j.1526-4610.1988.hed2807477.x
   MONTAGNA P, 1994, CEPHALALGIA, V14, P184, DOI 10.1046/j.1468-2982.1994.014003184.x
   MONTAGNA P, 1994, NEUROLOGY, V44, P666, DOI 10.1212/WNL.44.4.666
   Montagna P, 1998, MUSCLE NERVE, V21, P127
   Montagna P, 2000, CEPHALALGIA, V20, P3, DOI 10.1046/j.1468-2982.2000.00003.x
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   Moskowitz MA, 2004, ANN NEUROL, V55, P276, DOI 10.1002/ana.20035
   Odawara M, 1997, MUSCLE NERVE, V20, P394
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ojaimi J, 1998, CEREBROVASC DIS, V8, P102, DOI 10.1159/000015826
   Okada H, 1998, HEADACHE, V38, P39, DOI 10.1046/j.1526-4610.1998.3801039.x
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406
   Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2
   PALADE GE, 1953, J HISTOCHEM CYTOCHEM, V1, P188, DOI 10.1177/1.4.188
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Peroutka SJ, 1998, CLIN NEUROSCI, V5, P34
   PHELPS ME, 1981, SCIENCE, V211, P1445, DOI 10.1126/science.6970412
   Powers HJ, 2003, AM J CLIN NUTR, V77, P1352
   PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829
   Rozen TD, 2002, CEPHALALGIA, V22, P137, DOI 10.1046/j.1468-2982.2002.00335.x
   RUSSELL MB, 1993, CEPHALALGIA, V13, P245, DOI 10.1046/j.1468-2982.1993.1304245.x
   RUSSELL MB, 1995, HUM GENET, V96, P726, DOI 10.1007/BF00210307
   RUSSELL MB, 1993, NEUROLOGY, V43, P1369, DOI 10.1212/WNL.43.7.1369
   Russell MB, 1997, ACTA NEUROL SCAND, V96, P171
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   SACQUEGNA T, 1992, ACTA NEUROL SCAND, V86, P376, DOI 10.1111/j.1600-0404.1992.tb05104.x
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Sándor PS, 2005, NEUROLOGY, V64, P713, DOI 10.1212/01.WNL.0000151975.03598.ED
   SANGIORGI S, 1994, CEPHALALGIA, V14, P21, DOI 10.1046/j.1468-2982.1994.1401021.x
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   Schoenen J, 1996, BIOMED PHARMACOTHER, V50, P71, DOI 10.1016/0753-3322(96)84716-0
   Schoenen J, 1998, CLIN NEUROSCI, V5, P10
   Schoenen J, 1998, NEUROLOGY, V50, P466, DOI 10.1212/WNL.50.2.466
   SCHOLTE HR, 1995, BBA-MOL BASIS DIS, V1271, P75, DOI 10.1016/0925-4439(95)00013-T
   Seibel P, 1996, J NEUROL, V243, P305, DOI 10.1007/BF00868402
   SHERRATT HSA, 1991, REV NEUROL, V147, P417
   SHIMOMURA T, 1994, LANCET, V344, P625, DOI 10.1016/S0140-6736(94)92015-X
   Shimomura TKA, 1995, CEPHALALGIA, V15, P10
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   SKINHOJ E, 1973, ARCH NEUROL-CHICAGO, V29, P95, DOI 10.1001/archneur.1973.00490260039007
   Smith M, 2002, NEUROLOGY, V58, P1308, DOI 10.1212/WNL.58.8.1308-a
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   STADHOUDERS AM, 1987, J INHERIT METAB DIS, V10, P62, DOI 10.1007/BF01812848
   Takeshima T, 2001, CEPHALALGIA, V21, P987, DOI 10.1046/j.1468-2982.2001.00305.x
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Tyni T, 2004, PEDIATR RES, V56, P744, DOI 10.1203/01.PDR.0000141967.52759.83
   UNCINI A, 1995, J NEUROL SCI, V129, P214, DOI 10.1016/0022-510X(94)00283-T
   Vanmolkot KRJ, 2003, ANN NEUROL, V54, P360, DOI 10.1002/ana.10674
   Wallace DC, 2001, MENT RETARD DEV D R, V7, P158, DOI 10.1002/mrdd.1023
   Wanic-Kossowska M, 1997, POL ARCH MED WEWN, V97, P534
   Watanabe H, 1996, NEUROLOGY, V47, P1093
   Welch KMA, 1998, CURR OPIN NEUROL, V11, P193, DOI 10.1097/00019052-199806000-00001
   Welch KMA, 2003, NEUROLOGY, V61, PS2, DOI 10.1212/WNL.61.8_suppl_4.S2
   WELCH KMA, 1990, NEUROL CLIN, V8, P817, DOI 10.1016/S0733-8619(18)30319-0
   WELCH KMA, 1989, NEUROLOGY, V39, P538, DOI 10.1212/WNL.39.4.538
   Young William B, 2004, CURR PAIN HEADACHE REP, V8, P244, DOI 10.1007/s11916-004-0059-z
   Zhou L, 1997, J NEUROSCI, V17, P7746
NR 125
TC 135
Z9 142
U1 0
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0333-1024
EI 1468-2982
J9 CEPHALALGIA
JI Cephalalgia
PD APR 15
PY 2006
VL 26
IS 4
BP 361
EP 372
DI 10.1111/j.1468-2982.2005.01059.x
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 024VJ
UT WOS:000236224100001
PM 16556237
DA 2024-11-01
ER

PT J
AU Mohamed, SA
   Hanke, T
   Erasmi, AW
   Bechtel, MJF
   Scharfschwerdt, M
   Meissner, C
   Sievers, HH
   Gosslau, A
AF Mohamed, SA
   Hanke, T
   Erasmi, AW
   Bechtel, MJF
   Scharfschwerdt, M
   Meissner, C
   Sievers, HH
   Gosslau, A
TI Mitochondrial DNA deletions and the aging heart
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE mitochondrial DNA; 4.977 bp deletion; oxidative stress; apotosis; aging
ID oxidative stress; cardiovascular-disease; vitamin-e; skeletal-muscle; polymerase-gamma; free-radicals; human tissue; copy number; cell-death; apoptosis
AB Mitochondrial DNA (mtDNA) mutations appear to be associated with a wide spectrum of human disorders and proposed to be a potential contributor of aging. However, in an age-dependent increase of the common 4977 bp deletion of human mtDNA still many unanswered questions remain. Comparing mtDNA copy levels in different tissues revealed that cardiac muscle had the highest, while the cortex cerebelli showed the lowest copy number of mtDNA in every donor. Intriguingly, mtDNA copy number showed no changes during aging, In heart tissue, the amount of 4977 bp mtDNA deletion increased in an age-dependent manner showing significant differences at the age of 40 years and older (p < 0.005). In vitro studies analyzing human normal cells transfected with telomerase (BJ-T) revealed that oxidative stress (OS)-a well accepted promoter of aging-induced 4977 bp deletion and point mutations as demonstrated by real-time PCR and DHPLC analysis. Interestingly, OS induced apoptosis only in transformed human fibroblasts by activation of the intrinsic (mitochondrial-mediated) signalling pathway as indicated by morphological damage of mitochondria, DNA laddering and increase of the Bax/Bcl-2 ratio. In conclusion, in heart tissue, the amount of the 4977 bp deletion increased in an age-dependent manner and it was more detectable after the 4th decade of life, although there was some scatter in the data. Since, apoptosis was induced by the mitochondria-mediated pathway only in transformed cells, the role for apoptosis in normal tissue of the aging heart remains unclear. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Schleswig Holstrein, Dept Cardiac Surg, D-23538 Lubeck, Germany.
   Univ Schleswig Holstrein, Dept Forens Med, D-23538 Lubeck, Germany.
   Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ USA.
C3 University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Rutgers University System; Rutgers University New Brunswick
RP Mohamed, SA (corresponding author), Univ Schleswig Holstrein, Dept Cardiac Surg, Campus Luebeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM s.mohamed@herzchirurgie-luebeck.de
CR Arai T, 2003, AGING CLIN EXP RES, V15, P1
   ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P
   Bågenholm R, 1998, PEDIATR RES, V43, P271, DOI 10.1203/00006450-199802000-00019
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312
   Bayat A, 2005, INT J IMMUNOGENET, V32, P199, DOI 10.1111/j.1744-313X.2005.00508.x
   BECKMAN KB, 1998, ANN NY ACAD SCI, V20, P118
   BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x
   Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345
   Bernecker Oliver Y, 2003, CARDIOVASC TOXICOL, V3, P183, DOI 10.1385/CT:3:3:183
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   Cottrell DA, 2000, ANN NY ACAD SCI, V908, P199
   Davies K J, 1995, OXIDATIVE STRESS: THE PARADOX OF AEROBIC LIFEBIOCHEMICAL SOCIETY SYMPOSIA, V0, P1
   Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   DICE JF, 1993, PHYSIOL REV, V73, P149, DOI 10.1152/physrev.1993.73.1.149
   Frahm T, 2005, MECH AGEING DEV, V126, P1192, DOI 10.1016/j.mad.2005.06.008
   GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H
   Gosslau A, 2005, BRIT J CANCER, V92, P513, DOI 10.1038/sj.bjc.6602300
   Gosslau A, 2004, NUTRITION, V20, P95, DOI 10.1016/j.nut.2003.09.017
   Goyns MH, 2002, MECH AGEING DEV, V123, P791, DOI 10.1016/S0047-6374(01)00424-9
   Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Ide T, 2001, CIRC RES, V88, P529, DOI 10.1161/01.RES.88.5.529
   JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990
   KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899
   Kim UK, 2000, BASIC RES CARDIOL, V95, P163, DOI 10.1007/s003950050178
   Kumar D, 2003, J LAB CLIN MED, V142, P288, DOI 10.1016/S0022-2143(03)00148-3
   Lakatta EG, 2003, CIRCULATION, V107, P346, DOI 10.1161/01.CIR.0000048893.62841.F7
   Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1159/000025424
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Marín-García J, 2002, J CARD FAIL, V8, P347, DOI 10.1054/jcaf.2002.127774
   MarinGarcia J, 1996, CARDIOVASC RES, V31, P306
   Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21
   McKenzie D, 2002, EUR J BIOCHEM, V269, P2010, DOI 10.1046/j.1432-1033.2002.02867.x
   Meydani M, 2004, ANN NY ACAD SCI, V1031, P271, DOI 10.1196/annals.1331.027
   MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Mohamed SA, 2004, EXP GERONTOL, V39, P181, DOI 10.1016/j.exger.2003.10.011
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MUELLERHOECKER J, 1994, VERH DTSCH GES PATHO, V78, P48
   Munteanu A, 2004, J CELL MOL MED, V8, P59, DOI 10.1111/j.1582-4934.2004.tb00260.x
   Murakami E, 2003, J BIOL CHEM, V278, P36403, DOI 10.1074/jbc.M306236200
   Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427
   Papiha SS, 1998, J CLIN PATHOL, V51, P117, DOI 10.1136/jcp.51.2.117
   Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1
   Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726
   Sastre J, 2000, FREE RADICAL RES, V32, P189, DOI 10.1080/10715760000300201
   Sharma P, 1998, GERONTOLOGY, V44, P78, DOI 10.1159/000021988
   SHAY JW, 1990, J BIOL CHEM, V265, P14802
   SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x
   Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59
   TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929
   van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1
   Violi F, 2004, ANN NY ACAD SCI, V1031, P292, DOI 10.1196/annals.1331.029
   Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x
   WEISFELDT M, 1992, AGING HEART HEART DI, V0, P0
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302
   Zhang CF, 1999, BIOCHEM BIOPH RES CO, V254, P152, DOI 10.1006/bbrc.1998.9914
NR 68
TC 56
Z9 70
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 
J9 EXP GERONTOL
JI Exp. Gerontol.
PD MAY 15
PY 2006
VL 41
IS 5
BP 508
EP 517
DI 10.1016/j.exger.2006.03.014
PG 10
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 054UQ
UT WOS:000238404500010
PM 16632292
DA 2024-11-01
ER

PT J
AU Maagaard, A
   Holberg-Petersen, M
   Kollberg, G
   Oldfors, A
   Sandvik, L
   Bruun, JN
AF Maagaard, Anne
   Holberg-Petersen, Mona
   Kollberg, Gittan
   Oldfors, Anders
   Sandvik, Leiv
   Bruun, Johan N.
TI Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients
SO ANTIVIRAL THERAPY
LA English
DT Article
ID reverse-transcriptase inhibitors; subcutaneous adipose-tissue; antiretroviral therapy; dna depletion; positive patients; zidovudine; toxicity; myopathy; mutations; fat
AB Objectives: Most data on mitochondrial toxicity have been derived from peripheral blood mononuclear cells (PBMCs). However, whether mitochondrial DNA (mtDNA) content in PBMCs reflects the mitochondrial state in tissues remains elusive. We report herein on mitochondrial toxicity in skeletal muscle in HIV-infected patients naive to antiretroviral treatment (ART [HIV+ART-naive]; n=10) patients exposed to nucleoside reverse transcriptase inhibitors (NRTIs [HIV+NRTI+]; n=24) and healthy controls (n=11), and compare these tissue data with mtDNA in PBMCs. Methods: Muscle biopsies were examined for (i) mtDNA and nuclear DNA (nDNA) content using TaqMan realtime PCR system, (ii) mtDNA deletions using long expand PCR with subsequent gel electrophoresis, and (iii) mitochondrial myopathy expressed as cytochrome c oxidase (COX)-deficient muscle fibres. Results: The mt/n DNA ratio in muscle from HIV+NRTI+ patients was reduced compared with HIV-negative controls (P=0.028). Moreover, mtDNA deletions were more frequent in HIV+NRTI+ patients than in both HIV-negative controls (P=0.009) and HIV+ART-naive patients (P=0.005). HIV+NRTI+ also tended to have more COX-deficient fibres than HIV-negative controls (P=0.076). COX-deficient fibres were positively correlated with mtDNA deletions in HIV+NRTI+ patients (r=0.83, P<0.001). Patients with current use of didanosine (ddl) had more frequent mtDNA deletions and COX-deficient fibres than HIV+NRTI+ not on current treatment with ddl. It should be noted that mitochondrial alterations were not correlated with mtDNA/cell in PBMCs in any group. Conclusions: In skeletal muscle, HIV+NRTI+ had a reduced mt/n DNA ratio, more frequent mtDNA deletions and possibly more COX-deficient muscle fibres than HIV-negative controls. However, the mtDNA/cell in peripheral blood was decreased in both HIV+NRTI+ and HIV+ART-naive patients. Thus, mtDNA in peripheral blood may not be a relevant marker of mitochondrial toxicity in organ-specific tissue.
C1 Ullevaal Univ Hosp, Dept Infect Dis, Oslo, Norway.
   Univ Oslo, Fac Div, Oslo, Norway.
   Ullevaal Univ Hosp, Dept Microbiol, Oslo, Norway.
   Ullevaal Univ Hosp, Clin Res Ctr, Oslo, Norway.
   Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
C3 University of Oslo; University of Oslo; University of Oslo; University of Oslo; Sahlgrenska University Hospital
RP Maagaard, A (corresponding author), Ullevaal Univ Hosp, Dept Infect Dis, Oslo, Norway.
EM anne.maagaard@medisin.uio.no
CR Andréasson H, 2002, BIOTECHNIQUES, V33, P402, DOI 10.2144/02332rr07
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bergersen BM, 2004, SCAND J INFECT DIS, V36, P186, DOI 10.1080/00365540410019273
   Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004
   Casula M, 2005, J INFECT DIS, V191, P1468, DOI 10.1086/429412
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/00126334-200207010-00002
   Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113
   Christensen ER, 2004, CLIN INFECT DIS, V39, P1371, DOI 10.1086/424881
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   Haugaard SB, 2005, J MED VIROL, V77, P29, DOI 10.1002/jmv.20410
   Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   López S, 2004, ANTIVIR THER, V9, P47
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maagaard A, 2006, HIV MED, V7, P53, DOI 10.1111/j.1468-1293.2005.00336.x
   Mallon PWG, 2005, J INFECT DIS, V191, P1686, DOI 10.1086/429697
   Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001
   McComsey GA, 2005, AIDS, V19, P15, DOI 10.1097/00002030-200501030-00002
   Miró O, 2000, AIDS, V14, P1855, DOI 10.1097/00002030-200008180-00024
   Miró O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176
   Montaner JSG, 2004, CLIN INFECT DIS, V38, PS73, DOI 10.1086/381449
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Pace CS, 2003, ANTIVIR THER, V8, P323
   POLO R, 2001, J ACQ IMMUN DEF SYND, V34, P32
   Raidel SM, 2002, AM J PHYSIOL-HEART C, V282, PH1672, DOI 10.1152/ajpheart.00955.2001
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
NR 36
TC 48
Z9 49
U1 0
U2 3
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
EI 
J9 ANTIVIR THER
JI Antivir. Ther.
PD JUN 15
PY 2006
VL 11
IS 5
BP 601
EP 608
DI 
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 076UY
UT WOS:000239984700008
PM 16964828
DA 2024-11-01
ER

PT J
AU Betts, J
   Jaros, E
   Perry, RH
   Schaefer, AM
   Taylor, RW
   Abdel-All, Z
   Lightowlers, RN
   Turnbull, DM
AF Betts, J.
   Jaros, E.
   Perry, R. H.
   Schaefer, A. M.
   Taylor, R. W.
   Abdel-All, Z.
   Lightowlers, R. N.
   Turnbull, D. M.
TI Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE MELAS; mitochondrial myopathy; stroke-like episodes and migraine
ID stroke-like episodes; ragged-red fibers; mitochondrial encephalomyopathy melas; lactic-acidosis; spreading depression; point mutation; blood-vessels; succinate-dehydrogenase; skeletal-muscle; cerebral-cortex
AB Mitochondrial DNA (mtDNA) disease is an important genetic cause of neurological disability. A variety of different clinical features are observed and one of the most common phenotypes is MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes). The majority of patients with MELAS have the 3243A > G mtDNA mutation. The neuropathology is dominated by multifocal infarct-like lesions in the posterior cortex, thought to underlie the stroke-like episodes seen in patients. To investigate the relationship between mtDNA mutation load, mitochondrial dysfunction and neuropathological features in MELAS, we studied individual neurones from several brain regions of two individuals with the 3243A > G mutation using dual cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) histochemistry, and Polymerase Chain Reaction Restriction Fragment Lenght Polymorphism (PCR-RFLP) analysis. We found a low number of COX-deficient neurones in all brain regions. There appeared to be no correlation between the threshold level for the 3243A > G mutation to cause COX deficiency within single neurones and the degree of pathology in affected brain regions. The most severe COX deficiency associated with the highest proportion of mutated mtDNA was present in the walls of the leptomeningeal and cortical blood vessels in all brain regions. We conclude that vascular mitochondrial dysfunction is important in the pathogenesis of the stroke-like episodes in MELAS patients. As migraine is a commonly encountered feature in MELAS, we propose that coupling of the vascular mitochondrial dysfunction with cortical spreading depression (CSD) might underlie the selective distribution of ischaemic lesions in the posterior cortex in these patients.
C1 Newcastle Univ, Sch Med, Mitochondrial Res Grp, Dept Neurol,Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Sch Med, Dept Neuropathol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Newcastle Univ, Sch Med, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle University - UK
RP Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Dept Neurol,Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM D.M.Turnbull@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Bancroft JD, 1990, THEORY PRACTICE HIST, V0, P0
   Bowyer S, 1999, CEPHALALGIA, V19, P542, DOI 10.1046/j.1468-2982.1999.1906541-5.x
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Clark JM, 1996, NEUROLOGY, V46, P223, DOI 10.1212/WNL.46.1.223
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   FRACKOWIAK RSJ, 1988, BRAIN, V111, P1009, DOI 10.1093/brain/111.5.1009
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE S, V3, P107
   Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Kamada K, 2001, J NEUROL NEUROSUR PS, V70, P675, DOI 10.1136/jnnp.70.5.675
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   KURIYAMA M, 1984, NEUROLOGY, V34, P72, DOI 10.1212/WNL.34.1.72
   LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199
   Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   LOVE S, 1993, J PATHOL, V170, P9, DOI 10.1002/path.1711700103
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Mori O, 2000, ACTA NEUROPATHOL, V100, P712, DOI 10.1007/s004010000209
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   OHAMA E, 1987, ACTA NEUROPATHOL, V75, P1, DOI 10.1007/BF00686785
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Prayson RA, 1998, ARCH PATHOL LAB MED, V122, P978
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822, DOI 10.1152/jn.1975.38.4.822
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Tsuchiya K, 1999, ACTA NEUROPATHOL, V97, P520, DOI 10.1007/s004010051023
   Zhou L, 1997, J NEUROSCI, V17, P7746
NR 58
TC 111
Z9 124
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1846
EI 1365-2990
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD AUG 15
PY 2006
VL 32
IS 4
BP 359
EP 373
DI 10.1111/j.1365-2990.2006.00731.x
PG 15
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 061RZ
UT WOS:000238891400001
PM 16866982
DA 2024-11-01
ER

PT J
AU Van Goethem, G
AF Van Goethem, Gert
TI Autosomal disorders of mitochondrial DNA maintenance
SO ACTA NEUROLOGICA BELGICA
LA English
DT Review
DE mitochondrial DNA; depletion; multiple mtDNA deletions; progressive external opthalmoplegia; sensory ataxic neuropathy; Alpers' syndrome; MNGIE
ID progressive external ophthalmoplegia; onset spinocerebellar ataxia; polymerase-gamma mutations; multiple deletions; polg mutations; neurogastrointestinal encephalomyopathy; dilated cardiomyopathy; sensory neuropathy; genetic features; mtdna deletions
AB Mitochondrial DNA (mtDNA) is maternally inherited. After birth, secondary mtDNA defects can arise. MONA depletion is a reduction in the amount of mtDNA in particular tissues. Multiple deletions of mtDNA accumulate as somatic mutations in mainly postmitotic tissues. These disorders of mtDNA maintenance frequently show Mendelian inheritance. Positional cloning has identified several genes involved in the control of mtDNA stability. Recessive mutations in the genes ECGF1, dGK, TK2, SUCLA2 and POLG cause mtDNA depletion syndromes (MDS). Generally, MDS has infantile onset tissue specific features. Mutations in the genes ECGF1, ANT1, C10orf2 and POLG are associated with multiple mtDNA deletions. The nature of these mutations is dominant in ANTI, C10orf2 and POLG and recessive in ECGF1, C10orf2 and POLG. Mutations in these genes frequently cause progressive external ophthalmoplegia (PEO). However clinical heterogeneity results in different neurological syndromes with considerable overlap. The most common features are PEO, neuropathy, myopathy, ataxia, epilepsy and hepatopathy.
C1 Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium.
   Univ Antwerp Hosp, Neuromuscular Reference Ctr, Antwerp, Belgium.
   Univ Antwerp VIB, Dept Mol Genet, B-2000 Antwerp, Belgium.
C3 University of Antwerp; University of Antwerp; Flanders Institute for Biotechnology (VIB); University of Antwerp
RP Van Goethem, G (corresponding author), Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium.
EM gert.vangoethem@ua.ac.be
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLOPSTOCK T, 1994, NEUROLOGY, V44, P862, DOI 10.1212/WNL.44.5.862
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   Vogel RO, 2005, FEBS J, V272, P5317, DOI 10.1111/j.1742-4658.2005.04928.x
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 55
TC 5
Z9 5
U1 0
U2 3
PU ACTA MEDICA BELGICA
PI BRUSSELS
PA AVENUE CIRCULAIRE 138-A, B-1180 BRUSSELS, BELGIUM
SN 0300-9009
EI 
J9 ACTA NEUROL BELG
JI Acta Neurol. Belg.
PD JUN 15
PY 2006
VL 106
IS 2
BP 66
EP 72
DI 
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 063ON
UT WOS:000239029200004
PM 16898256
DA 2024-11-01
ER

PT J
AU Duvezin-Caubet, S
   Jagasia, R
   Wagener, J
   Hofmann, S
   Trifunovic, A
   Hansson, A
   Chomyn, A
   Bauer, MF
   Attardi, G
   Larsson, NG
   Neupert, W
   Reichert, AS
AF Duvezin-Caubet, Stephane
   Jagasia, Ravi
   Wagener, Johannes
   Hofmann, Sabine
   Trifunovic, Aleksandra
   Hansson, Anna
   Chomyn, Anne
   Bauer, Matthias F.
   Attardi, Giuseppe
   Larsson, Nils-Goeran
   Neupert, Walter
   Reichert, Andreas S.
TI Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID dynamin-related protein; dominant optic atrophy; cytochrome-c; human-cells; fusion; apoptosis; membrane; dna; fission; gtpase
AB Many muscular and neurological disorders are associated with mitochondrial dysfunction and are often accompanied by changes in mitochondrial morphology. Mutations in the gene encoding OPA1, a protein required for fusion of mitochondria, are associated with hereditary autosomal dominant optic atrophy type I. Here we show that mitochondrial fragmentation correlates with processing of large isoforms of OPA1 in cybrid cells from a patient with myoclonus epilepsy and ragged-red fibers syndrome and in mouse embryonic fibroblasts harboring an error-prone mitochondrial mtDNA polymerase gamma. Furthermore, processed OPA1 was observed in heart tissue derived from heart-specific TFAM knock-out mice suffering from mitochondrial cardiomyopathy and in skeletal muscles from patients suffering from mitochondrial myopathies such as myopathy encephalopathy lactic acidosis and stroke-like episodes. Dissipation of the mitochondrial membrane potential leads to fast induction of proteolytic processing of OPA1 and concomitant fragmentation of mitochondria. Recovery of mitochondrial fusion depended on protein synthesis and was accompanied by resynthesis of large isoforms of OPA1. Fragmentation of mitochondria was prevented by overexpressing OPA1. Taken together, our data indicate that proteolytic processing of OPA1 has a key role in inducing fragmentation of energetically compromised mitochondria. We present the hypothesis that this pathway regulates mitochondrial morphology and serves as an early response to prevent fusion of dysfunctional mitochondria with the functional mitochondrial network.
C1 Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany.
   GSF, Inst Dev Genet, Natl Res Ctr Environm & Hlth, D-85764 Munich, Germany.
   Karolinska Inst, Dept Lab Med, Div Metrol Dis, Novum, S-14186 Huddinge, Sweden.
   CALTECH, Div Biol, Pasadena, CA 91125 USA.
   Acad Hosp, Diabet Res Inst, D-80804 Munich, Germany.
   Acad Hosp, Inst Clin Chem Mol Diagnost & Mitochondrial Genet, D-80804 Munich, Germany.
C3 University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet; California Institute of Technology
RP Reichert, AS (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.
EM Andreas.Reichert@med.uni-muenchen.de
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Arnoult D, 2005, J BIOL CHEM, V280, P35742, DOI 10.1074/jbc.M505970200
   Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7
   Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022
   Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200
   Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0
   Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184
   Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316
   Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.e02-06-0330
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   Lyamzaev KG, 2004, BIOCHEM SOC T, V32, P1070, DOI 10.1042/BST0321070
   Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014
   Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087
   Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233
   Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697
   Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7
   Sesaki H, 2003, BIOCHEM BIOPH RES CO, V308, P276, DOI 10.1016/S0006-291X(03)01348-2
   Sesaki H, 2003, MOL BIOL CELL, V14, P2342, DOI 10.1091/mbc.E02-12-0788
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Skulachev VP, 2004, MOL CELL BIOCHEM, V256, P341, DOI 10.1023/B:MCBI.0000009880.94044.49
   Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 48
TC 351
Z9 397
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 8
PY 2006
VL 281
IS 49
BP 37972
EP 37979
DI 10.1074/jbc.M606059200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 111TH
UT WOS:000242477100076
PM 17003040
DA 2024-11-01
ER

PT J
AU Orcesi, S
   Gorni, K
   Termine, C
   Uggetti, C
   Veggiotti, P
   Carrara, F
   Zeviani, M
   Berardinelli, A
   Lanzi, G
AF Orcesi, Simona
   Gorni, Ksenija
   Termine, Cristiano
   Uggetti, Carla
   Veggiotti, Pierangelo
   Carrara, Franco
   Zeviani, Massimo
   Berardinelli, Angela
   Lanzi, Giovanni
TI Bilateral putantinal necrosis associated with the mitochondrial DNA A8344G myoclonus epilepsy with ragged red fibers (MERRF) mutation: An infantile case
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID striatal necrosis; clinical-features; methanol intoxication; point mutation; disease; gene; heterogeneity; mtdna; mr
AB Myoclonus epilepsy with ragged red fibers (MERRF) is one of the major mitochondrial encephalomyopathies. Its main clinical features are myoclonus epilepsy, ataxia, and myopathy with ragged red fibers. Whereas there is a close correlation between MERRF syndrome and the A8344G mutation of mitochondrial DNA, the reverse is not true. In fact, this mutation is also responsible for various other syndromes, such as Leigh syndrome, spinocerebellar degeneration, atypical Charcot-Marie-Tooth disease, and multiple truncal lipomas. We describe a child with the A8344G mutation of mitochondrial DNA and an unusual clinical, neuroradiologic, and biochemical phenotype, characterized by early-onset, nonprogressive cerebellar ataxia, and subclinical myoclonias in association with bilateral putaminal necrosis on magnetic resonance imaging and a reduction in complex V activity. Our case confirms the existence of a relationship between alteration in adenosine triphosphatase activity and basal ganglia involvement. We recommend that the possibility of a mitochondrial pathology should always be taken into consideration in the presence of bilateral symmetric lesions of the basal ganglia, even when the typical clinical picture is lacking.
C1 Univ Pavia, IRCCS, C Mondino Fdn,Reg Referral Ctr Neuromuscular Diso, Dept Child Neurol & Psychiat, I-27100 Pavia, Italy.
   Univ Pavia, IRCCS, C Mondino Fdn, Neuroradiol Unit, I-27100 Pavia, Italy.
   Ist Nazl Neurol Carlo Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Milan, Italy.
C3 University of Pavia; IRCCS Fondazione Casimiro Mondino; IRCCS Fondazione Casimiro Mondino; University of Pavia; Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Orcesi, S (corresponding author), Univ Pavia, IRCCS, C Mondino Fdn,Reg Referral Ctr Neuromuscular Diso, Dept Child Neurol & Psychiat, Via Mondino 23, I-27100 Pavia, Italy.
EM simona.orcesi@mondino.it
CR Basel-Vanagaite L, 2004, NEUROLOGY, V62, P87, DOI 10.1212/01.WNL.0000101680.49036.69
   Campos Y, 1997, BIOCHEM BIOPH RES CO, V238, P323, DOI 10.1006/bbrc.1997.7166
   DAVIS PC, 1987, AM J NEURORADIOL, V8, P71
   DEMEIRLEIR L, 1995, PEDIATR NEUROL, V13, P242, DOI 10.1016/0887-8994(95)00184-H
   DiMauro S, 2002, ADV NEUROL, V89, P217
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   Howell N, 1996, NEUROLOGY, V46, P219, DOI 10.1212/WNL.46.1.219
   Kawano H, 2000, PEDIATR NEUROL, V22, P222, DOI 10.1016/S0887-8994(99)00123-X
   Krähenbühl S, 2000, LIVER, V20, P346, DOI 10.1034/j.1600-0676.2000.020004346.x
   Martínez-Bermejo A, 2001, REV NEUROLOGIA, V33, P101, DOI 10.33588/rn.3302.2001122
   Nissenkorn A, 2000, J CHILD NEUROL, V15, P44, DOI 10.1177/088307380001500110
   Ragan CI, 1987, MITOCHONDRIA PRACTIC, V0, P79
   Roberge RJ, 1998, VET HUM TOXICOL, V40, P95
   ROIG M, 1993, PEDIATR NEUROL, V9, P349, DOI 10.1016/0887-8994(93)90103-J
   RUBINSTEIN D, 1995, AM J NEURORADIOL, V16, P1492
   Santorelli FM, 1998, MUSCLE NERVE, V21, P681
   Santorelli FM, 1996, PEDIATR RES, V39, P914, DOI 10.1203/00006450-199605000-00028
   Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Solano A, 2003, ANN NEUROL, V54, P527, DOI 10.1002/ana.10682
   Straussberg R, 2002, NEUROLOGY, V59, P983, DOI 10.1212/WNL.59.7.983
   SWEENEY MG, 1994, J NEUROL SCI, V121, P57, DOI 10.1016/0022-510X(94)90157-0
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
NR 24
TC 23
Z9 26
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JAN 15
PY 2006
VL 21
IS 1
BP 79
EP 82
DI 10.1177/08830738060210010901
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 046SP
UT WOS:000237831600017
PM 16551460
DA 2024-11-01
ER

PT J
AU Giordano, C
   Sebastiani, M
   Plazzi, G
   Travaglini, C
   Sale, P
   Pinti, M
   Tancredi, A
   Liguori, R
   Montagna, P
   Bellan, M
   Valentino, ML
   Cossarizza, A
   Hirano, M
   d'Amati, G
   Carelli, V
AF Giordano, C
   Sebastiani, M
   Plazzi, G
   Travaglini, C
   Sale, P
   Pinti, M
   Tancredi, A
   Liguori, R
   Montagna, P
   Bellan, M
   Valentino, ML
   Cossarizza, A
   Hirano, M
   d'Amati, G
   Carelli, V
TI Mitochondrial Neurogastrointestinal encephalomyopathy: Evidence of mitochondrial DNA depletion in the small intestine
SO GASTROENTEROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; familial visceral myopathy; mutation; disorder; a5814g; mngie
AB Background & Aims: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disease clinically defined by gastrointestinal dysmotility, cachexia, ptosis, ophthalmoparesis, peripheral neuropathy, white-matter changes in brain magnetic resonance imaging, and mitochondrial abnormalities. Loss-of-function mutations in thymidine phosphorylase gene induce pathologic accumulations of thymidine and deoxyuridine that in turn cause mitochondrial DNA (mtDNA) defects (depletion, multiple deletions, and point mutations). Our study is aimed to define the molecular basis of gastrointestinal dysmotility in a case of MNGIE. Methods: By using laser capture microdissection techniques, we correlated histologic features with mtDNA abnormalities in different tissue components of the gastrointestinal wall in a MNGIE patient and ten controls. Results: The patient's small intestine showed marked atrophy and mitochondrial proliferation of the external layer of muscularis propria. Genetic analysis revealed selective depletion of mtDNA in the small intestine compared with esophagus, stomach, and colon, and microdissection analysis revealed that mtDNA depletion was confined to the external layer of muscularis propria. Multiple deletions were detected in the upper esophagus and skeletal muscle. Site-specific somatic point mutations were detected only at low abundance both in the muscle and nervous tissue of the gastrointestinal tract. Analysis of the gastrointestinal tract from 10 controls revealed a non-homogeneous distribution of mtDNA content; the small intestine had the lowest levels of mtDNA. Conclusion: Atrophy, mitochondrial proliferation, and mtDNA depletion in the external layer of muscularis propria of small intestine indicate that visceral myopathy is responsible for gastrointestinal dysmotility in this MNGIE patient.
C1 Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy.
   Univ Bologna, Dipartimento Sci Neurol, Bologna, Italy.
   IRCCS San Raffaele, Rome, Italy.
   Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, Sez Patol Gen, Emilia, Italy.
   Univ Roma La Sapienza, Dipartimento Geoecon, Rome, Italy.
   Columbia Univ, Coll Phys & Surg, New York, NY USA.
C3 Sapienza University Rome; University of Bologna; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS San Raffaele Pisana; Universita di Modena e Reggio Emilia; Sapienza University Rome; Columbia University
RP Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.
EM carla.giordano@uniroma1.it
CR ANURAS S, 1983, GASTROENTEROLOGY, V84, P346
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   CAVE DR, 1990, NEW ENGL J MED, V322, P829
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   FENOGLIOPREISER CM, 1998, GASTROINTESTINAL PAT, V0, P614
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   IONASESCU V, 1983, J NEUROL SCI, V59, P215, DOI 10.1016/0022-510X(83)90039-4
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Manfredi G, 1996, HUM MUTAT, V7, P158
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MONTAGNA P, 1995, J NEUROL NEUROSUR PS, V58, P640, DOI 10.1136/jnnp.58.5.640
   Mueller LA, 1999, GASTROENTEROLOGY, V116, P959, DOI 10.1016/S0016-5085(99)70080-6
   Neuman M I, 1998, J PERINATOL, V18, P20
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pinhero J, 2000, MIXED EFFECTS MODELS, V0, P0, DOI DOI 10.1007/978-1-4419-0318-1
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
NR 25
TC 48
Z9 49
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAR 15
PY 2006
VL 130
IS 3
BP 893
EP 901
DI 10.1053/j.gastro.2006.01.004
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 024QC
UT WOS:000236210100030
PM 16530527
DA 2024-11-01
ER

PT J
AU Ueki, I
   Koga, Y
   Povalko, N
   Akita, Y
   Nishioka, J
   Yatsuga, S
   Fukiyama, R
   Matsuishi, T
AF Ueki, I
   Koga, Y
   Povalko, N
   Akita, Y
   Nishioka, J
   Yatsuga, S
   Fukiyama, R
   Matsuishi, T
TI Mitochondrial tRNA gene mutations in patients having mitochondrial disease with lactic acidosis
SO MITOCHONDRION
LA English
DT Article
DE mitochondrial tRNA gene; point mutation; lactic acidosis
ID stroke-like episodes; trna(lys) gene; dna mutations; mtdna mutation; myoclonic epilepsy; a3243g mutation; cardiomyopathy; myopathy; a8296g; encephalopathy
AB Lactic acidosis has been associated with a variety of clinical conditions and can be due to mutation in nuclear or mitochondrial genes. We performed mutations screening of all rnitochondrial tRNA genes in 44 patients who referred as hyperlactic acidosis. Patients showed heterogeneous phenotypes including Leigh disease in four, MELAS in six, unclassified rnitochondrial myopathy in 10, cardiomyopathy in five, MERRF in one, pure lactic acidosis in six, and others in 12 including facio-scaplo-femoral muscular dystrophy (FSFD), familial cerebellar ataxia, recurrent Reye syndrome, cerebral palsy with mental retardation. We measured enzymatic activities of pyruvate dehydrogenase complex, and respiratory chain enzymes. All mitochondrial tRNA genes and known mutation of ATPase 6 were studied by single strand conformation polymorphism (SSCP), automated DNA sequence and PCR-RFLP methods. We have found one patient with PDHC deficiency and six patients with Complex I + IV deficiency, though the most of the patients showed subnormal to deficient state of respiratory chain enzyme activities. We have identified one of the nucleotide changes in 29 patients. Single nucleotide changes in rnitochondrial tRNA genes are found in 27 patients and one in ATPase 6 gene in two patients. One of four pathogenic point mutations (A3243G, C3303T, A8348G, and T8993G) was identified in 12 patients who showed the phenotype of Leigh syndrome, MELAS, cardimyopathy and cerebral palsy with epilepsy. Seventeen patients have one of the normal polymorphisms in the mitochondrial tRNA gene reported before. SSCP and PCR-RFLP could detect the heteroplasmic condition when the percentage of mutant up to 5, however, it cannot be observed by direct sequencing method. It is important to screen the mtDNA mutation not only by direct sequence but also by PCR-RFLP and the other sensitive methods to detect the heroplasmy when lactic acidosis has been documented in the patients who are not fulfilled the criteria of mitochondrial disorders. (c) 2005 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan.
   RAMNS, Med Genet Res Ctr, Moscow 115478, Russia.
C3 Kurume University; Research Centre for Medical Genetics
RP Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
EM yasukoga@med.kurume-u.ac.jp
CR AKITA Y, 1999, HUM MUTAT, V0, P0
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Aral B, 1997, AM J HUM GENET, V61, P1318, DOI 10.1086/301653
   Arenas J, 1999, NEUROLOGY, V52, P377, DOI 10.1212/WNL.52.2.377
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bornstein B, 2005, BIOCHEM J, V387, P773, DOI 10.1042/BJ20040949
   CHOMYN A, 1994, AM J HUM GENET, V54, P966
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Iwanaga R, 2001, ACTA NEUROPATHOL, V101, P179
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Marotta R, 2004, INTERN MED J, V34, P10, DOI 10.1111/j.1444-0903.2004.t01-3-.x
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   Naito E, 2002, J NEUROL SCI, V201, P33, DOI 10.1016/S0022-510X(02)00187-9
   Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   ROBINSON BH, 1987, AM J HUM GENET, V40, P50
   Rozen TD, 2004, HEADACHE, V44, P674, DOI 10.1111/j.1526-4610.2004.04126.x
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Santorelli FM, 1996, AM J HUM GENET, V58, P933
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Terasaki F, 2001, JPN CIRC J, V65, P691, DOI 10.1253/jcj.65.691
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
   YOON KL, 1993, PEDIATR RES, V33, P433, DOI 10.1203/00006450-199305000-00002
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
   Zhang B, 2003, BIOCHEM SOC T, V31, P444, DOI 10.1042/BST0310444
NR 46
TC 21
Z9 26
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD FEB 15
PY 2006
VL 6
IS 1
BP 29
EP 36
DI 10.1016/j.mito.2005.10.003
PG 8
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 039AY
UT WOS:000237273100002
PM 16337222
DA 2024-11-01
ER

PT J
AU Coon, KD
   Valla, J
   Szelinger, S
   Schneider, LE
   Niedzielko, TL
   Brown, KM
   Pearson, JV
   Halperin, R
   Dunckley, T
   Papassotiropoulos, A
   Caselli, RJ
   Reiman, EM
   Stephan, DA
AF Coon, Keith D.
   Valla, Jon
   Szelinger, Szabolics
   Schneider, Lonnie E.
   Niedzielko, Tracy L.
   Brown, Kevin M.
   Pearson, John V.
   Halperin, Rebecca
   Dunckley, Travis
   Papassotiropoulos, Andreas
   Caselli, Richard J.
   Reiman, Eric M.
   Stephan, Dietrich A.
TI Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing
SO MITOCHONDRION
LA English
DT Article
DE mitochondria; Alzheimer's disease; heteroplasmy; microarray; resequencing
ID cytochrome-c-oxidase; human mitochondrial-dna; complex-i deficiency; ragged-red fibers; alzheimers-disease; point mutations; skeletal-muscle; control-region; human-genome; copy number
AB The role of mitochondrial dysfunction in the pathogenesis of Alzheimer's disease (AD) has been well documented. Though evidence for the role of mitochondria in AD seems incontrovertible, the impact of mitochondrial DNA (mtDNA) mutations in AD etiology remains controversial. Though mutations in mitochondrially encoded genes have repeatedly been implicated in the pathogenesis of AD, many of these studies have been, plagued by lack of replication as well as potential contamination of nuclear-encoded mitochondrial pseudogenes. To assess the role of mtDNA mutations in the pathogenesis of AD, while avoiding the pitfalls of nuclear-encoded mitochondrial pseudogenes encountered in previous investigations and showcasing the benefits of a novel resequencing technology, we sequenced the entire coding region (15,452 bp) of mtDNA from 19 extremely well-characterized AD patients and 18 age-matched, unaffected controls utilizing a new, reliable, high-throughput array-based resequencing technique, the Human MitoChip. High-throughput, array-based DNA resequencing of the entire mtDNA coding region from platelets of 37 subjects revealed the presence of 208 loci displaying a total of 917 sequence variants. There were no statistically significant differences in overall mutational burden between cases and controls, however, 265 independent sites of statistically significant change between cases and controls were identified. Changed sites were found in genes associated with complexes I (30.2%), III (3.0%), IV (33.2%), and V (9.1%) as well as tRNA (10.6%) and rRNA (14.0%). Despite their statistical significance, the subtle nature of the observed changes makes it difficult to determine whether they represent true functional variants involved in AD etiology or merely naturally occurring dissimilarity. Regardless, this study demonstrates the tremendous value of this novel mtDNA resequencing platform, which avoids the pitfalls of erroneously amplifying nuclear-encoded mtDNA pseudogenes, and our proposed analysis paradigm, which utilizes the availability of raw signal intensity values for each of the four potential alleles to facilitate quantitative estimates of mtDNA heteroplasmy. This information provides a potential new target for burgeoning diagnostics and therapeutics that could truly assist those suffering from this devastating disorder. (c) 2006 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ 85004 USA.
   St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
   Univ Zurich, Div Psychiat Res, Zurich, Switzerland.
   Mayo Clin, Dept Neurol, Scottsdale, AZ USA.
   Univ Arizona, Dept Psychiat, PET Ctr, Banner Good Smaritan Med Ctr, Tucson, AZ 85721 USA.
   Arizona Alzheimers Dis Consortium, Phoenix, AZ USA.
C3 Translational Genomics Research Institute; St. Joseph's Hospital and Medical Center; Barrow Neurological Institute; University of Zurich; Mayo Clinic; Mayo Clinic Phoenix; Banner Research; Banner Health; University of Arizona
RP Stephan, DA (corresponding author), Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ 85004 USA.
EM dstephan@tgen.org
FU NIA NIH HHS [P30 AG19610] Funding Source: Medline
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   BALAZS L, 1994, NEUROCHEM RES, V19, P1131, DOI 10.1007/BF00965146
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   BENDALL KE, 1995, AM J HUM GENET, V57, P248
   Bensasson D, 2003, J MOL EVOL, V57, P343, DOI 10.1007/s00239-003-2485-7
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   CALIFANO J, 2005, AFFYMETRIX MICROARRA, V0, P0
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   Chang SW, 2000, BIOCHEM BIOPH RES CO, V273, P203, DOI 10.1006/bbrc.2000.2885
   CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0
   Chinnery PF, 2001, AM J HUM GENET, V68, P529, DOI 10.1086/318204
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   Conley YP, 2003, BRAIN RES PROTOC, V12, P99, DOI 10.1016/j.brainresprot.2003.08.005
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201
   Davis JN, 1998, BIOCHEM BIOPH RES CO, V244, P877, DOI 10.1006/bbrc.1998.8353
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Frahm T, 2005, MECH AGEING DEV, V126, P1192, DOI 10.1016/j.mad.2005.06.008
   Ghosh SS, 1999, ANN NY ACAD SCI, V893, P176, DOI 10.1111/j.1749-6632.1999.tb07825.x
   Gibson GE, 2000, ANN NEUROL, V48, P297, DOI 10.1002/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z
   Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200
   Hazkani-Covo E, 2003, J MOL EVOL, V56, P169, DOI 10.1007/s00239-002-2390-5
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hirano M, 1997, P NATL ACAD SCI USA, V94, P14894, DOI 10.1073/pnas.94.26.14894
   Hou JH, 1998, MUTAT RES-FUND MOL M, V403, P75, DOI 10.1016/S0027-5107(98)00054-2
   JAKUPCIAK J, 2005, NEW MICROARRAY IMPRO, V0, P0
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Khan SM, 2000, ANN NEUROL, V48, P148, DOI 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7
   Kroemer G, 1998, CELL DEATH DIFFER, V5, P547, DOI 10.1038/sj.cdd.4400387
   Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514
   Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513
   LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, P0, DOI 10.1093/nar/gng060
   Mourier T, 2001, MOL BIOL EVOL, V18, P1833, DOI 10.1093/oxfordjournals.molbev.a003971
   PALMER AM, 1994, BRAIN RES, V645, P338, DOI 10.1016/0006-8993(94)91670-5
   PAPPOLLA MA, 1992, AM J PATHOL, V140, P621
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   PARKER WD, 1995, NEUROLOGY, V45, P482, DOI 10.1212/WNL.45.3.482
   Perier C, 2005, P NATL ACAD SCI USA, V102, P19126, DOI 10.1073/pnas.0508215102
   PETTEGREW JW, 1995, NEUROBIOL AGING, V16, P973, DOI 10.1016/0197-4580(95)02017-9
   PETTEGREW JW, 1994, NEUROBIOL AGING, V15, P117, DOI 10.1016/0197-4580(94)90152-X
   Ramassamy C, 2000, NEUROBIOL DIS, V7, P23, DOI 10.1006/nbdi.1999.0273
   Schapira AHV, 1998, ANN NEUROL, V44, PS89, DOI 10.1002/ana.410440714
   Sciacco M, 2005, J NEUROL SCI, V239, P21, DOI 10.1016/j.jns.2005.07.008
   SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Simon DK, 2001, GENOMICS, V73, P113, DOI 10.1006/geno.2001.6515
   SMEETS B, 2005, GENOME SCAN FINDS MU, V0, P0
   Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, P0, DOI 10.1093/nar/29.3.e13
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tengan CH, 1998, BBA-MOL BASIS DIS, V1406, P73, DOI 10.1016/S0925-4439(97)00087-2
   Terasaki F, 2001, JPN CIRC J, V65, P691, DOI 10.1253/jcj.65.691
   Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wragg MA, 1995, NEUROSCI LETT, V201, P107, DOI 10.1016/0304-3940(95)12146-3
   Yan SD, 1997, NATURE, V389, P689
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   Zhang L, 2005, NUCLEIC ACIDS RES, V33, P0, DOI 10.1093/nar/gni156
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 79
TC 39
Z9 46
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD AUG 15
PY 2006
VL 6
IS 4
BP 194
EP 210
DI 10.1016/j.mito.2006.07.002
PG 17
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 095VM
UT WOS:000241336400004
PM 16920408
DA 2024-11-01
ER

PT J
AU Kiyomoto, BH
   Tengan, CH
   Costa, CK
   Oliveira, AS
   Schmidt, B
   Gabbai, AA
AF Kiyomoto, BH
   Tengan, CH
   Costa, CK
   Oliveira, AS
   Schmidt, B
   Gabbai, AA
TI Frequency of dystrophic muscle abnormalities in chronic progressive external ophthalmoplegia: analysis of 86 patients
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID mitochondrial myopathy; mutation; gene; complex
AB Background: There are few reports describing the coexistence of dystrophic features with those typical of mitochondrial myopathies in muscle biopsy. A recent study suggested that dystrophic features are frequent in patients with chronic progressive external ophthalmoplegia ( CPEO) with a high mutation load, but the actual frequency of these abnormalities in CPEO remains undetermined. Objective: To review the occurrence of dystrophic abnormalities in a large series of patients with CPEO to assess the frequency of such abnormalities and to verify whether they are correlated with specific mitochondrial DNA ( mtDNA) mutations. Methods: Retrospective survey of case series ( 86 patients with CPEO). Results: Only three cases with dystrophic abnormalities were found: two with a large scale mtDNA deletion and one with the A3251G mutation. All three patients showed predominantly proximal muscular weakness resembling limb girdle muscular dystrophy. Conclusions: Dystrophic abnormalities are rare in CPEO and are not correlated with a specific molecular defect.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, BR-04039032 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Pathol, BR-04039032 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)
RP Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Rua Pedro Toledo 781,Setimo Andar, BR-04039032 Sao Paulo, Brazil.
EM beatriz-neuro@pesquisa.epm.br
CR BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P71, DOI 10.1016/0960-8966(93)E0006-G
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Kiyomoto BH, 1997, J NEUROL SCI, V152, P160, DOI 10.1016/S0022-510X(97)00158-5
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Porter JD, 2001, NEUROMUSCULAR DISORD, V11, P197, DOI 10.1016/S0960-8966(00)00171-1
   REICHMANN H, 1993, ACTA NEUROPATHOL, V85, P679, DOI 10.1007/BF00334681
   SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Shoffner JM, 1999, ANN NY ACAD SCI, V893, P42, DOI 10.1111/j.1749-6632.1999.tb07817.x
   SWEENEY MG, 1993, Q J MED, V86, P709
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
NR 14
TC 7
Z9 8
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD APR 15
PY 2006
VL 77
IS 4
BP 541
EP 543
DI 10.1136/jnnp.2005.079954
PG 3
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 031JT
UT WOS:000236701400030
PM 16543540
DA 2024-11-01
ER

PT J
AU Trifunovic, A
AF Trifunovic, Aleksandra
TI Mitochondrial DNA and ageing
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
DE mitochondria; ageing; mtDNA mutations; mtDNA deletion
ID mtdna point mutations; human skeletal-muscle; gene-expression; control region; human brain; deletions; mice; age; accumulate; cells
AB The accumulation of mitochondrial DNA mutations has been proposed as a potential mechanism in the physiological processes of ageing and age-related disease. Although mitochondria have long been anticipated as a perpetrator of ageing, there was little experimental evidence to link these changes directly with the cellular pathology of ageing. Recently, considerable progress in understanding basic mitochondrial genetics and in identifying acquired mtDNA mutations in ageing has been made. Furthermore, the creation of mtDNA-mutator mice has provided the first direct evidence that accelerating the mtDNA mutation rate can result in premature ageing, consistent with the view that loss of mitochondrial function is a major causal factor in ageing. This review will, therefore, focus on recent developments in ageing research related to the role played by mtDNA. (c) 2006 Elsevier B.V. All rights reserved.
C1 Karolinska Inst, Novum, Dept Lab Med, Div Metab Dis, SE-14186 Stockholm, Sweden.
C3 Karolinska Institutet
RP Trifunovic, A (corresponding author), Karolinska Inst, Novum, Dept Lab Med, Div Metab Dis, SE-14186 Stockholm, Sweden.
EM aleksandra.trifunovic@ki.se
CR ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2
   CORTOPASSI GA, 1992, MUTAT RES, V277, P239, DOI 10.1016/0165-1110(92)90046-C
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   EDRIS W, 1994, MUTAT RES-DNAGING G, V316, P69, DOI 10.1016/0921-8734(94)90009-4
   Eshaghian A, 2006, J INVEST DERMATOL, V126, P336, DOI 10.1038/sj.jid.5700088
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hoppel CL, 2002, BIOGERONTOLOGY, V3, P41, DOI 10.1023/A:1015251212039
   KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LEE CM, 1993, J GERONTOL, V48, P201
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   MELOV S, 1994, NUCLEIC ACIDS RES, V22, P1075, DOI 10.1093/nar/22.6.1075
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nie F, 1996, J COMP NEUROL, V370, P350, DOI 10.1002/(SICI)1096-9861(19960701)370:3<350::AID-CNE6>3.0.CO;2-3
   Pallotti F, 1996, AM J HUM GENET, V59, P591
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Song XF, 2005, GENE, V350, P193, DOI 10.1016/j.gene.2005.02.008
   SOONG NW, 1992, NAT GENET, V2, P318
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200
   TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TRIFUNOVIC A, 2005, P NATL ACAD SCI US, V0, P0
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang ED, 1997, MUTAT RES-FUND MOL M, V377, P157, DOI 10.1016/S0027-5107(97)00091-2
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   YEN TC, 1992, BIOCHEM INT, V26, P457
NR 49
TC 83
Z9 96
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD MAY-JUN 15
PY 2006
VL 1757
IS 5-6
BP 611
EP 617
DI 10.1016/j.bbabio.2006.03.003
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 069XF
UT WOS:000239481800041
PM 16624248
DA 2024-11-01
ER

PT J
AU Jacobs, LJAM
   de Wert, G
   Geraedts, JPM
   de Coo, IFM
   Smeets, HJM
AF Jacobs, LJAM
   de Wert, G
   Geraedts, JPM
   de Coo, IFM
   Smeets, HJM
TI The transmission of OXPHOS disease and methods to prevent this
SO HUMAN REPRODUCTION UPDATE
LA English
DT Review
DE mitochondria; OXPHOS disease; PGD; PND; transmission
ID mitochondrial-dna mutations; transcription factor-a; progressive external ophthalmoplegia; random genetic drift; mtdna copy number; prenatal-diagnosis; human oocytes; oxidative-phosphorylation; skeletal-muscle; dilated cardiomyopathy
AB Diseases owing to defects of oxidative phosphorylation (OXPHOS) affect approximately 1 in 8000 individuals. Clinical manifestations can be extremely variable and range from single-affected tissues to multisystemic syndromes. In general, tissues with a high energy demand, like brain, heart and muscle, are affected. The OXPHOS system is under dual genetic control, and mutations in both nuclear and mitochondrial genes can cause OXPHOS diseases. The expression and segregation of mitochondrial DNA (mtDNA) mutations is different from nuclear gene defects. The mtDNA mutations can be either homoplasmic or heteroplasmic and in the latter case disease becomes manifest when the mutation exceeds a tissue-specific threshold. This mutation load can vary between tissues and often an exact correlation between mutation load and phenotypic expression is lacking. The transmission of mtDNA mutations is exclusively maternal, but the mutation load between embryos can vary tremendously because of a segregational bottleneck. Diseases by nuclear gene mutations show a normal Mendelian inheritance pattern and often have a more constant clinical manifestation. Given the prevalence and severity of OXPHOS disorders and the lack of adequate therapy, existing and new methods for the prevention of transmission of OXPHOS disorders, like prenatal diagnosis (PND), preimplantation genetic diagnosis (PGD), cytoplasmic transfer (CT) and nuclear transfer (NT), are technically and ethically evaluated.
C1 Univ Maastricht, Dept Genet & Cell Biol, NL-6200 MD Maastricht, Netherlands.
   Univ Maastricht, Res Inst GROW, NL-6200 MD Maastricht, Netherlands.
   Univ Maastricht, Dept Eth & Philosophy, NL-6200 MD Maastricht, Netherlands.
   Univ Med Ctr, Erasmus MC, Dept Child Neurol, Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University; Maastricht University; Erasmus University Rotterdam; Erasmus MC
RP Univ Maastricht, Dept Genet & Cell Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM bert.smeets@molcelb.unimaas.nl
CR Akbari M, 2004, SCAND J CLIN LAB INV, V64, P86, DOI 10.1080/00365510410004209
   Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Amiel J, 2001, PRENATAL DIAG, V21, P602, DOI 10.1002/pd.126
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Arnon S, 2002, PRENATAL DIAG, V22, P34, DOI 10.1002/pd.232
   ASHLEY MV, 1989, NUCLEIC ACIDS RES, V17, P7325, DOI 10.1093/nar/17.18.7325
   Asin-Cayuela J, 2005, J BIOL CHEM, V280, P25499, DOI 10.1074/jbc.M501145200
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   Barritt J A, 2000, REPROD BIOMED ONLINE, V1, P96
   Barritt JA, 1999, MOL HUM REPROD, V5, P927, DOI 10.1093/molehr/5.10.927
   Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   BARRITT JA, 2001, REPROD BIOMED ONLINE, V3, P47
   Bartley J, 1996, AMERICAN JOURNAL OF HUMAN GENETICS, V59, P0
   Bendall KE, 1996, AM J HUM GENET, V59, P1276
   Berdanier CD, 2001, MUTAT RES-FUND MOL M, V475, P169, DOI 10.1016/S0027-5107(01)00068-9
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Biousse V, 2002, J NEURO-OPHTHALMOL, V22, P279, DOI 10.1097/00041327-200212000-00005
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Brenner CA, 1998, MOL HUM REPROD, V4, P887, DOI 10.1093/molehr/4.9.887
   Brenner CA, 2000, FERTIL STERIL, V74, P573, DOI 10.1016/S0015-0282(00)00681-6
   Briggs DA, 2000, LANCET, V355, P1520, DOI 10.1016/S0140-6736(00)02171-1
   Broekmans FJ, 2004, GYNECOL OBSTET INVES, V58, P225, DOI 10.1159/000080794
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Brown GK, 1997, J INHERIT METAB DIS, V20, P2, DOI 10.1023/A:1005336903888
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Brown TA, 2002, NUCLEIC ACIDS RES, V30, P2004, DOI 10.1093/nar/30.9.2004
   Buchanan A, 2000, CHANCE CHOICE GENETI, V0, P0
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Carew Jennifer S, 2002, MOL CANCER, V1, P9, DOI 10.1186/1476-4598-1-9
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 2004, REPROD BIOMED ONLINE, V8, P16, DOI 10.1016/S1472-6483(10)60494-4
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 2003, TRENDS GENET, V19, P60, DOI 10.1016/S0168-9525(02)00030-6
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Chou YJ, 2004, PRENATAL DIAG, V24, P367, DOI 10.1002/pd.876
   Cibelli JB, 2002, NAT BIOTECHNOL, V20, P13, DOI 10.1038/nbt0102-13
   CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U
   COHEN CB, 1996, MED ETHICS SERIES, V0, P0
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Cottrell D A, 2000, CURR OPIN CLIN NUTR METAB CARE, V3, P473, DOI 10.1097/00075197-200011000-00009
   Cummins J, 1998, REV REPROD, V3, P172, DOI 10.1530/revreprod/3.3.172
   Cummins JM, 1998, INT J ANDROL, V21, P47
   Cummins JM, 2001, HUM REPROD UPDATE, V7, P217, DOI 10.1093/humupd/7.2.217
   Danan C, 1999, AM J HUM GENET, V65, P463, DOI 10.1086/302484
   de Bruin JP, 2004, BIOL REPROD, V70, P419, DOI 10.1095/biolreprod.103.015784
   Dean NL, 2003, MOL HUM REPROD, V9, P631, DOI 10.1093/molehr/gag077
   deCoo IFM, 1996, AM J HUM GENET, V58, P636
   Degoul F, 1997, J INHERIT METAB DIS, V20, P49, DOI 10.1023/A:1005357506614
   DEWERT G, 2002, REPROD MED MOL CELLU, V40, P645
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Díez-Sánchez C, 2003, BIOL REPROD, V68, P180, DOI 10.1095/biolreprod.102.005140
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Enriquez JA, 1996, EUR J BIOCHEM, V237, P601, DOI 10.1111/j.1432-1033.1996.0601p.x
   Ethics Comm Amer Society Reprod Me, 2004, FERTIL STERIL, V81, P527, DOI 10.1016/j.fertnstert.2003.11.011
   Ferlin T, 1997, J PEDIATR-US, V131, P447, DOI 10.1016/S0022-3476(97)80074-1
   Fernández-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   Fulka H, 2004, REPRODUCTION, V127, P195, DOI 10.1530/rep.1.00093
   Gao J, 2001, GENOMICS, V74, P109, DOI 10.1006/geno.2001.6536
   Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003
   Goto Y, 2001, J INHERIT METAB DIS, V24, P181, DOI 10.1023/A:1010366917652
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Graff C, 2000, PRENATAL DIAG, V20, P426, DOI 10.1002/(SICI)1097-0223(200005)20:5<426::AID-PD845>3.3.CO;2-B
   Graff C, 2002, BEST PRACT RES CL OB, V16, P715, DOI 10.1053/beog.2002.0315
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Guan MX, 2001, HUM MOL GENET, V10, P573, DOI 10.1093/hmg/10.6.573
   Hammarsund M, 2001, HUM GENET, V109, P542, DOI 10.1007/s00439-001-0610-5
   HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0
   HARDING AE, 1992, AM J HUM GENET, V50, P629
   HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686
   Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V226, P369, DOI 10.1006/bbrc.1996.1363
   Hayashida K, 2005, CELL BIOL INT, V29, P472, DOI 10.1016/j.cellbi.2004.09.016
   HECHT NB, 1984, DEV BIOL, V102, P452, DOI 10.1016/0012-1606(84)90210-0
   Hoekstra R F, 2000, HUM REPROD, V15 Suppl 2, P102
   HOLDING C, 1989, LANCET, V2, P532
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Holyoake AJ, 2001, INT J ANDROL, V24, P175, DOI 10.1046/j.1365-2605.2001.00292.x
   Houstek J, 1999, PRENATAL DIAG, V19, P552, DOI 10.1002/(SICI)1097-0223(199906)19:6<552::AID-PD588>3.0.CO;2-C
   HOWELL N, 1992, HUM GENET, V90, P117
   Hsieh RH, 2002, FERTIL STERIL, V77, P1012, DOI 10.1016/S0015-0282(02)02994-1
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   Hurvitz H, 2002, AM J MED GENET, V111, P446, DOI 10.1002/ajmg.10613
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Jacobs LJAM, 2005, MOL HUM REPROD, V11, P223, DOI 10.1093/molehr/gah152
   Jacobs LJAM, 2004, J INHERIT METAB DIS, V27, P47, DOI 10.1023/B:BOLI.0000016601.49372.18
   Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304
   Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118
   Jansen R P, 2000, HUM REPROD, V15 Suppl 2, P112
   Jansen RPS, 1998, MOL CELL ENDOCRINOL, V145, P81, DOI 10.1016/S0303-7207(98)00173-7
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Johns DR, 2003, ANN NEUROL, V54, P422, DOI 10.1002/ana.10771
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Kagawa Y, 1997, GENE THER, V4, P6, DOI 10.1038/sj.gt.3300347
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Kalfoglou A L, 2001, AM J BIOETH, V1, P0
   Kalfoglou AL, 2000, WOMEN HEALTH ISS, V10, P226, DOI 10.1016/S1049-3867(00)00057-8
   Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010
   Kanki T, 2004, MOL CELL BIOL, V24, P9823, DOI 10.1128/MCB.24.22.9823-9834.2004
   Kao SH, 1998, MOL HUM REPROD, V4, P657, DOI 10.1093/molehr/4.7.657
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KEEFE DL, 1995, FERTIL STERIL, V64, P577, DOI 10.1016/S0015-0282(16)57796-6
   Khaidakov M, 2003, MUTAT RES-FUND MOL M, V526, P1, DOI 10.1016/S0027-5107(03)00010-1
   Koc EC, 2002, J BIOL CHEM, V277, P35541, DOI 10.1074/jbc.M202498200
   Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200
   Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200
   KOEHLER CM, 1991, GENETICS, V129, P247
   KOSOVSKY MJ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P101, DOI 10.1016/0167-4838(93)90117-A
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Larsson NG, 1997, HUM MOL GENET, V6, P185, DOI 10.1093/hmg/6.2.185
   Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782
   LEE CM, 1993, J GERONTOL, V48, PB201, DOI 10.1093/geronj/48.6.B201
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Leshinsky-Silver E, 2003, PRENATAL DIAG, V23, P31, DOI 10.1002/pd.516
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Ling MF, 1997, GENE, V197, P325, DOI 10.1016/S0378-1119(97)00279-5
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Lochmüller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Lutz S, 2000, INT J LEGAL MED, V113, P155, DOI 10.1007/s004140050288
   Ma JH, 1996, J BIOL CHEM, V271, P5805, DOI 10.1074/jbc.271.10.5805
   Maassen JA, 2002, ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, V110, P186, DOI 10.1076/apab.110.3.186.8294
   Maassen JA, 2004, DIABETES, V53, PS103, DOI 10.2337/diabetes.53.2007.S103
   Mancuso M, 2004, ACTA NEUROL SCAND, V110, P72, DOI 10.1111/j.1600-0404.2004.00254.x
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   Marchington DR, 2002, MOL HUM REPROD, V8, P1046, DOI 10.1093/molehr/8.11.1046
   May-Panloup P, 2003, HUM REPROD, V18, P550, DOI 10.1093/humrep/deg096
   McConnell JML, 2004, REPROD BIOMED ONLINE, V9, P418, DOI 10.1016/S1472-6483(10)61277-1
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Meirelles FV, 1997, GENETICS, V145, P445
   Meirelles FV, 2001, GENETICS, V158, P351
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P1419, DOI 10.1093/nar/23.8.1419
   MICHAELS GS, 1982, DEV BIOL, V94, P246, DOI 10.1016/0012-1606(82)90088-4
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Moilanen JS, 2001, EUR J HUM GENET, V9, P59, DOI 10.1038/sj.ejhg.5200550
   Molnar MJ, 1999, NEUROMUSCULAR DISORD, V9, P521
   MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Nakada K, 2001, SEMIN CELL DEV BIOL, V12, P459, DOI 10.1006/scdb.2001.0283
   NASS MMK, 1966, P NATL ACAD SCI USA, V56, P1215, DOI 10.1073/pnas.56.4.1215
   Niers LEM, 2001, PRENATAL DIAG, V21, P871, DOI 10.1002/pd.162
   OTA Y, 1994, RETINA-J RET VIT DIS, V14, P270, DOI 10.1097/00006982-199414030-00015
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   Poulton J, 1998, AM J HUM GENET, V62, P752, DOI 10.1086/301811
   Poulton J, 2002, REPRODUCTION, V123, P751, DOI 10.1530/rep.0.1230751
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   POULTON J, 1994, NAT GENET, V8, P313, DOI 10.1038/ng1294-313
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rantanen A, 2000, HUM REPROD, V15 Suppl 2, P86
   Rechitsky S, 1999, J ASSIST REPROD GEN, V16, P192, DOI 10.1023/A:1020312823155
   Reyes A, 2005, J BIOL CHEM, V280, P3242, DOI 10.1074/jbc.M411916200
   Reynier P, 2001, MOL HUM REPROD, V7, P425, DOI 10.1093/molehr/7.5.425
   Reynier P, 1998, BIOCHEM BIOPH RES CO, V252, P373, DOI 10.1006/bbrc.1998.9651
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Roberts RM, 1999, AM J MED GENET, V87, P265, DOI 10.1002/(SICI)1096-8628(19991126)87:3<265::AID-AJMG14>3.0.CO;2-S
   Robertson JA, 2004, HUM REPROD, V19, P1693, DOI 10.1093/humrep/deh326
   Robertson JA, 1999, FERTIL STERIL, V71, P219
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   Rötig A, 2003, J AM SOC NEPHROL, V14, P2995, DOI 10.1097/01.ASN.0000095481.24091.C9
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Ruiz-Pesini E, 2000, CLIN CHIM ACTA, V300, P97, DOI 10.1016/S0009-8981(00)00305-3
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669
   Schaefer Andrew M, 2001, CURRENT OPINION IN PHARMACOLOGY, V1, P288
   Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008
   Schwartz M, 2003, BIOCHEM BIOPH RES CO, V310, P247, DOI 10.1016/j.bbrc.2003.09.037
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SCHWARZE SR, 1995, MECH AGEING DEV, V83, P91, DOI 10.1016/0047-6374(95)01611-3
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Shitara H, 2000, GENETICS, V156, P1277
   Shitara H, 1998, GENETICS, V148, P851
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Smith PM, 2004, BBA-BIOENERGETICS, V1659, P232, DOI 10.1016/j.bbabio.2004.09.003
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spiropoulos J, 2002, MOL HUM REPROD, V8, P719, DOI 10.1093/molehr/8.8.719
   St John J, 2000, LANCET, V355, P200, DOI 10.1016/S0140-6736(99)03842-8
   St John JC, 2001, MOL HUM REPROD, V7, P103, DOI 10.1093/molehr/7.1.103
   St John JC, 2005, INT J ANDROL, V28, P65, DOI 10.1111/j.1365-2605.2005.00515.x
   Steinbock B, 2004, MT SINAI J MED, V71, P255
   Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P88, DOI 10.1002/jemt.10319
   Sutovsky P, 2004, REPROD BIOMED ONLINE, V8, P24, DOI 10.1016/S1472-6483(10)60495-6
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, ADV DRUG DELIVER REV, V49, P121, DOI 10.1016/S0169-409X(01)00130-2
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Thundathil J, 2005, MOL REPROD DEV, V71, P405, DOI 10.1002/mrd.20260
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Treem WR, 1998, SEMIN LIVER DIS, V18, P237, DOI 10.1055/s-2007-1007160
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tsao K, 1999, BRIT J OPHTHALMOL, V83, P577, DOI 10.1136/bjo.83.5.577
   Usami S, 2000, J MED GENET, V37, P38, DOI 10.1136/jmg.37.1.38
   Van Blerkom J, 2001, HUM REPROD, V16, P719, DOI 10.1093/humrep/16.4.719
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Van Coster RN, 1998, PRENATAL DIAG, V18, P1041, DOI 10.1002/(SICI)1097-0223(1998100)18:10<1041::AID-PD407>3.0.CO;2-J
   van den Heuvel L, 2001, BIOESSAYS, V23, P518, DOI 10.1002/bies.1071
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VANBLERKOM J, 1995, HUM REPROD, V10, P415, DOI 10.1093/oxfordjournals.humrep.a135954
   VANDENOUWELAND JMW, 1995, MUSCLE NERVE, V0, PS124
   Vekemans BC, 2003, PRENATAL DIAG, V23, P884, DOI 10.1002/pd.713
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   Weitzel JM, 2003, EXP PHYSIOL, V88, P121, DOI 10.1113/eph8802506
   White SL, 1999, PRENATAL DIAG, V19, P1165, DOI 10.1002/(SICI)1097-0223(199912)19:12<1165::AID-PD719>3.3.CO;2-4
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
   Wong LJC, 2002, GENET MED, V4, P78, DOI 10.1097/00125817-200203000-00005
   XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zeviani M, 2001, SEMIN CELL DEV BIOL, V12, P407, DOI 10.1006/scdb.2001.0278
   Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998
   Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1
NR 255
TC 32
Z9 38
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1355-4786
EI 1460-2369
J9 HUM REPROD UPDATE
JI Hum. Reprod. Update
PD MAR-APR 15
PY 2006
VL 12
IS 2
BP 119
EP 136
DI 10.1093/humupd/dmi042
PG 18
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 011PL
UT WOS:000235280500003
PM 16199488
DA 2024-11-01
ER

PT J
AU Auré, K
   Fayet, G
   Lacène, E
   Romero, NB
   Lombès, A
AF Auré, K
   Fayet, G
   Lacène, E
   Romero, NB
   Lombès, A
TI Apoptosis in mitochondrial myopathies is linked to mitochondrial proliferation
SO BRAIN
LA English
DT Article
DE apoptosis; mitochondrial myopathies; mitochondrial DNA; deletion
ID c-oxidase deficiency; dna deletions; mutation load; muscle-fibers; cell-death; in-vivo; gene; encephalomyopathy; disorders; defects
AB Increased susceptibility to apoptosis has been shown in many models of mitochondrial defects but its relevance to human diseases is still discussed. We addressed the presence of apoptosis in muscle from patients with mitochondrial DNA (mtDNA) disorders. Taking advantage of the mosaic pattern of muscle morphological anomalies associated with heteroplasmic mtDNA alterations, we have used an in situ approach to address the relationship between apoptosis and respiratory defect, mitochondrial proliferation and mutation load. Different patterns of mitochondrial morphological alterations were provided by the analysis of muscles with large mtDNA deletion (16 cases) or with the MELAS mutation (4 cases). The patient's age at biopsy ranged from 0.4 to 66 years and the muscle mutant mtDNA proportion from 32 to 82%. Apoptotic muscle fibres were observed in a small proportion of muscle fibres of 16 out of the 20 biopsies by three different detection methods for different steps of apoptosis: caspase 3 activation, fragmentation of nuclear DNA [terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay] or overexpression of the pro-apoptotic factor Bax. Analysis of apoptotic features in parallel to cytochrome c oxidase (COX) and succinate dehydrogenase activity of more than 34 000 individual muscle fibres showed that apoptosis occurred only in muscle fibres with mitochondrial proliferation (ragged red fibres, RRF) irrespective of their COX activity. Molecular analyses of single muscle fibres evidenced that, as expected, the presence of COX defect was associated with higher proportion of mutant mtDNA and lower amount of normal mtDNA. Within COX-defective fibres, the presence of mitochondrial proliferation was associated with increase of the mtDNA content but without change in the ratio between normal and mutant mtDNA molecules, thus showing that mitochondrial proliferation was accompanied by similar amplification of normal and mutant mtDNA molecules. Within RRF, apoptosis was associated with higher mutation proportion, suggesting that it was provoked by severe respiratory defect in the same time as increased mitochondrial mass. In conclusion, apoptosis most probably contributes to mitochondrial pathology. It is tightly linked to mitochondrial proliferation and high mutation load. When considering training therapeutics, one will have to take into account the possibility to induce apoptosis in parallel to mitochondrial proliferation.
C1 Grp Hosp Pitie Salpetriere, INSERM, Inst Myol, F-75013 Paris, France.
   Univ Paris 06, F-75013 Paris, France.
   CHU Pitie Salpetriere, AP HP, Inst Myol, F-75013 Paris, France.
   Hop Ambroise Pare, AP HP, Boulogne, France.
   UFR Med Paris Ile France Ouest, Paris, France.
   Hop Morvan, Serv Anat Pathol, Brest, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; CHU Brest; Universite de Bretagne Occidentale
RP Grp Hosp Pitie Salpetriere, INSERM, Inst Myol, 47-83 Blvd Hop, F-75013 Paris, France.
EM a.lombes@myologie.chups.jussieu.fr
CR Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X
   Carrozzo R, 2004, J NEUROCHEM, V90, P490, DOI 10.1111/j.1471-4159.2004.02505.x
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   Duan WR, 2003, J PATHOL, V199, P221, DOI 10.1002/path.1289
   Fagiolari G, 2002, MUSCLE NERVE, V26, P265, DOI 10.1002/mus.10172
   FORMICHI P, 2003, CYTOL PATHOL, V35, P29
   Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   PRELLE A, 1994, ACTA NEUROPATHOL, V87, P371
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Tanji K, 2000, BRAIN PATHOL, V10, P422
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wyllie A H, 1980, INT REV CYTOL, V68, P251
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
NR 39
TC 62
Z9 69
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD MAY 15
PY 2006
VL 129
IS 
BP 1249
EP 1259
DI 10.1093/brain/awl061
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 035JV
UT WOS:000236998000019
PM 16537564
DA 2024-11-01
ER

PT J
AU Bouchet, C
   Steffann, J
   Corcos, J
   Monnot, S
   Paquis, V
   Rötig, A
   Lebon, S
   Levy, P
   Royer, G
   Giurgea, I
   Gigarel, N
   Benachi, A
   Dumez, Y
   Munnich, A
   Bonnefont, JP
AF Bouchet, C.
   Steffann, J.
   Corcos, J.
   Monnot, S.
   Paquis, V.
   Rotig, A.
   Lebon, S.
   Levy, P.
   Royer, G.
   Giurgea, I.
   Gigarel, N.
   Benachi, A.
   Dumez, Y.
   Munnich, A.
   Bonnefont, J. P.
TI Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and stroke-like syndrome:: contribution to understanding mitochondrial DNA segregation during human embryofetal development
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID mtdna mutation; melas; heteroplasmy; fetus; load
AB Introduction: Myopathy, encephalopathy, lactic acidosis, and stroke-like (MELAS) syndrome, a maternally inherited disorder that is among the most common mitochondrial DNA ( mtDNA) diseases, is usually associated with the m. 3242A > G mutation of the mitochondrial tRNA(leu) gene. Very few data are available with respect to prenatal diagnosis of this serious disease. The rate of mutant versus wild-type mtDNA (heteroplasmy) in fetal DNA is indeed considered to be a poor indicator of postnatal outcome. Materials and methods: Taking advantage of a novel semi-quantitative polymerase chain reaction test for m. 3243A > G mutant load assessment, we carried out nine prenatal diagnoses in five unrelated women, using two different fetal tissues (chorionic villi v amniocytes) sampled at two or three different stages of pregnancy. Results: Two of the five women, although not carrying m. 3243A > G in blood or extra-blood tissues, were, however, considered at risk for transmission of the mutation, as they were closely related to MELAS-affected individuals. The absence of 3243A > G in the blood of first degree relatives was associated with no mutated mtDNA in the cardiovascular system (CVS) or amniocytes, and their three children are healthy, with a follow-up of 3 months-3 years. Among the six fetuses from the three carrier women, three were shown to be homoplasmic (0% mutant load), the remaining three being heteroplasmic, with a mutant load ranging from 23% to 63%. The fetal mutant load was fairly stable at two or three different stages of pregnancy in CVS and amniocytes. Although pregnancy was terminated in the case of the fetus with a 63% mutant load, all other children are healthy with a follow-up of 3 months-6 years. Conclusion: These data suggest that a prenatal diagnosis for MELAS syndrome might be helpful for at-risk families.
C1 Unite INSERM, U781, F-75015 Paris, France.
   Hop Necker Enfants Malad, Dept Genet, Paris, France.
   Hop Archet 2, Dept Genet, Nice, France.
   Hop Necker Enfants Malad, Dept Obstet, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP
RP Bonnefont, JP (corresponding author), Unite INSERM, U781, F-75015 Paris, France.
EM bonnefon@necker.fr
CR Cardaioli E, 2000, J NEUROL, V247, P885, DOI 10.1007/s004150070080
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chou YJ, 2004, PRENATAL DIAG, V24, P367, DOI 10.1002/pd.876
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Frederiksen AL, 2006, J MED GENET, V43, P0, DOI 10.1136/jmg.2005.039339
   Gigarel N, 2005, MOL GENET METAB, V84, P289, DOI 10.1016/j.ymgme.2004.10.008
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   Meirelles FV, 1998, GENETICS, V148, P877
   Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
NR 13
TC 34
Z9 37
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD OCT 15
PY 2006
VL 43
IS 10
BP 788
EP 792
DI 10.1136/jmg.2005.034140
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 100UD
UT WOS:000241693600002
PM 16690729
DA 2024-11-01
ER

PT J
AU Santoro, L
   Manganelli, E
   Lanzillo, R
   Tessa, A
   Barbieri, E
   Pierelli, R
   Di Giacinto, G
   Nigro, V
   Santorelli, EM
AF Santoro, L.
   Manganelli, E.
   Lanzillo, R.
   Tessa, A.
   Barbieri, E.
   Pierelli, R.
   Di Giacinto, G.
   Nigro, V.
   Santorelli, E. M.
TI A new <i>POLG1</i> mutation with peo and severe axonal and demyelinating sensory-motor neuropathy
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE POLG1; PEO; neuropathy; mitochondrial disorders
ID progressive external ophthalmoplegia; dna-polymerase-gamma; mtdna deletions; disorder; twinkle; ataxia; ant1
AB Background Progressive external ophthalmoplegia (PEO) is a mitochondrial disorder associated with defective enzymatic activities of oxidative phosphorylation (OXPHOS), depletion of mitochondrial DNA (mtDNA) and/or accumulation of mtDNA mutations and deletions. Recent positional cloning studies have linked the disease to four different chromosomal loci. Mutations in POLGI are a frequent cause of this disorder. Methods We describe two first-cousins: the propositus presented with PEO, mitochondrial myopathy and neuropathy, whereas his cousin showed a Charcot-Marie-Tooth phenotype. Neurophysiological studies, peroneal muscle and sural nerve biopsies, and molecular studies of mtDNA maintenance genes (ANT1, Twinkle, POLGI, TP) and non dominant CMT-related genes (GDAP1, LMNA, GJB1) were performed. Results A severe axonal degeneration was found in both patients whereas hypomyelination was observed only in the patient with PEO whose muscle biopsy specimen also showed defective OXPHOS and multiple mtDNA deletions. While no pathogenetic mutations in GDAP1, LMNA, and GJB1 were found, we identified a novel homozygous POLGI mutation (G763R) in the PEO patient. The mutation was heterozygous in his healthy relatives and in his affected cousin. Conclusions A homozygous POLG1 mutation might explain PEO with mitochondrial abnormalities in skeletal muscle in our propositus, and it might have aggravated his axonal and hypomyelinating sensory-motor neuropathy. Most likely, his cousin had an axonal polyneuropathy with CMT phenotype of still unknown etiology.
C1 Univ Naples Federico II, Dipartimento Sci Neurol, I-80131 Naples, Italy.
   Univ Naples Federico II, Dept Neurol Sci, Naples, Italy.
   IRCCS, Childrens Hosp Bambino Gesu, Rome, Italy.
   Univ Roma La Sapienza, Dept Neurol & ORL, Rome, Italy.
   Univ Roma La Sapienza, Dept Neurol & ORL, Rome, Italy.
   IRCCS Neuromed, Pozzilli, Italy.
C3 University of Naples Federico II; University of Naples Federico II; IRCCS Bambino Gesu; Sapienza University Rome; Sapienza University Rome; IRCCS Neuromed
RP Santoro, L (corresponding author), Univ Naples Federico II, Dipartimento Sci Neurol, Via Sergio Pansini 5, I-80131 Naples, Italy.
EM lusantor@unina.it
FU Telethon [TGM06S01, TGM03Z02] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Berciano J, 2003, CURR OPIN NEUROL, V16, P613, DOI 10.1097/00019052-200310000-00008
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Morocutti C, 2002, NEUROEPIDEMIOLOGY, V21, P241, DOI 10.1159/000065642
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nelis E, 2002, NEUROLOGY, V59, P1865, DOI 10.1212/01.WNL.0000036272.36047.54
   Santorelli FM, 2000, J INHERIT METAB DIS, V23, P155, DOI 10.1023/A:1005617916260
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 17
TC 20
Z9 20
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUL 15
PY 2006
VL 253
IS 7
BP 869
EP 874
DI 10.1007/s00415-006-0082-6
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 070YO
UT WOS:000239563200006
PM 16715201
DA 2024-11-01
ER

PT J
AU Majamaa-Voltti, KAM
   Winqvist, S
   Remes, AM
   Tolonen, U
   Pyhtinen, J
   Uimonen, S
   Kärppä, M
   Sorri, M
   Peuhkurinen, K
   Majamaa, K
AF Majamaa-Voltti, K. A. M.
   Winqvist, S.
   Remes, A. M.
   Tolonen, U.
   Pyhtinen, J.
   Uimonen, S.
   Karppa, M.
   Sorri, M.
   Peuhkurinen, K.
   Majamaa, K.
TI A 3-year clinical follow-up of adult patients with 3243A&gt;G in mitochondrial DNA
SO NEUROLOGY
LA English
DT Article
ID stroke-like episodes; a3243g mutation; lactic-acidosis; melas; involvement; encephalomyopathy; impairment; spectrum; carriers; diseases
AB Objective: To follow the clinical course of patients with the mitochondrial DNA mutation 3243A > G for 3 years. Methods: Thirty-three adult patients with the 3243A > G mutation entered a 3-year follow-up study. They were clinically evaluated annually, audiometry was performed, and samples were drawn for the analysis of blood chemistry and mutation heteroplasmy in leukocytes. Holter recording was performed three times during the follow-up and echocardiography, neuropsychological assessment, and quantitative EEG and brain imaging conducted at entry and after 3 years. Results: The incidence of new neurologic events was low during the 3-year follow-up. Sensorineural hearing impairment (SNHI) progressed, left ventricular wall thickness increased, mean alpha frequency in the occipital and parietal regions decreased, and the severity of disease index ( modified Rankin score) progressed significantly. The rate of SNHI progression correlated with mutation heteroplasmy in muscle. The increase in left ventricular wall thickness was seen almost exclusively in diabetic patients. Seven patients died during the follow-up, and they were generally more severely affected than those who survived. Conclusions: Significant changes in the severity of disease, sensorineural hearing impairment, left ventricular hypertrophy, and quantitative EEG were seen in adult patients with 3243A > G during the 3-year follow-up.
C1 Univ Oulu, Dept Internal Med, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Radiol, FIN-90014 Oulu, Finland.
   Univ Oulu, Dept Otorhinolaryngol, FIN-90014 Oulu, Finland.
   Oulu Univ Hosp, Dept Clin Neurophysiol, Oulu, Finland.
   Univ Kuopio, Dept Internal Med, FIN-70211 Kuopio, Finland.
   Univ Turku, Dept Neurol, FIN-20520 Turku, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Eastern Finland; University of Turku
RP Majamaa-Voltti, KAM (corresponding author), Univ Oulu, Dept Internal Med, POB 5000, FIN-90014 Oulu, Finland.
EM kirsi.majamaa-voltti@oulu.fi
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   BENTON AL, 1978, BENTON REVISED VISUA, V0, P0
   Carugo S, 2001, J HYPERTENS, V19, P1675, DOI 10.1097/00004872-200109000-00021
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CHRISTENSEN AL, 1975, LURIAS NEUROPSYCHOLI, V0, P0
   Damian MS, 1998, EUR NEUROL, V39, P9, DOI 10.1159/000007892
   DEVEREUX RB, 1986, AM J CARDIOL, V57, P1388, DOI 10.1016/0002-9149(86)90224-9
   Devereux RB, 2000, CIRCULATION, V101, P2271, DOI 10.1161/01.CIR.101.19.2271
   Diagnosis, 2003, DIABETES CARE, V26, Ps5, DOI 10.2337/diacare.26.2007.S5
   Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Elliott PM, 2000, J AM COLL CARDIOL, V36, P2212, DOI 10.1016/S0735-1097(00)01003-2
   *EUR WORK GROUP GE, 1996, BIOM HLTH RES PROGR, V0, P0
   FEIGENBAUM H, 1994, MITRAL VALVE FLOW EC, V188, P0
   FEIGENBAUM H, 1994, ECHOCARDIOGRAPHIC ME, V658, P0
   GUY E, 1976, ECDEU ASSESSMENT MAN, V0, P218
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kessels RPC, 2000, J NEUROL NEUROSUR PS, V69, P389, DOI 10.1136/jnnp.69.3.389
   Klopstock T, 1999, NEUROLOGY, V53, P855, DOI 10.1212/WNL.53.4.855
   KNOPMAN DS, 1994, NEUROLOGY, V44, P2315, DOI 10.1212/WNL.44.12.2315
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   LAFFEY PA, 1984, NEURORADIOLOGY, V26, P273
   Lezak MD, 1995, NEUROPSYCHOLOGICAL ASSESSMENT, V3rd ed., P0
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   LIU XZ, 1994, ANN OTO RHINOL LARYN, V103, P428, DOI 10.1177/000348949410300602
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa-Voltti Kirsi, 2002, BMC CARDIOVASC DISORD, V2, P12
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   PARVING ANV, 1995, GUIDELINES DESCRIPTI, V0, P2
   Phillips RA, 1998, J CLIN ENDOCR METAB, V83, P4284, DOI 10.1210/jc.83.12.4284
   RANKIN J, 1957, SCOTT MED J, V2, P254
   REISBERG B, 1982, AM J PSYCHIAT, V139, P1136
   Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509
   REZEK DL, 1987, NEUROLOGY, V37, P1365, DOI 10.1212/WNL.37.8.1365
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schiller N B, 1989, J AM SOC ECHOCARDIOGR, V2, P358
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wechsler D, 1997, WECHSLER ADULT INTELLIGENCE SCALE - FOURTH EDITION (WAIS-IV), V0, P0
   Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223
NR 44
TC 53
Z9 59
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 23
PY 2006
VL 66
IS 10
BP 1470
EP 1475
DI 10.1212/01.wnl.0000216136.61640.79
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 044XM
UT WOS:000237706900004
PM 16717204
DA 2024-11-01
ER

PT J
AU Kasahara, A
   Ishikawa, K
   Yamaoka, M
   Ito, M
   Watanabe, N
   Akimoto, M
   Sato, A
   Nakada, K
   Endo, H
   Suda, Y
   Aizawa, S
   Hayashi, JI
AF Kasahara, A
   Ishikawa, K
   Yamaoka, M
   Ito, M
   Watanabe, N
   Akimoto, M
   Sato, A
   Nakada, K
   Endo, H
   Suda, Y
   Aizawa, S
   Hayashi, JI
TI Generation of trans-mitochondrial mice carrying homoplasmic mtDNAs with a missense mutation in a structural gene using ES cells
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID dna-less cells; protein-synthesis; mouse mtdna; elimination; mutant; complementation; expression; phenotypes; myopathy; deafness
AB Generation of various kinds of trans-mitochondrial mice, mito-mice, each carrying mtDNAs with a different pathogenic mutation, is required for precise investigation of the pathogenesis of mitochondrial diseases. This study used two respiration-deficient mouse cell lines as donors of mtDNAs with possible pathogenic mutations. One cell line expressed 45-50% respiratory activity due to mouse mtDNAs with a T6589C missense mutation in the COI gene (T6589C mtDNA) and the other expressed 40% respiratory activity due to rat (Rattus norvegicus) mtDNAs in mouse cells. By cytoplasmic transfer of these mtDNAs to mouse ES cells, we isolated respiration-deficient ES cells. We obtained chimeric mice and generated their F-6 progeny carrying mouse T6589C mtDNAs by its female germ line transmission. They were respiration-deficient and thus could be used as models of mitochondrial diseases caused by point mutations in mtDNA structural genes. However, chimeric mice and mito-mice carrying rat mtDNAs were not obtained, suggesting that significant respiration defects or some deficits induced by rat mtDNAs in mouse ES cells prevented their differentiation to generate mice carrying rat mtDNAs.
C1 Univ Tsukuba, Grad Sch Life & Environm Sci, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 3058572, Japan.
   Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan.
   RIKEN, CDB, Lab Vertebrate Body Plan, Kobe, Hyogo 6500047, Japan.
C3 University of Tsukuba; University of Tsukuba; Jichi Medical University; RIKEN
RP Univ Tsukuba, Grad Sch Life & Environm Sci, Inst Biol Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR Acín-Pérez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Dey R, 2000, J BIOL CHEM, V275, P31520, DOI 10.1074/jbc.M004053200
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446
   JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403
   Matsuoka R, 1999, BIOCHEM BIOPH RES CO, V257, P228, DOI 10.1006/bbrc.1999.0443
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   McKenzie M, 2000, J BIOL CHEM, V275, P31514, DOI 10.1074/jbc.M004070200
   McKenzie M, 2004, P NATL ACAD SCI USA, V101, P1685, DOI 10.1073/pnas.0303184101
   MIYABAYASHI S, 1989, J INHERIT METAB DIS, V12, P373, DOI 10.1007/BF01799245
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   Shitara H, 2000, GENETICS, V156, P1277
   Shitara H, 1998, GENETICS, V148, P851
   Shoubridge EA, 2000, NAT GENET, V26, P132, DOI 10.1038/79832
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458
   Yamaoka M, 2000, GENETICS, V155, P301
   Yamaoka M, 2001, BIOCHEM BIOPH RES CO, V282, P707, DOI 10.1006/bbrc.2001.4646
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   ZIEGLER ML, 1981, SOMAT CELL GENET, V7, P73, DOI 10.1007/BF01544749
NR 35
TC 58
Z9 65
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 15
PY 2006
VL 15
IS 6
BP 871
EP 881
DI 10.1093/hmg/ddl005
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 018NS
UT WOS:000235771800006
PM 16449238
DA 2024-11-01
ER

PT J
AU Punga, AR
   Ahlqvist, K
   Bartoccioni, E
   Scuderi, F
   Marino, M
   Suomalainen, A
   Kalimo, H
   Stålberg, EV
AF Punga, A. Rostedt
   Ahlqvist, K.
   Bartoccioni, E.
   Scuderi, F.
   Marino, M.
   Suomalainen, A.
   Kalimo, H.
   Stalberg, E. V.
TI Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE myasthenia gravis; quantitative EMG; single-fiber EMG; MuSK; myopathy; mtDNA deletions
ID acetylcholine-receptor antibody; single-fiber electromyography; tyrosine kinase musk; autoantibody; emg; mg; ab
AB Objective: To compare the electrophysiological and histopathological features of immunological myasthenia gravis (MG) subtypes. Methods: Fifty MG patients underwent clinical examination, MuSK-Ab and AChR-Ab analysis. The majority underwent quantitative and single-fiber electromyography (QEMG, SFEMG), repetitive nerve stimulation and deltoid muscle biopsy. From muscle specimens with histological mitochondrial dysfunction, we amplified mitochondrial DNA (mtDNA). In specimens with mtDNA deletions, the nuclear gene POLG1 was sequenced. Results: Five AChR-Ab seropositive [AChR(+)] and 5 seronegative [AChR(-)] patients were MuSK-Ab seropositive [MuSK(+)]. Five of 7 neurophysiologically examined MuSK(+) patients (71%) had proximal myopathic pattern, compared to 7 of 31 MuSK(-)/AChR(+) patients (23%) (P=0.012). SFEMG was abnormal in all examined MuSK(+) patients. All 7 biopsied MuSK(+) and 32 MuSK(-) patients (89%) had cytochrome c oxidase (COX) negative fibers. Three of five MuSK(+) and 13 of 20 MuSK(-) patients analyzed had multiple mtDNA deletions but no POLG1 mutations. Conclusions: Similar degree of SFEMG abnormalities was present in proximal muscles among MuSK(+) and AChR(+) patients. Proximal myopathy was over represented in MuSK(+) patients; however, both MuSK(+) and MuSK(-) patients had mild myopathy with frequent mitochondrial abnormalities. Significance: The weakness in MuSK(+) patients is most likely due to disturbed neuromuscular transmission. The frequently encountered mitochondrial dysfunction in MG warrants further study. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All fights reserved.
C1 Univ Uppsala Hosp, Dept Clin Neurophysiol, S-75185 Uppsala, Sweden.
   Univ Cattolica Sacro Cuore, Inst Gen Pathol, Rome, Italy.
   Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden.
   Univ Helsinki Hosp, Dept Pathol, Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Helsinki, Finland.
   Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland.
C3 Uppsala University; Uppsala University Hospital; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Uppsala University; Uppsala University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital
RP Punga, AR (corresponding author), Univ Uppsala Hosp, Dept Clin Neurophysiol, S-75185 Uppsala, Sweden.
EM anna.rostedt@swipnet.se
CR BROOKE MH, 1969, NEUROLOGY, V19, P221, DOI 10.1212/WNL.19.3.221
   Caress JB, 2005, ARCH NEUROL-CHICAGO, V62, P1002, DOI 10.1001/archneur.62.6.1002
   Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, V2nd, P0
   ENGEL WK, 1966, ANN NY ACAD SCI, V135, P68, DOI 10.1111/j.1749-6632.1966.tb45464.x
   Evoli A, 2003, BRAIN, V126, P2304, DOI 10.1093/brain/awg223
   Farrugia ME, 2006, MUSCLE NERVE, V33, P568, DOI 10.1002/mus.20491
   GILCHRIST JM, 1992, MUSCLE NERVE, V15, P151
   HENRIKSSON KG, 1979, ACTA NEUROL SCAND, V59, P317
   Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520
   Jaretzki A, 2000, NEUROLOGY, V55, P16, DOI 10.1212/WNL.55.1.16
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   LEFVERT AK, 1978, J NEUROL NEUROSUR PS, V41, P394, DOI 10.1136/jnnp.41.5.394
   LINDSTROM J, 1977, CLIN IMMUNOL IMMUNOP, V7, P36, DOI 10.1016/0090-1229(77)90027-7
   LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Nemoto Y, 2005, J NEUROL NEUROSUR PS, V76, P714, DOI 10.1136/jnnp.2004.043125
   Ohta K, 2005, NEUROLOGY, V65, P1988, DOI 10.1212/01.wnl.0000188881.46043.44
   Ohta K, 2004, NEUROLOGY, V62, P2132, DOI 10.1212/01.WNL.0000129274.12702.92
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   PESTRONK A, 1985, MUSCLE NERVE, V8, P245, DOI 10.1002/mus.880080311
   Sanders DB, 2003, NEUROLOGY, V60, P1978, DOI 10.1212/01.WNL.0000065882.63904.53
   Sanders DB, 1996, MUSCLE NERVE, V19, P1069
   Scuderi F, 2002, LAB INVEST, V82, P1139, DOI 10.1097/01.LAB.0000028144.48023.9B
   Selcen D, 2004, NEUROLOGY, V62, P1945, DOI 10.1212/01.WNL.0000128048.23930.1D
   SOLIVEN BC, 1988, NEUROLOGY, V38, P514, DOI 10.1212/WNL.38.4.514
   SONOO M, 1993, ELECTROEN CLIN NEURO, V89, P291, DOI 10.1016/0168-5597(93)90068-Z
   STALBERG E, 1995, ELECTROMYOGR MOTOR C, V97, P145, DOI 10.1016/0924-980X(95)00007-8
   STALBERG E, 1978, ACTA ANAESTH SCAND, V0, P112
   STALBERG E, 1980, J NEUROL NEUROSUR PS, V43, P622, DOI 10.1136/jnnp.43.7.622
   Stalberg E, 1976, MOTOR SYSTEM NEUROPH, V0, P79
   Stickler DE, 2005, CLIN NEUROPHYSIOL, V116, P2065, DOI 10.1016/j.clinph.2005.06.003
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VINCENT A, 1993, ANN NY ACAD SCI, V681, P529, DOI 10.1111/j.1749-6632.1993.tb22936.x
   Zhou L, 2004, MUSCLE NERVE, V30, P55, DOI 10.1002/mus.20069
NR 38
TC 41
Z9 42
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUL 15
PY 2006
VL 117
IS 7
BP 1434
EP 1443
DI 10.1016/j.clinph.2006.03.028
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 066KB
UT WOS:000239227100004
PM 16737845
DA 2024-11-01
ER

PT J
AU Tay, SHK
   Nordli, DR
   Bonilla, E
   Null, E
   Monaco, S
   Hirano, M
   DiMauro, S
AF Tay, SHK
   Nordli, DR
   Bonilla, E
   Null, E
   Monaco, S
   Hirano, M
   DiMauro, S
TI Aortic rupture in mitochondrial encephalopathy lactic acidosis, and stroke-like episodes
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID vascular involvement; myopathy; angiopathy; mutation; melas
AB Background: Microangiopathy has been well described in the brain and muscle of patients with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Objective: To describe a patient with the common A3243G/MELAS point mutation who had aortic rupture and whose mother also died of large vessel rupture. Design: Case report. Setting: Collaboration between a primary care hospital and 2 academic tertiary care hospitals. Results: Histologically, there was marked disarray of the smooth muscle architecture of the aorta, and immunohistochemical staining with antibodies against the mitochondrial DNA-encoded cytochrome-C oxidase I subunit showed uniformly decreased immunostaining of the endothelial and smooth muscle cells of the aorta and vasa vasorum. Polymerase chain reaction and restriction fragment length polymorphism analysis showed that the mutation load was 40.5% in blood but 85.3% in the blood vessels. Conclusions: The severe vasculopathy in this patient is probably directly related to the high mutation load in the blood vessels. Although aortic rupture is an unusual manifestation of MELAS, it is an important potential complication in patients undergoing minor surgical procedures.
C1 Natl Univ Singapore, Dept Pediat, Singapore 117548, Singapore.
   Childrens Mem Hosp, Dept Neurol, Chicago, IL 60614 USA.
   Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA.
   Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
   Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA.
   OSF St Francis Med Ctr, Dept Pathol, Peoria, IL USA.
C3 National University of Singapore; Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Columbia University; Columbia University
RP Coll Phys & Surg 4 420, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline
CR FORSTER C, 1992, NEUROPEDIATRICS, V23, P165, DOI 10.1055/s-2008-1071335
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   SATO W, 1994, AM HEART J, V128, P733, DOI 10.1016/0002-8703(94)90272-0
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Takahashi N, 2005, AM J MED SCI, V329, P265, DOI 10.1097/00000441-200505000-00008
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
NR 8
TC 34
Z9 39
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD FEB 15
PY 2006
VL 63
IS 2
BP 281
EP 283
DI 10.1001/archneur.63.2.281
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 010LH
UT WOS:000235195700016
PM 16476819
DA 2024-11-01
ER

PT J
AU Gago, MF
   Rosas, MJ
   Guirnaraes, J
   Ferreira, M
   Vilarinho, L
   Castro, L
   Carpenter, S
AF Gago, Miguel Fernandes
   Rosas, M. J.
   Guirnaraes, Joana
   Ferreira, Mariana
   Vilarinho, Laura
   Castro, Ligia
   Carpenter, Stirling
TI SANDO: Two novel mutations in POLG1 gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE SANDO; sensory ataxic neuropathy; dysarthria; ophthalmoparesis; POLG1 gene
ID progressive external ophthalmoplegia; polymerase-gamma mutations; sensory ataxic neuropathy; mitochondrial
AB Sensory ataxia with neuropathy, dysarthria and ophthalmoparesis represent the clinical triad of SANDO, a specific mitochondrial phenotype first reported in 1997 in association with multiple mitochondrial DNA deletions and mutations in POLGI or more rarely in the C10orf2 (twinkle-helicase) gene. We report a 44-year-old man with SANDO who harboured two novel mutations (P648R/R807C) in the POLGI gene. (C) 2006 Elsevier B.V. All rights reserved.
C1 Hosp Sao Joao, Dept Neurol, Oporto, Portugal.
C3 Sao Joao Hospital
RP Gago, MF (corresponding author), Hosp Sao Joao, Dept Neurol, Oporto, Portugal.
EM miguelfgago@yahoo.com
CR Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 10
TC 35
Z9 40
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG 15
PY 2006
VL 16
IS 8
BP 507
EP 509
DI 10.1016/j.nmd.2006.05.016
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 101RV
UT WOS:000241759100007
PM 16919951
DA 2024-11-01
ER

PT J
AU Reichenbach, J
   Schubert, R
   Horváth, R
   Petersen, J
   Fütterer, N
   Malle, E
   Stumpf, A
   Gebhardt, BR
   Koehl, U
   Schraven, B
   Zielen, S
AF Reichenbach, Janine
   Schubert, Ralf
   Horvaeth, Rita
   Petersen, Jens
   Fuetterer, Nancy
   Malle, Elisabeth
   Stumpf, Andreas
   Gebhardt, Boris R.
   Koehl, Ulrike
   Schraven, Burkhart
   Zielen, Stefan
TI Fatal neonatal-onset mitochondrial respiratory chain disease with T cell immunodeficiency
SO PEDIATRIC RESEARCH
LA English
DT Article
ID polymerase-gamma-a; dna depletion; point mutations; deficiency; disorders; encephalomyopathy; anemia; kinase; defect; mtdna
AB We present the clinical and laboratory features of a boy with a new syndrome of mitochondrial depletion syndrome and T cell immunodeficiency. The child suffered from severe recurrent infectious diseases, anemia, and thrombocytopenia. Clinically, he presented with severe psychomotor retardation, axial hypotonia, and a disturbed pain perception leading to debilitating biting of the thumb, lower lip, and tongue. Brain imaging showed hypoplasia of corpus callosum and an impaired myelinization of the temporooccipital region with consecutive supratentorial hydrocephalus. Histologic examination of a skeletal muscle biopsy was normal. Biochemical investigation showed combined deficiency of respiratory chain complexes II+III and IV. MtDNA depletion was found by real-time PCR. No pathogenic mutations were identified in the TK2, SUCLA2, DGUOK, and ECGF1 genes. A heterozygous missense mutation was found in POLG1. The pathogenic relevance of this mutation is unclear. Interestingly, a lack of CD8(+) T lymphocytes as well as NK cells was also observed. The percentage of CD45RO-expressing cells was decreased in activated CD8(+) T lymphocytes. Activation of T lymphocytes via IL-2 was diminished. The occurrence of the immunologic deficiency in our patient with mtDNA depletion is a rare finding, implying that cells of the immune system might also be affected by mitochondrial disease.
C1 Univ Frankfurt, Dept Gen Paediat, D-60590 Frankfurt, Germany.
   Univ Frankfurt, Dept Paediat Haematol Oncol & Haemostaseol, D-60590 Frankfurt, Germany.
   Tech Univ Munich, Inst Clin Chem Mol Diagnost & Mitochondrial Genet, D-80804 Munich, Germany.
   Tech Univ Munich, Acad Hosp Schwabing Munich, Childrens Hosp, D-80804 Munich, Germany.
   Tech Univ Munich, Inst Med Genet, D-80804 Munich, Germany.
   Univ Munich, Dept Neurol, Friedrich Baur Inst, D-80336 Munich, Germany.
   Otto Von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt; Technical University of Munich; Technical University of Munich; University of Munich; Technical University of Munich; University of Munich; Otto von Guericke University
RP Reichenbach, J (corresponding author), Univ Childrens Hosp Zurich, Dept Immunol Hematol BMT, Steinweisstr 75, CH-8032 Zurich, Switzerland.
EM janine.reichenbach@kispe.unizh.ch
CR Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   BADERMEUNIER B, 1994, BRIT J HAEMATOL, V87, P381, DOI 10.1111/j.1365-2141.1994.tb04926.x
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   CormierDaire V, 1996, AM J MED GENET, V66, P457, DOI 10.1002/(SICI)1096-8628(19961230)66:4<457::AID-AJMG15>3.0.CO;2-T
   de Vries E, 2000, PEDIATR RES, V47, P528, DOI 10.1203/00006450-200004000-00019
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   Hirano M, 2000, BRAIN PATHOL, V10, P451
   Koehl U, 2004, BLOOD CELL MOL DIS, V33, P261, DOI 10.1016/j.bcmd.2004.08.013
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SAMSOM JF, 1994, EUR J PEDIATR, V153, P510, DOI 10.1007/BF01957007
   Setzer B, 2005, J INFECT DIS, V191, P848, DOI 10.1086/427655
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   von Kleist-Retzow JC, 2003, J PEDIATR-US, V143, P208, DOI 10.1067/S0022-3476(03)00130-6
   Zielen S, 1996, J IMMUNOL METHODS, V193, P1, DOI 10.1016/0022-1759(96)00033-6
NR 28
TC 29
Z9 34
U1 0
U2 0
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA
SN 0031-3998
EI 
J9 PEDIATR RES
JI Pediatr. Res.
PD SEP 15
PY 2006
VL 60
IS 3
BP 321
EP 326
DI 10.1203/01.pdr.0000233252.60457.cf
PG 6
WC Pediatrics
SC Pediatrics
GA 075CW
UT WOS:000239861300015
PM 16857757
DA 2024-11-01
ER

PT J
AU González-Vioque, E
   Blázquez, A
   Fernández-Moreira, D
   Bornstein, B
   Bautista, J
   Arpa, J
   Navarro, C
   Campos, Y
   Fernández-Moreno, MA
   Garesse, R
   Arenas, J
   Martín, MA
AF González-Vioque, E
   Blázquez, A
   Fernández-Moreira, D
   Bornstein, B
   Bautista, J
   Arpa, J
   Navarro, C
   Campos, Y
   Fernández-Moreno, MA
   Garesse, R
   Arenas, J
   Martín, MA
TI Association of novel <i>POLG</i> mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in a Spanish population
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; polymerase-gamma; autosomal-dominant; heterogeneity; depletion; muscle; peo
AB Background: Both dominant and recessive mutations were reported in the gene encoding the mitochondrial (mt) DNA polymerase gamma (POLG) in patients with progressive external oplithalmoplegia (PEO). Phenotypes other than PEO were recently documented in patients with mutations in the POLG gene. Objective: To screen patients with mitochondrial disease and multiple mtDNA deletions in muscle for mutations in the coding regions of the POLG, PEO1, and SLC25A4 genes. Design: To identify the underlying molecular defect in a group of patients with multiple mtDNA deletions comparing their molecular genetic findings with those of healthy controls. Patients: Twenty-four patients (16 men and 8 women) diagnosed with mitochondrial disease and having multiple mtDNA deletions in muscle by Southern blot analysis. Thirteen patients had PEO; 2 had PEO alone, 4 had PEO and myopathy, and 5 had PEO and multisystem involvement. Four patients had multisystem disease without PEO. The remaining 9 patients had isolated myopathy. DNA from 100 healthy individuals was also studied. Results: No mutation was identified in the PEO1 or SLC25A4 genes. Nine POLG mutations were observed in 6 of 24 patients. Four novel mutations were detected and mapped in the linker region (M603L) and in the pol domain of the enzyme (R853W; D1184N; R1146C). Five patients with PEO had mutations: 2 were compound heterozygotes, 1 was homozygous, and another showed a mutation in a single allele. The remaining patient also showed a sole mutation and had an unusual phenotype lacking ocular involvement. Conclusions: POLG molecular defects were found in 25% of our patients with multiple mtDNA deletions and mitochondrial disease. The uncommon phenotype found in I of these patients stresses the clinical variability of patients harboring POLG mutations. Molecular studies in the POLG gene should be addressed in patients with mitochondrial disease, particularly in those with PEO, and multiple mtDNA deletions.
C1 Univ Madrid, Hosp 12 Octubre, Ctr Invest, Madrid 28041, Spain.
   Univ Madrid, Hosp La Paz, Serv Neurol, Madrid 3, Spain.
   Hosp Virgen Rocio, Serv Neurol, Seville, Spain.
   Hosp Do Meixoeiro, Serv Anat Patol, Vigo, Spain.
   UAM, CSIC, Fac Med, Dept Bioquim,Inst Invest Biomed Alberto Sols, Madrid, Spain.
C3 Hospital Universitario 12 de Octubre; Hospital Universitario La Paz; Virgen del Rocio University Hospital; Complexo Hospitalario Universitario de Vigo; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid
RP Univ Madrid, Hosp 12 Octubre, Ctr Invest, Avda Cordoba S-N, Madrid 28041, Spain.
EM mamcasanueva@h12o.es
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Martinez B, 2001, J NEUROCHEM, V78, P1054, DOI 10.1046/j.1471-4159.2001.00487.x
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
NR 16
TC 49
Z9 51
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JAN 15
PY 2006
VL 63
IS 1
BP 107
EP 111
DI 10.1001/archneur.63.1.107
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 001OT
UT WOS:000234546900013
PM 16401742
DA 2024-11-01
ER

PT J
AU Krishnan, KJ
   Birch-Machin, MA
AF Krishnan, Kim J.
   Birch-Machin, Mark A.
TI The incidence of both tandem duplications and the common deletion in mtDNA from three distinct categories of sun-exposed human skin and in prolonged culture of fibroblasts
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID human mitochondrial-dna; large-scale deletions; d-loop; direct repeats; muscle; damage; repair; mutations; disease; rearrangements
AB The use of mtDNA damage as a biomarker of cumulative sunlight exposure in human skin is a relatively new field of research. Previous investigations have simply compared the frequency of occurrence of the mtDNA common deletion (CD), and to a much lesser extent that of tandem duplications (TDs), to distinguish between sun-protected and sun- exposed skin. This approach is limited because non-melanoma skin cancer is predominantly formed on body sites that are "usually'' sun-exposed as opposed to sites that are "occasionally'' sun- exposed and as such they differ in their cumulative UV exposure. This study addresses this limitation by investigating the frequency of occurrence of the CD and TDs in 116 age-matched human skin samples taken from three different sun- exposed body sites. There was a greater frequency of the mtDNA damage in "usually'' sun- exposed compared to "occasionally'' sun-exposed body sites for both the CD and the TDs (P < 0.0001 and P = 0.058, respectively). In addition, we identified a 260 bp triplication of the mtDNA D-loop for the first time in skin. No evidence of the CD or TDs was observed in sun- protected (ie rarely exposed) skin (n = 20). Comparatively little is known about mtDNA damage in prolonged skin cell culture. We have furthered this work by studying the level of the CD and the frequency of the TDs during continued culture of human fibroblasts derived from skin samples taken from usually sun- exposed sites (n = 7 patients). The level of the CD decreases with culture, whereas the frequency of TDs can be maintained.
C1 Univ Newcastle Upon Tyne, Sch Clin & Lab Sci, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Birch-Machin, MA (corresponding author), Univ Newcastle Upon Tyne, Sch Clin & Lab Sci, Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM m.a.birch-machin@ncl.ac.uk
CR Armstrong BK, 2004, CANC PREV CANC CAUSE, V3, P89
   Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345
   Berneburg M, 1997, PHOTOCHEM PHOTOBIOL, V66, P271, DOI 10.1111/j.1751-1097.1997.tb08654.x
   Birch-Machin MA, 2000, CLIN EXP DERMATOL, V25, P141, DOI 10.1046/j.1365-2230.2000.00605.x
   Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x
   Bouzidi MF, 1998, HUM MOL GENET, V7, P385, DOI 10.1093/hmg/7.3.385
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   BROCKINGTON M, 1993, NAT GENET, V4, P67, DOI 10.1038/ng0593-67
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409
   DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493
   Durham SE, 2003, BRIT J CANCER, V88, P90, DOI 10.1038/sj.bjc.6600773
   Hao HL, 1997, AM J HUM GENET, V60, P1363, DOI 10.1086/515474
   HOU JH, 1996, BIOCHEM J, V318, P1965
   IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B
   Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025
   KADENBACH B, 1993, AGING-CLIN EXP RES, V5, P73, DOI 10.1007/BF03324129
   Koch H, 2001, J INVEST DERMATOL, V117, P892, DOI 10.1046/j.0022-202x.2001.01513.x
   Kowald A, 1999, EXP GERONTOL, V34, P605, DOI 10.1016/S0531-5565(99)00011-X
   Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x
   LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   LEE HC, 1994, FEBS LETT, V354, P79, DOI 10.1016/0014-5793(94)01063-3
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7
   PANG CY, 1994, ARCH BIOCHEM BIOPHYS, V312, P534, DOI 10.1006/abbi.1994.1342
   Pascucci B, 1997, J MOL BIOL, V273, P417, DOI 10.1006/jmbi.1997.1268
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   Ray AJ, 2000, J INVEST DERMATOL, V115, P674, DOI 10.1046/j.1523-1747.2000.00092.x
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHINDO Y, 1994, J INVEST DERMATOL, V102, P122, DOI 10.1111/1523-1747.ep12371744
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wei YH, 1996, ANN NY ACAD SCI, V786, P82, DOI 10.1111/j.1749-6632.1996.tb39054.x
   YANG JH, 1995, ARCH DERMATOL RES, V287, P641
   Yang JH, 2004, ANTICANCER RES, V24, P1753
   YANG JH, 1994, ARCH DERMATOL RES, V286, P386, DOI 10.1007/BF00371798
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
NR 50
TC 32
Z9 34
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD FEB 15
PY 2006
VL 126
IS 2
BP 408
EP 415
DI 10.1038/sj.jid.5700099
PG 8
WC Dermatology
SC Dermatology
GA 062TV
UT WOS:000238968400025
PM 16374450
DA 2024-11-01
ER

PT J
AU Lodi, T
   Bove, C
   Fontanesi, F
   Viola, AM
   Ferrero, I
AF Lodi, T
   Bove, C
   Fontanesi, F
   Viola, AM
   Ferrero, I
TI Mutation D104G in ANT1 gene:: Complementation study in <i>Saccharomyces cerevisiae</i> as a model system
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE ANTI; AAC2; PEO; mitochondrial diseases; ADP/ATP carrier; yeast
ID mitochondrial adp/atp carrier; adenine-nucleotide translocator; proteins; equivalent; expression; dna
AB Mutations in the human ANT1 gene, coding for the ADP/ATP carrier, are responsible for the autosomal dominant and recessive forms of progressive external ophthalmoplegia, mitochondrial disorders characterized by the presence of multiple deletions of mitochondrial DNA in affected tissues. By introducing these mutations at equivalent position in AAC2, the yeast orthologue of ANT1, we created a suitable model for validation of the pathogenicity of the human mutations. Here, we describe the use of this approach in the case of mutations mapping in domains not conserved between human and yeast, taking advantage of a yAAC2/hANT1 chimeric construction as a template to introduce pathogenic hANT1 mutations. Application to the case of the D104G mutation indicated that the chimeric construction could be a tool for validation of pathogenic ANT1 mutations in yeast. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy.
C3 University of Parma
RP Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy.
EM tiziana.lodi@unipr.it
FU Telethon [GGP030039] Funding Source: Medline
CR ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626
   Ausubel FM, 1994, CURR. PROTOC. MOL. BIOL, V0, P0
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BULDER CJE, 1964, ANTON VAN LEE J M S, V30, P442, DOI 10.1007/BF02046758
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V
   Dujon B, 1981, MOL BIOL YEAST SACCH, V0, P505
   Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8
   Hatanaka T, 2001, BIOL PHARM BULL, V24, P595, DOI 10.1248/bpb.24.595
   ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLINGENBERG M, 1979, TRENDS BIOCHEM SCI, V4, P249, DOI 10.1016/0968-0004(79)90215-9
   KOLAROV J, 1990, J BIOL CHEM, V265, P12711
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   LAWSON JE, 1988, J BIOL CHEM, V263, P14812
   Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Sambrook J, 1990, COLD SPRING HARBOR LABORATORIES, V186, P182
   Sherman F, 1986, LAB COURSE MANUAL ME, V0, P0
NR 22
TC 15
Z9 16
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 17
PY 2006
VL 341
IS 3
BP 810
EP 815
DI 10.1016/j.bbrc.2006.01.034
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 014PW
UT WOS:000235493200022
PM 16438935
DA 2024-11-01
ER

PT J
AU Kollberg, G
   Moslemi, AR
   Darin, N
   Nennesmo, I
   Bjamadottir, I
   Uvebrant, P
   Holme, E
   Melberg, A
   Tulinius, M
   Oldfors, A
AF Kollberg, Gittan
   Moslemi, Ali-Reza
   Darin, Niklds
   Nennesmo, Inger
   Bjamadottir, Ingibjorg
   Uvebrant, Paul
   Holme, Elisabeth
   Melberg, Atle
   Tulinius, Mar
   Oldfors, Anders
TI POLG1 mutations associated with progressive encephalopathy in childhood
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Alpers-Huttenlocher syndrome; COX deficiency; mitochondrial myopathy; MtDNA deletions; MtDNA depletion; polymerase gamma
ID mitochondrial-dna polymerase; external ophthalmoplegia; alpers-syndrome; autosomal-dominant; multiple deletions; gamma mutations; valproic acid; kinase gene; degeneration; depletion
AB We have identified compound heterozygous missense mutations in POLG1, encoding the mitochondrial DNA polymerase gamma (Pol gamma), in 7 children with progressive encephalopathy from 5 unrelated families. The clinical features in 6 of the children included psychomotor regression, refractory seizures, stroke-like episodes, hepatopathy, and ataxia compatible with Alpers-Huttenlocher syndrome. Three families harbored a previously reported A467T substitution, which was found in compound with the earlier described G848S or the W748S substitution or a novel R574W substitution. Two families harbored the W748S change in compound with either of 2 novel mutations predicted to give an R232H or M1163R substitution. Muscle morphology showed mitochondrial myopathy with cytochrome c oxidase (COX)-deficient fibers in 4 patients. mtDNA analyses in muscle tissue revealed mtDNA depletion in 3 of the children and mtDNA deletions in the 2 sibling pairs. Neuropathologic investigation in 3 children revealed widespread cortical degeneration with gliosis and subcortical neuronal loss, especially in the thalamus, whereas there were only subcortical neurodegenerative findings in another child. The results support the concept that deletions as well as depletion of mtDNA are involved in the pathogenesis of Alpers-Huttenlocher syndrome and add 3 new POLG1 mutations associated with an early-onset neurodegenerative disease.
C1 Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
   Queen Silvia Childrens Hosp, Gothenburg, Sweden.
   Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden.
   Univ Uppsala Hosp, Dept Neurol, S-75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital; Queen Silvia Children's Hospital; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital
RP Oldfors, A (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM anders.oldfors@pathology.gu.se
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Andréasson H, 2002, BIOTECHNIQUES, V33, P402, DOI 10.2144/02332rr07
   BECKER CM, 1983, ARCH BIOCHEM BIOPHYS, V223, P381, DOI 10.1016/0003-9861(83)90602-1
   Bryant AE, 1996, NEUROLOGY, V46, P465, DOI 10.1212/WNL.46.2.465
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   COULTER DL, 1991, J CHILD NEUROL, V6, P7, DOI 10.1177/088307389100600102
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HAAS R, 1981, NEUROLOGY, V31, P1473, DOI 10.1212/WNL.31.11.1473
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kayihan N, 2000, PEDIATR TRANSPLANT, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 36
TC 70
Z9 71
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
EI 
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD AUG 15
PY 2006
VL 65
IS 8
BP 758
EP 768
DI 10.1097/01.jnen.0000229987.17548.6e
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 100TR
UT WOS:000241692300003
PM 16896309
DA 2024-11-01
ER

PT J
AU Curbo, S
   Lagier-Tourenne, C
   Carrozzo, R
   Palenzuela, L
   Lucioli, S
   Hirano, M
   Santorelli, F
   Arenas, J
   Karlsson, A
   Johansson, M
AF Curbo, S
   Lagier-Tourenne, C
   Carrozzo, R
   Palenzuela, L
   Lucioli, S
   Hirano, M
   Santorelli, F
   Arenas, J
   Karlsson, A
   Johansson, M
TI Human mitochondrial pyrophosphatase: cDNA cloning and analysis of the gene in patients with mtDNA depletion syndromes
SO GENOMICS
LA English
DT Article
DE human pyrophosphatase; inorganic pyrophosphate; mitochondrial DNA; mitochondrial depletion syndrome; mitochondrial localization; mitochondrial enzyme
ID rat-liver mitochondria; inorganic pyrophosphatase; escherichia-coli; expression; localization; dna; cerevisiae; deletions; kinase; assay
AB Pyrophosphatases (PPases) catalyze the hydrolysis of inorganic pyrophosphate generated in several cellular enzymatic reactions. A novel human pyrophosphatase cDNA encoding a 334-amino-acid protein approximate to 60% identical to the previously identified human cytosolic PPase was cloned and characterized. The novel enzyme, named PPase-2, was enzymatically active and catalyzed hydrolysis of pyrophosphate at a rate similar to that of the previously identified PPase-1. A functional mitochondrial import signal sequence was identified in the N-terminus of PPase-2, which targeted the enzyme to the mitochondrial matrix. The human pyrophosphatase 2 gene (PPase-2) was mapped to chromosome 4q25 and the 1.4-kb mRNA was ubiquitously expressed in human tissues, with highest levels in muscle, liver, and kidney. The yeast homologue of the mitochondrial PPase-2 is required for mitochondrial DNA maintenance and yeast cells lacking the enzyme exhibit mitochondrial DNA depletion. We sequenced the PPA2 gene in 13 patients with mitochondrial DNA depletion syndromes (MDS) of unknown cause to determine if mutations in the PPA2 gene of these patients were associated with this disease. No pathogenic mutations were identified in the PPA2 gene of these patients and we found no evidence that PPA2 gene mutations are a common cause of MDS in humans. (c) 2005 Elsevier Inc. All rights reserved.
C1 Karolinska Inst, Div Metab Disorders, Stockholm, Sweden.
   Columbia Univ Coll Phys & Surg, New York, NY 10027 USA.
   Childrens Hosp Bambino Gesu, Unit Mol Med, Rome, Italy.
   Hosp 12 Octubre, Ctr Invest, E-28041 Madrid, Spain.
C3 Karolinska Institutet; Columbia University; IRCCS Bambino Gesu; Hospital Universitario 12 de Octubre
RP Karolinska Inst, Novum, Dept Lab Med, Div Metab Disorders, S-14157 Huddinge, Sweden.
EM magnus.johansson@mbb.ki.se
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8
   Carrozzo R, 2003, HUM MUTAT, V21, P0, DOI 10.1002/humu.9135
   CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990
   COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y
   DUBNOVA EB, 1992, ARCH BIOCHEM BIOPHYS, V292, P16, DOI 10.1016/0003-9861(92)90044-W
   Fairchild TA, 1999, BBA-GENE STRUCT EXPR, V1447, P133, DOI 10.1016/S0167-4781(99)00175-X
   GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X
   Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441
   LAHTI R, 1988, J BACTERIOL, V170, P5901, DOI 10.1128/jb.170.12.5901-5907.1988
   Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177
   LUNDIN M, 1991, J BIOL CHEM, V266, P12168
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MANSUROVA SE, 1989, BIOCHIM BIOPHYS ACTA, V977, P237, DOI 10.1016/S0005-2728(89)80078-7
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X
   Rumsfeld J, 2000, PROTEIN EXPRES PURIF, V18, P303, DOI 10.1006/prep.1999.1189
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SHATTON JB, 1983, CANCER RES, V43, P3742
   Sivula T, 1999, FEBS LETT, V454, P75, DOI 10.1016/S0014-5793(99)00779-6
   VOLK SE, 1984, BIOCHIM BIOPHYS ACTA, V791, P198, DOI 10.1016/0167-4838(84)90009-8
   VOLK SE, 1983, BIOCHIM BIOPHYS ACTA, V744, P127, DOI 10.1016/0167-4838(83)90081-X
   YANG ZH, 1992, J BIOL CHEM, V267, P24634
   YANG ZH, 1992, J BIOL CHEM, V267, P24641
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 28
TC 24
Z9 26
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD MAR 15
PY 2006
VL 87
IS 3
BP 410
EP 416
DI 10.1016/j.ygeno.2005.09.017
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 017VD
UT WOS:000235720500010
PM 16300924
DA 2024-11-01
ER

PT J
AU Celotto, AM
   Frank, AC
   McGrath, SW
   Fergestad, T
   Van Voorhies, WA
   Buttle, KF
   Mannella, CA
   Palladino, MJ
AF Celotto, AM
   Frank, AC
   McGrath, SW
   Fergestad, T
   Van Voorhies, WA
   Buttle, KF
   Mannella, CA
   Palladino, MJ
TI Mitochondrial encephalomyopathy in <i>Drosophila</i>
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE ATP6; ANT; ATP synthase; neurodegeneration; muscle degeneration; aging; mitochondria
ID progressive external ophthalmoplegia; nucleotide translocator-1 gene; multiple deletions; point mutation; leigh-syndrome; atp synthase; oxidative-phosphorylation; behavioral mutants; structural-changes; dna mutations
AB Mitochondrial encephalomyopathies are common and devastating multisystem genetic disorders characterized by neuromuscular dysfunction and tissue degeneration. Point mutations in the human mitochondrial ATP6 gene are known to cause several related mitochondrial disorders: NARP( neuropathy, ataxia, and retinitis pigmentosa), MILS ( maternally inherited Leigh's syndrome), and FBSN ( familial bilateral striatal necrosis). We identified a pathogenic mutation in the Drosophila mitochondrial ATP6 gene that causes progressive, adult-onset neuromuscular dysfunction and myodegeneration. Our results demonstrate ultrastructural defects in the mitochondrial innermembrane, neural dysfunction, and a marked reduction in mitochondrial ATP synthase activity associated with this mutation. This Drosophila mutant recapitulates key features of the human neuromuscular disorders enabling detailed in vivo studies of these enigmatic diseases.
C1 Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodgenerat Dis, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.
   Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.
   New York State Dept Hlth, Resource Visualizat Biol Complex, Wadsworth Ctr, Albany, NY 12201 USA.
   New Mexico State Univ, Program Mol Biol, Las Cruces, NM 88003 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Wadsworth Center; State University of New York (SUNY) System; New Mexico State University
RP Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodgenerat Dis, 200 Lothrop,Biomed Sci Tower E1355, Pittsburgh, PA 15261 USA.
EM mjp44@pitt.edu
FU NCRR NIH HHS [RR01219, P41 RR001219] Funding Source: Medline; NINDS NIH HHS [T32NS07391-07, T32 NS007391] Funding Source: Medline
CR Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   DEMEIRLEIR L, 1995, PEDIATR NEUROL, V13, P242, DOI 10.1016/0887-8994(95)00184-H
   Deng YR, 1999, J STRUCT BIOL, V127, P231, DOI 10.1006/jsbi.1999.4147
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   Frangakis AS, 2001, J STRUCT BIOL, V135, P239, DOI 10.1006/jsbi.2001.4406
   Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030
   Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1
   FRYER A, 1994, ARCH DIS CHILD, V71, P419, DOI 10.1136/adc.71.5.419
   GANETZKY B, 1982, GENETICS, V100, P597
   HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269
   Hart PE, 2002, MITOCHONDRIAL DISORDERS IN NEUROLOGY, V2, P35
   HARTZOG PE, 1993, J BIOL CHEM, V268, P12250
   HOLT IJ, 1989, NUCLEIC ACIDS RES, V17, P4465, DOI 10.1093/nar/17.12.4465
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Holyoake AJ, 1999, ANDROLOGIA, V31, P339, DOI 10.1046/j.1439-0272.1999.00150.x
   HOMYK T, 1977, GENETICS, V87, P95
   HUIZING M, 1998, THESIS U NIJMEGEN NE, V0, P0
   Iborra FJ, 2004, BMC BIOL, V2, P0, DOI 10.1186/1741-7007-2-9
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kawasaki F, 1998, J NEUROSCI, V18, P10241
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kretzschmar D, 1997, J NEUROSCI, V17, P7425
   LAMMINEN T, 1995, AM J HUM GENET, V56, P1238
   Manfredi G, 2001, METHOD CELL BIOL, V65, P133, DOI 10.1016/S0091-679X(01)65008-8
   Marin-Garcia J, 2001, CARDIOVASC RES, V49, P17, DOI 10.1016/S0008-6363(00)00241-8
   Marko M, 1996, J STRUCT BIOL, V116, P93, DOI 10.1006/jsbi.1996.0016
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   Min KT, 1997, CURR BIOL, V7, P885, DOI 10.1016/S0960-9822(06)00378-2
   Min KT, 1997, P NATL ACAD SCI USA, V94, P10792, DOI 10.1073/pnas.94.20.10792
   Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MITCHELL P, 1967, NATURE, V213, P137, DOI 10.1038/213137a0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Palladino MJ, 2003, J NEUROSCI, V23, P1276, DOI 10.1523/JNEUROSCI.23-04-01276.2003
   Palladino MJ, 2002, GENETICS, V161, P1197
   Pallotti F, 2004, BIOCHEM J, V384, P287, DOI 10.1042/BJ20040561
   PASTORES GM, 1994, AM J MED GENET, V50, P265, DOI 10.1002/ajmg.1320500310
   Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221
   PENCZEK P, 1995, ULTRAMICROSCOPY, V60, P393, DOI 10.1016/0304-3991(95)00078-X
   Radermacher M, 1992, WEIGHTED BACK PROJEC, V0, P0
   Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224
   Rogina B, 1997, P NATL ACAD SCI USA, V94, P6303, DOI 10.1073/pnas.94.12.6303
   SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   SCHERER B, 1974, BIOCHEMISTRY-US, V13, P161, DOI 10.1021/bi00698a025
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281
   Sciacco M, 2003, J NEUROL, V250, P1498, DOI 10.1007/s00415-003-0246-6
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   SLAUTTERBACK DB, 1965, J CELL BIOL, V24, P1, DOI 10.1083/jcb.24.1.1
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Voorhies WA, 2004, J APPL PHYSIOL, V97, P1915, DOI 10.1152/japplphysiol.00505.2004
   Van Voorhies WA, 2003, J APPL PHYSIOL, V95, P2605, DOI 10.1152/japplphysiol.00448.2003
   Vergani L, 1999, HUM MOL GENET, V8, P1751, DOI 10.1093/hmg/8.9.1751
   WALKER JE, 1995, BBA-MOL BASIS DIS, V1271, P221, DOI 10.1016/0925-4439(95)00031-X
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang YQ, 1999, GENETICS, V153, P891
NR 78
TC 58
Z9 76
U1 0
U2 10
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
EI 1529-2401
J9 J NEUROSCI
JI J. Neurosci.
PD JAN 18
PY 2006
VL 26
IS 3
BP 810
EP 820
DI 10.1523/JNEUROSCI.4162-05.2006
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 003XG
UT WOS:000234715000012
PM 16421301
DA 2024-11-01
ER

PT J
AU Gambello, MJ
   Bai, RK
   Chen, TJ
   Dimachkie, M
   Wong, LJC
AF Gambello, Michael J.
   Bai, Ren-Kui
   Chen, Tian-Jian
   Dimachkie, Mazen
   Wong, Lee-Jun C.
TI Exercise intolerance associated with a novel 8300T&gt;C mutation in mitochondrial transfer RNA<SUP>lys</SUP>
SO MUSCLE & NERVE
LA English
DT Article
DE exercise intolerance; mtDNA mutation; mitochondrial myopathy; transfer RNA; tRNA(lys)
ID transfer-rnas; dna; disease; disorders; gene
AB Mutations in the mitochondrial genome contribute to the pathophysiology of many neuromuscular diseases. Recently there has been an increased appreciation of the role of mitochondrial DNA (mtDNA) mutations in the etiology of exercise intolerance. Using TTGE (temporal temperature-gradient gel electrophoresis) and sequence analyses of the entire mitochondrial genome, we identified a novel heteroplasmic mutation (8300T > C) in the tRNA(lys) gene (MTTK) from a patient with unexplained exercise intolerance. The mutation was present in blood, hair, and muscle, with the highest percentage of heteroplasmy found in muscle. The results of muscle respiratory chain enzyme analysis are consistent with tRNA mutation. These data suggest that this novel mutation is yet another mtDNA mutation associated with muscle disease and should be considered in patients with similar symptoms.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Univ Texas, Hlth Sci Ctr, Div Med Genet, Dept Pediat, Houston, TX USA.
   Univ S Alabama, Dept Med Genet, Mobile, AL USA.
   Univ Texas, Hlth Sci Ctr, Dept Neurol, Houston, TX USA.
C3 Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of South Alabama; University of Texas System; University of Texas Health Science Center Houston
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, P0
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Larsson NG, 1999, FEBS LETT, V455, P199, DOI 10.1016/S0014-5793(99)00854-6
   Liang HM, 1998, CLIN CHEM, V44, P1578
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Matsumoto M, 1999, OPHTHALMIC GENET, V20, P153, DOI 10.1076/opge.20.3.153.2281
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Odawara M, 1996, BIOCHEM BIOPH RES CO, V227, P147, DOI 10.1006/bbrc.1996.1481
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 25
TC 7
Z9 8
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD OCT 15
PY 2006
VL 34
IS 4
BP 437
EP 443
DI 10.1002/mus.20605
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 089OR
UT WOS:000240890600007
PM 16810691
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Hirano, M
   Schon, EA
AF DiMauro, Salvatore
   Hirano, Michio
   Schon, Eric A.
TI Approaches to the treatment of Mitochondrial Diseases - Invited review
SO MUSCLE & NERVE
LA English
DT Review
DE exercise; gene shifting; genetic counseling; ooplasmic transfer; oxygen radical scavenging; palliative therapy; preimplantation diagnosis; supplementation; therapy
ID coenzyme q(10) deficiency; kearns-sayre-syndrome; progressive external ophthalmoplegia; copper-binding protein; complex-iii deficiency; human skeletal-muscle; peptide nucleic-acid; stroke-like episodes; cultured human-cells; cytochrome-b gene
AB Therapy for mitochondrial diseases is woefully inadequate. However, lack of a cure does not equate with lack of treatment. Palliative therapy is dictated by good medical practice and includes anticonvulsant medication, control of endocrine dysfunction, and surgical procedures. Removal of noxious metabolites is centered on combating lactic acidosis, but extends to other metabolites. Attempts to bypass blocks in the respiratory chain by administration of electron acceptors have not been successful, but this may be amenable to genetic engineering. Administration of metabolites and cofactors is the mainstay of real-life therapy and is especially important in disorders due to primary deficiencies of specific compounds, such as carnitine or coenzyme Q10 (CoQ10). There is increasing interest in the administration of reactive oxygen radicals (ROS) scavengers, both in primary mitochondrial diseases and in neurodegenerative diseases. Gene therapy is a challenge because of polyplasmy and heteroplasmy, but novel experimental approaches are being pursued. One important strategy is to decrease the ratio of mutant to wild-type mitochondrial genomes ("gene shifting") by different means: (1) converting mutated mitochondrial DNA (mtDNA) genes into normal nuclear DNA genes ("allotopic expression"); (2) importing cognate genes from other species ("xenotopic expression"); (3) correcting mtDNA mutations by importing specific restriction endonucleases; (4) selecting for respiratory function; and (5) inducing muscle regeneration. Germline therapy raises ethical problems but is being considered for prevention of maternal transmission of mtDNA mutations. Preventive therapy through genetic counseling and prenatal diagnosis is becoming increasingly important for nuclear DNA-related disorders.
C1 Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.
EM sdl2@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS1176] Funding Source: Medline
CR ALLEN RJ, 1983, ANN NEUROL, V13, P679, DOI 10.1002/ana.410130620
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, EYE, V13, P769, DOI 10.1038/eye.1999.225
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Auré K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   BAKER SK, 2003, EXPERT OPIN INV DRUG, V12, P1
   Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   BICKNESE AR, 1992, ANN NEUROL, V32, P767, DOI 10.1002/ana.410320610
   Bindoff L, 2006, MITOCHONDRIAL MEDICINE, V0, P143
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9
   Bonnet D, 2001, HEART, V86, P570, DOI 10.1136/heart.86.5.570
   Brenner CA, 2000, FERTIL STERIL, V74, P573, DOI 10.1016/S0015-0282(00)00681-6
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Carelli V, 2006, MITOCHONDRIAL MEDICINE, V0, P105
   Carroll PV, 1997, CLIN ENDOCRINOL, V47, P113, DOI 10.1046/j.1365-2265.1997.2241031.x
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   Chinnery PF, 2006, MITOCHONDRIAL MED, V0, P161
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   DEVIVO DC, 1999, PEDIAT NEUROLOGY PRI, V1, P494
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2006, MITOCHONDRIAL MEDICINE, V0, P261
   DOUGADOS M, 1983, ANN NEUROL, V13, P687, DOI 10.1002/ana.410130624
   Edmonds JL, 2004, MITOCHONDRION, V4, P543, DOI 10.1016/j.mito.2004.07.012
   Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   Flierl A, 2005, GENE THER, V12, P570, DOI 10.1038/sj.gt.3302443
   Flierl A, 2003, MOL THER, V7, P550, DOI 10.1016/S1525-0016(03)00037-6
   Freisinger P, 2004, J INHERIT METAB DIS, V27, P67, DOI 10.1023/B:BOLI.0000016614.47380.2f
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   GATTERMANN N, 2006, MITOCHONDRIAL MED, V0, P209
   Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7
   Grad LI, 2005, P NATL ACAD SCI USA, V102, P18367, DOI 10.1073/pnas.0506939102
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Hakkaart GAJ, 2006, EMBO REP, V7, P341, DOI 10.1038/sj.embor.7400601
   Hargreaves IP, 2005, J INHERIT METAB DIS, V28, P81, DOI 10.1007/s10545-005-4160-1
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hassanein T, 2004, MITOCHONDRION, V4, P609, DOI 10.1016/j.mito.2004.07.015
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   Hays AP, 2006, MITOCHONDRIAL MEDICINE, V0, P45
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hirano M, 2006, MITOCHONDRIAL MEDICINE, V0, P27
   Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c
   Iuso A, 2006, J BIOL CHEM, V281, P10374, DOI 10.1074/jbc.M513387200
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   KENNAWAY NG, 1984, PEDIATR RES, V18, P991
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Klopstock T, 1999, NEUROLOGY, V52, P0
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Manfredi G, 2004, ANN NEUROL, V56, P171, DOI 10.1002/ana.20243
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Marriage BJ, 2004, MOL GENET METAB, V81, P263, DOI 10.1016/j.ymgme.2003.12.008
   McGregor A, 2003, BBA-GENE STRUCT EXPR, V1629, P73, DOI 10.1016/j.bbaexp.2003.08.005
   Melacini P, 2001, TRANSPLANT P, V33, P1596, DOI 10.1016/S0041-1345(00)02607-5
   Millhouse-Flourie TJ, 2004, MITOCHONDRION, V4, P549, DOI 10.1016/j.mito.2004.07.013
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Oguro H, 2004, INTERNAL MED, V43, P427, DOI 10.2169/internalmedicine.43.427
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Pineda M, 2006, ANN NEUROL, V59, P394, DOI 10.1002/ana.20746
   Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Rake JP, 2000, EUR J PEDIATR, V159, P523, DOI 10.1007/s004310051324
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Rotig A, 2006, MITOCHONDRIAL MEDICINE, V0, P197
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   SCHON EA, 2006, MITOCHONDRIAL MED, V0, P329
   Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Shults CW, 2001, NEUROLOGY, V57, P375, DOI 10.1212/WNL.57.3.375
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Steffann J, 2006, J MED GENET, V43, P244, DOI 10.1136/jmg.2005.032326
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2005, MED SCI SPORT EXER, V37, P2094, DOI 10.1249/01.mss.0000177446.97671.2a
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Tein I, 2003, J INHERIT METAB DIS, V26, P147, DOI 10.1023/A:1024481016187
   TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020
   Templeton A, 2002, NEW ENGL J MED, V346, P773, DOI 10.1056/NEJM200203073461013
   THORBURN DR, 2006, MITOCHONDRIAL MED, V0, P241
   Tieu K, 2006, MITOCHONDRIAL MEDICINE, V0, P279
   Towbin JA, 2006, MITOCHONDRIAL MEDICINE, V0, P75
   TRANCHANT C, 1993, NEUROMUSCULAR DISORD, V3, P561, DOI 10.1016/0960-8966(93)90116-2
   Visch HJ, 2004, J BIOL CHEM, V279, P40328, DOI 10.1074/jbc.M408068200
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
   Wong VA, 2002, OPHTHALMOLOGY, V109, P1023, DOI 10.1016/S0161-6420(02)01009-6
   YIALAMAS MA, 2006, MITOCHONDRIAL MED, V0, P179
NR 128
TC 99
Z9 109
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD SEP 15
PY 2006
VL 34
IS 3
BP 265
EP 283
DI 10.1002/mus.20598
PG 19
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 074XX
UT WOS:000239846800002
PM 16810684
DA 2024-11-01
ER

PT J
AU Schapira, AHV
AF Schapira, Anthony H. V.
TI Mitochondrial disease
SO LANCET
LA English
DT Review
ID cytochrome-c-oxidase; hereditary optic neuropathy; progressive external ophthalmoplegia; respiratory-chain disorders; intracytoplasmic sperm injection; electron-transport chain; amyloid-beta peptide; gamma-gene polg; parkinsons-disease; alzheimers-disease
AB Defects of mitochondrial metabolism cause a wide range of human diseases that include examples from all medical subspecialties. This review updates the topic of mitochondrial diseases by reviewing the most important recent advances in this area. The factors influencing inheritance, maintenance and replication of mtDNA are reviewed and the genotype-phenotype of mtDNA disorders has been expanded, with new insights into epidemiology, pathogenesis and its role in ageing. Recently identified nuclear gene mutations of mitochondrial proteins include mutations of frataxin causing Friedreich's ataxia, PINK1, DJ1 causing Parkinson's disease and POLG causing infantile mtDNA depletion syndrome, ophthalmoplegia, parkinsonism, male subfertility and, in a transgenic mouse model, premature senescence. Mitochondrial defects in neurodegenerative diseases include Parkinson's, Alzheimer's and Huntington's disease. Improved understanding of mtDNA inheritance and mutation penetrance patterns, and novel techniques for mtDNA modification offer significant prospects for more accurate genetic counselling and effective future therapies.
C1 UCL, Inst Neurol, London NW3 2PF, England.
   Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England.
C3 University of London; University College London; University of London; University College London
RP Schapira, AHV (corresponding author), Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England.
EM a.schapira@medasch.ucl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4
   Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   BOHNERT B, 1974, ARCH PSYCHIAT NERVEN, V218, P353, DOI 10.1007/BF00342578
   Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9
   Canet-Avilés RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101
   Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x
   Chandrasekaran K, 1997, MOL BRAIN RES, V44, P99, DOI 10.1016/S0169-328X(96)00191-X
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   COCK HR, 1995, NEUROLOGY, V45, P0
   Coenen MJH, 2004, ANN NEUROL, V56, P560, DOI 10.1002/ana.20229
   COOPER JM, 1993, LANCET, V341, P969, DOI 10.1016/0140-6736(93)91269-R
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   DAurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Danan C, 1999, AM J HUM GENET, V65, P463, DOI 10.1086/302484
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Du Yan S, 1999, J BIOL CHEM, V274, P2145, DOI 10.1074/jbc.274.4.2145
   Entelis NS, 2001, J BIOL CHEM, V276, P45642, DOI 10.1074/jbc.M103906200
   Ezquerra M, 2005, ARCH NEUROL-CHICAGO, V62, P306, DOI 10.1001/archneur.62.2.306
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   HARDING AE, 1995, AM J HUM GENET, V57, P77
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   Hart PE, 2005, ARCH NEUROL-CHICAGO, V62, P621, DOI 10.1001/archneur.62.4.621
   Hausse AO, 2002, HEART, V87, P346, DOI 10.1136/heart.87.4.346
   Höglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 1997, HUM MOL GENET, V6, P1251, DOI 10.1093/hmg/6.8.1251
   Houshmand M, 1997, J ASSIST REPROD GEN, V14, P223, DOI 10.1007/BF02766114
   Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   Lee SJ, 2003, ANTIOXID REDOX SIGN, V5, P337, DOI 10.1089/152308603322110904
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Lodi R, 2001, ANN NEUROL, V49, P590
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Marchington DR, 2002, MOL HUM REPROD, V8, P1046, DOI 10.1093/molehr/8.11.1046
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Mootha VK, 2005, P NATL ACAD SCI USA, V102, P10405, DOI 10.1073/pnas.0505194102
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Müftüoglu M, 2004, MOVEMENT DISORD, V19, P544, DOI 10.1002/mds.10695
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ojaimi J, 1999, ANN NEUROL, V46, P656, DOI 10.1002/1531-8249(199910)46:4<656::AID-ANA16>3.3.CO;2-H
   Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302
   PARKER WD, 1995, NEUROLOGY, V45, P482, DOI 10.1212/WNL.45.3.482
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426
   REICHMANN H, 1993, J NEUROL, V240, P377, DOI 10.1007/BF00839971
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Schapira AHV, 2002, J NEUROL NEUROSUR PS, V72, P144, DOI 10.1136/jnnp.72.2.144
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042
   Seznec H, 2004, HUM MOL GENET, V13, P1017, DOI 10.1093/hmg/ddh114
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smith PM, 2004, BBA-BIOENERGETICS, V1659, P232, DOI 10.1016/j.bbabio.2004.09.003
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   St John J, 2000, LANCET, V355, P200, DOI 10.1016/S0140-6736(99)03842-8
   Sutovsky P, 2004, REPROD BIOMED ONLINE, V8, P24, DOI 10.1016/S1472-6483(10)60495-6
   Sutovsky P, 1999, NATURE, V402, P371, DOI 10.1038/46466
   Taanman JW, 2005, NEUROSCI LETT, V376, P56, DOI 10.1016/j.neulet.2004.11.023
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tang YY, 2000, MOL BIOL CELL, V11, P2349, DOI 10.1091/mbc.11.7.2349
   Tay SKH, 2004, ARCH NEUROL-CHICAGO, V61, P1935, DOI 10.1001/archneur.61.12.1935
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236
   Valentino ML, 2002, ANN NEUROL, V51, P774, DOI 10.1002/ana.10193
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   WALLACE DC, 1992, ANN NEUROL, V32, P113, DOI 10.1002/ana.410320123
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   Yan SD, 1997, NATURE, V389, P689
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 139
TC 504
Z9 626
U1 0
U2 72
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 1
PY 2006
VL 368
IS 9529
BP 70
EP 82
DI 10.1016/S0140-6736(06)68970-8
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 058TQ
UT WOS:000238687900032
PM 16815381
DA 2024-11-01
ER

PT J
AU Vanniarajan, A
   Nayak, D
   Reddy, AG
   Singh, L
   Thangaraj, K
AF Vanniarajan, Ayyasamy
   Nayak, Dinesh
   Reddy, Alla G.
   Singh, Lalji
   Thangaraj, Kumarasaray
TI Clinical and genetic uniqueness in an individual with MELAS
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE genetic uniqueness; late onset; MELAS; mitochondrial DNA; mutation
ID mitochondrial-dna; diabetes-mellitus; lactic-acidosis; mutation; genome; encephalopathy; myopathy; sequence; episodes; patient
AB Mitochondrial encephalopathy lactic acidosis stroke like episodes (MELAS) is a progressive neurodegenerative disorder with varying age of onset. It is a clinically and genetically heterogeneous disease. Molecular etiology of MELAS is not known in several cases. We have identified a unique individual with late onset MEILAS at the age of 55 years. We have analyzed the complete mitochondrial genome of the tissue and blood samples of the patient. One novel heteroplasmic mutation (C13565A) in NADH dehydrogenase 5 subunit (ND5) gene was found only in the tissue sample but not in the blood. This mutation is missense causing a change of amino acid serine to tyrosine at position 410. This mutation was found neither in controls nor in world populations. This study has also confirmed ND5 as a hotspot for the mitochondrial diseases. This will be of great help for the clinicians in the diagnosis of MELAS. (c) 2006 Wiley-Liss, Inc.
C1 Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
   Kovai Med Ctr & Hosp, Dept Neurol, Coimbatore, Tamil Nadu, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)
RP Thangaraj, K (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.
EM thangs@ccmb.res.in
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   Coble MD, 2004, INT J LEGAL MED, V118, P137, DOI 10.1007/s00414-004-0427-6
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, PD749, DOI 10.1093/nar/gkj010
   Kimata KG, 1998, ARCH NEUROL-CHICAGO, V55, P722, DOI 10.1001/archneur.55.5.722
   *MITOMAP, 2005, HUM MIT GEN DAT, V0, P0
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Servidei Serenella, 2004, NEUROMUSCUL DISORD, V14, P107
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Thangaraj K, 2005, SCIENCE, V308, P996, DOI 10.1126/science.1109987
   Thangaraj K, 2002, J ANDROL, V23, P815
   Thomas AW, 1996, J MED GENET, V33, P253, DOI 10.1136/jmg.33.3.253
NR 23
TC 12
Z9 13
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUL 5
PY 2006
VL 141B
IS 5
BP 440
EP 444
DI 10.1002/ajmg.b.30302
PG 5
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 057VC
UT WOS:000238622300002
PM 16741938
DA 2024-11-01
ER

PT J
AU Blakely, EL
   Rennie, KJ
   Jones, L
   Elstner, M
   Chrzanowska-Lightowlers, ZMA
   White, CB
   Shield, JPH
   Pilz, DT
   Turnbull, DM
   Poulton, J
   Taylor, RW
AF Blakely, EL
   Rennie, KJ
   Jones, L
   Elstner, M
   Chrzanowska-Lightowlers, ZMA
   White, CB
   Shield, JPH
   Pilz, DT
   Turnbull, DM
   Poulton, J
   Taylor, RW
TI Sporadic intragenic inversion of the mitochondrial DNA <i>MTND1</i> gene causing fatal infantile lactic acidosis
SO PEDIATRIC RESEARCH
LA English
DT Article
ID complex-i deficiency; leigh-syndrome; nd3 gene; mutations; disease; mtdna; diagnosis; disorder; deletion; patient
AB Mutations of mitochondrial DNA (mtDNA) are an important cause of genetic disease, yet rarely present in the neonatal period. Here we report the clinical, biochemical, and molecular genetic findings of an infant who died at the age of 1 mo with marked biventricular hypertrophy, aortic coarctation, and severe lactic acidosis due to a previously described but unusual mtDNA mutation, a 7-bp intragenic inversion within the mitochondrial gene encoding ND1 protein of complex I (MTND1). In direct contrast to the previous case, an adult with exercise intolerance who only harbored the mutation in muscle, the MTND1 inversion in our patient was present at high levels in several tissues including the heart, muscle, liver, and cultured skin fibroblasts. There was no evidence of the mutation or respiratory complex I defect in a muscle biopsy from the patient's mother. Transmitochondrial cytoplasmic hybrids (cybrids) containing high mutant loads of the inversion expressed the biochemical defect but apparently normal levels of the assembled complex. Our report highlights the enormous phenotypic diversity that exists among pathogenic mtDNA mutations and reemphasizes the need for appropriate genetic counseling for families affected by mtDNA disease.
C1 Univ Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Wales Hosp, Inst Med Genet, Cardiff CF14 4XW, Wales.
   Royal Hosp Children, Bristol BS2 8AE, Avon, England.
   John Radcliffe Hosp, Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
C3 Newcastle University - UK; Cardiff University; Bristol Royal Hospital For Children; University of Oxford
RP Univ Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Blakely EL, 2004, J MED GENET, V41, P0, DOI 10.1136/jmg.2003.011296
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Hofhaus G, 1996, METHODS ENZYMOL, V264, P476, DOI 10.1016/S0076-6879(96)64043-9
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Musumeci O, 2000, AM J HUM GENET, V66, P1900, DOI 10.1086/302927
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   POULTON J, 2001, J NEUROL SCI, V187, P0
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Taylor RW, 1997, ORGANELLE DISEASES : CLINICAL FEATURES, V0, Pathogenesis
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6
   Zickermann V, 1998, BIOCHEMISTRY-US, V37, P11792, DOI 10.1021/bi9810555
NR 30
TC 16
Z9 17
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD MAR 15
PY 2006
VL 59
IS 3
BP 440
EP 444
DI 10.1203/01.pdr.0000198771.78290.c4
PG 5
WC Pediatrics
SC Pediatrics
GA 016NK
UT WOS:000235626700018
PM 16492986
DA 2024-11-01
ER

PT J
AU Bass, MG
   Sokolova, VA
   Kustova, ME
   Grachyova, EV
   Kidgotko, OV
   Sorokin, AV
   Vasilyev, VB
AF Bass, Mikhail G.
   Sokolova, Vassilina A.
   Kustova, Maria E.
   Grachyova, Elena V.
   Kidgotko, Oksana V.
   Sorokin, Alexander V.
   Vasilyev, Vadim B.
TI Assaying the probabilities of obtaining maternally inherited heteroplasmy as the basis for modeling OXPHOS diseases in animals
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
DE energy metabolism; OXPHOS diseases modeling; human mtDNA; mtDNA transfer; transgenic mice; maternal inheritance
ID human mitochondrial-dna; transmitochondrial mice; mouse; organization; gene; chloramphenicol; microinjection; cytoskeleton; populations; segregation
AB Gross alterations in cell energy metabolism underlie manifestations of hereditary OXPHOS (oxidative phosphorylation) diseases, many of which depend on proportion of mutant mitochondrial DNA (mtDNA) in tissues. An animal model of OXPHOS disease with maternal inheritance of mitochondrial heteroplasmy might help understanding the peculiarities of abnormal mtDNA distribution and its effect on pre- and postnatal development. Previously we obtained mice that carry human mtDNA in some tissues. It co-existed with murine mtDNA (heteroplasmy) and was transmitted maternally to the progeny of animals developed from zygotes injected with human mitochondria. To analyze the probability of obtaining heteroplasmic mice we increased the number of experiments with early embryos and obtained more specimens from F-1. About 33% of zygotes injected with human mtDNA developed into post-implantation embryos (7th-13th days). Lower amount of such developed into neonate mice (ca. 21%). Among post-implantation embryos and in generations F-0 and F-1 percentages of human mtDNA-carriers were ca. 14-16%. Such percentages are sufficient for modeling maternally inherited heteroplasmy in small animal groups. More data are needed to understand the regularities of anomalous mtDNA distribution among cells and tissues and whether heart and muscles frequently carrying human mtDNA in our experiments are particularly susceptible to heteroplasmy. (c) 2006 Elsevier B.V. All rights reserved.
C1 Inst Expt Med, Dept Mol Genet, St Petersburg 197376, Russia.
C3 Institute of Experimental Medicine
RP Vasilyev, VB (corresponding author), Inst Expt Med, Dept Mol Genet, 12 Pavlov St, St Petersburg 197376, Russia.
EM vadim@biomed.spb.su
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BASS MG, 2005, MED ACAD J, V5, P55
   BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759
   BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7
   DVOIRIN VV, 1985, METHODS CONTROLLED C, V0, P0
   Dykens James A, 1997, P29, V0, P0
   Glantz S, 1994, PRIMER OF BIOSTATISTICS, V0, P0
   Hermann GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 1999, INT REV CYTOL, V186, P49
   Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Maniatis T, 1982, MOLECULAR CLONING: A LABORATORY MANUAL. VOL, V2, P0
   Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403
   Nagao Yasumitsu, 1998, JOURNAL OF REPRODUCTION AND DEVELOPMENT, V44, P129, DOI 10.1262/jrd.44.129
   PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251
   Poulton J, 1996, PRENATAL DIAG, V16, P1247, DOI 10.1002/(SICI)1097-0223(199612)16:13<1247::AID-PD99>3.0.CO;2-P
   Rinaudo P, 1999, FERTIL STERIL, V71, P912, DOI 10.1016/S0015-0282(99)00089-8
   Sokolova VA, 2004, MOL REPROD DEV, V68, P299, DOI 10.1002/mrd.20075
   TORRONI A, 1992, GENETICS, V130, P153
   TOURTE M, 1991, MOL REPROD DEV, V30, P353, DOI 10.1002/mrd.1080300410
   Vasilyev VB, 1999, ZYGOTE, V7, P279, DOI 10.1017/S0967199499000672
NR 26
TC 5
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD MAY-JUN 15
PY 2006
VL 1757
IS 5-6
BP 679
EP 685
DI 10.1016/j.bbabio.2006.05.021
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 069XF
UT WOS:000239481800049
PM 16829232
DA 2024-11-01
ER

PT J
AU Pagnamenta, AT
   Taanman, JW
   Wilson, CJ
   Anderson, NE
   Marotta, R
   Duncan, AJ
   Bitner-Glindzicz, M
   Taylor, RW
   Laskowski, A
   Thorburn, DR
   Rahman, S
AF Pagnamenta, Alistair T.
   Taanman, Jan-Willem
   Wilson, Callum J.
   Anderson, Neil E.
   Marotta, Rosetta
   Duncan, Andrew J.
   Bitner-Glindzicz, Maria
   Taylor, Robert W.
   Laskowski, Adrienne
   Thorburn, David R.
   Rahman, Shamima
TI Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma
SO HUMAN REPRODUCTION
LA English
DT Article
DE mitochondrial DNA depletion; parkinsonism; PEO; POLG; premature menopause
ID progressive external ophthalmoplegia; autosomal-dominant; oxidative-phosphorylation; depletion syndrome; male-infertility; polg mutations; quantification; cells; hypogonadism; menopause
AB BACKGROUND: Premature ovarian failure (POF) results in menopause before the age of 40. Recently, mutations in the catalytic subunit of mitochondrial DNA polymerase gamma (POLG) were shown to segregate with POF in families with progressive external ophthalmoplegia (PEO) and multiple large-scale rearrangements of mitochondrial DNA (mtDNA). METHODS AND RESULTS: A patient, mother and maternal grandmother are described, all presenting with POF and PEO. The mother developed parkinsonism in her sixth decade. Normal mtDNA sequence excluded mitochondrial inheritance. Sequence analysis of polymerase gamma revealed a dominant Y955C mutation that segregated with disease. Southern blot analysis demonstrated mtDNA depletion in fibroblasts (43% of controls). In contrast, multiple rearrangements of mtDNA were seen in skeletal muscle, consistent with the relative sparing of nuclear-encoded complex II activity compared with other respiratory chain enzymes. Immunoblotting of native gels showed that DNA polymerase gamma stability was not affected, whereas a reverse-transcriptase primer-extension assay suggested a trend towards reduced polymerase activity in fibroblasts. CONCLUSIONS: This study confirms that POLG mutations can segregate with POF and parkinsonism and demonstrates for the first time that the Y955C mutation can lead to mtDNA depletion. Future screening projects will determine the frequency with which POLG is involved in the aetiology of POF and its impact on reproductive counselling.
C1 Inst Child Hlth, Biochem Endocrinol & Metab Unit, London WC1N 1EH, England.
   UCL Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England.
   Auckland City Hosp, Dept Neurol, Auckland, New Zealand.
   St Vincents Hosp, Ctr Clin Neurosci & Neurol Res, Fitzroy, Vic 3065, Australia.
   Inst Child Hlth, Clin & Mol Genet Unit, London WC1N 1EH, England.
   Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Melbourne, Dept Paediat, Melbourne, Vic 3052, Australia.
   Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia.
C3 University of London; University College London; University of London; University College London; UCL Medical School; Auckland City Hospital; NSW Health; St Vincents Hospital Sydney; St Vincent's Health; St Vincent's Hospital Melbourne; University of London; University College London; Newcastle University - UK; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne
RP Rahman, S (corresponding author), Inst Child Hlth, Biochem Endocrinol & Metab Unit, London WC1N 1EH, England.
EM s.rahman@ich.ucl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Allingham-Hawkins SJ, 1999, AM J MED GENET, V83, P322, DOI 10.1002/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-B
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   Goswami D, 2005, HUM REPROD UPDATE, V11, P391, DOI 10.1093/humupd/dmi012
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   LUNDBERG PO, 1962, ACTA NEUROL SCAND, V38, P142
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8
   Murabito JM, 2005, J CLIN ENDOCR METAB, V90, P3427, DOI 10.1210/jc.2005-0181
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   POWELL CM, 1994, AM J MED GENET, V52, P19, DOI 10.1002/ajmg.1320520105
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Rowe LB, 1996, MAMM GENOME, V7, P886, DOI 10.1007/s003359900262
   Santos TA, 2006, FERTIL STERIL, V85, P584, DOI 10.1016/j.fertnstert.2005.09.017
   SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125
   Steuerwald N, 2000, ZYGOTE, V8, P209, DOI 10.1017/S0967199400001003
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   THARAPEL AT, 1993, AM J HUM GENET, V52, P463
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wycherley G, 2005, HUM REPROD, V20, P2757, DOI 10.1093/humrep/dei132
NR 32
TC 118
Z9 127
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD OCT 15
PY 2006
VL 21
IS 10
BP 2467
EP 2473
DI 10.1093/humrep/del076
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 090CQ
UT WOS:000240928600003
PM 16595552
DA 2024-11-01
ER

PT J
AU Saneto, RP
   Bouldin, A
AF Saneto, Russell P.
   Bouldin, Anthony
TI A boy with muscle weakness, hypercarbia, and the mitochondrial DNA A3243G mutation
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID transfer rnaleu(uur) gene; lactic-acidosis; episodes melas; point mutation; myopathy; encephalopathy
AB The point mutation in the mitochondrial genome tRNA(Leu) (A3243G) is associated with the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS). We report a boy presenting with respiratory compromise and hypercarbia owing to severe muscle weakness. Historically, he demonstrated idiopathic growth hormone deficiency, retarded bone age, and exercise avoidance. Owing to severe respiratory compromise out of proportion to expected recovery, a metabolic work-up was performed. Muscle biopsy demonstrated abnormal mitochondria structure and heteroplasmic A3243G mutation. Idiopathic growth hormone deficiency and retarded bone age have not been previously reported in MELAS, and these findings delayed testing for mitochondrial disease. This case demonstrates that isolated muscle weakness in the context of other organ system abnormalities should make the investigator consider MELAS.
C1 Univ Washington, Div Pediat Neurol, Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA.
C3 Seattle Children's Hospital; University of Washington; University of Washington Seattle
RP Saneto, RP (corresponding author), Univ Washington, Div Pediat Neurol, Childrens Hosp & Reg Med Ctr, Neurol 5D-4,4800 Sand Point Way NE, Seattle, WA 98105 USA.
EM russ.saneto@seattlechildrens.org
CR Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444
   Cholley F, 2001, NEUROPEDIATRICS, V32, P104, DOI 10.1055/s-2001-13878
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hanna MG, 1997, J NEUROL NEUROSUR PS, V62, P544, DOI 10.1136/jnnp.62.5.544
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   SCHAPIRA AHV, 1990, NEW ENGL J MED, V323, P37, DOI 10.1056/NEJM199007053230107
   Varanasi SS, 1999, OSTEOPOROSIS INT, V10, P143, DOI 10.1007/s001980050209
NR 11
TC 5
Z9 6
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JAN 15
PY 2006
VL 21
IS 1
BP 77
EP 79
DI 10.1177/08830738060210010601
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 046SP
UT WOS:000237831600016
PM 16551459
DA 2024-11-01
ER

PT J
AU Askanas, V
   Engel, WK
AF Askanas, V
   Engel, WK
TI Inclusion-body myositis -: A myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition
SO NEUROLOGY
LA English
DT Article
ID amyloid precursor protein; cultured human muscle; mitochondrial-dna deletions; alzheimers-disease; cystatin-c; mutant ubiquitin; transgenic mice; alpha-synuclein; secretase site; 26s proteasome
AB Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and there is no successful treatment. We summarize our most recent findings, which provide a better understanding of the steps in the pathogenetic cascade. We suggest that s-IBM is primarily a myodegenerative disease. Intriguing are the phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer disease, the most common neurodegenerative disease of older persons. In s-IBM, abnormal accumulation of the amyloid-beta (A beta) precursor protein and its proteolytic fragment, A beta, associated with the aging intracellular milieu of the muscle fiber, appear to be key upstream pathogenic events. We propose that the identified abnormal accumulation, misfolding, and aggregation of proteins, perhaps provoked by the aging milieu and aggravated by the oxidative stress, lead to the s-IBM-specific vacuolar degeneration and atrophy of muscle fibers.
C1 USC, Good Samaritan Hosp, Neuromuscular Ctr,Keck Sch Med, Dept Neurol, Los Angeles, CA 90017 USA.
C3 University of Southern California; University of Southern California Keck Hospital
RP USC, Good Samaritan Hosp, Neuromuscular Ctr,Keck Sch Med, Dept Neurol, 637 S Lucas Ave, Los Angeles, CA 90017 USA.
EM askanas@usc.edu
FU NIA NIH HHS [AG16768] Funding Source: Medline; NINDS NIH HHS [NS34103, NS31836] Funding Source: Medline
CR Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3
   Alvarez RB, 1998, NEUROLOGY, V50, P0
   Askanas V, 1998, AM J PATHOL, V153, P1673, DOI 10.1016/S0002-9440(10)65680-5
   Askanas V, 2000, J NEUROPATH EXP NEUR, V59, P592, DOI 10.1093/jnen/59.7.592
   Askanas V, 2003, CURR OPIN RHEUMATOL, V15, P737, DOI 10.1097/00002281-200311000-00009
   Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   ASKANAS V, 1992, NEUROSCI LETT, V143, P96, DOI 10.1016/0304-3940(92)90241-X
   Askanas V, 2001, J NEUROPATH EXP NEUR, V60, P1
   Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012
   AVLAREZ RB, 2000, NEUROLOGY, V54, P240
   Banwell BL, 2000, NEUROLOGY, V54, P1033, DOI 10.1212/WNL.54.5.1033
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bossy-Wetzel E, 2004, NAT MED, V10, PS2, DOI 10.1038/nm1067
   Broccolini A, 2000, NEUROLOGY, V54, P0
   Choi YC, 2000, J BIOL CHEM, V275, P8703, DOI 10.1074/jbc.275.12.8703
   Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8
   Cuello AC, 2005, BRAIN PATHOL, V15, P66
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Dalakas Marinos C, 2001, CURRENT OPINION IN PHARMACOLOGY, V1, P300, DOI 10.1016/S1471-4892(01)00053-4
   Deng A, 2001, AM J PATHOL, V159, P1061, DOI 10.1016/S0002-9440(10)61781-6
   DESNUELLE C, 1998, INCLUSION BODY MYOSI, V0, P318
   Echeverria V, 2002, MOL NEUROBIOL, V26, P299, DOI 10.1385/MN:26:2-3:299
   Ellis RJ, 2002, NATURE, V416, P483, DOI 10.1038/416483a
   Engel WK, 2006, NEUROLOGY, V66, PS20, DOI 10.1212/01.wnl.0000192260.33106.bb
   Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5
   Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425
   Fischer DF, 2003, FASEB J, V17, P2014, DOI 10.1096/fj.03-0205com
   Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999
   Forloni G, 2002, NEUROBIOL AGING, V23, P957, DOI 10.1016/S0197-4580(02)00076-3
   Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X
   Fratta P, 2004, NEUROLOGY, V63, P1114, DOI 10.1212/01.WNL.0000138574.56908.5D
   Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9
   Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x
   Gestwicki JE, 2004, SCIENCE, V306, P865, DOI 10.1126/science.1101262
   Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4
   Gonzalez-Cadavid NF, 2004, CURR OPIN CLIN NUTR, V7, P451, DOI 10.1097/01.mco.0000134365.99523.7f
   Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1
   Griggs RC, 2006, NEUROLOGY, V66, PS30, DOI 10.1212/01.wnl.0000192262.29924.9e
   Hashimoto M, 2003, NEUROMOL MED, V4, P21, DOI 10.1385/NMM:4:1-2:21
   Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884
   Jaworska-Wilczynska M, 2002, NEUROLOGY, V58, P438, DOI 10.1212/WNL.58.3.438
   Jin LW, 1998, AM J PATHOL, V153, P1679, DOI 10.1016/S0002-9440(10)65681-7
   Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x
   Kefi M, 2002, NEUROLOGY, V58, P0
   Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x
   Klein WL, 2002, NEUROBIOL AGING, V23, P231, DOI 10.1016/S0197-4580(01)00312-8
   Kopito RR, 2000, NAT CELL BIOL, V2, PE207, DOI 10.1038/35041139
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Levy E, 2001, J NEUROPATH EXP NEUR, V60, P94, DOI 10.1093/jnen/60.1.94
   Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456
   Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200
   Mastaglia FL, 2003, MUSCLE NERVE, V27, P407, DOI 10.1002/mus.10313
   McFerrin J, 1998, NEUROREPORT, V9, P3201, DOI 10.1097/00001756-199810050-00013
   McFerrin J, 2005, NEUROLOGY, V64, P0
   McFerrin J, 2002, NEUROLOGY, V58, P0
   MIKOL J, 2004, MYOLOGY BASIC CLIN, V0, P0
   Nogalska A, 2005, NEUROLOGY, V64, P0
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   OLDFORS A, 1998, INCLUSION BODY MYOSI, V0, P306
   Ozturk A, 2004, NEUROLOGY, V62, P0
   POCKLEY AG, 2001, EXPERT REV MOL MED, V0, P1
   Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798
   Salon ML, 2003, EXP NEUROL, V180, P131, DOI 10.1016/S0014-4886(02)00060-2
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   SARKOZI E, 1993, NEUROREPORT, V4, P815, DOI 10.1097/00001756-199306000-00055
   Schröder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741
   Selkoe DJ, 2003, NEUROCHEM RES, V28, P1705, DOI 10.1023/A:1026065122854
   Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5
   Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114
   Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785
   Stege GJJ, 1999, BIOCHEM BIOPH RES CO, V262, P152, DOI 10.1006/bbrc.1999.1167
   Sugarman MC, 2002, P NATL ACAD SCI USA, V99, P6334, DOI 10.1073/pnas.082545599
   van Leeuwen FW, 2000, NEUROBIOL AGING, V21, P879, DOI 10.1016/S0197-4580(00)00151-2
   van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242
   Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1
   Vattemi G, 2003, J NEUROCHEM, V85, P1539, DOI 10.1046/j.1471-4159.2003.01798.x
   Vattemi G, 2003, EXP NEUROL, V179, P150, DOI 10.1016/S0014-4886(02)00025-0
   Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0
   Vattemi G, 2003, NEUROLOGY, V60, P315
   VATTEMI G, 2003, NEUROLOGY, V60, P333
   Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015
   Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005
   Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a
   Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Wójcik S, 2005, ACTA NEUROPATHOL, V110, P173, DOI 10.1007/s00401-005-1035-3
   YUNIS EJ, 1971, LAB INVEST, V25, P240
NR 93
TC 126
Z9 148
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 15
PY 2006
VL 66
IS 
BP S39
EP S48
DI 10.1212/01.wnl.0000192128.13875.1e
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 005RX
UT WOS:000234842600007
PM 16432144
DA 2024-11-01
ER

PT J
AU Hofman, P
   Nelson, AM
AF Hofman, Paul
   Nelson, Ann Marie
TI The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE AIDS; HIV; antiretroviral therapy; pathology; toxicity; lipodystrophy; immune restoration syndrome
ID hiv-infected patients; progressive multifocal leukoencephalopathy; immune restoration disease; reconstitution inflammatory syndrome; pneumocystis-carinii pneumonia; avascular necrosis; cytomegalovirus retinitis; mitochondrial-dna; lactic-acidosis; nucleoside analog
AB The use of highly active antiretroviral therapy (HAART) has considerably improved the quality of life and has increased the survival of HIV-infected individuals. Although HAART can successfully suppress viral replication in the long term, it is not without significant toxicity, which can seriously compromise treatment effectiveness. Moreover, the rapid rate of virus mutation and subsequent emergence of drug-resistant HIV variants threaten the longer-term efficacy of HIV treatment. The most common adverse effects caused by HAART include a metabolic syndrome with lipodystrophy, hyperlipidemia and insulin resistance, deterioration in the clinical status due to various exaggerated local and systemic inflammatory reactions during the immunerestoration disease, and various hepatic, peripheral and cardiac muscle, kidney, bone, bone marrow, retinal, ear, and skin toxicities. The heterogeneity in the organs affected by the different drugs and the morphological features observed in tissues in HAART-treated patients raise possible explanations including differential distribution or activation of these agents. Antiretroviral drugs from new classes, as well as new drugs from existing classes with favorable resistance and side effect profiles are in various stages of development. However, new tissue disorders will be certainly described in the future in patients treated with these drugs. The different pathophysiology of the main adverse effects and the less common known side effects of antiretroviral therapy against HIV are described here, with special emphasis on the histological features induced by HAART.
C1 Hop Louis Pasteur, Lab Clin & Expt Pathol, F-06002 Nice 01, France.
   Univ Nice Sophia Antipolis, INSERM, ESPRI 2006, F-06108 Nice 2, France.
   Armed Forces Inst Pathol, Div AIDS Pathol, Washington, DC 20306 USA.
C3 CHU Nice; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); United States Department of Defense
RP Hofman, P (corresponding author), Hop Louis Pasteur, Lab Clin & Expt Pathol, BP69, F-06002 Nice 01, France.
EM hofman@unice.fr
CR Abino JF, 2002, AIDS, V16, P1429, DOI 10.1097/00002030-200207050-00018
   Aboulafia DM, 2000, AIDS PATIENT CARE ST, V14, P13, DOI 10.1089/108729100318091
   Aldeen T, 2000, HIV MED, V1, P252, DOI 10.1046/j.1468-1293.2000.00037.x
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Babl FE, 1999, LANCET, V353, P1243, DOI 10.1016/S0140-6736(98)05754-7
   Bachmeyer C, 2000, BRIT J DERMATOL, V143, P1336, DOI 10.1046/j.1365-2133.2000.03924.x
   Barbaro G, 2001, LANCET INFECT DIS, V1, P115, DOI 10.1016/S1473-3099(01)00067-6
   BELMONTE MA, 1993, J RHEUMATOL, V20, P1425
   Bersoff-Matcha SJ, 2001, CLIN INFECT DIS, V32, P124, DOI 10.1086/317536
   BISSUEL F, 1994, J INTERN MED, V235, P367, DOI 10.1111/j.1365-2796.1994.tb01088.x
   Blanche P, 1998, SCAND J INFECT DIS, V30, P615, DOI 10.1080/00365549850161223
   Blanche P, 2002, CLIN INFECT DIS, V34, P1279, DOI 10.1086/338720
   Breton G, 2006, AIDS, V20, P119, DOI 10.1097/01.aids.0000199014.66139.39
   Breton G, 2002, AM J MED, V113, P155, DOI 10.1016/S0002-9343(02)01130-0
   Brown P, 2001, CLIN INFECT DIS, V32, P1221, DOI 10.1086/319745
   CANOSO RT, 1987, BRIT J HAEMATOL, V65, P495, DOI 10.1111/j.1365-2141.1987.tb04157.x
   Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6
   Carr A, 2000, CLIN INFECT DIS, V30, PS135, DOI 10.1086/313854
   Carr A, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(05)62892-9
   Carr A, 1998, AIDS, V12, PF51, DOI 10.1097/00002030-199807000-00003
   Carr A, 1996, AIDS, V10, P635, DOI 10.1097/00002030-199606000-00009
   Carr A, 2002, LANCET, V360, P81, DOI 10.1016/S0140-6736(02)09341-8
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Carr A, 1998, LANCET, V351, P1736, DOI 10.1016/S0140-6736(05)77775-8
   Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1
   Casariego Z, 2001, MED ORAL, V6, P19
   Chariot P, 1991, NEUROMUSCUL DISORD, V1, P357, DOI 10.1016/0960-8966(91)90122-9
   CHARIOT P, 1993, ANN NEUROL, V34, P561, DOI 10.1002/ana.410340409
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   CHATTHA G, 1993, ANN INTERN MED, V118, P37, DOI 10.7326/0003-4819-118-1-199301010-00007
   Cheng VCC, 2000, CLIN INFECT DIS, V30, P882, DOI 10.1086/313809
   Cherry CL, 2003, J CLIN VIROL, V26, P195, DOI 10.1016/S1386-6532(02)00118-X
   CHEUNG NT, 1995, BRIT J RHEUMATOL, V34, P387
   CHEVALIER X, 1993, J BONE JOINT SURG BR, V75, P160, DOI 10.1302/0301-620X.75B1.8421018
   Chien JW, 1998, CHEST, V114, P933, DOI 10.1378/chest.114.3.933
   CHIMELLI L, 1992, NEUROPATH APPL NEURO, V18, P478, DOI 10.1111/j.1365-2990.1992.tb00815.x
   Cinque P, 2001, J NEUROVIROL, V7, P358
   Cossarizza A, 2002, J BIOL REG HOMEOS AG, V16, P18
   Cossarizza A, 2001, BIOESSAYS, V23, P1070, DOI 10.1002/bies.1152
   Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Dean GL, 2002, AM J RESP CRIT CARE, V165, P1670, DOI 10.1164/ajrccm.165.12.165121
   Deayton J, 1999, AIDS, V13, P1203, DOI 10.1097/00002030-199907090-00008
   Deayton JR, 2000, AIDS, V14, P1163, DOI 10.1097/00002030-200006160-00013
   Diri E, 2000, J RHEUMATOL, V27, P2711
   Domingo P, 1999, AIDS, V13, P2261, DOI 10.1097/00002030-199911120-00008
   Dworkin MS, 1998, ARCH INTERN MED, V158, P1828, DOI 10.1001/archinte.158.16.1828
   Emery S, 1997, CURR OPIN IMMUNOL, V9, P568, DOI 10.1016/S0952-7915(97)80112-4
   FESSEL WJ, 2000, ANTIVIR THER S, V5, P25
   FORTGANG IS, 1995, AM J GASTROENTEROL, V90, P1433
   Foudraine NA, 1999, AIDS, V13, P177, DOI 10.1097/00002030-199902040-00005
   Foulon G, 2004, CLIN INFECT DIS, V38, P418, DOI 10.1086/381094
   Fox P A, 1999, HIV MED, V1, P10, DOI 10.1046/j.1468-1293.1999.00003.x
   French MA, 2004, AIDS RES HUM RETROV, V20, P157, DOI 10.1089/088922204773004879
   Furrer H, 1999, AM J MED, V106, P371, DOI 10.1016/S0002-9343(99)00015-7
   Gea-Banacloche JC, 1999, AIDS, V13, P0
   Gerster JC, 1998, J RHEUMATOL, V25, P604
   GERSTER JC, 1991, J RHEUMATOL, V18, P300
   GOORNEY BP, 1990, GENITOURIN MED, V66, P451
   HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537
   Heath KV, 2002, J ACQ IMMUN DEF SYND, V30, P440, DOI 10.1097/01.QAI.0000021701.48448.20
   Hofman P, 1999, PATHOL RES PRACT, V195, P209, DOI 10.1016/S0344-0338(99)80037-5
   HOFMAN P, 1993, BRIT HEART J, V70, P376, DOI 10.1136/hrt.70.4.376
   HOFMAN P, 1993, PATHOL RES PRACT, V189, P894
   Hofman V, 2000, HUM PATHOL, V31, P75, DOI 10.1016/S0046-8177(00)80202-6
   Jacobson Jeffrey M, 2005, CURR HIV/AIDS REP, V2, P90, DOI 10.1007/s11904-005-0024-4
   Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8
   Jaquet D, 2000, AIDS, V14, P2123, DOI 10.1097/00002030-200009290-00008
   Jenny-Avital ER, 2002, CLIN INFECT DIS, V35, PE128, DOI 10.1086/344467
   John M, 1998, AIDS, V12, P2289, DOI 10.1097/00002030-199817000-00010
   Jubault V, 2000, J CLIN ENDOCR METAB, V85, P4254, DOI 10.1210/jc.85.11.4254
   Kalkut G, 2005, CURR OPIN ONCOL, V17, P479, DOI 10.1097/01.cco.0000174035.39161.d8
   Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169
   KLATT EC, 1994, ARCH PATHOL LAB MED, V118, P884
   Koeger AC, 1999, J RHEUMATOL, V26, P752
   KOHLBRENNER V, 1996, INT C AIDS, V11, P89
   KOTECHA N, 1999, CLIN INFECT DIS, V28, P1152
   Koval CE, 2002, CLIN INFECT DIS, V35, P491, DOI 10.1086/341974
   Krambovitis E, 2005, ACTA PHARMACOL SIN, V26, P1165, DOI 10.1111/j.1745-7254.2005.00193.x
   LAI KK, 1991, ANN INTERN MED, V115, P283, DOI 10.7326/0003-4819-115-4-283
   Langford TD, 2002, AIDS, V16, P1019, DOI 10.1097/00002030-200205030-00008
   Lanzafame M, 1999, CHEST, V116, P848, DOI 10.1378/chest.116.3.848-a
   Lascaux AS, 2001, AIDS, V15, P819, DOI 10.1097/00002030-200104130-00028
   Lawn SD, 2003, CLIN INFECT DIS, V36, PE5, DOI 10.1086/344446
   Lefkowitch JH, 1997, SEMIN LIVER DIS, V17, P335, DOI 10.1055/s-2007-1007210
   Lenzo NP, 1997, AIDS, V11, P1294, DOI 10.1097/00002030-199710001-00003
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lewis W, 2001, LAB INVEST, V81, P1527, DOI 10.1038/labinvest.3780366
   Lewis W, 2000, PROG CARDIOVASC DIS, V43, P151, DOI 10.1053/pcad.2000.9031
   Li QS, 2004, J INFECT DIS, V189, P572, DOI 10.1086/381396
   Llauger J, 1998, AM J ROENTGENOL, V171, P987, DOI 10.2214/ajr.171.4.9762981
   Lloreta J, 2002, VIRCHOWS ARCH, V441, P599, DOI 10.1007/s00428-002-0667-0
   Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X
   MANJI H, 1993, J NEUROL, V240, P479, DOI 10.1007/BF00874117
   Martín-Carbonero L, 2002, AIDS, V16, P1423, DOI 10.1097/00002030-200207050-00016
   Martínez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019
   Mayo J, 1998, AIDS, V12, P1720
   MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702
   Meyer D, 1999, AIDS, V13, P1147, DOI 10.1097/00002030-199906180-00025
   MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607
   Miller J, 2000, AIDS, V14, P2406, DOI 10.1097/00002030-200010200-00025
   Miralles P, 2001, AIDS, V15, P1900, DOI 10.1097/00002030-200109280-00028
   Mirmirani P, 1999, J AM ACAD DERMATOL, V41, P285, DOI 10.1016/S0190-9622(99)70364-6
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594
   Monier P, 2000, CLIN INFECT DIS, V31, P1488, DOI 10.1086/317503
   Morris AAM, 1999, LANCET, V354, P1046, DOI 10.1016/S0140-6736(99)00301-3
   Mur A, 2005, PEDIATR INFECT DIS J, V24, P742, DOI 10.1097/01.inf.0000172936.20623.fd
   Naccache JM, 1999, AM J RESP CRIT CARE, V159, P2009, DOI 10.1164/ajrccm.159.6.9807152
   Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001
   Naseri A, 2001, BRIT J OPHTHALMOL, V85, P1390
   Navas E, 2002, ARCH INTERN MED, V162, P97, DOI 10.1001/archinte.162.1.97
   Nguyen QD, 2000, AM J OPHTHALMOL, V129, P634, DOI 10.1016/S0002-9394(00)00356-1
   Nolan RC, 2003, CLIN INFECT DIS, V36, P1191, DOI 10.1086/374603
   Núñez M, 2005, DRUG SAFETY, V28, P53
   Núñez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002
   Nussenblatt RB, 1998, AM J OPHTHALMOL, V125, P374, DOI 10.1016/S0002-9394(99)80149-4
   OLANO JP, 1995, CLIN INFECT DIS, V21, P973, DOI 10.1093/clinids/21.4.973
   Orenstein JM, 1999, AIDS, V13, P2219, DOI 10.1097/00002030-199911120-00004
   PANEGYRES PK, 1990, J NEUROL NEUROSUR PS, V53, P649, DOI 10.1136/jnnp.53.8.649
   Panse I, 2000, BRIT J DERMATOL, V142, P496, DOI 10.1046/j.1365-2133.2000.03363.x
   PEZESHKPOUR G, 1991, HUM PATHOL, V22, P1281, DOI 10.1016/0046-8177(91)90112-3
   Phillips P, 1999, J ACQ IMMUN DEF SYND, V20, P122, DOI 10.1097/00042560-199902010-00003
   Piliero PJ, 2003, CLIN INFECT DIS, V36, PE111, DOI 10.1086/368311
   Proia LA, 2000, AM J MED, V108, P249, DOI 10.1016/S0002-9343(99)00437-4
   Pujol RM, 2000, J AM ACAD DERMATOL, V42, P193, DOI 10.1016/S0190-9622(00)90125-7
   Puoti M, 2003, JAIDS-J ACQ IMM DEF, V32, P259, DOI 10.1097/00126334-200303010-00004
   Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3
   Rademaker J, 1997, J RHEUMATOL, V24, P601
   Reeves JD, 2005, DRUGS, V65, P1747, DOI 10.2165/00003495-200565130-00002
   REICHERT CM, 1983, AM J PATHOL, V112, P357
   Ridolfo AL, 2000, J INFECTION, V40, P199, DOI 10.1053/jinf.1999.0630
   Roge BT, 2002, AIDS, V16, P973, DOI 10.1097/00002030-200205030-00003
   Rubio A, 2002, CLIN EXP IMMUNOL, V130, P121, DOI 10.1046/j.1365-2249.2002.01950.x
   Ruiz L, 1999, AIDS, V13, PF1, DOI 10.1097/00002030-199901140-00001
   Safdar A, 2002, CLIN INFECT DIS, V35, P1250, DOI 10.1086/344056
   Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002
   Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009
   Salama C, 2003, CLIN INFECT DIS, V37, PE35, DOI 10.1086/375895
   Schacker TW, 2002, J CLIN INVEST, V110, P1133, DOI 10.1172/JCI200216413
   Sellier P, 2000, AM J MED, V109, P510, DOI 10.1016/S0002-9343(00)00562-3
   SeminoMora C, 1997, LAB INVEST, V76, P487
   Shelburne SA, 2002, MEDICINE, V81, P213, DOI 10.1097/00005792-200205000-00005
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   SHOUBRIDGE EA, 1994, J BIOENERG BIOMEMBR, V26, P301, DOI 10.1007/BF00763101
   SORICE M, 1994, THROMB RES, V73, P165, DOI 10.1016/0049-3848(94)90095-7
   Spring M, 2001, VIROLOGY, V279, P221, DOI 10.1006/viro.2000.0720
   STAHL CP, 1993, BLOOD, V81, P1801
   Stone SF, 2001, J INFECT DIS, V184, P1073, DOI 10.1086/323599
   Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005
   Sutinen J, 2005, CURR OPIN INFECT DIS, V18, P25, DOI 10.1097/00001432-200502000-00005
   Tanji N, 2001, HUM PATHOL, V32, P734, DOI 10.1053/hupa.2001.25586
   Tantisiriwat W, 1999, CLIN INFECT DIS, V28, P1152, DOI 10.1086/514762
   Trevenzoli M, 2002, J INFECTION, V45, P173, DOI 10.1053/jinf.2002.1052
   Viraben R, 1998, AIDS, V12, PF37, DOI 10.1097/00002030-199806000-00001
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Woods ML, 1998, AIDS, V12, P1491, DOI 10.1097/00002030-199812000-00011
   YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
   Zietz C, 1999, NEW ENGL J MED, V340, P1923, DOI 10.1056/NEJM199906173402415
NR 160
TC 31
Z9 34
U1 1
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JUN 15
PY 2006
VL 13
IS 26
BP 3121
EP 3132
DI 10.2174/092986706778742891
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 090DR
UT WOS:000240931300002
PM 17168701
DA 2024-11-01
ER

PT J
AU Finch, CE
AF Finch, CE
TI A perspective on sporadic inclusion-body myositis - The role of aging and inflammatory processes
SO NEUROLOGY
LA English
DT Article
ID amyloid precursor protein; nonsteroidal antiinflammatory drugs; mitochondrial-dna deletions; gene-expression profile; human skeletal-muscle; alzheimers-disease; caloric restriction; in-vitro; transgenic mice; a-beta
AB Sporadic inclusion-body myositis (sIBM) is an age-related condition manifested after midlife. This review points out salient features of sIBM that are shared with normal aging in muscle and with inflammatory changes in vascular atheromas and senile plaques of Alzheimer disease (AD). The amyloid precursor protein (APP) and derived Abeta peptides are found in both AD and sIBM. Because transgenic expression of human APP induces sIBM like changes, it is of potential interest that an inducer of APP, IL-1, increases during aging in mouse muscle. Because various subsets of the usual aging changes in aging brain, muscle, and vessels can be attenuated in rodents by caloric intake and possibly in humans by drugs with anti-inflammatory and anticoagulant activities, this study suggests that diet and inflammation may be useful experimental variations in exploring the pathogenesis of sIBM.
C1 Univ So Calif, Dept Biol Sci, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA.
C3 University of Southern California
RP Univ So Calif, Dept Biol Sci, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock, Los Angeles, CA 90089 USA.
EM cefinch@usc.edu
FU NIA NIH HHS [AG13499] Funding Source: Medline
CR ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P
   AKAABOUNE M, 1994, J NEUROBIOL, V25, P503, DOI 10.1002/neu.480250505
   AKAABOUNE M, 1995, J CELL PHYSIOL, V165, P503, DOI 10.1002/jcp.1041650308
   Askanas V, 1998, AM J PATHOL, V153, P1673, DOI 10.1016/S0002-9440(10)65680-5
   Askanas V, 2003, CURR OPIN RHEUMATOL, V15, P737, DOI 10.1097/00002281-200311000-00009
   Askanas V, 2003, NEUROLOGY, V61, P257, DOI 10.1212/01.WNL.0000071219.85847.4E
   Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081
   Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257
   Barja G, 2004, BIOL REV, V79, P235, DOI 10.1017/S1464793103006213
   Boyd-Kimball D, 2004, J ALZHEIMERS DIS, V6, P515
   BRAAK H, 1991, ACTA NEUROPATHOL, V0, P82
   Breitner JCS, 2001, NEW ENGL J MED, V345, P1567, DOI 10.1056/NEJM200111223452110
   Bronikowski AM, 2003, PHYSIOL GENOMICS, V12, P129, DOI 10.1152/physiolgenomics.00082.2002
   Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1
   Buxbaum JN, 2006, NEUROLOGY, V66, PS110, DOI 10.1212/01.wnl.0000192311.78890.3e
   Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X
   Colton CA, 2005, NEUROBIOL AGING, V26, P363, DOI 10.1016/j.neurobiolaging.2004.08.001
   Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015
   DArmiento FP, 2001, STROKE, V32, P2472, DOI 10.1161/hs1101.098520
   Dalakas MC, 1998, ARCH NEUROL-CHICAGO, V55, P1509, DOI 10.1001/archneur.55.12.1509
   Dalakas MC, 2006, NEUROLOGY, V66, PS33, DOI 10.1212/01.wnl.0000192129.65677.87
   Dalakas MC, 2004, CURR OPIN NEUROL, V17, P561, DOI 10.1097/00019052-200410000-00006
   Davies KJA, 2006, NEUROLOGY, V66, PS93, DOI 10.1212/01.wnl.0000192308.43151.63
   Di Iorio A, 2003, CYTOKINE, V22, P198, DOI 10.1016/S1043-4666(03)00152-2
   Drabe N, 2001, EUR J CARDIO-THORAC, V20, P609, DOI 10.1016/S1010-7940(01)00842-9
   Engel WK, 2006, NEUROLOGY, V66, PS20, DOI 10.1212/01.wnl.0000192260.33106.bb
   Finch Caleb E, 2002, P275, V0, P0
   Finch CE, 2004, Q REV BIOL, V79, P3, DOI 10.1086/381662
   Finch CE, 2005, NEUROBIOL AGING, V26, P281, DOI 10.1016/j.neurobiolaging.2004.03.015
   Fournier JA, 2004, AM J CARDIOL, V94, P989, DOI 10.1016/j.amjcard.2004.06.051
   Fratta P, 2004, NEUROLOGY, V63, P1114, DOI 10.1212/01.WNL.0000138574.56908.5D
   Fukagawa NK, 1999, FREE RADICAL BIO MED, V27, P1437, DOI 10.1016/S0891-5849(99)00189-6
   Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9
   Georges JL, 2003, AM J CARDIOL, V92, P515, DOI 10.1016/S0002-9149(03)00717-3
   Glabe CG, 2006, NEUROLOGY, V66, PS74, DOI 10.1212/01.wnl.0000192103.24796.42
   Glidzic V, 1972, MED GLAS, V26, P248
   Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1
   GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611
   Hacham M, 2004, EUR CYTOKINE NETW, V15, P37
   Hacham M, 2002, EUR CYTOKINE NETW, V13, P55
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   Hoyer A, 2005, J NEURAL TRANSM, V112, P239, DOI 10.1007/s00702-004-0176-1
   Hu PF, 2004, J GERONTOL A-BIOL, V59, P849
   Huang YD, 2006, NEUROLOGY, V66, PS79, DOI 10.1212/01.wnl.0000192102.41141.9e
   Iijima K, 1998, BIOCHEM J, V330, P29, DOI 10.1042/bj3300029
   Jansson M, 2000, ACTA NEUROPATHOL, V100, P23, DOI 10.1007/s004010051188
   Jin LW, 1998, AM J PATHOL, V153, P1679, DOI 10.1016/S0002-9440(10)65681-7
   JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F
   Jozsi AC, 2000, MECH AGEING DEV, V120, P45, DOI 10.1016/S0047-6374(00)00178-0
   Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5
   Kopsidas G, 1998, MUTAT RES-FUND MOL M, V421, P27, DOI 10.1016/S0027-5107(98)00150-X
   Kopsidas G, 2002, BIOGERONTOLOGY, V3, P29, DOI 10.1023/A:1015290810222
   Kopsidas G, 2000, ANN NY ACAD SCI, V908, P226
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Lekander M, 2004, PSYCHOSOM MED, V66, P559, DOI 10.1097/01.psy.0000130491.95823.94
   Liang P, 1997, DIABETES, V46, P920, DOI 10.2337/diabetes.46.5.920
   Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007
   Maklashina E, 2004, AGING CELL, V3, P21, DOI 10.1111/j.1474-9728.2003.00078.x
   McGeer PL, 1997, BRAIN RES, V749, P135, DOI 10.1016/S0006-8993(96)01324-8
   Molnar M, 1998, ACTA NEUROPATHOL, V96, P41, DOI 10.1007/s004010050858
   Moreira PI, 2006, NEUROLOGY, V66, PS97, DOI 10.1212/01.wnl.0000192307.15103.83
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Murphy MP, 2006, NEUROLOGY, V66, PS65, DOI 10.1212/01.wnl.0000192108.02654.ac
   Musa A, 2001, DEV GENES EVOL, V211, P563, DOI 10.1007/s00427-001-0189-9
   Napoli C, 2005, NEUROBIOL AGING, V26, P293, DOI 10.1016/j.neurobiolaging.2004.02.031
   OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P
   Oldfors A, 2006, NEUROLOGY, V66, PS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Oyama F, 1998, J NEUROCHEM, V71, P313
   Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967
   Panegyres PK, 2001, REV NEUROSCIENCE, V12, P1
   Patel NV, 2002, NEUROBIOL AGING, V23, P707, DOI 10.1016/S0197-4580(02)00017-9
   Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
   Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100
   Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7
   Small GW, 2002, J MOL NEUROSCI, V19, P17, DOI 10.1007/s12031-002-0005-7
   Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, PE38, DOI 10.1152/ajpendo.00387.2001
   Steinman L, 2006, NEUROLOGY, V66, PS56, DOI 10.1212/01.wnl.0000192110.22621.09
   Suzuki S, 1999, DIABETES RES CLIN PR, V45, P161, DOI 10.1016/S0168-8227(99)00046-7
   Szekely CA, 2004, NEUROEPIDEMIOLOGY, V23, P159, DOI 10.1159/000078501
   Tsuzuki K, 1997, INT J EXP PATHOL, V78, P1, DOI 10.1046/j.1365-2613.1997.9950333.x
   van Leeuwen FW, 2006, NEUROLOGY, V66, PS86, DOI 10.1212/01.wnl.0000193882.46003.6d
   van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242
   Vetrivel KS, 2006, NEUROLOGY, V66, PS69, DOI 10.1212/01.wnl.0000192107.17175.39
   Weaver JD, 2002, NEUROLOGY, V59, P371, DOI 10.1212/WNL.59.3.371
   Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x
   Xie Z, 2003, EXP NEUROL, V182, P135, DOI 10.1016/S0014-4886(03)00057-8
   Yao J, 2004, J NEUROCHEM, V90, P1011, DOI 10.1111/j.1471-4159.2004.02532.x
   Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3
   Zanjani H, 2005, ALZ DIS ASSOC DIS, V19, P55, DOI 10.1097/01.wad.0000165506.60370.94
NR 89
TC 13
Z9 17
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JAN 15
PY 2006
VL 66
IS 
BP S1
EP S6
DI 10.1212/01.wnl.0000192259.34541.e4
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 005RX
UT WOS:000234842600002
PM 16432135
DA 2024-11-01
ER

PT J
AU Hudson, G
   Deschauer, M
   Taylor, RW
   Hanna, MG
   Fialho, D
   Schaefer, AM
   He, LP
   Blakely, E
   Turnbull, DM
   Chinnery, PF
AF Hudson, G
   Deschauer, M
   Taylor, RW
   Hanna, MG
   Fialho, D
   Schaefer, AM
   He, LP
   Blakely, E
   Turnbull, DM
   Chinnery, PF
TI <i>POLG1</i>, <i>C10ORF2</i>, and <i>ANT1</i> mutations are uncommon in sporadic progressive external ophthalmoplegia with multiple mitochondrial DNA deletions
SO NEUROLOGY
LA English
DT Article
ID disorders
AB The authors sequenced POLG1, C10ORF2, and ANT1 in 38 sporadic progressive external ophthalmoplegia patients with multiple mitochondrial DNA (mtDNA) deletions. Causative mutations were identified in approximately 10% of cases, with two unrelated individuals harboring a novel premature stop codon mutation (1356T > G). None had a mutation in C10ORF2 or ANT1. In the majority of patients, the primary nuclear genetic defect is likely to affect other unknown genes important for mtDNA maintenance.
C1 Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Halle Wittenberg, Dept Neurol, Halle, Saale, Germany.
   UCL, Inst Neurol, Dept Mol Neurosci, London, England.
C3 Newcastle University - UK; Newcastle University - UK; Martin Luther University Halle Wittenberg; University of London; University College London
RP Newcastle Univ, Sch Med, Mitochondrial Res Grp, Neurol M4104,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
NR 10
TC 20
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 9
PY 2006
VL 66
IS 9
BP 1439
EP 1441
DI 10.1212/01.wnl.0000210486.32196.24
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 040FS
UT WOS:000237365000030
PM 16682683
DA 2024-11-01
ER

PT J
AU Swalwell, H
   Deschauer, M
   Hartl, H
   Strauss, M
   Turnbull, DM
   Zierz, S
   Taylor, RW
AF Swalwell, H
   Deschauer, M
   Hartl, H
   Strauss, M
   Turnbull, DM
   Zierz, S
   Taylor, RW
TI Pure myopathy associated with a novel mitochondrial tRNA gene mutation
SO NEUROLOGY
LA English
DT Article
ID disease; dna; diagnosis
AB The authors describe a 47-year-old man who presented with proximal muscle weakness, myalgia, elevated creatine kinase, and features of a pure myopathic syndrome in whom they have identified a novel mutation in the mitochondrial tRNAAla gene. This 5591G > A transition is heteroplasmic, segregates with cytochrome c oxidase deficiency in single muscle fibers, and fulfills recognized criteria for pathogenicity. This case exemplifies the wide-ranging clinical spectrum of mitochondrial disease presentations.
C1 Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochodrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Halle Wittenberg, Dept Neurol, Halle, Germany.
C3 Newcastle University - UK; Martin Luther University Halle Wittenberg
RP Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochodrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Laval SH, 2004, NEUROPATH APPL NEURO, V30, P91, DOI 10.1111/j.1365-2990.2004.00555.x
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
NR 10
TC 22
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 14
PY 2006
VL 66
IS 3
BP 447
EP 449
DI 10.1212/01.wnl.0000196490.36349.83
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 012ON
UT WOS:000235348600035
PM 16476954
DA 2024-11-01
ER

PT J
AU Stopinska, K
   Grzybowski, T
   Malyarchuk, BA
   Derenko, MV
   Miscicka-Sliwka, D
AF Stopinska, Katarzyna
   Grzybowski, Tomasz
   Malyarchuk, Boris A.
   Derenko, Miroslava V.
   Miscicka-Sliwka, Danuta
TI Optimization of the Y831C mutation detection in human DNA polymerase gamma by allelic discrimination assay
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE single nucleotide polymorphisms (SNPs); polymerase gamma; progressive external ophthalmoplegia; real-time PCR
ID progressive external ophthalmoplegia; single-nucleotide polymorphisms; mitochondrial-dna; male-infertility; polg mutations; parkinsonism; neuropathy; disorders; disease; genes
AB Many well-defined mutations in the gene for the catalytic subunit of polymerase gamma (POLG1) have been found to be associated with disease, whereas the status of several mutations remains unresolved due to the conflicting reports on their frequencies in populations of healthy individuals. Here, we have developed a highly sensitive, real-time allelic discrimination assay enabling detection of the Y831C mutation in the POLG1 gene. The Y831C mutation is present in the Polish population at a frequency of 2.25%. The new assay is well suited to both extensive population studies and molecular diagnostics of POLG1.
C1 Nicholas Copernicus Univ, Ludwik Rydygiers Coll Med, Chair Forens Med, Dept Mol & Forens Genet, Bydgoszcz, Poland.
   Russian Acad Sci, Inst Biol Problems N, Far E Branch, Magadan, Russia.
C3 Nicolaus Copernicus University; Russian Academy of Sciences; Institute of Biological Problems of the North
RP Grzybowski, T (corresponding author), Nicholas Copernicus Univ, Ludwik Rydygiers Coll Med, Chair Forens Med, Dept Mol & Forens Genet, Bydgoszcz, Poland.
EM tgrzyb@cm.umk.pl
CR Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bandelt HJ, 2005, SCHIZOPHR RES, V72, P267, DOI 10.1016/j.schres.2004.05.003
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Finnilä S, 1999, MUTAT RES-GENOMICS, V406, P109, DOI 10.1016/S1383-5726(99)00007-2
   Fornage M, 2005, METH MOLEC MED, V108, P159
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Johnson VJ, 2004, CYTOKINE, V27, P135, DOI 10.1016/j.cyto.2004.05.002
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Malyarchuk BA, 2002, ANN HUM GENET, V66, P261, DOI 10.1017/S0003480002001161
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Martin ER, 2000, AM J HUM GENET, V67, P383, DOI 10.1086/303003
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 24
TC 10
Z9 10
U1 0
U2 1
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02-093 WARSAW, POLAND
SN 0001-527X
EI 1734-154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PD JUN 15
PY 2006
VL 53
IS 3
BP 591
EP 595
DI 
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 090EB
UT WOS:000240932300019
PM 16929381
DA 2024-11-01
ER

PT J
AU Deschauer, M
   Swalwell, H
   Strauss, M
   Zierz, S
   Taylor, RW
AF Deschauer, Marcus
   Swalwell, Helen
   Strauss, Maria
   Zierz, Stephan
   Taylor, Robert W.
TI Novel mitochondrial transfer RNA<SUP>Phe</SUP> gene mutation associated with late-onset neuromuscular disease
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID dna mutations; muscle; mtdna; deletion; single
AB Background: An extensive range of molecular defects have been identified in the human mitochondrial genome (mitochondrial DNA); many are associated with well-characterized, progressive neurological syndromes, but a minority of patients have uncharacteristic phenotypes in which symptoms may be relatively mild. Objective: To describe a novel transfer RNA(Phe) mutation of mitochondrial DNA in a late-onset case with a mild phenotype of mitochondrial disease. Design: Case report. Patient: A 66-year-old woman presented with a 4-year history of walking difficulties due to exercise intolerance and paresthesia in the feet. Clinical examination results were normal. Her deceased mother had similar walking difficulties, but her sister and 2 children were unaffected. Results: The demonstration of a marked histochemical defect in cytochrome c oxidase activity on muscle biopsy prompted molecular investigation of mitochondrial DNA, revealing a novel maternally inherited mutation in the variable loop of the mitochondrial transfer RNA(Phe) gene. This 622G > A transition was heteroplasmic and segregated with cytochrome c oxidase deficiency in single fibers. Conclusion: This case serves to illustrate that primary defects of the mitochondrial genome should be considered even in older patients with late-onset, mild neuromuscular symptoms.
C1 Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Halle Wittenberg, Dept Neurol, Halle, Germany.
C3 Newcastle University - UK; Martin Luther University Halle Wittenberg
RP Taylor, RW (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Deschauer M, 2004, GENET TEST, V8, P395, DOI 10.1089/gte.2004.8.395
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, Part. no., DOI 10.1093/nar/29.15.e74
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 13
TC 24
Z9 26
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JUN 15
PY 2006
VL 63
IS 6
BP 902
EP 905
DI 10.1001/archneur.63.6.902
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 051YM
UT WOS:000238197600017
PM 16769874
DA 2024-11-01
ER

PT J
AU Oldfors, A
   Moslemi, AR
   Jonasson, L
   Ohlsson, M
   Kollberg, G
   Lindberg, C
AF Oldfors, A
   Moslemi, AR
   Jonasson, L
   Ohlsson, M
   Kollberg, G
   Lindberg, C
TI Mitochondrial abnormalities in inclusion-body myositis
SO NEUROLOGY
LA English
DT Article
ID progressive external ophthalmoplegia; negative muscle-fibers; human mtdna deletions; dna deletions; inflammatory myopathy; skeletal-muscle; resonance-spectroscopy; mutations; encephalomyopathy; apoptosis
AB Mitochondrial changes are frequently encountered in sporadic inclusion-body myositis (s-IBM). Cytochrome c oxidase (COX)-deficient muscle fibers and large-scale mitochondrial DNA ( mtDNA) deletions are more frequent in s-IBM than in age-matched controls. COX deficient muscle fibers are due to clonal expansion of mtDNA deletions and point mutations in segments of muscle fibers. Such segments range from 75 mu m to more than 1,000 mu m in length. Clonal expansion of the 4977 bp "common deletion" is a frequent cause of COX deficient muscle fiber segments, but many other deletions also occur. The deletion breakpoints cluster in a few regions that are similar to what is found in human mtDNA deletions in general. Analysis in s-IBM patients of three nuclear genes associated with multiple mtDNA deletions, POLG1, ANT1 and C10orf2, failed to demonstrate any mutations. In s-IBM patients with high number of COX-deficient fibers, the impaired mitochondrial function probably contribute to muscle weakness and wasting. Treatment that has positive effects in mitochondrial myopathies may be tried also in s-IBM.
C1 Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Oldfors, A (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
EM anders.oldfors@pathology.gu.se
CR Aiken J, 2002, ANN NY ACAD SCI, V959, P412, DOI 10.1111/j.1749-6632.2002.tb02111.x
   Argov Z, 1998, MUSCLE NERVE, V21, P1523, DOI 10.1002/(SICI)1097-4598(199811)21:11<1523::AID-MUS22>3.0.CO;2-#
   Arnardottir S, 2003, J REHABIL MED, V35, P31, DOI 10.1080/16501970306110
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408
   BAUMER A, 1994, AM J HUM GENET, V54, P618
   Behrens L, 1997, BRAIN, V120, P929, DOI 10.1093/brain/120.6.929
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   Blume G, 1997, BRAIN, V120, P39, DOI 10.1093/brain/120.1.39
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   CARPENTER S, 1978, NEUROLOGY, V28, P8, DOI 10.1212/WNL.28.1.8
   Carpenter S, 1975, RECENT ADV MYOLOGY, V0, P374
   Carrozzo R, 2004, J NEUROCHEM, V90, P490, DOI 10.1111/j.1471-4159.2004.02505.x
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Dahlbom K, 2002, NEUROMUSCULAR DISORD, V12, P853, DOI 10.1016/S0960-8966(02)00098-6
   DESNUELLE C, 1998, INCLUSION BODY MYOSI, V0, P318
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Fyhr IM, 2002, ACTA NEUROL SCAND, V105, P403, DOI 10.1034/j.1600-0404.2002.01198.x
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   Levine TD, 1998, MUSCLE NERVE, V21, P1724, DOI 10.1002/(SICI)1097-4598(199812)21:12<1724::AID-MUS15>3.0.CO;2-2
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Lodi R, 1998, BRAIN, V121, P2119, DOI 10.1093/brain/121.11.2119
   Molnar M, 1998, ACTA NEUROPATHOL, V96, P41, DOI 10.1007/s004010050858
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   OLDFORS A, 1998, INCLUSION BODY MYOSI, V0, P306
   Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   SARKOZI E, 1993, NEUROREPORT, V4, P815, DOI 10.1097/00001756-199306000-00055
   Schon EA, 2003, CURR MED CHEM, V10, P2523, DOI 10.2174/0929867033456503
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vattemi G, 2000, J NEUROIMMUNOL, V111, P146, DOI 10.1016/S0165-5728(00)00381-7
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Yamanaka T, 2001, NUCL PHYS B-PROC SUP, V99B, P104, DOI 10.1016/S0920-5632(01)01368-8
   YUNIS EJ, 1971, LAB INVEST, V25, P240
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
NR 63
TC 88
Z9 98
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA
SN 0028-3878
EI 
J9 NEUROLOGY
JI Neurology
PD JAN 15
PY 2006
VL 66
IS 
BP S49
EP S55
DI 10.1212/01.wnl.0000192127.63013.8d
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 005RX
UT WOS:000234842600008
PM 16432145
DA 2024-11-01
ER

PT J
AU Zheng, WM
   Khrapko, K
   Coller, HA
   Thilly, WG
   Copeland, WC
AF Zheng, Weiming
   Khrapko, Konstantin
   Coller, Hilary A.
   Thilly, William G.
   Copeland, William C.
TI Origins of human mitochondrial point mutations as DNA polymerase γ-mediated errors
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE mitochondrial DNA; mutagenesis; DNA polymerase gamma
ID progressive external ophthalmoplegia; human-cells; polg mutations; stem-cells; human mtdna; replication; selection; fidelity; spectrum; gene
AB Mitochondrial mutational spectra in human cells, tissues and derived tumors for bp 10,030-10,130 are essentially identical, suggesting a predominant mutagenic role for endogenous processes. We hypothesized that errors mediated by mitochondrial DNA polymerase gamma were the primary sources of mutations. Point mutations created in this sequence by human DNA pol gamma in vitro were thus compared to the eighteen mutational hotspots, all single base substitutions, previously found in human tissues. The set of concordant hotspots accounted for 83% of these in vivo mutational events. About half of these mutations are insensitive to prolonged heating of DNA during PCR and half increase proportionally with heating time at 98 degrees C. Primary misincorporation errors and miscopying errors past thermal denaturing products such as dearninated cytosines (uracils) thus appear to be of approximately equal importance. For the sequence studied, these data support the conclusion that, endogenous error mediated by DNA pol gamma constitutes the primary source of mitochondrial point mutations in human tissues. Published by Elsevier B.V.
C1 Natl Inst Environm Hlth Sci, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
   MIT, Biol Engn Div, Cambridge, MA 02139 USA.
   Beth Israel Deaconess Med Ctr, Gerontol Div, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98119 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center
RP Copeland, WC (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, 111 TW Alexander Dr,Bldg 101,Rm E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
FU Intramural NIH HHS Funding Source: Medline; NIEHS NIH HHS [5P30ES02109, P01-ES07168] Funding Source: Medline
CR Andre P, 1997, GENOME RES, V7, P843, DOI 10.1101/gr.7.8.843
   Baluska F, 2004, ANN BOT-LONDON, V94, P9, DOI 10.1093/aob/mch109
   Bohr VA, 2002, J INHERIT METAB DIS, V25, P215, DOI 10.1023/A:1015681929316
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Coller HA, 2005, MUTAT RES-FUND MOL M, V578, P256, DOI 10.1016/j.mrfmmm.2005.05.014
   Coller HA, 1998, CANCER RES, V58, P1268
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Fuku N, 2002, BIOCHEM BIOPH RES CO, V290, P1199, DOI 10.1006/bbrc.2002.6330
   Gostjeva EV, 2006, CANCER GENET CYTOGEN, V164, P16, DOI 10.1016/j.cancergencyto.2005.05.005
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Khrapko K, 1997, NUCLEIC ACIDS RES, V25, P685, DOI 10.1093/nar/25.4.685
   Loewenstein W R, 1992, SEMIN CELL BIOL, V3, P59
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Marcelino LA, 1998, CANCER RES, V58, P2857
   Marcelino LA, 1999, MUTAT RES-DNA REPAIR, V434, P177, DOI 10.1016/S0921-8777(99)00028-2
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Mott JL, 2004, BIOCHEM BIOPH RES CO, V319, P1210, DOI 10.1016/j.bbrc.2004.05.104
   Muniappan BP, 2002, CANCER RES, V62, P3271
   Naviaux RK, 2004, MITOCHONDRION, V4, P351, DOI 10.1016/j.mito.2004.07.002
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642
   Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Starikovskaya EB, 2005, ANN HUM GENET, V69, P67, DOI 10.1046/j.1529-8817.2003.00127.x
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Thilly WG, 2003, NAT GENET, V34, P255, DOI 10.1038/ng1205
   Tomita-Mitchell A, 2003, CANCER RES, V63, P5793
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Zhang D, 2003, CARDIOVASC RES, V57, P147, DOI 10.1016/S0008-6363(02)00695-8
NR 50
TC 100
Z9 177
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0027-5107
EI 
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD JUL 25
PY 2006
VL 599
IS 1-2
BP 11
EP 20
DI 10.1016/j.mrfmmm.2005.12.012
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 071BH
UT WOS:000239571400002
PM 16490220
DA 2024-11-01
ER

PT J
AU Fattal, O
   Budur, K
   Vaughan, AJ
   Franco, K
AF Fattal, O
   Budur, K
   Vaughan, AJ
   Franco, K
TI Review of the literature on major mental disorders in adult patients with mitochondrial diseases
SO PSYCHOSOMATICS
LA English
DT Review
ID psychiatric-symptoms; depressive disorder; bipolar disorder; diabetes-mellitus; schizophrenia; dysfunction; mutation; melas; dna; encephalomyopathy
AB Mitochondria are intracellular organelles crucial to the production cellular energy. Mitochondrial disease results from a malfunction in this biochemical cascade. These disorders can affect any organ system, producing diverse signs and symptoms, including psychiatric ones. Several authors argue that mitochondrial dysfunction is related to the pathophysiology of bipolar disorder and schizophrenia. Also, the authors retrieved 19 case reports that describe patients with mitochondrial diseases and psychiatric disorders. Most of these patients have psychiatric presentations that preceded the diagnosis of mitochondrial disease. The most common physical findings are fatigue, muscle weakness with or without atrophy, and hearing loss.
C1 Cleveland Clin Fdn, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP P57,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM FrancoK@ccf.org
CR Amemiya S, 2000, NEUROLOGY, V55, P600, DOI 10.1212/WNL.55.4.600
   Ben-Shachar D, 2002, J NEUROCHEM, V83, P1241, DOI 10.1046/j.1471-4159.2002.01263.x
   Ben-Shachar D, 2004, INT REV NEUROBIOL, V59, P273
   CAVELIER L, 1995, GENOMICS, V29, P217, DOI 10.1006/geno.1995.1234
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DiMauro S, 2000, NEUROL SCI, V21, P0
   Gardner A, 2003, J AFFECT DISORDERS, V76, P55, DOI 10.1016/S0165-0327(02)00067-8
   Gardner A, 2003, ACTA PSYCHIAT SCAND, V107, P233, DOI 10.1034/j.1600-0447.2003.02188.x
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   Inagaki T, 1997, BIOL PSYCHIAT, V42, P1067, DOI 10.1016/S0006-3223(97)00351-X
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Johns DR, 1996, NAT MED, V2, P1065, DOI 10.1038/nm1096-1065
   Kato T, 1996, J AFFECT DISORDERS, V37, P67, DOI 10.1016/0165-0327(95)00050-X
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x
   Kiejna Andrzej, 2002, MED SCI MONIT, V8, P0
   King L, 1999, SYNAPSE, V31, P67, DOI 10.1002/(SICI)1098-2396(199901)31:1<67::AID-SYN9>3.0.CO;2-#
   Köller H, 2003, J NEUROL, V250, P1501, DOI 10.1007/s00415-003-0260-8
   Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300
   Lindholm E, 1997, EUR J HUM GENET, V5, P406, DOI 10.1159/000484799
   Mahoney DJ, 2002, CURR OPIN CLIN NUTR, V5, P619, DOI 10.1097/00075197-200211000-00004
   Maurer I, 2001, SCHIZOPHR RES, V48, P125, DOI 10.1016/S0920-9964(00)00075-X
   Miyaoka H, 1997, BIOL PSYCHIAT, V42, P524, DOI 10.1016/S0006-3223(97)00280-1
   MULCRONE J, 1995, SCHIZOPHR RES, V14, P203, DOI 10.1016/0920-9964(94)00040-F
   Odawara M, 1997, DIABETIC MED, V14, P503, DOI 10.1002/(SICI)1096-9136(199706)14:6<503::AID-DIA394>3.0.CO;2-1
   ODAWARA M, 2002, NUCL ACIDS RES S, V2, P253
   Onishi H, 1997, BIOL PSYCHIAT, V41, P1137, DOI 10.1016/S0006-3223(97)00005-X
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Prince JA, 2000, NEUROPSYCHOPHARMACOL, V22, P284, DOI 10.1016/S0893-133X(99)00111-6
   SAIJO T, 1991, NEUROPEDIATRICS, V22, P166, DOI 10.1055/s-2008-1071436
   Shanske AL, 2001, ARCH PEDIAT ADOL MED, V155, P1210
   Shinkai T, 2000, AUST NZ J PSYCHIAT, V34, P1034, DOI 10.1080/000486700286
   Spellberg B, 2001, ARCH INTERN MED, V161, P2497, DOI 10.1001/archinte.161.20.2497
   STEWART J B, 1990, MEDICAL SCIENCE RESEARCH, V18, P265
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUZUKI T, 1990, NEURORADIOLOGY, V32, P74, DOI 10.1007/BF00593949
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   Whatley SA, 1996, NEUROCHEM RES, V21, P995, DOI 10.1007/BF02532409
NR 38
TC 159
Z9 181
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0033-3182
EI 
J9 PSYCHOSOMATICS
JI Psychosomatics
PD FEB 15
PY 2006
VL 47
IS 1
BP 1
EP 7
DI 10.1176/appi.psy.47.1.1
PG 7
WC Psychiatry; Psychology
SC Psychiatry; Psychology
GA 997TD
UT WOS:000234270000001
PM 16384802
DA 2024-11-01
ER

PT J
AU Horvath, R
   Hudson, G
   Ferrari, G
   Fütterer, N
   Ahola, S
   Lamantea, E
   Prokisch, H
   Lochmüller, H
   McFarland, R
   Ramesh, V
   Klopstock, T
   Freisinger, P
   Salvi, F
   Mayr, JA
   Santer, R
   Tesarova, M
   Zeman, J
   Udd, B
   Taylor, RW
   Turnbull, D
   Hanna, M
   Fialho, D
   Suomalainen, A
   Zeviani, M
   Chinnery, PF
AF Horvath, Rita
   Hudson, Gavin
   Ferrari, Gianfrancesco
   Fuetterer, Nancy
   Ahola, Sofia
   Lamantea, Eleonora
   Prokisch, Holger
   Lochmueller, Hanns
   McFarland, Robert
   Ramesh, V.
   Klopstock, Thomas
   Freisinger, Peter
   Salvi, Fabrizio
   Mayr, Johannes A.
   Santer, Rene
   Tesarova, Marketa
   Zeman, Jiri
   Udd, Bjarne
   Taylor, Robert W.
   Turnbull, Douglass
   Hanna, Michael
   Fialho, Doreen
   Suomalainen, Anu
   Zeviani, Massimo
   Chinnery, Patrick F.
TI Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene
SO BRAIN
LA English
DT Article
DE mitochondrial encephalopathy; mitochondrial DNA; polymerase gamma; mtDNA; chronic progressive external ophthalmoplegia; Alpers syndrome
ID progressive external ophthalmoplegia; polg mutations; dna-polymerase; alpers-syndrome; ataxic neuropathy; deletions; expression; patient; family; muscle
AB Mutations in the gene coding for the catalytic subunit of the mitochondrial DNA (mtDNA) polymerase gamma (POLG1) have recently been described in patients with diverse clinical presentations, revealing a complex relationship between genotype and phenotype in patients and their families. POLG1 was sequenced in patients from different European diagnostic and research centres to define the phenotypic spectrum and advance understanding of the recurrence risks. Mutations were identified in 38 cases, with the majority being sporadic compound heterozygotes. Eighty-nine DNA sequence changes were identified, including 2 predicted to alter a splice site, 1 predicted to cause a premature stop codon and 13 predicted to cause novel amino acid substitutions. The majority of children had a mutation in the linker region, often 1399G -> A (A467T), and a mutation affecting the polymerase domain. Others had mutations throughout the gene, and 11 had 3 or more substitutions. The clinical presentation ranged from the neonatal period to late adult life, with an overlapping phenotypic spectrum from severe encephalopathy and liver failure to late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy. There was a strong gender bias in children, with evidence of an environmental interaction with sodium valproate. POLG1 mutations cause an overlapping clinical spectrum of disease with both dominant and recessive modes of inheritance. 1399G -> A (A467T) is common in children, but complete POLG1 sequencing is required to identify multiple mutations that can have complex implications for genetic counselling.
C1 Acad Hosp Schwabing, Inst Clin CHem Mol Diagnost & Mitochondrial Genet, Metab Dis Ctr, Munich, Germany.
   Childrens Hosp, Matab Dis Ctr, Munich, Germany.
   Tech Univ Munich, Inst Med Genet, D-8000 Munich, Germany.
   Univ Munich, Friedrich Baur Inst, Munich, Germany.
   Univ Munich, Dept Neurol, Munich, Germany.
   GSF, Res Ctr Environm & Hlth, Inst Human Genet, Neuherberg, Germany.
   Univ Hamburg, Med Ctr Eppendorf, Dept Pediat, Hamburg, Germany.
   Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Newcastle Gen Hosp, Dept Paediat Neurol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   UCL, Inst Neurol, Dept Mol Neurosci, London, England.
   Natl Neurol Inst, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Milan, Italy.
   Osped Bellaria, Dept Neurosci, Neurol Unit, Bologna, Italy.
   Univ Helsinki, Dept Med Genet, Programme Neurosci, FIN-00014 Helsinki, Finland.
   Vaasa Cent Hosp, Dept Neurol, Vaasa, Finland.
   Paracelsus Med Univ, Pediat Clin, Salzburg, Austria.
   Charles Univ Prague, Fac Med, Dept Pediat, Prague, Czech Republic.
   Charles Univ Prague, Fac Med, Ctr Appl Genom, Prague, Czech Republic.
C3 University of Munich; Technical University of Munich; University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Hamburg; Newcastle University - UK; Newcastle University - UK; Newcastle General Hospital; University of London; University College London; Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Helsinki; Vaasa Central Hospital; Paracelsus Private Medical University; Charles University Prague; Charles University Prague
RP Chinnery, PF (corresponding author), Sch Med, M4014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
FU Medical Research Council [G108/539] Funding Source: Medline; Telethon [GGP030039] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G108/539] Funding Source: UKRI
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   [Anonymous], 2002, STATISTICAL METHODS IN MEDICAL RESEARCH, V0, P0
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, P0, DOI 10.1002/humu.9203
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   He LP, 2002, NUCLEIC ACIDS RES, V30, P0, DOI 10.1093/nar/gnf067
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 31
TC 308
Z9 320
U1 0
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 
J9 BRAIN
JI Brain
PD JUL 15
PY 2006
VL 129
IS 
BP 1674
EP 1684
DI 10.1093/brain/awl088
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 059VV
UT WOS:000238761200011
PM 16621917
DA 2024-11-01
ER

PT J
AU Bhattacharjee, M
   Venugopal, B
   Wong, KT
   Goto, YI
   Bhattacharjee, MB
AF Bhattacharjee, M.
   Venugopal, B.
   Wong, K. T.
   Goto, Y. -I.
   Bhattacharjee, M. B.
TI Mitochondrial disorder, diabetes mellitus, and findings in three muscles, including the heart
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE diabetes mellitus; glycogen; mitochondria; myopathy; opthalmoplegia
ID kearns-sayre syndrome; gene-expression; ophthalmoplegia; dysfunction; cardiomyopathy; absence; cells; block; mtdna
AB The authors describe the case of a 50-year-old man with chronic progressive external ophthalmoplegia ( CPEO), diabetes mellitus (DM), and coronary artery disease. The patient had no cardiac conduction abnormalities. During coronary artery bypass surgery, his heart and two skeletal muscles were biopsied. All three muscles showed ragged red fibers. The heart muscle showed significant glycogen accumulation. Analysis of mitochondrial DNA ( mtDNA) showed a 5019-base-pair deletion, with no duplications. There were morphologically abnormal mitochondria in all 3 muscles, with clinically apparent difference in preservation of function. The combination of diabetes mellitus and mtDNA deletion is fortuitous, as they can be causally linked. The cardiac pathology allows speculation about the possible adaptive processes that may occur in the heart in DM. There are few reported cases with CPEO and excess glycogen in the heart. Most show deposition of fat and poorer clinical outcomes as compared to those with glycogen deposition. This observation may lend support to the hypothesis that in the myocardium, adaptive responses are mediated via changes in glucose handling, whereas alterations in fat metabolism likely represent maladaptation.
C1 Natl Heart Inst, Kuala Lumpur, Malaysia.
   Univ Texas, Hlth Sci Ctr Houston, Sch Med, Houston, TX USA.
   Univ Malaya, Dept Pathol, Kuala Lumpur, Malaysia.
   Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, NCNP, Tokyo, Japan.
   Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
C3 Institute Jantung Negara; University of Texas System; University of Texas Health Science Center Houston; Universiti Malaya; National Center for Neurology & Psychiatry - Japan; Baylor College of Medicine
RP Bhattacharjee, M (corresponding author), Univ Texas, Sch Med, Hlth Sci Ctr Houston, Dept Internal Med,Lynda B Johnson Hosp, 4-PO 30 012A-H 5656 Kelly, Houston, TX 77026 USA.
EM Modushudan.Bhattacharjee@uth.tmc.edu
CR BIELAWASKA AE, 1997, AM J PATHOL, V46, P169
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   CHARLES R, 1981, CIRCULATION, V63, P214, DOI 10.1161/01.CIR.63.1.214
   Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947
   Depre C, 2000, J MOL CELL CARDIOL, V32, P985, DOI 10.1006/jmcc.2000.1139
   DiMauro S, 1998, CURR OPIN CARDIOL, V13, P190
   Enríquez JA, 1999, BIOL CHEM, V380, P737, DOI 10.1515/BC.1999.094
   GALLASTEGUI J, 1987, AM J CARDIOL, V60, P385, DOI 10.1016/0002-9149(87)90255-4
   Hofhaus G, 1999, BIOL CHEM, V380, P871, DOI 10.1515/BC.1999.107
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   JAGER BV, 1960, AM J MED, V29, P888, DOI 10.1016/0002-9343(60)90122-4
   KEARNS THOMAS P, 1965, TRANS AMER OPHTHALMOL SOC, V63, P559
   MCCOMISH M, 1976, BRIT HEART J, V38, P526
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Ponticos M, 1998, EMBO J, V17, P1688, DOI 10.1093/emboj/17.6.1688
   Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6
   Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Young ME, 2002, CIRCULATION, V105, P1861, DOI 10.1161/01.CIR.0000012467.61045.87
NR 20
TC 7
Z9 7
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD NOV-DEC 15
PY 2006
VL 30
IS 6
BP 481
EP 487
DI 10.1080/01913120600689624
PG 7
WC Microscopy; Pathology
SC Microscopy; Pathology
GA 119BB
UT WOS:000242986100011
PM 17183762
DA 2024-11-01
ER

PT J
AU Frederiksen, AL
   Andersen, PH
   Kyvik, KO
   Jeppesen, TD
   Vissing, J
   Schwartz, M
AF Frederiksen, A. L.
   Andersen, P. H.
   Kyvik, K. O.
   Jeppesen, T. D.
   Vissing, J.
   Schwartz, M.
TI Tissue specific distribution of the 3243A→G mtDNA mutation
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID mitochondrial-dna mutations; a3243g mutation; human oocytes; prenatal-diagnosis; genetic bottleneck; mutant mtdna; heteroplasmy; segregation; disease; trna(leu(uur))
AB Background: The 3243A -> RG is a common pathogenic mitochondrial DNA (mtDNA) point mutation causing a variety of different phenotypes. Segregation of this mutation to different tissues during embryonic life and postnatally is still enigmatic. Objective: To investigate the tissue distribution of this mutation. Methods: In 65 individuals from nine families segregating the 3243A -> G mutation, the mutation load (% mutated mtDNA) was determined in various tissues. Mutation load was measured in two to four cell types-blood leucocytes, buccal cells, skeletal muscle cells, and urine epithelial cells (UEC)-derived from all three embryogenic germ layers. Results: There was a significant correlation among mutation loads in the four tissues (r = 0.80-0.89, p < 0.0001). With blood serving as reference, the mutation load was increased by 16% in buccal mucosa, by 31% in UEC, and by 37% in muscle. There were significant differences between the mitotic tissues blood, buccal mucosa, and UEC (p < 0.0001), but no difference between UEC and muscle. Using the present data as a cross sectional investigation, a negative correlation of age with the mutation load was found in blood, while the mutation load in muscle did not change with time; 75% of the children presented with higher mutation loads than their mothers in mitotic tissues but not in the post-mitotic muscle. Conclusions: There appears to be a uniform distribution of mutant mtDNA throughout the three germ layers in embryogenesis. The significant differences between mutation loads of the individual tissue types indicate tissue specific segregation of the 3243A -> G mtDNA later in embryogenesis.
C1 Ribe Cty Hosp, Dept Endocrinol, Esbjerg, Denmark.
   Univ So Denmark, Inst Publ Hlth, Odense, Denmark.
   Univ Copenhagen, Rigshosp, Neuromust Res Unit, Dept Neurol, DK-1123 Copenhagen, Denmark.
   Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-1123 Copenhagen, Denmark.
   Univ Hosp, Rigshosp, Dept Clin Genet, Copenhagen, Denmark.
C3 University of Southern Denmark; University of Copenhagen; Rigshospitalet; Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet
RP Schwartz, M (corresponding author), Ribe Cty Hosp, Dept Endocrinol, Esbjerg, Denmark.
EM schwartz@rh.hosp.dk
CR Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Cardaioli E, 2000, J NEUROL, V247, P885, DOI 10.1007/s004150070080
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   CRIMMINS D, 1993, J NEUROL NEUROSUR PS, V56, P900, DOI 10.1136/jnnp.56.8.900
   Dean NL, 2003, MOL HUM REPROD, V9, P631, DOI 10.1093/molehr/gag077
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HART LT, 1996, HUM MUTAT, V7, P193
   Jansen R P, 2000, HUM REPROD, V15 Suppl 2, P112
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   LESTIENNE P, 1988, LANCET, V1, P885
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   Marchington DR, 1997, AM J HUM GENET, V60, P408
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   Poulton J, 2002, REPRODUCTION, V123, P751, DOI 10.1530/rep.0.1230751
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Steffann J, 2006, J MED GENET, V43, P244, DOI 10.1136/jmg.2005.032326
   Steinborn R, 2000, NAT GENET, V25, P255, DOI 10.1038/77000
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
NR 31
TC 74
Z9 79
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 
J9 J MED GENET
JI J. Med. Genet.
PD AUG 15
PY 2006
VL 43
IS 8
BP 
EP 
DI 10.1136/jmg.2005.039339
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 069FZ
UT WOS:000239433100007
PM 16490799
DA 2024-11-01
ER

